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Abstract 
 
  During atherosclerosis, smooth muscle cells (SMC) migrate to the intima, losing their 
contractile ability and reacquiring characteristics seen during development: migration, proliferation, 
and synthesis of extracellular matrix – a process known as “phenotypic modulation”.  I hypothesised 
that these phenotypic and functional characteristics indicate underlying differences in protein 
expression between intimal and medial SMC, which could constitute a characteristic signature 
indicative of the diseased state.  
  I utilised 2-dimensional gel electrophoresis (2DE) and tandem mass spectrometry to compare 
the cytosolic proteome of the human SMC from atherosclerotic lesions with that of non-diseased 
SMC.  Novel findings were validated by immunoblotting and immunohistochemistry.  I detected 
decreases in contractile proteins and an increase in the oxidised form of peroxiredoxins in carotid 
atheroma-derived SMC - compared to non-diseased SMC.  These changes indicate respectively loss of 
contractile features and exposure to oxidative stress, and are in accordance with the existing literature.  
I also identified significant decreases in the key mitochondrial proteins ATP synthase subunit-β and 
aldehyde dehydrogenase-2 potentially linked to mitochondrial damage.  
 More notably, I described for the first time that differences in expression of members of the 
annexin family distinguish SMC derived from stable atheroma and unstable atheroma.  The anti-
inflammatory protein Annexin I was significantly up regulated in SMC derived from stable plaques. 
Annexin II, a protein involved in facilitating fibrinolysis, was significantly down regulated in SMC 
derived from unstable plaques.  These novel findings suggest that the failure of anti-inflammatory and 
antithrombotic mechanisms provided by SMC might play a role in plaque instability. 
 Finally, I investigated the effect of the exposure to pro-atherogenic factors -cholesterol and the 
proinflammatory cytokine tumour necrosis factor α (TNFα) - on the proteome of SMC.  With this, I 
was able to reproduce some of the features distinguishing atheroma-derived SMC, including the down 
regulation of contractile proteins and signs of mitochondrial damage.  In addition I uncovered features 
of priming to challenge with TNFα in atheroma-derived SMC, potentially mediated by an increase of 
the p75 receptor.  In contrast, cholesterol loading of SMC induced changes primarily in endoplasmic 
reticulum proteins, in line with current hypotheses in the literature of the activation of the Unfolded 
Protein Response – a protective mechanism engaged in conditions of endoplasmic reticulum stress. 
  The proteome of SMC in advanced human atheroma has never been investigated before, 
particularly in the context of an unstable plaque.  My data reveal an intricate relationship between 
inflammation, oxidative stress, mitochondrial damage and down regulation of mechanisms of 
resolution of inflammation in SMC in the context of vascular disease and its complications.  
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“As we acquire more knowledge, things do not become more 
comprehensible, but more mysterious” 
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Abbreviations 
 
2D    2-Dimensional 
2DE   2-Dimension Electrophoresis 
ApoE   Apolipoprotein E 
AthSMC  Human atherosclerotic SMC 
aAthSMC  Human atherosclerotic SMC derived from asymptomatic patient 
sAthSMC  Human atherosclerotic SMC derived from symptomatic patient 
AoSMC  Human aortic SMC 
BMT   Bone marrow transplantation 
CAD   Coronary artery disease 
CHAPS  3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate 
COX-2   Cyclooxygenase 2 
CVD   Cardiovascular Disease 
DNA   Deoxyribosenucleic acid 
DTT   1, 4-Dithiothreitol 
EC   Endothelial Cell 
ECM   Extra Cellular Matrix 
EPC   Endothelial progenitor cell 
ESI   Electrospray Ionisation 
EVG   Elastin Von Giesson 
FCS   Fetal Calf Serum 
FGF   Fibroblast Growth Factor 
FSP-1   Fibroblast Surface Protein-1 
GFP   Green fluorescent protein 
AoSMC  Human Aortic Smooth Muscle Cells 
HDL   High density lipoprotein 
HSP   Heat shock protein 
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HSF   Human Skin Fibroblasts 
HSS   High shear stress 
IAA   Iodoacetamide 
ICAM-1  Intercellular adhesion molecule 
IEF   Isoelectric focusing 
IFNγ   Interferon-gamma 
IL-1   Interleukin 1 
IMT   Intimal:medial thickness ratio 
iNOS   Inducible Nitric Oxide Synthase 
IP-10   10kDa Interferon-gamma induce protein 
IPG   Immobiline pH gradient 
ITS   Insulin, Transferrin and Selenite 
kVh   kilo-Volt Hour 
LDL   Low density Lipoprotein 
Lp-PLA2  Lipoprotein associated phospholipase A2 
LPS   Lipopolysaccharide 
LSS   Low shear stress 
MALDI  Matrix-Assisted Laser/Desorption ionisiation 
MAPK   Mitogen Activated Protein Kinase 
MCP-1   Monocyte Chemoattractant Protein 1 
MHC class II  Major Histocompatibility Complex class II 
MIF   Macrophage Migration Inhibitory Factor 
MIP1α   Macrophage Inhibitory Protein 1α 
mmLDL  Minimally modified Low Density Lipoprotein 
MMP   Matrix Metalloproteinase 
MS   Mass Spectrometry 
MS/MS   Tandem Mass Spectrometry 
NFκB   Nuclear Factor kappa B 
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NM-MHC  Non-muscle myosin heavy chain 
NO   Nitric oxide 
m/z   Mass to charge ratio 
OSS   Oscillatory shear stress 
oxLDL   Pxidised Low Density Lipoprotein 
oxPAPC  oxidised 1-palmitoyl-2-arachidonyl-sn-glycer-3-phosphoryl-choline 
PDGF   Platelet Derived Growth Factor 
pI   Isoelectric point 
PI   Propidium Iodide 
PLA2   Phospholipase A2 
PRDX   Peroxiredoxin 
PVDF   Polyvinylidine fluoride 
RA   Rheumatoid arthritis 
RANTES  Regulated upon Activation, Normal T cell Expressed and Secreted 
RNS   Reactive Nitrogen species 
ROS   Reactive Oxygen Species 
SDF-1α  Stromal Cell Derived Factor 1α 
SDS   Sodium Dodecyl Sulphate 
SDS-PAGE  Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
SILAC   Stable Isotope Labelling by amino acids in Cell Culture 
SLE   Systemic Lupus Erythamatosus 
αSMA   Smooth Muscle alpha-Actin 
SM-MHC  Smooth Muscle Myosin Heavy Chain 
SMC   Smooth Muscle Cells 
SPC   Smooth muscle progenitor cell 
TGFβ   Transforming Growth Factor-beta 
TIA   Transient ischemic attack 
TIMP   Tissue Inhibitor of Matrix Metalloproteinases  
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TNFα   Tumour Necrosis Factor-alpha 
TOF   Time of Flight 
tPa   Tissue plasminogen activator 
TRAF   TNF receptor associated protein 
VCAM   Vascular Cell Adhesion Molecule 
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1. Cardiovascular Disease 
 
Cardiovascular disease (CVD) is the main cause of death in developed countries and increasingly 
worldwide.  The World Health Organisation estimated that 17.1 million people died from CVD in 
2004 - which represented 29% of all global deaths (World Health Organisation Fact sheet No317), 
with 7.2 million deaths due to coronary heart disease and 5.7 million due to stroke.  Accordingly, 
cerebrovascular disease and ischemic heart disease are leading causes of mortality (Lopez, Mathers et 
al. 2006).  Recent statistics show that in the UK alone, there were 193,000 deaths from CVD in 2007 
(British Heart Foundation statistics, www.heartstats.org). 
 
1.1 Atherosclerosis 
 
At the core of cardiovascular disease, is atherosclerosis – an accumulation of lipid in the artery wall 
which leads to formation of a plaque.  Atherosclerosis affects the large and medium-sized muscular 
arteries that supply blood to vital organs such as the heart and the brain.  Atherosclerotic lesions are 
asymmetrical focal thickenings of the intima, the innermost layer of the arterial wall, composed of 
lipids, cells and connective tissue.  Lesions or ‘plaques’ form at predetermined sites of the artery wall 
such as at branches or curvatures, where there is non-laminar flow (Caro, Fitz-Gerald et al. 1969). 
 
The accumulation of cholesterol and lipid are initiating events in the disease process.  Previously 
thought of as inert molecules, they are now known to induce a proinflammatory response by recruiting 
monocytes to the arterial wall and driving production of inflammatory mediators (Duewell, Kono et 
al.).   Thus, this disease is now recognised as a lipid-driven inflammatory disease also involving 
endothelial dysfunction, vascular inflammation and immune responses (Ross 1999) (Hansson, Libby 
et al. 2002) (Hansson 2005).  Inflammation was first described in the arteries by Rudolf Virchow and 
Carl von Rokitansky in the middle of the 19th century (Mayerl, Lukasser et al. 2006).  Lipid and 
cholesterol also play a part in atherosclerosis disease progression throughout later stages (Tabas 1997; 
Duewell, Kono et al. 2010) 
 
1.1.1 Risk Factors  
 
Major risk factors for the development of atherosclerosis can be divided into ‘modifiable’ and ‘non-
modifiable’.  Non-modifiable risk factors include age, gender, and family history.  The modifiable risk 
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factors include hypercholesterolemia, hyperhomocysteinemia, physical inactivity, obesity, smoking, 
type II diabetes, excessive alcohol consumption and low high-density lipoprotein (HDL) levels.  
Treatment with the lipid lowering agent statins (3-HMG CoA reductase inhibitors) has proven to be 
one of the most effective strategies in reducing cardiovascular mortality.  Statins have reduced 
cardiovascular morbidity and mortality by up to 50% in the general population (Shepherd, Cobbe et al. 
1995; MRC/BHF 2002; Sever, Dahlof et al. 2003). Statins inhibit the enzyme HMG Co-A Reductase, 
which is the rate-limiting enzyme in the cholesterol biosynthesis pathway.  Their lipid lowering 
properties come from their inhibition of endogenous cholesterol biosynthesis and also induction of the 
LDLR on hepatocytes, resulting in enhanced clearance of circulating cholesterol (Jain and Ridker 
2005).  Several large clinical trials have shown that statins significantly reduce LDL-cholesterol levels 
and prevent recurrence of CV events (study 1994; Sacks, Pfeffer et al. 1996; trial 1998) and also 
prevent first CV events in those without overt CHD (Downs, Clearfield et al. 1998) demonstrating an 
important role in primary and secondary prevention of CVD in the general population.  There is also 
growing evidence for immuno-modulatory and anti-inflammatory properties of statins (Kwak, 
Mulhaupt et al. 2000) (Jain and Ridker 2005), suggesting they have a broader role than anticipated.  
As a result of these properties, statins have become one of the most widely prescribed drugs 
wordlwide (Montecucco and Mach 2009).   
 
1.1.2 Prevalence of atherosclerosis in other inflammatory diseases 
 
The role of inflammation in atherosclerosis is supported by the fact that atherosclerosis is the main 
cause of increased mortality in patients with other chronic inflammatory disease such as rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE).  Patients with RA have a 2-fold greater risk of 
myocardial infarction than non-RA subjects (Solomon, Karlson et al. 2003) and are twice as likely to 
experience sudden death (Maradit-Kremers, Nicola et al. 2005).  Women with SLE between the ages 
of 35 and 44 years have a 50-fold increased risk for MI compared with age-matched and sex-matched 
control individuals (Manzi, Meilahn et al. 1997). 
 
While it is true that RA and SLE patients are likely to have increased risk factors for CVD, including 
physical inactivity and altered lipid profile, the presence of these risk factors does not explain the 
increased atherosclerosis in these patients.  Severe articular disease has been shown to correlate with 
increased CVD in RA patients (Turesson, McClelland et al. 2007).  In the Pima Indian populations, the 
number of swollen joints was a predictor of death from CVD (Jacobsson, Turesson et al. 2001).  RA is 
in fact an independent risk factor for developing atherosclerosis (Warrington, Kent et al. 2005) and 
recent reports suggest that the risk is similar to that of type II diabetes (Peters, van Halm et al. 2009).  
Chapter 1   Introduction 
 
 
 
21
There are several common features in the pathogenesis of RA and atherosclerosis (Figure 1.1), which 
suggests that chronic systemic inflammation may be the link between these diseases (Full, Ruisanchez 
et al. 2009) (Full and Monaco 2010).  Furthermore, histological analysis of coronary arteries from RA 
patients showed evidence of increased inflammation and vulnerable plaque phenotype compared to 
non-RA subjects, despite no difference in the amount of stenosis (Aubry, Maradit-Kremers et al. 
2007), suggesting that the lesions of RA patients are more inflammatory. 
 
Treatments for RA may have cardiovascular benefits, again underlining the role of inflammation in 
atherosclerosis.  For example, biological therapies such as anti-TNF were shown to improve 
endothelial function (Van Doornum, McColl et al. 2005) and reduce sub-clinical atherosclerosis, as 
measured by intimal-media thickness ratio (Del Porto, Lagana et al. 2007).  However, there were 
concerns about its effects on heart failure (Mann, McMurray et al. 2004).  Retrospective analyses also 
show that patients receiving anti-TNF treatment had reduced incidence of first cardiovascular event 
(reviewed in (Full and Monaco 2010)).  Similarly, in RA statins have been shown to reduce the 
disease activity score and the inflammatory marker CRP (McCarey, McInnes et al. 2004). 
 
 
Figure 1.1 Similarities between atherosclerotic lesions and rheumatoid arthritis joint.  
Proinflammatory mediators are present in both the RA joint and atherosclerotic artery.  A) A healthy joint is on 
the left hand side of the diagram and the RA joint on the right hand side.  There is recruitment and infiltration of 
immune cells.  Production of cytokines, matrix metalloproteinases (MMPs) and growth factors leads to 
angiogenesis, proliferation of synovial fibroblasts and joint destruction. B) The development of the atheroma is 
accelerated due to circulating, systemic inflammation, which is increased in RA patients.  Monocytes and T-
lymphocytes are recruited to the site and migrate into the intimal space.  Smooth muscle cells migrate from the 
media and form a fibrous cap encompassing the inflammatory core.  The core contains macrophages, foam cells 
and lymphocytes.  Inflammation can lead to degradation and rupture of the fibrous cap leading to thrombus 
formation, which cause acute events.  Taken from Full et al 2010 
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1.1.3 Animal Models of Atherosclerosis 
 
In 1913, the pathologist Anitschow noticed that when he fed purified cholesterol dissolved in 
sunflower oil cholesterol to rabbits, they developed lesions similar to humans (Steinberg 2004).  In 
contrast, the control rabbits that were fed sunflower oil alone did not develop such lesions.  Anitschow 
and colleagues made many observations including that lesions first developed at the aortic root and 
aortic arch, and that the site of lesion formation was probably due to hemodynamic factors; in early 
lesions, lipid was held in large vacuoles in the cells; over long periods of cholesterol feeding there was 
accumulation of connective tissue and formation of a fibrous cap.  He even speculated that cholesterol 
as entering the artery wall from the blood and that the lipid-laden cells which he observed were white 
blood cells that had infiltrated the artery from the blood.  Although today we recognise these 
observations to be true, these findings were not followed up at the time, or could not be reproduced in 
other animal models (Steinberg 2004).   
 
Since then, the use of animal models has greatly contributed to our knowledge of the atherosclerotic 
disease process.  Murine models of atherosclerosis are the most widely used as mice are small, cheap 
to maintain, easy to handle and they can be examined in large numbers.  Mice do not spontaneously 
develop atherosclerosis and atherosclerosis can only be induced with a high cholesterol diet.  Even 
then, different strains of in-bred mice have different susceptibilities to lesion formation, with C57BL/6 
mice being the most susceptible, while BALB/c mice are the least (Paigen, Morrow et al. 1985).  The 
lesions in these mice were however very small, largely confined to the aortic root and did not progress 
to advanced lesions with SMC accumulation.  This model was not considered a useful model of 
atherosclerosis as the lesions were very different from that of humans (Jawien, Nastalek et al. 2004).   
 
In 1992, the apolipoprotein E-deficient mouse was generated (Plump, Smith et al. 1992) (Piedrahita, 
Zhang et al. 1992).  Apolipoprotein E (apo E) is an apolipoprotein component of lipoprotein particles 
other than LDL.  It has an important role in lipid metabolism, as it is a high affinity ligand for several 
lipoprotein receptors, including the LDL receptor.  It is necessary for the uptake of apoE-containing 
particles by cells.  Disruption of this gene leads to a change in the plasma lipid profile of these mice.  
In contrast to humans who have the majority of their serum cholesterol in LDL particles, mice carry 
cholesterol mainly in their HDL.  However, apoE-deficient mice (apoE-/-) mice have less HDL and 
increased VLDL (Zhang, Reddick et al. 1992).  Additionally, there is an overall increase in plasma 
cholesterol concentrations- approximately 5-times higher than in normal mice.  ApoE-/- mice 
spontaneously develop lesions, which resemble those in humans, when fed a normal ‘chow’ diet.  
Additionally, the timescale of lesion development is practical for experimental research, with fatty 
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streaks developing at 6-10 weeks (Jawien, Nastalek et al. 2004).   Advanced lesions with fibrous cap 
are present from approximately 20 weeks.  Lesion formation can be accelerated with feeding of a 
‘western’ high fat diet.  Mice respond to this diet with earlier lesion formation and increased lesion 
size, similarly to humans.   
 
The generation of the LDL receptor (LDLR) deficient mouse in 1993 also provided another model for 
experimental atherosclerosis (Ishibashi, Brown et al. 1993).  The LDLR removes cholesterol from the 
circulation by receptor mediated endocytosis of lipoprotein particles LDL and IDL (Brown and 
Goldstein 1986).  LDLR-/- mice have impaired clearance of LDL and IDL particles.  On a chow diet, 
they have only a moderate 2-fold increase in serum cholesterol levels, with an increase in IDL and 
LDL but no change in HDL levels (Ishibashi, Brown et al. 1993).  When fed a high fat diet, these mice 
have large increases in serum cholesterol levels, as a result of even larger increases in IDL and LDL 
fractions.  Of note, the increase in cholesterol concentrations is not as severe as in apoE-/- mice.  
Lesion development in LDLR-/- mice progresses from the fatty streak to fibrous lesions that have lipid 
cores (Ishibashi, Goldstein et al. 1994) although it is not as severe as apoE-/- mice fed a similar diet, 
probably as the hypercholesterolemia in LDLR-/- mice is not as severe compared to the apoE-/-.    
 
A disadvantage of these models has been that they do not develop advanced lesions that spontaneously 
rupture, as is seen in humans.  However, observations in chow-fed apoE-/- mice over 42 weeks of age 
have shown that advanced plaques with a ‘vulnerable’ plaque phenotype occur in the bracheocephalic 
artery (innominate artery) and even show signs of plaque rupture and intraplaque haemorrhage 
(Rosenfeld, Polinsky et al. 2000).  Plaque rupture has also been observed when apoE-/- mice a fed a 
high fat feeding for 14 months (Johnson and Jackson 2001).  In these animals, plaque rupture was 
observed mainly in the in the bracheocephalic artery but also the descending thoracic aortic, 
abdominal aorta and aortic sinus.  Ruptures were associated with luminal thrombus as well as 
intraplaque haemorrhage.  Plaque rupture in the bracheocephalic artery has since been found to occur 
at earlier time points of just 8 weeks with high fat diet (Johnson, Carson et al. 2005)  
 
1.1.4 Lesion formation 
 
In humans, lesions develop over several decades.  One of the precursors to atherosclerotic lesions is 
the “fatty streak”, which is characterised by subendothelial accumulation of macrophage foam cells 
and lipid droplets (Stary, Chandler et al. 1994).  Fatty streaks have been found in children and even in 
foetuses (Napoli, D'Armiento et al. 1997).  The “gelatinous lesions” is another precursor; an intimal 
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thickening with a macroscopically gelatinous appearance, but microscopically they contain little or no 
lipid, few cells with an abundance of extracellular matrix (Stary, Chandler et al. 1994).   
 
The first event in lesion formation is thought to be localised endothelial injury, as proposed by Ross 
and Glomset in the 1970’s with the “response to injury” hypothesis (Ross and Glomset 1973) (Ross 
1993).  In this model, endothelial denudation leads to smooth muscle cell migration from the media 
into the intima, resulting in accumulation of these cells. This was supported by evidence that 
endothelial cells were often absent from human lesions (Ross, Glomset et al. 1977).  Since these initial 
observations, this hypothesis has been revised and now endothelial activation or dysfunction, rather 
than actual endothelial denudation is now the more common theory (Ross 1993).  Endothelial 
dysfunction can result from elevated circulating LDL, accumulating oxidised LDL in the intima, free 
radicals, hypertension, elevated plasma homocysteine or infectious organisms (Ross 1999).  
Dysfunction results in induction of a proinflammatory state with expression of adhesion molecules 
such as vascular cell adhesion molecule (VCAM) -1, which serve to recruit circulating monocytes and 
lymphocytes to the artery wall (Figure 1.2).  Adhered immune cells migrate into the sub-endothelial 
space, the intima.  Monocytes are heterogeneous and in humans there are at least 2 main monocyte 
subsets (Swirski, Weissleder et al. 2009), which are recruited to the atherosclerotic lesion.  These 
subsets are defined by their expression of the cell surface markers CD14 and CD16.  The main human 
monocyte subset is CD14hiCD16-, which also expresses the chemokine receptors CCR2 and CXCR2.  
Another major subset is CD14lowCD16+, which expresses chemokine receptor CX3CR1 but not CCR2.  
Similarly, in the mouse, monocyte subsets are based on their expression of surface markers Ly-6C, 
also called Gr1, as well as the expression of chemokines receptors.  Ly-6Chi monocytes also express 
CCR2, corresponding to the human monocyte subset CD14hiCD16-.  The Ly-6Clo monocytes 
correspond to human CD14+CD16+ subset and express CX3CR1 but not CCR2 (Swirski, Weissleder et 
al. 2009).  In the lesion, monocytes differentiate into macrophages.  Macrophages are also diverse and 
have different roles in the plaque.  They can be activated by different stimuli, such as TNFα and IFNγ 
giving rise to the classical ‘M1’ macrophages, which are proinflammatory (Gordon and Taylor 2005).  
M1 macrophages can take up oxidised lipoproteins and form foam cells.  The alternate ‘M2’ 
macrophage is activated by IL-4 or IL-13 and has more of a regulatory role, suppressing inflammation 
and promoting tissue repair (Gordon and Taylor 2005), (Swirski, Weissleder et al. 2009).  T-cells 
present in atherosclerotic lesions are predominantly CD4+, which recognise antigens present via 
interaction of the T-cell receptor and major-histocompatibility complex (MHC) class II molecules on 
antigen presenting cells.  Proatherogenic TH1 cytokines such as interferon-γ (IFNγ) and tumour 
necrosis factor-α (TNFα) predominate in human and murine models of atherosclerosis (Hansson and 
Libby 2006).   
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Appearance of SMC in the intima denotes the progression of the fatty streak into a plaque.  SMC are 
thought to primarily migrate to the intima from the media although some SMC may also originate 
from the adventitia (Hu, Zhang et al. 2004) or blood borne progenitor cells (Sata, Saiura et al. 2002), 
as discussed further in section 1.2.3.  Intimal SMC synthesise extra-cellular matrix (ECM) proteins 
such as collagens type I, III, IV, VI and VIII and proteoglycans including perlecan and versican 
(Raines 2000).  As the lesion develops with increasing macrophages and SMC numbers, a fibrous cap, 
mainly composed of collagens, forms over the cells, lipid and debris.  Over the course of plaque 
development apoptosis of macrophages and SMC ensues.  Normally, under physiological conditions, 
apoptotic cells are cleared by neighbouring cells – a process called efferocytosis (Tabas 2007).  
However, in the plaque defective efferocytosis occurs, which leads to inflammation and necrosis, 
resulting in formation of a necrotic core (Li, Sun et al. 2009) (Tabas 2007).  The fibrous cap isolates 
the necrotic core from the arterial blood flow.  In advanced lesions, the fibrous cap may weaken due to 
SMC apoptosis (Bennett, Evan et al. 1995) and proteolytic cleavage of ECM proteins in the cap 
(Newby 2006), leaving the plaque vulnerable to rupture.  Plaque rupture exposes the contents of the 
core, which is thrombogenic, to the blood.  This initiates the clotting cascade by tissue factor leading 
to platelet aggregation and coagulation of the infiltrating blood.  Plaque rupture with thrombus is the 
main cause of acute coronary syndrome or myocardial infarction (Falk, Shah et al. 1995) (Naghavi, 
Libby et al. 2003) as discussed in more detail in section 1.1.11.   
 
Despite increases in the thickness of the intima during plaque development, luminal narrowing, or 
stenosis does not occur until the late stages.  Vessels undergo outward remodelling to preserve the 
lumen area.  Glagov reported for the first time that the diameter of the internal elastic lamina of 
coronary arteries was proportional to the lesion area (Glagov, Weisenberg et al. 1987).  However, this 
compensation is only effective up until the lesion occupies less than 40% of the internal elastic lamina 
area.  Above 40%, there was a decrease in the lumen area as the plaque intruded into the lumen.  This 
partly explains the slow development of an atherosclerotic plaque over a period of many years during 
which the individual may be asymptomatic.   
 
Chapter 1   Introduction 
 
 
 
26
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The development of an atherosclerotic plaques.  Endothelial cell dysfunction leads to 
recruitment of inflammatory cells to the vessel wall, which subsequently migrate into the intima.  
Macrophages take up oxLDL and become foam cells.  Inflammatory cells become activated and 
produce cytokines (i.e. TNFα and IFNγ and IL-1) as well as matrix metalloproteinases (MMPs).  
Smooth muscle cells (SMC) become activated, proliferate and migrate into the intima from the medial 
layer of the artery.  They produce extra cellular matrix proteins, forming the fibrous cap over 
accumulating lipid and often necrotic core.  Plaque rupture can occur due to the proinflammatory 
microenvironment, which can lead to apoptosis of SMC, and the action of metalloproteinases on the 
ECM proteins, which weaken the cap.  Exposure of this material to the blood flow causes thrombosis, 
which leads to artery occlusion and clinical symptoms.  Taken from Full, L. E., C. Ruisanchez, et al. 
(2009). The inextricable link between atherosclerosis and prototypical inflammatory diseases 
rheumatoid arthritis and systemic lupus erythematosus Arthritis Res Ther 11(2): 217 
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1.1.5. The Effect of Hemodynamic Forces in Atherosclerosis  
 
It has been recognised for several decades that hemodynamic forces dictate the site of atherosclerotic 
lesion development (Caro, Fitz-Gerald et al. 1969).  Plaque development occurs in regions of non-
laminar flow such as areas of vessel curvature or branching such as the bifurcation of the common 
carotid artery and lesser curvature of the aortic arch.  In areas of laminar flow, arteries are protected 
from atherosclerosis.  
 
Shear stress is the mechanical drag forces on the endothelium, caused by the blood flow.  It is the most 
important hemodynamic factor in atherosclerosis.  Shear stress has important biological affects on the 
endothelium, which acts as a mechano-sensor.  Shear stress is thought to be sensed by the primary 
cilia on endothelial cells (Iomini, Tejada et al. 2004) and this induces conformational changes of 
cytoskeletal proteins which activates intracellular signalling cascades (Helderman, Segers et al. 2007).  
In support of this, it was shown in chick embryos that primary cilia are found on endothelial cells in 
regions of low shear stress (Van der Heiden, Groenendijk et al. 2006).  Low shear stress permits the 
recruitment and adhesion of circulating immune cells to the endothelium.  Acute exposure of 
endothelial cells to shear stress in vitro can induce expression of adhesion molecules, via MAPK and 
NFκB signalling pathways, facilitating adhesion of lymphocytes and monocytes (Helderman, Segers 
et al. 2007).   
 
En-face staining of aortas from atherosclerotic mice has shown that in areas of non-laminar flow there 
is increased proinflammatory molecule expression including adhesion molecules (Nakashima, Raines 
et al. 1998), NFκB (Hajra, Evans et al. 2000) and TLR-2 (Mullick, Soldau et al. 2008).  Areas of the 
vasculature that experience low shear stress may express higher levels of NFκB, suggesting that they 
are ‘primed’ for activation (Hajra, Evans et al. 2000).  In contrast, pre-exposure of endothelial cells to 
prolonged shear stress in vitro followed by stimulation with TNFα, results in expression of 
cytoprotective genes such as MnSOD and Bcl-2 and a decrease in E-selectin, VCAM-1 and IL-8 
(Partridge, Carlsen et al. 2007).  Shear stress has also been shown to inhibit TNF-induced 
proinflammatory pathways by preventing association of TNFR1 with TNF receptor associated factor 
(TRAF)-2 (Yamawaki, Lehoux et al. 2003). 
 
The effect of flow on SMC is less well studied although one study has investigated the effects in vitro 
(Hastings, Simmers et al. 2007).  Hastings et al used a co-culture system of ECs and SMCs separated 
by a permeable membrane, and exposed the cells to shear stress similar to those experienced in 
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‘atheroprone’ and ‘atheroprotective’ areas of the carotid artery.  In areas of laminar flow, EC were 
elongated and aligned in the direction of the flow and SMC were aligned perpendicular to the direction 
of flow.  However, under low shear stress, EC became more disorganised, whereas SMC become more 
elongated and aligned with the direction of flow suggesting they are affected by flow, either directly or 
indirectly through communication with EC.  Additionally, the expression of SMC markers smooth 
muscle α-actin (αSMA) and myocardin were decreased in regions of low shear stress, which was 
accompanied by an increase in proinflammatory gene VCAM-1, although interestingly expression of 
IL-8 and MCP-1 was decreased.   
 
An in vivo model has been developed to investigate the effect of shear stress on the development of 
atherosclerotic lesions (Cheng, van Haperen et al. 2005).  Placement of a perivascular cast on a 
straight artery creates areas of low shear stress upstream of the cast, high shear stress in the cast and 
oscillatory shear stress downstream of the cast.  When this cast was placed on the carotid artery of 
apoE-/- mice, lesions developed in areas of low shear stress and oscillatory shear stress but not in areas 
of high shear stress (Cheng, Tempel et al. 2006).  In addition, the plaque composition differed in areas 
of low shear stress compared to oscillatory shear stress.  The plaques that developed upstream of the 
cast (low shear stress) had a vulnerable plaque phenotype with increased macrophages, lipid 
accumulation, a thin fibrous cap with few SMC and little collagen and increased MMP activity.  In 
contrast the plaques in regions of oscillatory shear stress, exhibited a more stable phenotype with less 
lipid and more SMC and collagen and low MMP activity.  Furthermore, evidence of intraplaque 
haemorrhage was observed in the regions of low shear stress, which is a feature of plaque instability.  
 
Shear stress can modulate the expression of chemokines, influencing the recruitment of immune cells 
to the site and hence plaque composition and stability.  Using this in vivo model of inducible shear 
stress, Cheng et al has shown that the chemokines MCP-1(CCL2), Fractalkine (CX3CL1), GROα/KC 
and IP-10 are increased at sites of low shear stress and oscillatory shear stress, but not RANTES, SDF-
1 or eotaxin (Cheng, Tempel et al. 2007).  Fractalkine was particularly increased at areas of low shear 
stress compared to the control or areas of oscillatory shear stress.  Inhibition of fractalkine with a 
neutralising antibody resulted in a 50% reduction in the plaque area in regions of low shear stress, with 
reduced macrophage content and increased numbers of SMC and increased cap thickness, which 
resulted in a more stable plaque phenotype (Cheng, Tempel et al. 2007).   
 
Changes in shear stress patterns occur during vascular remodelling and plaque progression.  Initially, 
lesions form at sites of low shear stress, but as the plaque encroaches on the lumen, the proximal or 
upstream region of the plaque is exposed to increased shear stress (Slager, Wentzel et al. 2005).  
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Plaque rupture is mostly likely to occur in this proximal region (Lovett and Rothwell 2003) (Slager, 
Wentzel et al. 2005).  This may be partly explained by the plaque composition in this region, with 
significantly higher numbers of macrophages and increased MMP production (Dirksen, van der Wal et 
al. 1998) (Slager, Wentzel et al. 2005).  In contrast the distal plaque has increased SMC and matrix 
synthesis, promoting plaque stability.   
 
1.1.6 Lipids 
 
The retention of lipids in the intima and their progressive oxidation is a key step in the initiation of 
atherosclerosis.  The “altered lipid hypothesis” by Daniel Steinberg and colleagues postulated that 
oxidised lipoproteins lead to primary foam cells in the intima (Steinberg and Witztum 1990).  This 
was later modified to the “retention of modified lipoproteins” when it was realised that native LDL 
enters the intimal space where it is then modified and acts as a chemoattractant for macrophages and 
SMC (Navab, Berliner et al. 1996).  The modification of native LDL is necessary for its uptake by 
macrophages and SMC to form foam cells.  This was first noted by Steinberg who observed that 
patients lacking the LDL receptor still developed lipid laden foam cells similar to those with the LDL 
receptor (Steinberg 1997).  Additionally, foam cell formation could not be induced by incubation of 
macrophages or SMC with high concentrations of native LDL, although uptake could be induced if the 
LDL was acetylated (Steinberg 1997).  The receptors responsible for the uptake of modified LDL were 
designated ‘scavenger receptors’ (Kodama, Freeman et al. 1990).   
 
Oxidation of LDL occurs from the actions of enzymes from the cells in the vascular wall, such as 
NADPH oxidases, lipoxygenases and myeloidperoxidases.  Minimally modified LDL (mmLDL) has 
proinflammatory effects and contributes to the initial events in atherosclerotic lesion formation.  For 
example, it can induce expression of MCP-1 and GM-CSF from endothelial cells (Cushing, Berliner et 
al. 1990) (Rajavashisth, Andalibi et al. 1990).  LDL that has been oxidised more than mmLDL 
(oxidised LDL, oxLDL) is also chemotactic for monocytes (Quinn, Parthasarathy et al. 1987).  These 
effects may be mediated by oxLDL activating signalling pathways in target cells, including those 
involving cyclic AMP, increasing calcium levels and mitogen-activated proteins kinases (MAPKs) 
(Leitinger 2003).  Some of the effects of oxLDL may be through TLR-4, as oxLDL in vitro 
stimulation of a monocyte cells line resulted in increased NFκB activity, IL-8 and MCP-1 production, 
and inhibition of TLR-4 expression by siRNA lowered production of these chemokines (Geng, Wang 
et al. 2010).  However, oxPAPC (oxidised 1-palmitoyl-2-arachidonyl-sn-glycer-3-phosphoryl-choline) 
has been shown to inhibit LPS signalling via TLR-4 (Bochkov, Kadl et al. 2002).  T-cells can be 
activated by oxLDL as it can be presented as an antigen via MHC class II (Stemme, Faber et al. 1995). 
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There is a broad spectrum of oxidation products that can arise from the oxidation of LDL.  Analysis 
with mass spectrometry has identified several different phospholipids derived from mmLDL that can 
be oxidised and which are present in atherosclerotic lesions (Watson, Leitinger et al. 1997).  The main 
component of mmLDL is oxPAPC, from which other biologically active oxidised phospholipids are 
derived, including 1-palmitoyl-2-(5-oxyvaleroyl)-sn-glycero-3-phosphorylcholine (POVPC) and 1-
palmitoyl-(2-glutaroyl)-sn-glycero-3-phosphorylcholine (PGPC).  OxPAPC specifically can induce 
production of MCP-1 and IL-8 from endothelial cells enabling the binding of monocytes (Lee, Shi et 
al. 2000).  Interestingly, circulating levels of oxLDL in patients correlates with the severity of acute 
coronary syndromes, as higher oxLDL levels were found in those patients that experienced acute MI 
(Ehara, Ueda et al. 2001), highlighting the proatherogenic role of these lipid species. 
 
1.1.7 Inflammation 
 
It has been recognised for several years, that inflammation plays a dominant role in atherosclerosis 
(Ross 1999).  Inflammation is the response of vascular tissue to harmful stimuli such as an invading 
pathogen or irritant.  It is the body’s response to remove the stimuli and repair the damaged tissue.  
Inflammation can either be acute or chronic.  Acute inflammation is resolved within a few days and 
stops upon clearance of the harmful stimulus.  It involves the infiltration of neutrophils, monocytes 
and macrophages and is characterised by 5 main signs: rubor (redness), calor (increased heat), dolor 
(pain), tumour (swelling) and loss of function.  Chronic inflammation arises due to persistent irritants 
or pathogens.  It can last many months or even years, involving cells including T-cells, macrophages 
and fibroblasts that produce proinflammatory cytokines such as IFNγ and TNFα.  Fibrosis may also 
occur to heal the damaged tissue.  Atherosclerosis has many features of a chronic inflammatory 
disease.   
 
Inflammation is involved in all steps of plaque development.  Even in the early fatty streak are 
macrophages and T-cells present in the intima (Stary, Chandler et al. 1994).  These cells are recruited 
by the expression of adhesion molecules on the luminal side of the endothelium, which are themselves 
induced by proinflammatory stimuli such as oxidised lipoproteins.  Activation of macrophages and T-
cells leads to production of cytokines such as TNF-α, IL-1 and IFNγ, which stimulate production of 
other mediators including the growth factors such as PDGF; chemokines and MMPs, and also 
encourages recruitment of more immune cells.  Oxidised phospholipids are triggers of 
proinflammatory responses as described in section 1.1.6. (Leitinger 2003).  SMC migration, 
proliferation and ECM synthesis is stimulated by TNF and IL-1, as discussed in section 1.2.  In 
advanced plaques, inflammation is present at the site of plaque rupture as shown by the presence of 
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cells expressing HLA-DR and may contribute to plaque destabilisation (van der Wal, Becker et al. 
1994).   
 
1.1.8 Inflammatory mediators in Atherosclerosis 
1.1.8.1 Cytokines 
 
Cytokines are low molecular weight proteins released by cells of the immune system.  They act as 
extracellular signalling molecules to communicate between cells.  Each cytokine has a cell surface 
receptor, to which it can bind and initiate intracellular signalling cascades that lead to changes in gene 
expression and ultimately cell function.  The best known and probably the most potent cytokines in 
atherosclerosis are described below. 
 
TNFα is a potent proinflammatory cytokine that plays dominant role in atherosclerosis.  It is produced 
mainly by macrophages and T-cells in the atherosclerotic plaque (Barath, Fishbein et al. 1990).  There 
are two cell surface receptors through which TNF can signal; TNFRI and TNFRII.  These receptors 
are discussed in more detail in chapter 5, but they engage several signalling pathways including the 
MAP kinases and NFκB, resulting in the diverse effects of TNFα (MacEwan 2002).  TNFα can 
induce cell proliferation and migration, inflammatory responses such as cytokine, chemokine and 
MMP production.  It can initiate endothelial dysfunction by inducing adhesion molecule expression 
and tissue factor expression, which is part of the coagulation cascade, therefore disrupting the natural 
anti-thrombotic properties of the endothelium (Pober and Sessa 2007).  TNFα can also induce 
apoptosis (MacEwan 2002).  It is also involved in the acute phase response by inducing IL-6.  Genetic 
deletion of TNFα in apoE-/- mice results in a 50% reduction of atherosclerotic lesions compared to 
apoE-/- mice (Branen, Hovgaard et al. 2004).  In addition, apoE-/- mice that receive bone marrow 
transplant from apoE-/-TNF-/- mice have an 83% reduction in lesion size (Branen, Hovgaard et al. 
2004).  The effects of TNF on SMC are discussed in more detail in chapter 5.  
 
Interleukin-1 (IL-1) is another key proinflammatory cytokine produced mainly by macrophages but 
also endothelial cells and SMC.  IL-1 is a class I cytokine and belongs to a large family of 
interleukins, of which there are 33 members.  There are two main forms of IL-1; IL-1α is anchored to 
the plasma membrane and IL-1β is secreted.  Both forms of IL-1 signal through the IL-1 receptor (IL-
1R), which can activate NFκB or MAP kinase pathways (Tedgui and Mallat 2006).  A cytoplasmic 
domain of the IL-1R shares some homology with that of Toll like Receptors (TLR).  This domain is 
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called the TLR-IL-1 receptor (TIR) homology domain (Frantz, Ertl et al. 2007).  IL-1 can signal 
through adapter molecules such as MyD88, which are also used by TLRs.  IL-1 signalling induces 
expression of several genes such as adhesion molecules and other proinflammatory mediators 
including IL-6 and IL-8.  IL-1 can also induce SMC proliferation (Libby, Warner et al. 1988).  Lesions 
in IL-1β-/- apoE-/- mice are 30% smaller compared to those in apoE-/- mice, (Kirii, Niwa et al. 2003), 
possibly due to decreased adhesion molecule expression.  IL-1 receptor antagonist (IL-1Ra) is an 
endogenous antagonist, which competes with IL-1 for the IL-1 receptor.  Human recombinant IL-1Ra 
(Anakinra) has been shown to reduce joint damage and CRP levels in rheumatoid arthritis patients 
(Bresnihan, Alvaro-Gracia et al. 1998).  Due to these beneficial effects, it has been proposed that IL-1 
blockade may also be effective in treatment of other inflammatory diseases and trials of IL-1Ra in 
patients with acute coronary syndromes are underway (Crossman, Morton et al. 2008). 
 
IFNγ is a class II cytokine produced by activated T-cells and macrophages.  Interferons signal through 
the JAK/STAT pathway (Tedgui and Mallat 2006).  IFNγ improves antigen presentation and amplifies 
production of TNFα and IL-1.  IFNγ inhibits proliferation of SMC (Hansson, Hellstrand et al. 1989) 
and the production of collagen (Amento, Ehsani et al. 1991).  ApoE-/- mice lacking the IFNγ receptor 
have decreased atherosclerosis with decreased lipid accumulation, decreased cellularity and increased 
collagen content (Gupta, Pablo et al. 1997).  However, in apoE-/- IFNγ-/- mice gender specific effects of 
have been observed, with a decrease in lesion size seen only in the males (Whitman, Ravisankar et al. 
2002). 
 
Anti-inflammatory cytokines IL-10 and transforming growth factorβ (TGFβ) are involved in 
attenuating the proinflammatory signals in the plaque.  IL-10 deficiency in apoE-/- mice results in 
increased atherosclerosis with increased Th1 cytokines and an increase in procoagulant activity 
(Caligiuri, Rudling et al. 2003).  In irradiated LDLR-/- mice receiving bone marrow transfer from IL10-
/- or mice, lesion size was increased 2-fold compared to those mice receiving bone marrow from IL-
10+/+ mice (Potteaux, Esposito et al. 2004).  The lesions of these mice contained increased numbers of 
lymphocytes and macrophages, and less collagen.  TGFβ induces synthesis of collagens, therefore 
promoting production of the fibrous cap (Amento, Ehsani et al. 1991).  ApoE-/- mice with dominant 
negative TGFβ receptors in T-cells showed increased plaque size with increased inflammation and 
reduced collagen fibres (Robertson, Rudling et al. 2003) suggesting that TGFβ has a role in regulating 
T-cell activity.  Similarly, inhibition of TGFβ signalling in apoE-/- mice using antibodies led to 
accelerated atherosclerosis, with plaques having increased inflammation and decreased collagen 
(Mallat, Gojova et al. 2001). 
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1.1.8.2 Chemokines 
 
Chemokines belong to a large family of low molecular weight, structurally related ‘chemotactic 
cytokines’.  Chemokines are divided into 4 families; CC, CXC, CX3C and XC, which is dependent on 
the position of the first 2 cysteine residues at the N-terminus (Weber, Schober et al. 2004).  
Chemokines direct mononuclear cells to the site of inflammation and their expression by cells of the 
vascular wall serves as a chemoattractant to these cells.  Chemokines act through G protein coupled 
receptors on target cells and signalling through these chemokine receptors leads to responses such as 
cell activation and transmigration of mononuclear cells through the endothelial layer, as occurs in the 
initial stages of atherosclerosis.  Genetic deletion of chemokines and their receptors in mouse models 
of atherosclerosis have demonstrated the importance of immune cells in atheroclerosis development.  
The importance of chemokines in atherosclerosis was first realised with the deletion of monocyte 
chemoattractant protein-1 (MCP-1) CCL-2.  Knockout of MCP-1 in LDLR-/- mice protects these mice 
from atherosclerosis, suggesting an important role of MCP-1 in atherosclerosis (Gu, Okada et al. 
1998).  Similarly deficiency of the MCP-1 receptor, CCR2 also results in decreased lesion formation 
in LDLR-/- and apoE-/- mice (Boring, Gosling et al. 1998) (Dawson, Kuziel et al. 1999).  ApoE3-
Leiden mice which received CCR2-/- bone marrow developed less atherosclerosis than those mice 
receiving CCR2+/+ bone marrow indicating the importance of this receptor on monocytes (Guo, Van 
Eck et al. 2003).  MCP-1 expression can be induced in endothelial cells and SMC by oxidised LDL 
(Cushing, Berliner et al. 1990).   
 
CCL5, also known as RANTES (Regulated on activation normal T-cell expressed and secreted) is also 
important in atherosclerosis.  It is expressed by T-cells as well as macrophages in atherosclerotic 
plaques and it is also produced by platelets (Weber 2005).  RANTES can bind several receptors 
including CCR1 and CCR5.  CCR5 deficiency in apoE-/- mice on a normal diet did not lead to 
significant changes in lesion size evident at 16 weeks (Kuziel, Dawson et al. 2003).  However, in 
another study, CCR5 deficiency in apoE-/- mice fed either a normal diet or a high fat diet led to a 
significant reduction in lesion area (Braunersreuther, Zernecke et al. 2007).  Additionally, the plaque 
phenotype at later time points was more stable, with increased SMC, IL-10 and reduced T-cells and 
monocytes.  In the same study by Braunersreuther the deficiency of receptor CCR1 actually increased 
lymphocyte numbers and over all lesion size, showing that the effects of RANTES on T-cell 
recruitment were mainly through CCR5.  This confirmed results of another study of LDLR-/- mice 
transplanted with CCR1-/- bone marrow, which also showed increases in lesion area and lymphocyte 
numbers (Potteaux, Combadiere et al. 2005).   
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Fractalkine (CX3CL1) is a membrane bound chemokine that can also be cleaved to a soluble form by 
MMPs.  In its membrane bound form, it acts like an adhesion molecule to monocytes of a particular 
subset (Ly-6Clo), which express the receptor for fractalkine CX3CR1 (Geissmann, Jung et al. 2003).  
Fractalkine receptor expression is up regulated during atherosclerosis, primarily on SMC (Lesnik, 
Haskell et al. 2003).  In vitro studies showed that fractalkine expression on SMC can be strongly 
induced by stimulation with TNFα and IFNγ (Ludwig, Berkhout et al. 2002).  In murine arteries, 
fractalkine was expressed primarily in regions of induced low shear stress (Cheng, Tempel et al. 2007) 
and blockade of fractalkine inhibited development of the plaque, as described above in section 1.1.5.  
Additionally, ApoE-/- CX3CR1-/- mice have reduced lesion formation with significantly less 
macrophages than apoE-/- mice (Combadiere, Potteaux et al. 2003) (Lesnik, Haskell et al. 2003).  
Interestingly, the importance of fractalkine is underlined in humans with a polymorphism (V249I) that 
is protective for coronary artery disease (McDermott, Halcox et al. 2001).   
 
ApoE-/- mice deficient in both CCL2 and CX3CL1 showed a significant decrease in lesion size 
compared to apoE-/- CCL2-/- or apoE-/- CX3CL1-/- suggesting that these chemokines are non-redundant 
(Combadiere, Potteaux et al. 2008).  In the same study, an additional inhibition of the chemokine 
receptor CCR5, using a CCR5 antagonist, further reduced lesion size in the triple knockout mice.  
Combadiere and co-workers concluded that these three pathways accounted for the majority of 
macrophage accumulation with atherosclerotic lesions. 
 
Interferonγ- inducible protein-10 (IP10, CXCL10) is produced by monocytes, SMC and endothelial 
cells in atherosclerotic lesions and its expression is inducible by IFNγ (Mach, Sauty et al. 1999).  It is 
an important chemokine for the recruitment of T-cells to sites of inflammation.  IP-10 is related to 
other chemokines important for T-cell recruitment; monokine induced by IFNγ (MIG, CXCL9,) and 
IFN-inducible T cell chemoattractant (I-TAC, CXCL11), which all bind to CXCR3.  Unsurprisingly 
the apoE-/- CXCL10-/- mice has reduced atherosclerosis, with decreased CD4+ T-cells but increased 
regulatory T-cells, increased levels of IL-10 and TGF-β (Heller, Liu et al. 2006).   
 
CXCL8 (also known as IL-8) is a chemokine that can be expressed by macrophages, endothelial cells 
and SMC in the lesion.  The main role of IL-8 is to recruit neutrophils to sites of inflammation, 
although it also recruits macrophages.  Deficiency of its receptor CXCR2 in LDLR-/- mice resulted in 
reduced atherosclerosis, which was due to a reduction in macrophages, rather than neutrophils 
(Boisvert, Santiago et al. 1998).   
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1.1.8.3 Toll-like receptors 
 
The TLRs are part of the innate immune system and are involved in the first line of defence against 
invading organisms.  They detect pathogen associated molecular patterns (PAMPS) such as 
components of bacterial cell walls, lipopolysaccharide or double stranded RNA of viruses.  Activation 
of TLRs triggers a proinflammatory response involving activation of NFκB pathways and production 
of reactive oxygen/nitrogen species, cytokines, chemokines and MMPs (Tedgui and Mallat 2006).  In 
humans, there are 9 different TLRs, which form homo- or heterodimers upon activation.  TLRs are 
type 1 membrane proteins containing a leucine-rich repeat motif and a signalling motif similar to that 
of the IL-1 and IL-18 receptors known as the TLR-IL-1 receptor (TIR) homology domain (Frantz, Ertl 
et al. 2007).  Additionally, these two receptors share similar downstream effector molecules such as 
Myd88.  TLR signalling on antigen presenting cells such as macrophages may up regulate co-
stimulatory molecules, therefore activating the adaptive immune response.  TLRs have been shown to 
be involved in atherosclerosis, particularly TLR-2 and TLR-4.  Endogenous TLR ligands such as 
oxidised LDL, extra-domain of fibronection (EDA) and heat shock proteins, rather than exogenous 
ligands are thought to activate TLRs in atherosclerosis (Frantz, Ertl et al. 2007) (Michelsen, Doherty et 
al. 2004).  In LDLR-/- mice, up regulation of TLR-2 was shown in endothelial cells at sites of lesion 
formation. Additionally, hyperlipidemia induced in these mice was shown to be responsible for 
increase in TLR-2 (Mullick, Soldau et al. 2008).  Furthermore, apoE-/- TLR-2-/- mice show a decrease 
in lipid accumulation and chemokine production compared to apoE-/- mice (Liu, Ukai et al. 2008).  
More recently it has been shown that it is TLR-2 that drives inflammation in the plaque (Monaco, 
Gregan et al. 2009).  Increased TLR-4 is associated with sites of plaque rupture (Ishikawa, Satoh et al. 
2008) and has also been found in circulating monocytes of patients with acute MI (Methe, Kim et al. 
2005).  
 
1.1.8.4 Matrix Metalloproteinases  
 
Matrix metalloproteinases (MMPs) are a family of Zn2+ requiring proteases that degrade extracellular 
matrix proteins (Visse and Nagase 2003).  MMPs contribute to remodelling of the ECM during 
physiological processes such as embyrogenesis, tissue repair and angiogensis but MMPs are also up 
regulated in human diseases such as cancer, rheumatoid arthritis and atherosclerosis (Page-McCaw, 
Ewald et al. 2007).  There are 23 MMPs identified in humans, several of which are expressed in the 
vasculature (Table 1.1).  MMPs can be divided into 5 main groups depending on their substrate 
specificity, sequence similarity and domain organisation (Newby 2005).   
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Table 1.1 Matrix Metalloproteinases expressed in the vasculature.  Taken from Newby,A.C., Dual 
Role of Matrix Metalloproteinases in Intimal Thickening and Atherosclerotic Plaque rupture, 
Physiological Reviews, 2005 
 
In the early stages of lesion formation MMPs facilitate the migration of SMC from the media, to the 
intima by degradation of the internal elastic lamina, collagens and proteoglycans.  MT1-MMP is 
constitutively expressed by medial SMC but can be up regulated in response to proinflammatory 
stimuli such as TNFα, IL-1β and oxLDL (Rajavashisth, Xu et al. 1999).  This membrane bound MMP 
is thought to be crucial for the migration of SMC as an in vivo model of neointimal hyperplasia by 
carotid artery ligation showed significantly less SMC accumulation in MT1-MMP+/- mice compared to 
normal mice (Filippov, Koenig et al. 2005).  SMC constitutively express MMP-2 and proinflammatory 
stimuli also induce the expression of the active forms of MMP-1, -3 and -9 (Galis, Muszynski et al. 
1994).  Degradation of ECM may also lead to SMC proliferation as cell-matrix interactions (i.e. with 
heparan suphate proteoglycans such as perlecan) can inhibit proliferation (Bingley, Hayward et al. 
1998) (Kinsella, Tran et al. 2003).  ECM degradation can also release growth factors such as FGF-2 
and transforming growth factor β (TGFβ) sequestered in the matrix, which could stimulate SMC to 
proliferate.   
 
In advanced atherosclerosis, MMPs are thought to play a role in plaque destabilisation as they degrade 
the fibrous proteins that are needed to provide the tensile strength of the fibrous cap.  MMP-3 was the 
first MMP noted to be up regulated in plaques, compared to normal artery (Henney, Wakeley et al. 
1991).  In this study, MMP-3 was localised to SMC and macrophages.  A later study by Galis showed 
that in addition to MMP-3, MMP-1and -9 were also up regulated in plaques, localised to macrophages, 
SMC T-cells and endothelial cells (Galis, Sukhova et al. 1994).  Focal accumulation of these cells, 
such as at the shoulder areas, expressing activated MMPs promote local destruction of the ECM.  In 
carotid endarterectomy specimens, MMP-2 was associated with areas of SMC and stable plaques, 
whereas MMP-8 and -9 were detected in areas of the plaque rich in macrophages and associated with 
unstable plaques (Sluijter, Pulskens et al. 2006).  In the apoE-/- MMP-2-/- mouse, lesions of the aortic 
root and aortic arch were smaller due to reduced SMC numbers, suggesting that MMP-2 is important 
Group MMP Substrate 
Collagenases MMP-1, -8, -13, -18 Fibrillar collagen I, II and III 
Gelatinases MMP-2, -9 Type IV collagen, laminin, elastin 
Stromelysins MMP-3, -7, -10,  Fibronectin, type IV collagen, 
laminin, elastin, proteoglycans 
Membrane type MMP  
(MT-MMP) 
MT1-MMP (MMP-14),  
MT2-MMP (MMP-15),  
MT3-MMP (MMP16) 
 
Others MMP-12 (metalloelastase) elastin 
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in lesion formation (Kuzuya, Nakamura et al. 2006).  Additionally, the fibrous cap was thinner in the 
apoE-/- MMP-2-/- mice due to less collagen and SMC number, suggesting that MMP2 promotes plaque 
stability, in agreement with the observations of Sluijter.   
 
Tissue inhibitors of MMPs (TIMPs) are natural inhibitors that interact with MMPs directly controlling 
their activity.  Over expression of human TIMP-1 in apoE-/- mice on a high fat diet led to a significant 
reduction in lesion area by 32%, although lesions had increased collagen, elastin and SMC content 
compared to mice not over expressing TIMP-1 (Rouis, Adamy et al. 1999).  SMC express TIMP-1 and 
-2, which are known to inhibit MMP-2.  However, unlike MMPs their expression is not up regulated 
by proinflammatory cytokines (Galis, Muszynski et al. 1994) suggesting that the proinflammatory 
environment disrupts the balance of MMPs and TIMPs, which allows remodelling of the ECM. 
 
1.1.9 Oxidative stress 
 
Cellular oxidative stress can be defined as the imbalance between the production of reactive oxygen or 
nitrogen species and the ability of the cell to detoxify reactive intermediates and repair damage caused 
to proteins, lipids or DNA (i.e. the reduction/oxidation (redox) balance) (Valko, Leibfritz et al. 2007).  
Reactive oxygen species and reactive nitrogen species (ROS and RNS) are highly reactive and can 
react with biological macromolecules causing strand breaks in DNA, lipid peroxidation and oxidation 
or nitration of proteins which alters their function.  A major intracellular source of ROS is the 
mitochondria, where ROS are produced at complexes I and III of the electron transport chain.  
Additional sources of ROS particularly in SMC include NADPH oxidases (Nox), xanthine oxidases 
and lipoxygenases.  Low levels of reactive molecules, e.g. hydrogen peroxide (H2O2), hydroxyl radical 
(•OH), superoxide (O2-•), nitric oxide (•NO) and peroxynitrite (ONOO-), are produced naturally and 
act as second messengers in cell signalling pathways controlling differentiation, proliferation or 
apoptosis.  They’re also used as a defence mechanism against infectious agents (Valko, Leibfritz et al. 
2007).  Endogenous antioxidant proteins such as peroxidases and superoxide dismutases, constantly 
repair damage caused but at very high levels of ROS the cell’s ability to repair damage is exceeded, 
resulting in the accumulation of damaged proteins, leading to apoptosis and necrosis.   
 
In mice, increased oxidative stress has been detected at regions of the aorta prone to lesion formation 
(Haidari, Ali et al. 2010).  Additionally, gene expression of NADPH Oxidase subunits was also up 
regulated in these areas, suggesting a source of the ROS.  Cigarette smoke has also been associated 
with increased oxidative stress and mitochondrial damage.  For example, apoE-/- mice exposed to 
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second hand cigarette smoke developed larger aortic lesions compared to apoE-/- mice exposed to 
filtered air (Knight-Lozano, Young et al. 2002).  There was also increased protein nitration and 
mtDNA damage in the exposed mice, and this was significantly higher in the apoE-/- mice compared to 
wild type mice, suggesting that hypercholesterolemia accentuates the damaging effects of cigarette 
smoke.  Ageing has also been associated with increased oxidative stress.  In the ageing vasculature, 
there is evidence of the accumulation of oxidised proteins (Li and Fukagawa 2010).  Increases in 
superoxide anion O2-• levels and expression of NADPH oxidases have been correlated with increased 
medial thickness in the aorta of ageing rats (Li and Fukagawa 2010).  More interestingly, ageing has 
been shown to up regulate NFκB binding activity in mice hearts, without altering the expression levels 
of the p50 or p65 subunits or inhibitory IκB proteins (Helenius, Hanninen et al. 1996). 
 
As a consequence of being an abundant source of ROS, mitochondria are prone to ROS-mediated 
damage.  Damage to mitochondrial DNA (mtDNA) and proteins can be detrimental to mitochondrial 
function.  mtDNA is susceptible to damage by ROS due to its close proximity to the site of ROS 
production.  There is also a lack of histone proteins that protects mtDNA, and mitochondrial 
polymerases lack the base excision and repair mechanisms that the nuclear DNA polymerases possess.  
Consequently, accumulation of damaged mtDNA will impair synthesis of the proteins encoded by the 
mitochondrial genome, namely complexes of the electron transport chain.  Mitochondrial dysfunction 
is a feature of atherosclerotic lesions (Puddu, Puddu et al. 2009).  In human aortic specimens, PCR 
amplification demonstrated an increase in mtDNA damage in atherosclerotic tissue compared to non-
atherosclerotic tissue (Ballinger, Patterson et al. 2002).  Even more importantly, mitochondrial 
dysfunction is thought to contribute to inflammation and lesion formation at early stages.  In 3-week-
old apoE-/- mice, which have not yet developed lesions, there were significantly increased levels of 
mtDNA damage compared to age-matched apoE+/+ controls (Ballinger, Patterson et al. 2002).  In vitro 
studies in human aortic SMC have shown that mitochondrial damage can be induced by peroxynitrite 
and superoxide (Ballinger, Patterson et al. 2000).  Stimulation with peroxynitrite also decreased 
mitochondrial function, as demonstrated by reduced ATP production and decreased MTT reduction 
(which measures reduction of mitochondrial complex II).   
 
1.1.10 Endoplasmic Reticulum Stress and the Unfolded Protein response 
 
Endoplasmic reticulum (ER) stress is also a feature of atherosclerosis (Hotamisligil 2010) as well as 
other diseases such as metabolic syndrome, diabetes, cancer and Alzheimer’s disease (Hotamisligil 
2010).  ER stress can be defined as a ‘perturbation that compromises the protein folding functionality 
of the ER’ (Rutkowski and Kaufman 2007).  As the ER is the main site of protein folding, lipid 
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metabolism and calcium storage, disruption of these processes can influence normal cellular function 
and cell survival.  Stimuli that challenge the function of the ER (such as glucose deprivation, hypoxia 
or high fat diet) can induce ER stress. 
 
ER stress can influence the progression of atherosclerosis.  For example, ER stress can be linked to 
production of proinflammatory mediators and reactive oxygen species, altered lipid metabolism and 
altered insulin production.  Additionally, as the ER is also the site of processing and presentation of 
MHC class I proteins, ER stress can have detrimental effects on the immune system (Hotamisligil 
2010).  ER stress is particularly detrimental for macrophages as they engulf modified lipoproteins and 
saturated fatty acids.  Free cholesterol accumulation in macrophages can lead to apoptosis (Tabas 
1997) (Feng, Yao et al. 2003).   
 
In response to ER stress, the unfolded protein response (UPR) is activated (Rutkowski and Kaufman 
2007).  This encompasses an adaptive response to restore the balance of unfolded proteins.  Genes 
encoding for ER chaperones such as glucose related protein-78 (GRP-78, also known as 
immunoglobulin-binding protein or BiP, or HSPA5) are up regulated to enhance the protein folding 
function of the ER.  Translation of other new mRNAs is inhibited to allow the synthesis of chaperone 
proteins.  Three proteins in the ER membrane sense ER stress and are crucial during the UPR; Inositol 
requiring enzyme 1α (IRE1α), pancreatic ER eIF2α kinase (PERK) and activating transcription factor 
6α (ATF6α). These proteins are thought to be bound to GRP-78 and dissociate during times of stress 
to induce different signalling pathways of the UPR (Ron and Walter 2007).  For example, IRE1α 
induces transcription of genes for chaperones, lipid synthesis and ER degradation proteins.  IRE1α can 
also bind TRAF-2, which then activates the JNK MAP kinase pathway, leading to caspase activation 
and cell death (Ron and Walter 2007).  Activation of PERK under ER stress leads to the 
phosphorylation of eukaryote initiation factor 2α (eIF2α), which decreases translation of new 
mRNAs, thereby reducing the burden on the ER (Kim, Xu et al. 2008).  ATF6 is released into the 
cytoplasm when it dissociates from GRP-78 under conditions of ER stress.  It is transported to the 
Golgi and cleaved by resident proteases and a specific ATF6 fragment can then translocate to the 
nucleus and activate expression of genes involved in the inflammatory response (Ron and Walter 
2007).   
 
The UPR has been implicated in the pathogenesis of several diseases including Parkinson’s disease, 
Alzheimer’s disease, bipolar disorder, cancer, diabetes as well as atherosclerosis (Kim, Xu et al. 
2008).  Markers of UPR activation have been found at all stages of atherosclerosis in the apoE-/- 
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mouse, from early lesion macrophage foam cells, to those in advanced lesions (Zhou, Lhotak et al. 
2005).  However, apoptosis was not associated with UPR activation in early lesions suggesting the 
cells have some degree of adaptation to ER stress.   
 
1.1.11 Plaque rupture 
 
Morphological analyses from autopsy samples have shown us that the main cause of death in 
atherosclerotic coronary disease is due to plaque rupture (Davies 1992).  Davies showed that 73% of 
sudden coronary deaths were a result of plaque rupture, 8% were due to intra-plaque haemorrhage and 
the remaining 19% showed no evidence of thrombi (Davies 1992).  The composition of the ‘culprit 
lesion’ is more important than the size of the plaque or the amount of stenosis it causes in determining 
the plaque vulnerability.  Plaques most vulnerable to rupture have been categorised as a ‘thin-capped 
fibroatheroma’ (TCFA).  TCFAs have a fibrous cap less than 65µm thick infiltrated with macrophages 
(Burke, Farb et al. 1997).  There are also fewer SMC and less ECM, and there is a large lipid/necrotic 
core (Virmani, Kolodgie et al. 2000).  The size of the necrotic core appears to correlate with the risk of 
rupture and thrombosis (Falk, Shah et al. 1995).   
 
Plaque rupture often occurs at the shoulder region of the plaque - the junction between the plaque and 
the non-diseased vessel wall.  This area of the fibrous cap is often infiltrated by activated macrophages 
and T-cells as shown by van der Wal, et al indicating that inflammation plays a role in plaque rupture 
(van der Wal, Becker et al. 1994).  Mast cells have also been shown to be increased at the site of 
plaque rupture (Kaartinen, Penttila et al. 1994).  Mast cells and macrophages produce proteolytic 
enzymes, which degrade the ECM, therefore weakening the cap and increasing its vulnerability to 
rupture.   
 
Plaque erosions account for approximately 25-40% of coronary thrombi.  Erosions are characterised 
by thrombus formation despite no evident rupture of the fibrous cap and contact of the thrombus with 
the lipid pool (Farb, Burke et al. 1996).  Endothelial cells may be lacking and these plaques generally 
have a thick (and intact) fibrous cap.  Plaque erosions are more common in people below 50 years of 
age and are associated with smoking especially in pre-menopausal women (Farb, Burke et al. 1996; 
Virmani, Kolodgie et al. 2000).   
 
In carotid atherosclerotic disease, plaque rupture and the ensuing thrombosis is the main cause of 
ischemic stroke (Spagnoli, Mauriello et al. 2004).  Spagnoli, et al showed that thrombotically active 
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plaques were observed in 74% of patients with ipsilateral stroke.  Plaque rupture was present in 90% 
of those thrombosed plaques, with plaque erosion accounting for the other 10% (Spagnoli, Mauriello 
et al. 2004).  Additionally, there were increased inflammatory cells in the ruptured plaques compared 
to those plaques from patients who experienced trans-ischemic attack (TIA) or asymptomatic patients.  
As in coronary artery disease, the degree of stenosis does not appear to correlate with complications of 
atherosclerosis.  Symptomatic carotid plaques have increased numbers of macrophages, T cells and 
foam cells (Carr, Farb et al. 1996; Jander, Sitzer et al. 1998), again indicating that inflammation plays 
a role in plaque destabilisation, similar to coronary artery disease (van der Wal, Becker et al. 1994).  
High flow rates and the changes in shear stress at the carotid bifurcation give carotid plaques unique 
properties, not seen in coronary plaques.  For example, ulceration of carotid plaques is often seen, 
where part of the thrombus and plaque have embolised.  Total occlusion of the artery is less common 
compared in the carotid artery, probably due to increase blood flow rates (Virmani, Ladich et al. 
2006).  Plaque haemorrhage occurs more frequently in carotid plaques, which may lead to progression 
of the plaque and development of a larger necrotic core (Takaya, Yuan et al. 2005).   
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1.2 Smooth Muscle Cells 
 
In the normal artery, SMC are found in the media tunica layer, below the intimal layer containing 
primarily endothelial cells.  SMC are arranged in layers surrounded by elastic lamellae.  The internal 
elastic lamina separates SMC from endothelial cells and the external elastic lamina forms the 
boundary between the media and the adventitia, the outer layer of the artery wall, which contains 
fibroblasts, nerve fibres, connective tissue and the vasa vasorum.   
 
The principal function of vascular smooth muscle cells is the contraction and regulation of blood 
vessel tone, blood pressure and blood flow distribution (Owens, Kumar et al. 2004).  To fulfil this role, 
the cytoplasm of SMC contains large filaments of actin and myosin (Chamley-Campbell, Campbell et 
al. 1979) and contractile proteins make up a large percentage of total protein.  During development, 
SMC proliferate and synthesise extracellular matrix to stabilise newly formed vessels.  In adults, SMC 
proliferation occurs at extremely low rates and SMC exhibit low synthetic activity.  They express a 
unique repertoire of proteins specific for their contractile function.  In contrast to skeletal and cardiac 
muscle cells, vascular SMC are not terminally differentiated and retain a level of plasticity allowing 
them to undergo reversible changes in phenotype in response to changes in their local environment. 
This characteristic may have evolved to allow repair of the artery after injury (Owens 1995).  
Chamley-Campbell & Ross originally coined the term “phenotypic modulation” in 1979 to describe 
their observations that SMC change from a predominantly contractile state to a predominantly 
synthetic or mitotic state (Chamley-Campbell, Campbell et al. 1979).  Since then, this term has been 
used to describe the range of phenotypes adopted by SMC including that found in atherosclerotic 
SMC.  Phenotypic modulation of SMC is a dynamic and reversible process. 
 
The cytoplasm of the contractile SMC is filled with filaments, containing actin, tropomysoin and 
myosin.  The organelles are found at the periphery of the cell.  Early electron microscopy studies 
showed that the presence of many vesicles, which were thought to be important for calcium 
accumulation (Chamley-Campbell, Campbell et al. 1979).  The sarcoplasmic reticulum is a calcium 
store, required for contraction of the cells.  In contrast, the synthetic SMC exhibit fewer contractile 
filaments and increased number of organelles for synthesis throughout the cytoplasm; endoplasmic 
reticulum, Golgi apparatus, ribosomes and mitochondria, resembling that of SMC in development 
(Chamley-Campbell, Campbell et al. 1979).  Thus, phenotypic modulation is often considered a 
reversion to a developmental phenotype (Owens 1995). 
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1.2.1 Markers of SMC development 
 
The complexity of SMC differentiation and lack of specific SMC markers has confounded efforts to 
understand mechanisms that control SMC differentiation.  As a result, phenotypic characterisation of 
SMC has traditionally been a challenge, relying on morphological criteria (e.g. ‘spindle’ shape and 
‘hill and valley’ growth pattern) and a limited range of differentiation and lineage markers.  Logical 
candidates for SMC differentiation markers are contractile proteins.  SMC express large amounts of 
actin isoforms, with smooth muscle α-actin (αSMA) making up 40% of the total protein in SMC 
(Owens 1995).  However, use of αSMA as a marker of SMC identity alone is insufficient as other cell 
types express αSMA.  αSMA can be expressed by a variety of different cell types such as activated 
fibroblasts (myofibroblasts) in healing wounds, and tumours and endothelial cells in micro-vessels. 
 
Myosin heavy chains are the only SMC marker considered to be solely expressed by vascular SMC.  
Myosin is an essential component of the contractile apparatus.  It is a hexamer, composed of two 
myosin heavy chains (MHC), two light chains and two regulatory chains.  SMC are thought to express 
two smooth muscle specific and two non-muscle variants of the heavy chains.  Early work on the 
characterisation of SM-MHC was performed using the aortas from rabbits as a model (Kuro-o, Nagai 
et al. 1991).  The smooth muscle cell specific MHC (SM-MHC) chains SM1 and SM2 are produced 
by alterative splicing of the same gene.  These proteins are developmentally regulated, with SM1 
being expressed constitutively at all stages of development whereas SM2 expression appears after 
birth but then decreases with age (Aikawa, Sivam et al. 1993) (Figure 1.3).  A third SM-MHC isoform, 
SMemb was detected in rabbit embryonic SMC but down regulated after birth (Kuro-o, Nagai et al. 
1991).  SMemb, which is the same as the non-muscle myosin heavy chain IIB (NM-MHCIIB) was 
also found to be re-expressed in proliferating neointimal SMC in rabbit models of experimental 
atherosclerosis (Kuro-o, Nagai et al. 1991).  A similar characterisation of SM-MHC expression was 
performed in human arteries.  Aikawa reported that SM1 and SMemb protein were detected in the 
aorta and coronary arteries of developing foetuses and the adult aorta, but SM2 was only detected in 
the adult aorta, despite low levels of mRNA detected in the foetuses (Aikawa, Sivam et al. 1993).  
Levels of SMemb were lower in the adult compared to foetus.  In intimal SMC of atherosclerotic 
arteries, SMemb levels were decreased, but were still positive for SM1 and αSMA (Aikawa, Sivam et 
al. 1993).   
 
These studies demonstrate that SM-MHC could be useful differentiation markers of SMC.  The 
expression of SM1 is constitutive and therefore could be used as a marker for SMC identification, as it 
does not appear to be expressed by other cell types.  SM2 is expressed in adult SMC but decreased in 
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intimal SMC, suggesting that intimal SMC have de-differentiated.  Conversely, SMemb is expressed 
at higher levels in the foetus compared to adult, therefore the presence of this marker in intimal SMC 
suggest it may be a marker of a developmental SMC phenotype.   
 
Other proteins have also been noted as developmental markers of SMC, although their expression has 
also been detected in other cell types such as fibroblasts, cardiomyocytes and various tumour cells.  
Such proteins include calponin, SM22α and caldesmon (Owens 1995).  There are two isoforms of 
calponin, high molecular weight calponin (h1-calponin) and low molecular weight calponin (l-
calponin) with molecular weights of 34 and 28kDa respectively.  Calponin interacts with F-actin and 
tropomyosin and is thought to be involved in the regulation of SMC contraction, although its 
mechanism has not been elucidated (Winder, Sutherland et al. 1991).  The function of SM22α is 
unknown, although it contains sequence motifs homologues to calponin (Nishida, Kitami et al. 1993).  
Both of these proteins are detected at very early stages of development and have been detected in 
chick aortas at just 4- days of embryonic development.  H1-Caldesmon is detected at later stages of 
development compared to SM22α.  The expression of SMC differentiation markers during SMC 
development is shown in Figure 1.3.  
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Figure 1.3 Development of vascular smooth muscle cells and expression of differentiation 
markers.  The smooth muscle cell contractile proteins are expressed at different points during 
development and before birth.  SM2 expression is not detected until after birth.  Dotted line represents 
de-differentiation of SMC during atherosclerosis, where SMC may revert to a less differentiated 
phenotype and expression of these SMC proteins are altered compared to a more fully differentiated 
SMC.  (Modified from Owens, Regulation of differentiation of Vascular Smooth Muscle Cells, 
Physiological Reviews, 1995) 
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1.2.2 SMC in atherosclerosis 
 
The phenotypic modulation of SMC in atherosclerosis is the best-characterised example of phenotypic 
modulation.  SMC are one of the predominant cell types found in the plaque.  They make up much of 
the bulk of the plaque and their behaviour affects the progression and stability of the plaque.  SMC in 
the atherosclerotic intima are considered non-contractile, synthetic cells with fewer actin filaments 
than medial SMC.  SMC also undergo changes in their differentiated phenotype when grown in vitro 
as they are removed from their normal environment (Chamley-Campbell, Campbell et al. 1981).  Loss 
of contractile phenotype of SMC in vitro has been shown to be potentially reversible with SMC 
reverting back to their contractile phenotype upon serum withdrawal or treatment with heparin 
(Okamoto, Imataka et al. 1992) (Clowes, Clowes et al. 1988).  Intimal SMC have a diverse range of 
phenotypes, which alters over the course of the disease as the intimal environment changes.  
Proliferation and migration can be considered as ‘early’ characteristics of SMC in atherosclerosis, 
while senescence and apoptosis are characteristics observed in later stages of atherosclerosis.  These 
features are discussed in more detail below.   
 
1.2.2.1 SMC Proliferation 
 
Proliferation rates of SMC in vivo are in fact relatively low (Gordon, Reidy et al. 1990) and 
proliferation rates of SMC from advanced plaques are slower than that of non-diseased medial SMC 
(Bennett, Evan et al. 1995).  Nevertheless, low rates of proliferation over the many decades in which a 
plaque takes to form, may contribute to a large number of SMC in the plaques.  Early studies revealed 
that SMC of the contractile phenotype do not proliferate (Chamley-Campbell, Campbell et al. 1981) 
and proliferation is accompanied by a decrease in αSMA expression (Clowes, Clowes et al. 1988) 
(Jovinge, Hultgardh-Nilsson et al. 1997).  Organisation of the ECM in the media is vital for 
maintaining the contractile phenotype (Hultgardh-Nilsson and Durbeej 2007).  Disruption of the 
contacts between SMC and ECM via inhibition of integrins has been shown to increase proliferation 
(Welser, Lange et al. 2007).  Cell-cell contacts are also important in the inhibition of proliferation 
(Uglow, Slater et al. 2003). 
 
Proliferation can be induced by growth factors or proinflammatory stimuli.  In addition to its effects 
on migration PDGF is also a potent stimuli for SMC proliferation (Chamley-Campbell, Campbell et al. 
1981; Blank and Owens 1990).  PDGF is produced by SMC and it acts in an autocrine or paracrine 
manner to induce SMC proliferation (Libby, Warner et al. 1988).  TNFα can induce SMC proliferation 
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(Goetze, Xi et al. 1999) although it can also induce apoptosis (Niemann-Jonsson, Ares et al. 2001).  
Interestingly, the proinflammatory cytokine MIF appears to be a potent inducer of SMC proliferation.  
MIF-/- LDLR-/- mice do not develop advanced lesions containing SMC, compared to LDLR-/- mice 
(Pan, Sukhova et al. 2004).  In contrast IFNγ inhibits proliferation of SMC (Hansson and Holm 1991) 
(Hansson, Holm et al. 1991). 
 
1.2.2.2 SMC Migration 
 
SMC migration is an important step in plaque formation.  Medial SMC must migrate through the 
internal elastic lamina to get into the intima.  Proteolytic enzymes such as the MMPs promote matrix 
degradation allowing the migration of SMC.  Membrane bound MT1-MMP is required for this action 
(Filippov, Koenig et al. 2005).  SMC constitutively express MMP-2 but proinflammatory stimuli 
further up regulate MMP expression (Galis, Muszynski et al. 1994) as described in section 1.1.8.3.  
Cell-cell interactions can also induce MMP expression.  For example, T-cells have been shown to 
induce expression of MMP-1, -2, -3 and 9 in SMC via CD40/CD40L interactions (Schonbeck, Mach et 
al. 1997). 
 
Many soluble factors can stimulate SMC migration including basic fibroblast growth factor (bFGF), 
TGFβ, TNFα, IL1β and thrombin (reviewed in (Gerthoffer 2007)).  Platelet derived growth factor 
(PDGF) is a potent inducer of SMC migration (Jawien, Bowen-Pope et al. 1992) (Raines 2004).  
PDGF can be produced by several cell types including macrophages, endothelial cells and platelets, as 
well as intimal SMC.  Interestingly simvastatin has been shown to inhibit PDGF-mediated SMC 
migration (Hidaka, Eda et al. 1992).  Several chemokines have been associated with SMC migration.  
CCR2 deficient mice subjected to femoral arterial injury exhibited a 60% reduction in intima size and 
a similar reduction in intimal:medial thickness compared to control mice, which was attributed to 
decreased SMC migration and proliferation (Roque, Kim et al. 2002).  Similarly, deficiency of the 
ligand for CCR2, MCP-1, resulted in a 30% reduction in intimal hyperplasia (Kim, Chereshnev et al. 
2003).  Stromal cell derived factor 1α (SDF1α) has also been implicated in the migration of SMC, 
with SDF1α neutralisation resulting in 21% reduction in SMC in the neointima (Schober, Knarren et 
al. 2003).   
 
Interaction with the surrounding matrix is important for migration just as it is for proliferation (Raines 
2000).  Culture of SMC on fibrillar collagen leads to inhibition of SMC proliferation and migration, 
but upon culture with other ECM components, SMC undergo phenotypic modulation and are no 
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longer quiescent (Owens 1995).  Glycosaminoglycans such as heparin also inhibit migration (Clowes 
and Karnowsky 1977).  Deficiency of syndecan, a heparin sulphate proteoglycan led to increased 
noeintima production in mice subjected to carotid ligation (Fukai, Kenagy et al. 2009).  
 
1.2.2.3 Apoptosis and Senescence 
 
Both cell senescence and apoptosis are features of atherosclerotic plaques. Cell senescence can be 
defined as a withdrawal from the cell cycle and exhausted replicative capacity (Gorenne, Kavurma et 
al. 2006).  The proliferation capacity of SMC in atherosclerosis may be somewhat limited as SMC in 
advanced plaques show signs of senescence (reviewed in (Gorenne, Kavurma et al. 2006)).  Plaque 
SMC derived from human coronary artery specimens express markers of cell senescence and have 
disrupted cell cycle regulation, with a decrease in the phosphorylation of retinoblastoma protein 
(pRB), which is required for cell cycle entry (Matthews, Gorenne et al. 2006).  Telomere length is also 
shorter in plaque SMC compared to medial SMC from the same vessel.  Although this is likely to be 
due to an increase in replication during earlier lesion development, oxidative DNA damage may also 
accelerate telomere loss, which then leads to growth arrest.   
 
Apoptosis is ‘programmed cell death’ which occurs via activation of cell signalling pathways either 
from external or internal influences.  Apoptotic cells display changes in morphology such as 
membrane shrinking, chromatin precipitation and formation of membrane vesicles.  Apoptotic cells 
are phagocytosed by neighbouring cells.  Apoptosis has been detected in atherosclerotic plaque by 
terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) labelling and co-
localised with SMC, macrophages and T-lymphocytes (Kockx 1998).  In early lesions, apoptosis is 
thought to be a mechanism to modulate plaque volume.  However, in advanced atherosclerosis 
apoptosis can influence plaque stability.  Apoptosis of SMC in the fibrous cap is detrimental to the 
stability of the plaque as SMC are the only cells to synthesise ECM proteins.  Reduction in SMC 
numbers will reduce ECM production, which in turn will weaken the fibrous cap making it prone to 
rupture, as described in section 1.1.11.   
 
Much of the work by Bennett and colleagues has focused on the apoptosis of SMC.  In vitro studies of 
cultured SMC isolated from human coronary arteries, demonstrated that plaque SMC experience 
increased rates of apoptosis, even in high serum conditions (Bennett, Evan et al. 1995).  Levels of 
apoptosis could be reduced by the addition of cytokines such as PDGF-BB and insulin like growth 
factor-1 (IGF-1), but bFGF and EGF had no effect.  Induction of SMC specific apoptosis in the apoE-/- 
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mouse resulted in development of a vulnerable plaque phenotype characterised by loss of ECM and 
thinning of the fibrous cap (Clarke, Figg et al. 2006).  Additionally, there was impaired clearance of 
apoptotic debris and increased accumulation of inflammatory cells.  In contrast, SMC apoptosis in 
normal arteries of the apoE-/- mouse appeared to be silent, with efficient clearance of apoptotic cells 
and no inflammation, suggesting that debris is cleared by neighbouring SMC.  In the plaque, areas of 
SMC apoptosis co-localises with areas of inflammation suggesting that inflammatory cells can induce 
apoptosis.  Macrophages can induce SMC apoptosis by direct cell-cell contact via the interaction of 
Fas/FasL (Boyle, Bowyer et al. 2001).  Fas expression is increased in plaque SMC compared to medial 
SMC (Geng, Henderson et al. 1997) and stimulation of SMC with interferon-gamma (IFNγ) was 
shown to increase Fas expression at the cell surface (Geng, Henderson et al. 1997) (Rosner, Stoneman 
et al. 2006).   
 
1.2.3 Origins of Intimal SMC 
 
The paradigm that atherosclerotic intimal SMC originate from the media and have undergone a 
phenotypic modulation is still the most influential in conceptualising the differences between intimal 
and medial SMC.  However, there are other proposed models suggesting that intimal SMC may also 
be derived from the adventitia or progenitor cells.    
 
The concept of monoclonal origins of SMC was first suggested by Benditt and Benditt (Benditt and 
Benditt 1973), for which each lesion is derived from the proliferation of a single SMC.  Such theory 
has recently been revisited with suggestions that intimal lesions derive from pre-existing distinct SMC 
sub-populations in the normal arterial wall, which differ in their morphology and expression of 
differentiation markers as shown by differences in the expression levels of SM-MHC isoforms in 
normal artery walls (Okamoto, Imataka et al. 1992).  SMC with different morphologies, ‘spindle’ and 
‘epithelioid’ shape SMC obtained from porcine arteries were shown to have different rates of 
proliferation (Hao, Ropraz et al. 2002).  Different subtypes of SMC were also cloned from human 
internal thoracic arteries where ‘spindle’ shape SMC and ‘epithelioid’ SMC exhibited different 
expression levels of SMC markers, different proliferative abilities in the presence of serum and also 
different migratory abilities (Li, Fan et al. 2001).  Such specific subpopulations of SMC, with 
enhanced migratory and proliferative capacities may be involved in the pathogenesis of 
atherosclerosis.   
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Some authors have even likened such populations of SMC to the myofibroblast, an activated fibroblast 
found in wound healing and fibrotic diseases (Hao, Gabbiani et al. 2006).  Myofibroblasts express a 
repertoire of contractile proteins such as αSMA (Desmouliere, Geinoz et al. 1993) and also calponin 
and SM22α (Owens, Kumar et al. 2004).  However, studies have shown that the transcriptional control 
of αSMA is different in these two cell types (Gan, Yoshida et al. 2007).  TGFβ induces expression of 
αSMA in myofibroblasts (Desmouliere, Geinoz et al. 1993).  Similar responses to TGFβ are seen in 
SMC as well as inhibition of proliferation and migration (Christen, Bochaton-Piallat et al. 1999).  This 
has fuelled controversy into whether myofibroblasts and SMC are in fact the same cell type (Zalewski 
and Shi 1997).  A noteworthy difference in SMC and myofibroblasts appears to be that while SMC 
must down regulate their contractile proteins for migration and proliferation, myofibroblasts must 
acquire expression of contractile proteins in order to migrate (Sartore, Chiavegato et al. 2001). 
 
Adventitial fibroblasts may migrate inwards after arterial injury.  Adventitial fibroblasts labelled with 
β-galactosidase genes were transferred to the adventitia of rat carotid arteries immediately following 
balloon injury (Li, Chen et al. 2000).  These cells were detected in the media and intima within 4 and 7 
days respectively, whereas labelled cells in uninjured mice were only detected in the adventitia.  
 
Heterogeneity in SMC may be due to differences in their developmental origins, which have resulted 
in a mosaic of SMC in the arterial tree.  SMC from different embryonic developmental origins have 
been found to respond to stimuli differently even when tested under the same experimental conditions 
(Tomanek 2005; Majesky 2007).  Fate mapping has shown that there may be differences in the origin 
of the cells within one artery or one segment of artery.  For example, the coronary arteries, although 
continuous with the aortic lumen, are formed from vasculogenesis within the epicardium and then 
invade the aorta, rather than developing as outgrowths of the aorta (Tomanek 2005) whereas carotid 
artery SMC are thought to derive from neural crest (Majesky 2007). 
 
1.2.4 Smooth Muscle Cell Progenitors 
 
Stem cells have attracted a lot of interest due to their potential therapeutic benefits in the repair of 
regeneration of tissues.  Smooth muscle cell progenitors (SPC) have been implicated in the 
pathogenesis of atherosclerosis.  Circulating SPCs have been identified in the peripheral blood of 
patients with CAD (Sugiyama, Kugiyama et al. 2006).  Moreover, SPC were decreased in patients 
with ACS compared to those with stable angina suggesting they may play a role in plaque stability 
(Zoll, Fontaine et al. 2008).  In humans, SPC can be identified as expressing markers for CD105, 
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calponin, αSMA, SM22, SM-MHC and PDGFR-β.  In mice, progenitor cells can be identified by the 
markers Sca1+, c-kit, CD34 and flk-1 (Hristov and Weber 2008).   
 
Mobilisation of SPC from the bone marrow is thought to involve SDF-1α, also known as CXCL12, 
expressed on SMC.  In the apoE-/- mouse, carotid arterial injury results in the up regulation of SDF-1α 
expression in SMC as well as an increase in circulating SDF-1α levels (Schober, Knarren et al. 2003).  
Additionally, SDF-1α neutralisation with an anti-SDF antibody, for 3 weeks resulted in decreased 
neointimal area compared to the isotype control treated animals, with a significant decrease in SMC 
number but no difference in macrophage number (Schober, Knarren et al. 2003).  Arterial injury also 
resulted in an increase in circulating Sca1+ progenitor cells in the peripheral blood, which was also 
mediated by SDF-1α, suggesting it is involved in the homing of progenitor cells to sites or arterial 
injury.  Furthermore, SDF-1α is reduced in patients with unstable angina compared to healthy control 
subjects (Damas, Waehre et al. 2002).  This study also showed that in vitro, SDF-1α could act as an 
anti-inflammatory agent reducing the expression of MCP-1, IL-8, MMP-9 and tissue factor in 
peripheral blood mononuclear cells from patients with unstable angina.   
 
Studies suggest that some intimal SMC present in atherosclerotic lesions or neointima after arterial 
injury may originate from bone marrow-derived progenitor cells (Sata, Saiura et al. 2002).  Using bone 
marrow transplantation (BMT) techniques, with donor mice expressing green fluorescent protein 
(GFP) or LacZ/β-galactosidase, Sata et al could identify whether bone marrow derived cells were 
present at the sites of arterial injury, atherosclerotic plaques or in allografts.  In all these models, bone 
marrow derived cells were present and they had also differentiated into either SMC, as shown by 
immunostaining for the SMC markers αSMA, SM-MHC and calponin, or macrophages, as shown by 
the expression of MOMA-2, or endothelial cells shown by CD31 expression.  Additionally, autopsy 
analysis of human coronary arteries, from patients who had previously undergone sex mismatched 
BMT showed that atherosclerotic regions of coronary arteries were enriched with SMC of donor 
origin, compared to non-atherosclerotic regions of the same artery (Caplice, Bunch et al. 2003). 
 
More recent studies have investigated whether SPCs play a protective role in atherosclerosis.  Zoll et 
al injected human endothelial progenitor cells (EPCs) and SPCs and into ApoE-/- Rag2-/- mice (Zoll, 
Fontaine et al. 2008).  (Rag2 deficiency results in a deficiency of T-lymphocytes and B-lymphocytes 
making the mice immuno-tolerant to human cells)  Injection of SPCs just one week after starting a 
high fat diet led to a significant decrease (42%) in plaque area compared to PBS controls.  The area 
staining positive for macrophages was also significantly reduced.  Interestingly in more advanced 
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plaques, the injection of SPCs did not affect plaque area, although collagen levels were increased.  
These results suggest that SPC may affect development of atherosclerosis and also influence plaque 
stability.  This correlated with their other finding that SPC are decreased in the peripheral blood of 
patients with acute coronary syndrome (ACS) compared to stable angina (Zoll, Fontaine et al. 2008).   
 
However, other studies have found no contribution of bone marrow derived progenitor cells to the 
process of atherosclerosis.  In an experiment involving bone marrow transfer from GFP+ ApoE-/- mice 
to ApoE-/- no GFP+ SMC could be detected in the lesions suggesting that SMC in the atherosclerotic 
vessel wall originate from the vessel wall (Bentzon, Weile et al. 2006).  Furthermore, a study by the 
same group investigating whether bone marrow-derived SPCs are recruited to the lesions after plaque 
rupture, again could not detect any GFP+ SMC in lesions of advanced plaques (Bentzon, Sondergaard 
et al. 2007).  Consequently, the contribution of SPC to atherosclerosis remains unclear.  Differences in 
the outcome of these studies mentioned could be due to low-resolution confocal microscopy and 
reliance on αSMA as a marker for SMC (Hoofnagle, Thomas et al. 2006).  It is conceivable that a 
population of SPC is present to assist in vascular repair in case of injury, allowing medial SMC to 
maintain the contraction of artery.  Circulating SPCs have been cultured from human peripheral blood 
(Simper, Stalboerger et al. 2002) and increased in the circulation of patients with CAD, compared to 
controls (Sugiyama, Kugiyama et al. 2006).  
 
The adventitia may also be a source of SPCs, which contribute to atherosclerosis.  Sca1+ c-kit+ 
progenitor cells were identified in the adventitia of the aortic root in apoE-/- mice (Hu, Zhang et al. 
2004).  When these cells carrying the LacZ gene were transferred into the adventitia of transplanted 
vein grafts in apoE-/- mice, these cells migrated from the adventitia to the intima constituting a large 
proportion of neointimal cells.   
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1.3 Proteomics 
 
The proteome can be defined as the entire complement of proteins expressed by the genome and 
present in a cell, tissue or organism (Mallick and Kuster 2010).  The term “proteome” was originally 
first used 15 years ago, to describe the protein complement of the genome from the smallest known 
self-replicating organism Mycoplasma genitalium (Wasinger, Cordwell et al. 1995). The study of the 
proteome is termed “proteomics” and encompasses protein expression, structure, function, cellular 
localisation, modifications and interactions (de Hoog and Mann 2004).  It complements other levels of 
study such as genomics, the study of the genome, which includes genome sequencing as well as 
micro-array based expression profiling.  There is enormous molecular complexity to the proteome. 
The proteome is dynamic with developmental and temporal specificity, changing between the different 
tissues of an organism, and in response to drugs and disease.  Additionally, there is great variability in 
the dynamic range of concentrations between proteins as well as proteins being subject to varying 
post-translational modifications, adding to the complexity of functional protein studies.  Despite these 
challenges, proteomics is becoming an integral part of biological research.  The number of proteomic 
publications has grown exponentially in the past 10 years (Mallick and Kuster 2010).  Large-scale 
studies of proteins allow hypothesis-independent studies to be conducted, in that the proteins that are 
eventually identified to play a role in a process may have been thought previously to be unrelated to 
such a process.  Proteomics does not require the use of reagents specific to each protein, such as 
antibodies.  
 
Proteins confer the main biological functions of cells.  Although mRNA levels can give some 
indication of the level of protein expression between two states, there is no necessary correlation 
between mRNA and protein levels due to differential mRNA stability, protein stability and half life.  
Post-translational modifications of proteins can regulate cellular processes, e.g.; signal transduction 
pathways, targeting of protein for localisation within the cell or its secretion and also for its own 
destruction, none of which can be easily predicted with great accuracy by knowing primary sequence 
alone.  Protein concentration and interactions with other proteins are also crucial to their function.    
 
A typical proteomic workflow is shown in Figure 1.4, showing how proteins are identified from the 
initial protein separation to mass spectrometry and then bioinformatics.  Each part of this workflow is 
discussed in more detail below.   
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Figure 1.4 Schematic diagram representing the workflow from cell culture to identification of 
proteins.  Proteins from cell preparations are separated by electrophoresis or other methods and are 
then digested into smaller peptides.  Peptides are ionised and passed into the mass spectrometer 
providing information on their mass. Peptide sequences are matched to protein sequences held in 
databases.  Taken from Steen and Mann, Nature Medicine 2004 
 
 
1.3.1 Two-dimensional electrophoresis 
 
Two-dimensional gel electrophoresis (2DE) is a high-resolution technique developed in the early 
1970s (O'Farrell 1975).  It is based on the principal that by using two independent parameters of 
molecular weight and iso-electric point (pI) proteins can be resolved into individual spots, resulting in 
a defined pattern of protein spots.  In the first dimension of 2DE, proteins are separated by their 
isoelectric point, which is the pH at which the net charge of the protein is zero.  At this point, they can 
no longer migrate through a pH gradient.   
 
Early pH gradients were prepared in polyacrylamide gels cast in narrow tubes containing carrier 
ampholytes.  The pH gradients were unstable and used to drift towards the cathode, limiting the 
reproducibility of separation in the first dimension.  The development of the immobilised pH gradient 
(IPG) in 1982 allowed the pH gradient to remain stable and the first dimension to become more 
reproducible (Bjellqvist, Ek et al. 1982).  The IPG also had a high loading capacity and was cast onto a 
plastic backing making it easy to handle.  Today, a variety of pH ranges are commercially available to 
meet the needs of the researcher.  Narrow pH ranges enable increased resolution of protein separation 
enabling identification of low abundant proteins.   
 
The second dimension is SDS polyacrylamide gel electrophoresis (SDS-PAGE), which separates 
protein by their molecular mass.  Resolution of hundreds of individual proteins can be achieved in 
2DE from a few hundred micrograms of protein (Gorg, Weiss et al. 2004).  Proteins can be detected 
by gel staining methods with dyes such as Coomassie brilliant blue, which is easy and very rapid.  
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Other stains include silver staining, which uses silver nitrate, is more sensitive than Coomassie 
brilliant blue thus detecting smaller amounts of proteins, even in the femto-molar range (Chevallet, 
Luche et al. 2006) and is also compatible with mass spectrometry (Yan, Wait et al. 2000; Miller, 
Crawford et al. 2006).  Fluorescent stains are also commonly used, such as SYPRO-red and SYPRO -
orange, which are just as sensitive as silver staining, but staining is quicker (Sasse and Gallagher 
2009).  Phosphorylated proteins can be detected by Pro-Q Diamond, which is useful for studying 
phosphorylation of proteins such as those in signalling pathways where tyrosine and serine 
phosphorylation is important (Sasse and Gallagher 2009).   
 
The volume of the spot on the gel is proportional to the concentration of the corresponding protein, 
enabling quantitative differences to be found.  Computer software programmes that can analyse gel 
images and quantify differences in spot patterns and volumes of spots are providing a reliable method 
to quantitatively analyse proteomic data (Faergestad, Rye et al. 2007).    
 
One of the main advantages of 2DE is that it enables detection of the presence of post-translational 
modifications (PTMs) such as phosphorylation or acetylation, as they lead to a change in the charge of 
the protein, so creating shift of the protein from one location on the gel to another (Gorg, Weiss et al. 
2004).  PTMs such as phosphorylation are important as they are used by cells to alter signalling 
pathways.  Such modifications are not detectable in genetic based approaches.  However, it is 
important to bear in mind that other methods of detection are needed to determine the nature of the 
modification, such as mass spectrometry or western blotting with specific antibodies.  Limitations of 
2DE include poor resolution of very large, very acidic or very basic proteins.  Integral membrane 
proteins are not readily amendable to 2DE as they are large and very hydrophobic and can be difficult 
to solubilise.  Proteins that co-migrate in the same spot may hinder quantification by scanning 
densitometry.  Reproducible protein patterns are dependent on very careful sample preparation.  
 
However, image anlaysis of 2D gels can be very time consuming and comparison of the gel images is 
particularly difficult if the images are not perfectably superimposible.  Difference in gel 
electrophoresis (DIGE) is a technique that allows two samples to be run on the same gel (Unlu, 
Morgan et al. 1997).  The samples are labelled with two different fluorescent cyanine dyes, which 
differ in their excitation/emission wavelengths, before being mixed together and separated with IEF 
and 2DE.  Excitation at both wavelengths allows the images to be overlaid and differences between 
the two samples are visualised (Gorg, Weiss et al. 2004).  An internal standard can be added to all gels 
with the use of a third dye.  This internal standard is usually comprised of a mixutre of pooled 
samples.  DIGE minimises the experimental variation and leads to greater confidence in quantitation 
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of gel spots.  It is also useful for the analysing differential protein expression between samples under 
different experimental conditions and biological variance. 
 
For the identification of proteins by mass spectrometry, spots are excised from the gel and the silver 
nitrate ions are removed (“destaining”), which enhances the sensitivity of the mass spectrometer and 
the quality of the spectra obtained (Gharahdaghi, Weinberg et al. 1999).  Additionally, the protein 
must be broken down into smaller peptides, which fall within the mass range of the mass spectrometer.  
The mass spectrometer is most efficient at determining sequence information from peptides up to 
approximately 20 residues (Steen and Mann 2004).  Proteins separated by 2DE can be destained and 
enzymatically digested ‘in gel’ and then extracted.  Trypsin is the most commonly used enzyme for 
this purpose, as it is very active in a broad pH range, cleaving specifically at the carboxyl-terminus of 
arginine or lysine residues producing peptides with a basic terminal residue.  The enzyme itself has a 
low molecular mass enabling it to enter the gel, making it suitable for ‘in gel’ digestion.  With trypsin, 
the resulting peptides are also in the preferred mass range of mass spectrometry. Peptides are eluted 
into the mass spectrometer by liquid chromatography, allowing peptides of a similar mass to be eluted 
at the same time.   
 
1.3.2 Mass Spectrometry 
 
Although 2D gels have enabled the separation of proteins from complex mixtures, the high throughput 
of protein identification has only been possible with mass spectrometry.  Earlier techniques included 
the more laborious and less sensitive Edman-degradation.  To be detected by the mass analyser, the 
sample must be ionised.  The mass spectrometer detects ionised molecules according to their mass-to-
charge ratios (m/z).  Ions of different mass move differently in an electric field.  Upon ionisation, a 
proportion of the sample ions will dissociate and form fragment ions.  The mass of the molecular ions 
is visualised as a mass spectra, where the mass is plotted against relative abundance (Figure 1.6).   
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Figure 1.5 Principles of mass spectrometry.  Sample molecules are ionised and a portion of these 
ions are fragmented.  The mass of the fragment ions are measured and visualised as a mass spectrum, 
where mass is plotted against relative abundance.   
 
 
The most common methods of ionisation used in proteomic studies are Electrospray Ionisation (ESI) 
and Matrix Assisted Laser Desorption Ionisation (MALDI).  In ESI, peptides in solution are ionised at 
atmospheric pressure by passage through a small capillary maintained at high voltage, which generates 
an aerosol of charged droplets.  Successive droplet fission and solvent evaporation eventually results 
in desolvated sample ions which are accelerated into the mass spectrometer vacuum via an oppositely 
charged orifice (Glish and Vachet 2003).  In MALDI the analyte is mixed with a large excess of a UV 
absorbing compound, usually an aromatic molecule such as alpha cyano-4-hydroxy cinnamic acid and 
irradiated by pulses of laser energy, resulting in desorption of sample molecules and (in positive ion 
experiments) their ionization by abstraction of protons from the matrix in the plasma created by the 
laser pulse. These are then accelerated by an electric potential into the mass analyser (usually a Time 
of flight device) (Steen and Mann 2004). 
 
In a Time of Flight (TOF) mass analyser, the m/z of an ion is determined by the time it takes to reach 
the detector.  The ions formed at the source are accelerated through a fixed potential (usually 1-20kV) 
where the potential energy is converted to kinetic energy. The mass of the ion is measured as a ratio of 
mass per unit charge (measured in Daltons per unit charge). The ions with a lower m/z achieve higher 
velocity than those with a higher m/z and therefore reach the detector first.  This is measured against 
peak intensity, which is dependent on the concentration of the ion.  Accurate mass measurements of 
ionised peptides maybe sufficient for their identification but peptide ions can be further fragmented to 
obtain structural information and the primary amino acid sequence.  Coupling two stages of mass 
spectrometry to achieve this is known as Tandem Mass Spectrometry (MS/MS).  In this second step, 
ionized molecules can be fragemented by collision with neutral gas molecules, such as argon (collision 
induced dissociation, CID).  This produces a series of truncated peptide ions which differ in their mass 
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by the mass of successive amino acid residues, allowing the primary sequence to be determined.  
Different ions can be produced, depending on the point of cleavage.  The most useful fragmentation 
pathways are those where the peptide is fragmented between the peptide bonds (Figure 1.7).  Here, 
retention of the charge on the amino-terminal results in a-, b- or c-ions.  Similarly, a charge on the 
carboxyl-terminal produces x-, y- or z-ions.  Tryptic peptides with an arginine or lysine residue at their 
carboxyl-terminal predominantly produce y-ions upon fragmentation.  
 
 
 
 
 
 
 
Figure 1.6 Peptide fragmentation of the parent ion producing b and y ions.  Fragmentation mainly 
occurs along the peptide bond.  The peaks on the spectra for y2, y3, y4 and so on will be separated by 
the mass of one amino acid residue. Other fragmentation may occur, such as a-ions, which is loss of a 
carbonyl group (C=O) from the b-ion.  Taken from Steen and Mann, Nature Reviews Molecular and 
Cellular Biology, 2004. 
 
 
Although TOF is the type of mass spectrometry used in this thesis, there are other types of mass 
analysers.  The Quadrupole uses much lower voltages to accelerate the ions from the source analyser, 
(i.e. 2-50V rather than kV in TOF instruments).  Mass separation occurs on the premise that ions with 
different m/z have a different oscillation in a quadrupolar field, which is generated by applying an 
osscillating electric field between parallel rods.  Only ions of a specific m/z will have a stable 
trajectory and therefore reach the detector (Glish and Vachet 2003; Mallick and Kuster 2010).  
Changing the electrostatic field allows different ions to be detected in turn.  Quadrupoles do not offer 
very high resolution, in contrast to TOF, but are very sensitive and therefore able to detect low 
abundant ions 
 
The Ion Trap, or Quadrupole Ion Trap, works in a similar way.  The ion of specific m/z is trapped in 
the quadrupole electrostatic field and ejected to make contact with the detector.  As with quadrupoles, 
the stability of the ion is dependent on the electric field and different ions are ejected by varying the 
electrostatic field.  Ion traps are more senstive than quadrupoles but only moderate mass accuracy and 
resolution (Mallick and Kuster 2010).  
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Other quantitative protein separation techniques have emerged, which do not rely on electrophoretic 
techniques but are based on mass spectrometry.  Stable Isotope Labelling by Amino acids in Cell 
Culture (SILAC) uses amino acids labelled with stable isotopes such as Carbon-13.  Cells are cultured 
in medium lacking these amino acids, which are supplemented as the isotopically-labelled form.  Use 
of the stable isotope throughout cell culture leads to its incorporation into the proteome, without any 
adverse effects on the cell (Ong, Blagoev et al. 2002).  After lysis, equal amounts of the cell lysates 
from cells with incorporated label and without are mixed together.  Subsequent tryptic digestion and 
MS analysis can resolve the peaks of the ‘heavier’ peptides, as the isotopically labelled peptides will 
have a mass different to that of the non-labelled.  Intensities of the normal and isotopically labelled 
peptides can be directly compared enabling calculation of differential expression.  However, for the 
study described in this thesis, SILAC would be unsuitable as atherosclerotic SMC and non-diseased 
control SMC have different rates of  replication (Bennett, Evan et al. 1995).  SMC may also undergo 
replicative senescence (Matthews, Gorenne et al. 2006) and so there will be incomplete incorportation 
of the isotope (five to ten population doublings are usually required to achieve comple incorporation 
of the isotope into the proteome).   
 
Another method that uses stable isotopes is iTRAQ.  Here, the N-termini of all peptides in digest 
mixtures from several experimental conditions are tagged with one of four isotopically distinct but 
isobaric (with the same mass) reagents so that all derivatized peptides are isobaric and 
chromatographically indistinguishable (Ross, Huang et al. 2004).  Signature ions, specific to each tag, 
are generated only on MS/MS fragmentation, and the areas of these peaks are proportional to the 
relative amount of the peptide present in each experimental condition.  This approach is particularly 
valuable when 2DE is unsuitable, i.e. when investigating membrane proteins or when there is limited 
sample.  In addition, this technique can be used when SILAC or metabolic labelling is not impossible, 
(i.e. when investigating body fluids).  However, this technique is limited to comparing 4 to 8 samples 
and the technique does not easily distinguish between different post-translationally modified forms of 
a protein.  Conversely, 2DE allows comparison of unlimited samples and a main advantage is the 
detection of PTMs. 
 
1.3.3 Identification of peptides  
 
The spectrum generated by MS can be compared with the predicted fragmentation patterns of proteins 
from sequence databases such as those in SwissProt and NCBI.  Computer programs have been 
designed for protein identification using mass spectrometry data such as Mascot and Sequest.  
Identification of proteins through proteomic methods relies heavily on high throughput mass 
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spectrometer analysis and bioinformatics.  Sequencing of the human genome in 2003 and of other 
species has led to creation of databases containing not only nucleic acid sequences but also protein 
sequences to which identified peptides can be matched.  These databases are in the public domain 
allowing any research group to access this information. 
 
1.3.4 Vascular proteomics  
 
Proteomics is being used as a tool to investigate the mechanisms of atherosclerosis and to identify 
proteins that play a role in the pathogenesis of disease.  By examining the proteome of tissues, changes 
in protein expression between healthy and disease states may be identified, which may identify 
proteins involved in the disease.  For example, heat shock protein-27 (Hsp27) was identified in a study 
of the secretome (the complement of secreted proteins from a cell or tissue) of carotid 
endarterectomies.  Its expression was decreased in atherosclerotic tissue compared to non-
atherosclerotic control arteries (Martin-Ventura, Duran et al. 2004).  Subsequent investigation into 
whether this was also the case in patients revealed that serum levels of Hsp-27 were decreased 20-fold 
in patients with atherosclerosis compared to healthy subjects confirming results of the proteomic 
study.  As a result, Hsp27 was heralded as a potential biomarker for atherosclerosis.  Similarly, 
another proteomic study also detected decreased levels of Hsp27 levels in plaque compared to non-
atherosclerotic arterial sections (Park, Park et al. 2006).  However, plasma levels of Hsp27 were 
increased in patients with acute coronary syndromes and correlated to levels of Hsp-70, CRP and IL-6.  
 
The secretome from different carotid plaques was analysed by Duran, et al (Duran, Mas et al. 2003).  
More proteins were secreted from complicated plaques containing thrombus and plaque rupture 
compared to non-complicated plaques.  In comparison, normal arteries secreted very few proteins.  
This technique was also used to study the effect of atorvastatin on plaques (Duran, Martin-Ventura et 
al. 2007).  Duran found that plaque specimens treated in vitro with 10µmol/L atorvastatin for 24 hours 
had reduced protein expression over all with significant decreases in the expression of the protease 
Cathepsin D by approximately 4-fold.   
 
Proteomics studies have also been performed in the well-characterised atherosclerosis prone apoE-/- 
mouse (Mayr, Chung et al. 2005).  As this model allows the use of several animals to from the same 
genetic background, results should be reproducible and even allow pooling of samples to obtain 
enough protein for proteomic studies.  Analysis of the atherosclerotic aortas from apoE-/- mice and 
comparison with aortas of control mice using 2DE revealed changes in glycolytic enzymes and 
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oxidation state of antioxidant proteins (Mayr, Chung et al. 2005).  1-Cys peroxiredoxin was oxidised 
in apoE-/- mice, representing increased levels of oxidative stress.  Peroxiredoxins themselves become 
oxidised in order to reduce reactive species, which is a modification that is detectable on the 2D gel 
image (Mayr, Zhang et al. 2006) (Rabilloud, Heller et al. 2002).  
 
1.3.3.3 SMC proteomics  
 
Proteomics on single cell types is often a challenge if they are derived from a heterogeneous tissue.  
Cultured cells may lose their in vivo characteristics as cell culture represents an artificial environment 
(Mayr, Zhang et al. 2006).  Nevertheless, studying a single cell type may reduce the complexity of 
such a heterogeneous tissue and identify cell-specific contributions to disease processes.  Several 
studies have looked at SMC in different contexts and using 2DE and mass spectrometry, they have 
produced detailed reference maps of protein expression (McGregor, Kempster et al. 2001; Mayr, Mayr 
et al. 2005) (Dupont, Corseaux et al. 2005).  Additionally, comparative 2D gels of SMC under 
different experimental or pathophysiogical conditions have been used in attempt to understand the 
mechanism of SMC in atherosclerosis.  These studies are described below.   
 
McGregor, et al identified 129 proteins from SMC from the medial layer of human saphenous vein 
(HSV) using 2DE (McGregor, Kempster et al. 2001).  Human saphenous vein is often used in arterial 
bypass grafting.  These cells experience increased flow rates in the arterial environment compared to 
the venous environment.  Contractile proteins were identified including calponin, SM22α and αSMA.  
Many gel features could be attributed to different isoforms or post-translational modifications of these 
proteins, which affect the molecular mass and pI.  Exposure of these SMC to a simulated arterial flow, 
re-modelling of actin filaments was found to occur (McGregor, Kempster et al. 2004).  Additionally, 
expression of actin binding proteins was also altered.  Expression of Hsp27 and its phosphorylated 
forms were increased, while levels of the actin capping protein CapZ, decreased. 
 
The proteome and secretome from human arterial SMC derived from internal mammary arteries, 
which are also commonly used for bypass grafting in coronary artery disease were published by 
Dupont et al (Dupont, Corseaux et al. 2005).  Two-dimensional electrophoresis identified intracellular 
and extracellular proteins including the protease MMP-1 in the secretome compartment.  The profile 
of cytoskeletal proteins was similar to that identified by McGregor et al (McGregor, Kempster et al. 
2001).  
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Proteomics can also be used in mouse models of disease.  Mayr, et al mapped the proteome of mouse 
aortic SMC providing another reference map of SMC (Mayr, Mayr et al. 2005).  Published alongside 
this study was a protein map of embryonic stem cell antigen-1+ (Sca1+) progenitor cells, the 
precursors of SMC (Yin, Mayr et al. 2005).  A comparison of the protein expression patterns in Sca1+ 
progenitor cells and aortic SMC revealed differences in chaperones, cytoskeletal proteins and proteins 
involved in DNA maintenance, transcription and translation (Yin, Mayr et al. 2006).  
 
The Protein Kinase C-delta (PKCδ) knockout mice display increased neointima formation in vein 
grafts (Leitges, Mayr et al. 2001).   Proteomic studies of cultured SMC from PKCδ-/- mice showed 
altered protein expression for proteins involved in energy metabolism and cytoskeleton compared to 
PKCδ+/+ mice (Mayr, Siow et al. 2004).   
 
Different subpopulations of SMC from porcine arteries were isolated and analysed by 2DE (Brisset, 
Hao et al. 2007).  Rhomboid shaped SMC, which are found in higher proportion in stent-induced 
intimal thickening, proliferate at a higher rate compared to spindle shaped SMC, mainly found in the 
media.  Comparison of their 2D protein expression patterns revealed that rhomboid SMC express the 
protein S1004A.  Further investigation into the expression of this protein revealed that was involved in 
SMC migration, as knock down of S1004A expression using siRNA, led to a decrease in migration of 
these cells.  Even more interestingly, this finding was investigated in human SMC and Brisset et al 
revealed that it was expressed in intimal SMC of atheromas but not medial SMC.   
 
 
1.4 Study Rationale 
 
The direct comparison of the human atherosclerotic SMC with the non-atherosclerotic SMC is still to 
be performed.  Since the detailed characterisation of SMC by Chamley-Campbell and Ross in the late 
70’s, these cells have been intensively studied and much attention has been paid to their phenotypic 
modulation in atherosclerosis (reviewed in (Owens 1995; Owens, Kumar et al. 2004)).  However, the 
mechanisms of this intriguing biological process remain to be elucidated.  So why is there a lack of 
proteomic studies of human arterial SMC?  The reasons probably include the difficulty of obtaining 
atherosclerotic tissue samples and isolation of SMC to generate enough cellular material for proteomic 
analysis.  The cellular and chemical heterogeneity of the plaque contributes a further layer of 
complexity.  Maintenance of in vivo characteristics is a concern with cell culture, as described earlier.  
Additional obstacles may include obtaining suitable non-diseased control tissue.  
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1.5 Hypothesis 
 
The proinflammatory stimuli found in the neointima drive the “phenotypic modulation” of SMC in 
atherosclerosis.  As proteins are the main effectors of biological function, the atherosclerotic SMC 
may exhibit a characteristic protein expression pattern, distinct from non-atherosclerotic SMC.   
 
1.6 Aims 
 
Using a proteomic approach by way of 2-dimensional electrophoresis and high-resolution mass 
spectrometry, the aim of this thesis was to: 
 
1. Map the proteome of the human atherosclerotic smooth muscle cell from carotid endarterectomy 
specimens obtained in surgery. 
 
2. Identify differences in the 2D protein expression patterns between the atherosclerotic SMC and 
non-atherosclerotic SMC. 
 
3. Clarify the roles of differentially expressed proteins in SMC behaviour.  
 
4. Investigate the effect of proinflammatory stimuli on SMC protein expression, as a factor for 
“phenotypic modulation”. 
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2.1 Cell Culture 
2.1.1 Cell culture reagents 
 
Primary smooth muscle cells were used in all experiments in this thesis.  Porcine SMC were grown in 
DMEM supplemented with 10% FCS, 1% penicillin/streptomycin and 0.8% amphotericin.  Human 
SMC were cultured with SmGM2 medium, which contains 5% foetal calf serum, 0.5ng/ml epidermal 
growth factor, 2ng/ml basic fibroblast growth factor and 5µg/ml insulin.  
 
2.2. Isolation of SMC 
 
Carotid plaques were obtained from patients undergoing carotid endarterectomy at Charing Cross 
Hospital, London.  Ethical approval was obtained (Riverside Research Ethics Committee 2989) for 
this study and all patients gave their written consent.  Commercially available human aortic SMC 
(purchased from Promocell, Heidelberg, Germany) were used as a non-diseased comparator.  
 
A variety of methods have been described for obtaining SMC from tissues (Chamley-Campbell, 
Campbell et al. 1979).  The most widely used are enzymatic dispersion of tissue specimens, and 
explant growth techniques.  There are advantages and disadvantages to both methods.  Enzymatic 
digestion has a higher efficiency both in terms of cell number and time of isolation but may perturb 
cell membranes and cell surface receptors, which subsequently may alter their response to stimuli.  
Moreover, the disruption of the extracellular-matrix may influence the SMC phenotype.  In contrast, 
the explant growth methodology may select for subpopulations of SMCs with a greater migratory 
ability (Hao, Ropraz et al. 2002).  However, cells can be slow to migrate out of the tissue, taking up to 
14 days or longer.  Since the method of isolation may influence the SMC phenotype in vitro (Hao, 
Ropraz et al. 2002), I utilised both of these methodologies. 
 
2.2.1 Isolation of SMC from porcine arteries by enzymatic digestion 
 
Porcine carotid arteries were obtained from pigs slaughtered at a local abattoir.  The carotid artery was 
identified and isolated from surrounding tissues and the adventitia surgically dissected. Arteries were 
clamped at both ends and filled with enzyme mixture (perfusion digestion).  Endothelial cells were 
liberated by an initial 20 minute incubation with 0.36U/ml Collagenase A in HBSS, followed by a 2 
hour incubation with enzyme mixture containing 0.29U/ml Collagenase A (Roche), 2.5 U/ml Elastase 
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(Sigma) and 2mM CaCl2 in HBSS with 2% FCS, 1% penicillin/streptomycin and 0.8% Amphotericin 
(Monaco, Andreakos et al. 2002). 
 
Alternatively, arteries were cut longitudinally and the endothelium was thoroughly scraped off with a 
scalpel before the artery was cut into small sections.  The tissue fragments were added to enzyme 
mixture (as above).  Tissue was digested for 2 hours at 37°C with occasional shaking.  Both methods 
yielded SMC with no significant differences in terms of cell numbers or phenotype.  Porcine SMC 
were cultured in DMEM containing 1% penicillin/ streptomycin and 0.8% amphotericin.  These SMC 
were cultured for longer than human SMC and used at later passages, up to passage 10.  
 
2.2.1.2 Isolation of SMC from porcine arteries by explant method 
 
The adventitia was superficially dissected from carotid arteries, according to previous studies (Saward 
and Zahradka 1997).  Arteries were opened longitudinally, the endothelium scraped off, and cut into 
small squares before being placed in a 6 well plate, luminal-side in contact with the plastic.  These 
explants were labelled ‘square explants’. Placing the artery lumen side down should enable the SMC 
from the media layer of the artery to adhere to and migrate out onto the plastic of the well. 
Alternatively, after careful dissection of the adventitia, the artery was sectioned by cutting 
longitudinally 2-3mm thick ring-shaped sections. Such ‘ring explants’ were placed side-down onto a 
6-well plate.   
 
In both cases, explants were covered in DMEM containing 10% FCS, 1% penicillin/streptomycin and 
0.8% amphotericin to avoid any contamination.  Explants were observed every day for cell migration.  
Fresh medium was added every 2-3 days.  As the wells of the plate became filled with cells, the 
explants were removed and discarded (after 21 days, approximately).  When the cells were near 
confluence they were trypsinised and the fractions from each well were pooled.  Cells derived from 
the different explant methods were cultured separately.  
 
2.2.2 Isolation of SMC from carotid endarterectomy 
 
Enzymatic digestion was used to liberate cells from the endarterectomy specimen as described 
(Monaco, Andreakos et al. 2004) and similar to other publications that have derived SMC from human 
atherosclerotic tissue (Bennett, Evan et al. 1995).  Any segments of medial tissue were first stripped 
from the specimen.  Thrombus was removed and the tissue washed in red blood cell lysis buffer 
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(Sigma, UK).  After an additional wash with RPMI, tissue is cut into small sections and incubated with 
collagenase type I (400U/mL), elastase type III (5U/mL) and DNase (300U/mL), with 1mg/mL 
soybean trypsin inhibitor (Sigma, UK), polymyxin B (2.5µg/mL; Sigma, UK) and 2mM CaCl2, in 
RPMI (BioWhittaker, UK) with 5% FCS (GIBCO, UK) in a shaker at 37°C with occasional, for 2 
hours (Monaco, Andreakos et al. 2004). Cells were collected by filtering through an 80 µm Nylon 
mesh (Falcon, UK) and cultured as described. LPS content in all media, reagents and supernatants, 
was assessed via the Limulus Amebocyte lysate assay (BioWhittaker, UK) and was always below 
detection limit (<10 pg/mL).  
 
2.2.2.1 Isolation of SMC from carotid endarterectomy explants 
 
As the explant method for obtaining SMC was successful in porcine carotid arteries, it was applied to 
human plaque tissue.  Some modifications were made to the protocol, as human atherosclerotic 
plaques are typically eccentric and heterogeneous in their structure.  I carefully dissected as much as 
possible of the neighbouring medial layers and the macroscopically normal segments away from the 
main plaque bulk.  The medial layers were cultured separately (see section 2.2.2.1). 
 
The dissected segments were incubated in red cell lysis buffer for 5 minutes and washed in RPMI 
containing 5% FCS, before being cut into smaller pieces of approximately 3-4 mm2, and placed in 
wells of a 6-well plate.  Five to seven explants were placed apart from each other in each well, and 
were observed every day for signs of cell migration onto the dish.  Smooth muscle-like cells were seen 
migrating from the tissue after 3-6 days in culture. Explants were removed after 14 days and 
discarded.  Cells were allowed to proliferate until approximately 80-90% confluent, before being 
passaged and separated as described in section 2.2.3. 
 
2.2.2.2 Explant of medial layer of carotid endarterectomy 
 
Carotid endarterectomy specimens often contain medial segments (Figure 2.1), which are removed 
before enzymatic digestion as described.  I attempted to culture these small sections of tissue to obtain 
medial SMC.  Medial segments removed from carotid endarterectomy specimens were cut into small 
pieces of approximately 1-2mm2 and placed in the wells of a culture dish.  Explants were covered with 
approximately 100µl of SmGM2 medium to ensure the explants were covered but did not float. 
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Figure 2.1 Medial layers are present on carotid endarterectomy specimens.  A) EVG staining of 
carotid endarterectomy sections shows the medial layers.  Arrow points to internal elastic lamina.  B) 
αSMA staining correlates with the EVG staining indicating areas of SMC.   
 
 
2.2.2.3 Clinical criteria of patients undergoing carotid endarterectomy surgery 
 
Patients undergoing carotid endarterectomy surgery at Charing Cross Hospital were classified as either 
‘symptomatic’ or ‘asymptomatic’.  A carotid plaque was considered symptomatic if the patient had 
experienced focal neurological symptoms pertaining to the contralateral carotid artery (stroke, 
transient ischaemic attack) or ipsilateral (same side) carotid territory (amaurosis fugax), within the last 
6 months and this symptomatic status was confirmed by the neuro-vascular multi-disciplinary team.  
Such symptoms can include face, arm, leg weakness, slurred speech, difficulty understanding or 
conveying speech. 
 
Asymptomatic patients come to the attention of the surgeons if they are referred to for a carotid scan 
due to unusual symptoms (non-focal, or posterior circulation i.e. back of the brain, supplied by the 
vertebral arteries not the carotids), like dizziness or headache.  Although they have symptoms, these 
are still ‘asymptomatic’ from a carotid plaque point of view.  They may be also seen in clinic for other 
arterial disease or risk factors, for example claudication (pain in the legs when they walk due to 
peripheral arterial disease of in their legs) then they may get a ‘screening’ carotid scan.  If these cases 
show a stenosis, and the multi-disciplinary team recommends that it is appropriate, they proceed to 
carotid endarterectomy.  SMC were isolated from plaques from both symptomatic and asymptomatic 
patients.  Patient details can be found in Appendix 2. 
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2.2.3 Isolation of Smooth Muscle Cells by Negative Selection 
 
Cells obtained from the enzymatic digestion of carotid plaque were of mixed cell types, representing 
the heterogeneity of the human atherosclerotic plaque.  Lymphocytes (CD3+), macrophages (CD68+) 
and smooth muscle cells were present in the culture as shown previously (Monaco, Andreakos et al. 
2004).  After 24-48 hours non-adherent cells were removed and the adherent cells are left to expand in 
culture.  After reaching confluence, SMC were isolated by negative selection using magnetic cell 
sorting (MACS, Miltenyi Biotech Ltd, Surrey, UK), in order to remove contaminating mononuclear 
inflammatory cells (anti-CD45) and endothelial cells (anti-CD31), according to manufacturer’s 
instructions. Briefly, cells were trypsinised and pelleted by centrifugation.  The cells were resuspended 
in MACS buffer, containing 0.5%FCS, 2mM EDTA in PBS and incubated with anti-CD31 and anti-
CD45 microbeads at 4-8°C for 15 minutes.  Cells were pelleted again before being re-suspended in 
MACS buffer and passed through a MACS MS column in a magnetic field. The column is washed 3 
times with MACS buffer and the unlabelled cells are collected in the flow-through.  The labelled cells 
(CD31+, CD45+) are retained on the column in the magnetic field.  
 
2.2.4 Human Aortic Smooth Muscle Cells 
 
Cyropreserved primary human Aortic Smooth Muscle cells (AoSMC) are purchased from Promocell.  
Cells are plated at a density of 104cells/cm2.  With each vial of cells, a certificate of analysis was 
provided with age and gender of the donor from which the cells were isolated.   
2.2.5 Maintenance of cells 
 
Human SMC were cultured in smooth muscle cell medium SmGM2, which was replaced every 2-3 
days.  Cells cultures were incubated in a humidified incubator at 37°C with and 5% CO2.  Cells were 
passaged before reaching confluence using 0.25% Trypsin-EDTA and split at a ratio of 1:2 or 1:3.  
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2.3 Experimental setup  
 
All cells were used at early passage of 3 or 4 in experiments, in order to preserve the phenotype of the 
cell in vivo.   
 
2.3.1 SMC for Proteomic analysis 
 
For the main proteomic analyses, as described in chapters 3 and 4, SMC were unstimulated in order to 
compare the ‘baseline’ protein expression of AthSMC and AoSMC.  Cells were plated at passage 3 or 
4 in 50cm2 tissue culture dishes until almost confluent.  SMC were serum starved in DMEM 
containing 1% penicillin/streptomycin for 48 hours before being harvested.  After the first 24 hours, 
the medium was removed and replaced with fresh serum free DMEM, to ensure complete removal of 
serum proteins, which could stimulate the SMC.  For proteomic analysis of TNF and cholesterol-
stimulated SMC, cells were serum starved for 24 hours before stimulation for another 24 hours.  The 
unstimulated cells for comparison were therefore serum starved for 48 hours as before.   
  
After 48 hours the medium was removed and cells were washed twice with 10mls PBS and once with 
10ml 35mM sucrose.  Cells were scraped off the surface of the dish, in 1ml PBS per dish, transferred 
to 1.5ml Eppendorf tubes and centrifuged at 13.2k rpm for 1 minute to pellet cells.  PBS was removed 
and the cell pellet was lysed in urea lysis buffer containing protease inhibitor cocktail (Sigma) for 30 
minutes on ice, with vortexing every 10 minutes.  Cell debris was pelleted by centrifugation at 13.2k 
rpm, for 15minutes at 4°C and soluble lysates were removed and pooled together.  These were 
aliquotted into 100-200μl samples and frozen at -80°C until required. 
 
2.3.2 Cell stimulation 
 
For analysis of cell lysates by immunoblotting, or for analysis of conditioned medium by ELISA or 
Luminex, cells were plated in 12 or 24 well plates as required.  Cells were serum starved for 24 hours 
in DMEM with 1% penicillin/streptomycin prior to stimulation for 24 hours, unless otherwise stated.  
For gene expression studies SMC were plated in 50cm2 tissue culture dishes.  Cells were serum 
starved for 24 hours before stimulation for 5 hours. 
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2.3.3 TNF stimulation 
 
To examine the effects of the potent proinflammatory cytokine TNF, SMC were stimulated with or 
without human recombinant TNFα at a final concentration of 10ng/ml.  Gene expression and protein 
expression was investigated.  At the end of the experiment, supernatant was removed and collected in 
eppendorfs, which were centrifuged for 1 minute to pellet any cells or debris.   Supernatants were 
transferred to a fresh Eppendorf and stored at -20°C.  Cells were lysed in the appropriate buffers as 
described below and stored at -20°C. 
 
2.3.4 Cholesterol Loading of SMC 
 
To investigate the effect of cholesterol, I used a model of cholesterol loading already published (Porto, 
Palumbo et al. 2006) (Rong, Shapiro et al. 2003).  This model uses cholesterol complexed with 
methylcyclodextrin, which is a cyclic sugar molecule.  This enables the effect of free cholesterol to be 
examined, unlike other models such as acetylated or oxidised lipoproteins, which in addition to 
cholesterol contain other bioactive molecules. Cholesterol-methyl-β-cyclodextrin (Sigma-Aldrich, 
UK) is a water-soluble form of free cholesterol which is delivered to cells by via the plasma 
membrane (Christian, Haynes et al. 1997) rather than receptor mediated uptake as with modified 
lipoproteins.  Cholesterol-methyl-β-cyclodextrin purchased from Sigma-Aldrich, contains 
approximately 30mg cholesterol/g solid.  The molar ratio is approximately 1:6 (cholesterol: methyl-β-
cyclodextrin).  The amount of cholesterol per mg of complex was determined to ensure that all 
treatment concentrations were based on cholesterol.   
 
Cells were plated in 12 well plates and serum starved for 24 hours before incubation with 50μg/ml 
cholesterol in serum free DMEM for a further 24 hours.  Cell supernatants were removed and cells 
were lysed in 1 x RIPA buffer as described (section 2.4.1.1).  
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Figure 2.2 Molecular structures of cholesterol and methyl-β-cyclodextrin molecules 
 
2.3.4.1 Inhibition of cholesterol uptake 
 
To explore the mechanism of the effect of cholesterol on SMC, I used an intracellular inhibitor of 
cholesterol trafficking; 3β-(2-Diethylaminoethoxy)-Androstenone.HCl (also known as U18666A, 
Enzolifesciences).  SMC were plated in 12 well plates  and serum starved for 24 hours before 
stimulation with 50μg/ml cholesterol as before, in the presence or absence of U18666A at a final 
concentration of 70nM, for 24 hours.   
 
 
2.4 Molecular Biology techniques 
2.4.1 Immunoblotting 
 
2.4.1.1 Cell lysis  
 
For analysis of intracellular proteins by immunoblotting, cells were lysed in 1 x RIPA buffer 
containing protease inhibitor cocktail (Sigma) for 10minutes on ice, on a rotating platform.  Lysates 
were then transferred to 1.5ml Eppendorfs and cell debris was pelleted by centrifugation at 13.2krpm 
for 15minutes at 4°C.  The soluble protein fraction was transferred to fresh 1.5ml Eppendorf and 4x 
sample buffer was added and the sample boiled for 5 minutes at 95-100°C to fully reduce the samples.  
Samples were stored at -20°C until required. 
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To investigate expression of membrane proteins, SMC were lysed directly in 1 x non-reducing sample 
buffer.  Approximately 50µl was used per cm2.  Cells were lysed and then transferred to 1.5ml 
eppendorfs and sonicated for 30minutes (Ultrasonic water bath XB2, Grant Instruments, 
Cambridgeshire, UK).  Samples were frozen at -20°C until required.   
 
2.4.1.2 Electrophoresis of samples 
 
Cell lysates in 1xRIPA buffer with sample buffer were used for protein separation performed by 1-
dimensional electrophoresis, using a mini-gel system (Invitrogen); 3-8% Tris-Acetate gels for larger 
proteins and membrane proteins, or 4-12% Bis-Tris gels for smaller, intracellular proteins.  Gels were 
run at 150V until the loading dye had run off the gel.  Proteins from the gels were transferred to 
polyvinylidene difluoride (PVDF) or nitrocellulose membrane by electrophoresis at 110V for 1.3h in 
transfer buffer at 4°C.   
 
2.4.1.3 Immunodetection 
 
The membrane was blocked for 30 minutes at room temperature with blocking buffer (5% w/v non-fat 
milk powder in PBS/ 0.1% Tween-20 (PBS-T)).  Incubation with primary antibody, diluted at the 
appropriate concentration in 5% milk/PBS-T was for 1h at RT or overnight at 4°C.  After this time, 
membranes were washed 3 times in wash buffer (PBS-T), with 5 minutes for each wash.  Secondary 
antibody with horseradish peroxidase (HRP) conjugate was added at a dilution of 1:2000 for 1h.  
Membranes were washed 3 more times in wash buffer.  Bound antibody was visualised using 
enhanced chemiluminescence (ECL) (GE Healthcare, Amersham, UK).  For re-blotting a membrane 
with a different primary antibody, membranes were stripped using Re-blot stripping solution 
(Millipore, UK) for 15 minutes at RT.  Membranes were washed in wash buffer and then blocked in 
5% milk powder/PBS-T as before.  Antibodies to all phosphorylated proteins were diluted with TBS-T 
and used with TBS-T wash buffer rather than PBS-T, to avoid interference with the phosphorylated 
protein by phosphate ions. 
 
2.4.2 Immunofluorescence (IF) Microscopy 
 
SMC from different sources were characterised by immunostaining for the markers αSMA and SM-
SM-MHC.  Staining of cells with these antibodies was visualised by immunofluorescence microscopy 
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using a microscope with UV light (Olympus) and image analysis programme analySIS (Software 
Image System).   
 
Glass lab-tek 4-chamber slides (Nunc, Thermo-scientific Fischer, UK) were pre-coated with 1% LPS-
free gelatin for 20 minutes at room temperature and then fixed in 1% paraformaldehyde for 15 
minutes.  Slides were washed 3 times with DMEM containing 10% FCS. Cells were plated at a density 
of 104 cells/cm2 (approximately 2x104 cells per well).  After 3-4 days in culture, the medium was 
removed and cells were fixed with 4% paraformaldehyde in PBS for 10 minutes.  After 2 washes with 
PBS, cells were permeablised using 0.25% Triton X100 in PBS for 5 minutes.  Cells were washed 
twice before the addition of blocking solution (5% goat serum, 3% BSA in PBS) for 1 hour at room 
temperature.  The cells were incubated with primary antibody at a dilution of 1:1000, in blocking 
solution and sodium azide (1:1000) overnight at 4°C.  The following day the cells were washed twice 
in PBS and incubated with an anti-mouse secondary antibody conjugated to a fluorochrome (Alexa-
488, Invitrogen) at a dilution of 1:2000.  Propidium iodide (PI, which binds to DNA in a non-sequence 
specific manner, emitting a fluorescent signal), was added at a dilution of 1:100 as nuclear 
counterstaining. 
 
2.4.3 Enzyme-linked Immunosorbent Assay (ELISA) 
 
Sandwich ELISA was used to measure the concentrations of soluble analytes produced from SMC.  
Analytes were measured using matched antibody pairs (see Table 2.1).  A capture antibody is allowed 
to bind to the plastic surface of a 96 well plate, before being incubated with a sample.  Antigen will 
bind to the capture antibody and a detection antibody is then added, which binds to the antigen in a 
different region from the capture antibody, thus creating a sandwich.  The detection antibody contains 
biotin, which will bind to streptavidin conjugated to HRP enzyme.  Addition of a substrate results in 
development of a colorimetric signal, which can be measured by spectrophotometry.  This signal is 
proportional to the amount of antigen bound.   
 
Briefly, 96 well plates were coated with the purified capture antibody, diluted in PBS, and incubated 
over night at 4°C.  Plates were washed 3 times in PBS-T wash buffer and blocked with 2% BSA/PBS 
for 1h at RT.  Plates were re-washed as before and 100µl sample was added.  Samples were assayed in 
triplicate wells.  Protein standards of known concentrations were added to the plate, alongside the 
samples to generate a calibration curve in order to measure the concentration of the unknown samples.  
Samples and standards were incubated for 2 hours at RT or overnight at 4°C.  The plate was washed 3 
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times in wash buffer and the plates incubated with a biotinylated antibody for a further 2h at RT.  
Protein was detected using HRP conjugated to streptavidin (R&D), at a dilution of 1:400 in 0.5% 
BSA/PBS.  This was incubated for 1h at RT before addition of the HRP substrate (TMB, KPL 
Laboratories, Gaithersburg, USA).  This allowed colorimetric detection of the protein.  Reaction was 
stopped using 1M H2SO4.  Absorbance at 450nm was measured using a Multiskan plate reader and 
data was analysed using Ascent software (Thermo Electron, UK). 
 
2.4.4 Luminex 
 
Multi-analyte profiling using the Luminex systems Fluorokine (R&D Systems, UK) and Milliplex 
(Millipore Corporation, USA) was used to analyse the concentrations of several soluble mediators 
from the same sample, simultaneously.  Luminex uses fluorescently labelled beads or microspheres 
coated with capture antibodies specific to each analyte.  The analyte is captured on the bead and then 
bound by a biotinylated detection antibody, to form a sandwich complex similar to that in the ELISA.  
Incubation with streptavidin-phycoerythrin (PE) conjugate completes the reaction on the surface of the 
microsphere.  The microspheres are then passed through a laser, which excites the internal dye 
marking the microsphere and a second laser to excite the PE.  Detection of these two signals is 
quantified on each microsphere, giving the mean fluorescent intensity (MFI), which is directly 
proportional to the amount of analyte present. 
The choice of panel was determined by the availability of analytes from each manufacturer (cytokines 
and chemokine panel was purchased from Millipore.  MMP panel was purchased from R&D Systems).  
Cell culture supernatants were analysed at a dilution of 1:4 for detection of MMPs and 1:10 for 
cytokines and chemokines.  Samples were assayed in duplicate.  Assays were performed following the 
manufacturer’s instructions.  Briefly, the microsphere beads for each analyte were re-suspended in the 
appropriate buffer and pipetted into a 96 well filter plate.  Sample and standards (50μl per well) were 
added to the appropriate wells and the plate was sealed with an opaque lid and incubated for 1 hour at 
RT on a rotating platform.  Fluid was removed by vacuum manifold and the plate was washed twice 
with wash buffer, and the fluid removed by vacuum.  Detection antibody was added (25μl per well) 
and the plate re-incubated for 30 minutes at RT.  Streptavidin-PE (25μl per well) was added and given 
30 minutes further incubation before washing twice with wash buffer, using the vacuum manifold to 
remove liquid between the washes.  Sheath fluid was added (150μl per well) and the beads re-
suspended on a plate shaker for 5 minutes.  Samples were analysed using Luminex 100 analyser and 
STarStation version 2.0 (Applied Cytochemistry, Sheffield, UK).  Assay sensitivity is determined by 
the lowest concentration of the standard curve, which varies for each analyte. 
 
Chapter 2  Materials & Methods 
 
 
 
76
2.4.5 TNFRII ELISA 
 
Levels of soluble TNF Receptor II (sTNFRII) were measured by Quantikine human sTNFRII 
immunoassay (R&D Systems).  This is a solid phase ELISA, where the monoclonal capture antibody 
has been pre-coated onto a 96 well microplate.  This assay was performed according to the 
manufacturer’s instructions. Assay diluent was added (50µl per well), followed by cell culture 
supernatants (200µl per well, diluted 1 in 10) and standards (200µl per well).  Standards and samples 
were assayed in duplicate.  The plate was incubated for 2 hours at RT.  After washing to remove 
unbound substrate, TNFRII conjugate antibody was added (200µl per well) and incubated for 1 hour at 
RT.  Substrate solution was added (200µl per well) and incubated for 20 minutes, in the dark before 
the reaction was stopped.  Absorbance was measured at 450nm as before.   
 
2.4.6 Statistical analysis 
 
Statistical analysis of analytes from ELISAs or Luminex was performed using GraphPad Prism 
version 5.0 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com).  
Parametric tests were used with the assumption that values fit the Gaussian distribution.  For 
comparison of two groups, a two tailed T-test was used.  For analysis of three or more groups, One 
Way ANOVA with Tukey Post test was used.  Statistical significance was considered if there was a p 
value < 0.05.    
 
2.4.7. Oil red O staining 
 
Cholesterol uptake by SMC was visualised by oil red O staining, which is a stain for neutral 
triglycerides and lipids.  SMC were plated on glass slides pre-coated with 1% LPS-free gelatin.  Cells 
were plated at a density of 104cells/cm2 and allowed to adhere for 12-24 hours.  SMC were serum 
starved for 24 hours in serum free DMEM, before being incubated with 50μg/ml cholesterol-methyl-β-
cyclodextrin in serum free DMEM for 72 hours.  SMC were fixed in 4% PFA/PBS for 10 minutes and 
then washed in PBS.  Slides were then rinsed in 60% isopropanol for 30 seconds before staining with 
Oil red O solution (3 parts 1% oil red O solution in isopropanol and 2 parts 1% dextrin solution in 
water) for 30 minutes.  Slides were washed in water and counterstained with hemotoxylin.  Cover slips 
were mounted using glycergel.   
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2.4.8 Immunohistochemistry  
 
Immunohistochemistry staining of carotid endarterectomy specimens was performed using the Avidin-
Biotin enzyme Complex (ABC) method.  Cryosections 5μm thick were defrosted at room temperature 
and allowed to dry, before fixing in cold acetone for 5 minutes.  Slides were blocked for 1 hour in 
serum of the species that the secondary biotinylated antibody is raised in.  Endogenous biotin and 
avidin were blocked using Vector avidin biotin blocking kit, according to the manufacturer’s 
instructions, followed by incubation with the primary antibody for 45 minutes.  Slides were washed in 
1 x PBS for 5 minutes and then incubated with the secondary biotinylated antibody, at a dilution of 
1:400, for 40 minutes.  Endogenous peroxidase activity was quenched using 0.3% H2O2 in PBS for 15 
minutes.  Slides were then incubated with Avidin-Biotin complexes (ABC) for 40 minutes and washed 
for 5 minutes in PBS.  Bound peroxidase was detected using 3,3’-diaminobenzidine (DAB).  Colour 
change was observed for a maximum of 10 minutes before a final wash 5 minutes in PBS.  Sections 
were counterstained with hematoxylin for 30seconds and washed in 1% Sodium bicarbonate, to blue 
the nuclei.  Sections were dehydrated in subsequent washes in 70% and 100% ethanol for 1 minute 
each.  Histomount was used to mount the slides with a glass cover slip.  Slides were viewed with 
Olympus microscope with objective lenses at x4, 10x and 20x magnifications.  Details of the primary 
and secondary antibodies used are provided in Table 2.1 
 
2.4.9 Cell Viability Assay 
 
SMC viability was assessed using Cell Titer96® AQueous One Solution Cell Proliferation assay 
(Promega Corporation, WI, USA).  This protocol uses a colorimetric method to determine the number 
of viable cells.  The Cell Titer96® AQueous One Solution reagent contains a 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS), which is reduced by 
metabolically active cells into a coloured, soluble, formazan product that can be measured at an 
absorbance of 490nm.  The quantity of formazan product is directly proportional to the number of 
living cells in the sample.  This method was used as it only required one step in contrast to the MTT 
methodology, which requires an extra step to solubilise the formazan precipitate.   
 
SMC were plated at a density of 5x103 cells per well.  Between 3 and 6 wells were used per 
experimental condition.  Cells were treated simultaneously and identically to those cells stimulated for 
experiments.  At the end of the experiment, Cell Titer96® AQueous One Solution was added (20μl per 
well) and left for 1-4hours before being measuring the absorbance at 490nm with a Multiskan plate 
reader.   
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2.4.10 Cholesterol quantification 
 
Cholesterol levels in cell supernatants were assayed using a cholesterol quantitation kit (BioVision 
Research Products, CA, USA).  This assay measures free cholesterol and cholesterol esters by 
colorimetric methods.  Cholesterol esters are detected by their hydrolysis to cholesterol by the enzyme 
cholesterol esterase.  In this kit, cholesterol is oxidised by cholesterol oxidase to produce H2O2, which 
reacts with a probe to produce a colour that can be measured at 570nm.  Cholesterol quantitation was 
performed according to the manufacturer’s instructions.  Briefly, cholesterol standards were serially 
diluted to produce a range of concentrations (5, 4, 3, 2, 1, 0.1 and 0µg) to serve as the standard curve 
against which the unknown samples would be measured.  Supernatants were diluted 1 in 10 in cell 
culture medium.  Samples or standards were pipetted into a 96 well plate (50μl per well).  Standards 
and samples were assayed in duplicate.  Samples were assayed twice – in the presence or absence of 
cholesterol esterase to determine total and free cholesterol quantitation.  A further 50ul of reaction 
mixture, containing cholesterol enzyme mix and probe was added to each well.  The plate was covered 
and incubated at 37°C for 1 hour before measuring the absorbance at 570nm.  Unknown 
concentrations were calculated from the standard curves.  
 
2.5 Gene Expression Studies 
2.5.1 Isolation of RNA from SMC 
 
Cells were plated in 50cm2 tissue culture dishes and grown until near confluence.  Cells were serum 
starved for 24h before stimulation for 5hours.  Total cellular RNA was extracted from SMC using 
RNeasy® Mini Kit (Qiagen) according to the manufacturer’s instructions.    Cell culture medium was 
removed and cells were lysed by addition of 600µl RLT buffer (Qiagen) containing 10µl/ml β-
mercaptoethanol.  Lysates were homogenised by centrifugation through a Qiashredder spin column 
(Qiagen) and centrifuged for 2 minutes at 13.2krpm.  Each lysate was transferred to another spin 
column where RNA was retained.  After several washes, RNA was eluted in a final volume of 50µl 
RNase free water.   
 
To remove any residual genomic DNA, RNA samples were treated with DNase (TurboDNase, 
Ambion).  DNase treatment was performed according to the manufacturer's protocol.  Briefly, 1µl of 
DNase was added per 50µl RNA with 5µl 10x reaction buffer and samples were incubated at 37oC for 
30minutes.  After 30minutes DNase inactivation reagent was added.  After 2 minutes and re-
suspension of inactivation reagent, samples were centrifuged at 13.2 krpm for 1 minute to pellet 
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DNase and inactivation reagent.  RNA was transferred to fresh sterile Eppendorfs.   RNA was 
quantified by spectrophotometry at 260nm, using a NanoDrop 1000 spectrophotometer (Thermo 
Scientific).   
 
The absence of genomic DNA was assessed by performing polymerase chain reaction (PCR) using 
primers for GAPDH with RNA samples (see section 2.4.3).  A positive control of cDNA was used.  As 
the polymerase chain reaction cannot occur without a DNA template, a negative PCR result confirmed 
the absence of genomic DNA.  If a positive result was seen, then Turbo DNAse treatment was 
repeated to remove genomic DNA. 
 
2.5.2 Reverse Transcription (RT) PCR for cDNA synthesis 
 
Isolated RNA from SMC was used at 500ng per reaction with 1µl of oligo (dT) primers and nuclease 
free water, to a total volume of 13µl.  The mixture was heated to 70°C for 10 minutes and then placed 
on ice for 5 minutes.  12µl of master mix containing dNTPs, RNase inhibitor (RNasIn), reverse 
transcriptase buffer and MMLV reverse transcriptase was added to each reaction. The reaction was 
held at 40°C for 1 hours, then 70°C for 15 minutes.  The resulting cDNA stored at -20°C. 
 
2.5.3 Polymerase Chain Reaction  
 
Qualitative PCR was used to assess expression of genes of interest from cDNA.  It was also used to 
ensure the absence of genomic DNA in RNA samples as described above.  PCR amplifies DNA using 
a thermally stable DNA polymerase enzyme originally isolated from the bacterium Thermus aquaticus 
(Taq), , and free dinucleotide triphosphate (dNTP) molecules.  For each sample, 1µl of cDNA was 
incubated with 2µl dNTPs, 0.6µl MgCl2, 1µl forward primer, 1µl reverse primer and 0.2µl Taq 
polymerase.  Samples were run on a thermocycler as shown in Table 2.2.   
 
2.5.4 Electrophoresis 
 
PCR products were analysed by electrophoresis on 1.5% agarose gels in 1 x Tris-acetate buffer, 
containing SYBR safe DNA gel stain (1:10,000 dilution, Invitrogen).  For each PCR prduct, 10µl was 
mixed with 2 µl of loading buffer (40% glycerol and bromophenol blue) and loaded onto the gel.  A 
1kilobase (kb) DNA ladder was used to determine the size of the PCR product (Invitrogen).  An 
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electric field of 120V was applied until the dye was near the end of the gel.  Visualisation was carried 
out under ultraviolet light (UVP BioDoc-It System, Upland, CA). 
 
2.5.5 Primer Design 
 
PCR primers are specific sequences which are complementary to the DNA sequence to be amplified.  
They act as a template for DNA synthesis.  Primers were designed using Primer 3 tool 
(http://frodo.wi.mit.edu/primer3/).  The primer sequences are shown in Table 2.3.   
 
2.5.6 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) using 
Taqman probes 
 
Quantitative Real Time-PCR was used to quantify gene expression at mRNA levels.  This method 
measures mRNA levels by measuring the fluorescence emitted by a dye by specifically designed 
Taqman® probes (Applied Biosystems).  Due to high levels of sensitivity of this technique, even small 
changes in the concentration of cDNA template will result in large differences of calculated 
abundance.  Therefore, all results are normalised to a housekeeping gene.  In this study, beta-2-
microglobulin was used as the housekeeping gene on the assumption that the expression of beta-actin 
does not change upon treatment.  Taqman probes were used to investigate the expression of the genes 
for TNFRI, TNFRII, and CCR1.  The primer sequences for these genes are proprietary.   
Taqman gene expression assays contain unlabelled PCR primers and a Taqman probe with a 
fluorescent probe at the 5’ end and a non-fluorescent quencher at the 3’ end.  Taqman probes anneal 
within a DNA region that is amplified by the primers.  As long as the fluorescent probe and quencher 
are in proximity, the quenching inhibits the fluorescent signal.  During strand synthesis, the 
fluorescent probe is cleaved by the Taq polymerase, releasing it from the proximity of the quencher 
and the fluorescent signal is detected.  The amount of fluorescent detected is proportional to the 
amount of DNA template present.   
 
Reactions were set up in a final volume of 20µl.  Each reaction contained 1µl Primer/probe, 10µl 
Platinum® Quantitative PCR supermix UDG (Invitrogen), containing Taq DNA polymerase, Mg2+ and 
dNTPs, and 3µl ddH20.  cDNA was diluted 1:6 with ddH20, and 6µl of this was used per reaction.  
Samples were amplified on a Rotorgene 6000 real time rotary analyser (Corbett Life sciences, Sydney, 
Australia) using the following programme for 45 cycles; 2 minutes at 50°C, 3 minutes at 95°C and 40 
seconds at 60°C.  Data was analysed suing the 2-ΔΔCt method (Livak and Schmittgen 2001) and 
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calculated in Microsoft Excel 2007.  This method involves setting a threshold cycle value (ct value), 
which represents a fixed value of fluorescence.  In each sample, the relative fluorescence of the gene 
of interest (GOI) is compared to that of the housekeeping gene: 
ΔCt = Ct (GOI) - Ct (Housekeeping) 
 
This is then related to an external control, i.e. the unstimulated sample, to give the ΔΔCt value: 
ΔΔCt = ΔCt (stimulated) - ΔCt (unstimulated) 
 
The fold change is obtained by 2-ΔΔCt.   
 
2.5.7 RT2 qPCR Primer Assays (PCR arrays) 
 
RT2 qPCR Primer Assays (SABiosience Corporation, USA) were used to analyse the expression of a 
panel of genes related to atherosclerosis.  These PCR assays contain validated primer sets for 84 genes 
related to inflammation, lipid transport and metabolism, cell adhesion and blood coagulation, present 
in a 96 well plate format along with positive controls and 5 housekeeping genes (Table 2.4).  Controls 
are also included for genomic DNA contamination and PCR performance.  These arrays use SYBR 
green based PCR techniques for quantitative gene expression analysis.   
 
RNA was extracted from cells as described in section 2.4.1.  cDNA was prepared using the RT2 First 
Strand Kit according to the manufacturer’s instructions (catalogue number, C-03, SABioscience 
Corporation).  This kit includes a genomic DNA elimination step before reverse transcription of the 
RNA occurs to prevent any non-specific amplification.  Briefly, 500ng RNA was incubated with the 
genomic-DNA elimination buffer, at a final volume of 10µl per sample, at 42°C for 5 minutes and 
placed on ice for 1 minute.  10µl of Reverse Transcription cocktail was added to each sample, for a 
final volume of 20µl, and incubated at 42°C for a further 15minutes.  RNA was hydrolysed and 
reverse transcription inactivated by heating to 95°C for 5 minutes.  cDNA was frozen at -20°C until 
needed. 
 
For the RT-PCR reaction, cDNA was mixed with the RT2 qPCR Master Mix according to the 
instructions.  To each well of the PCR array, 25μl of the reaction mixture was added.  The plate was 
sealed and the reaction was performed using a ABI 7700 machine with the following program: 10 
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minutes at 95°C to activate the DNA polymerase, 15 seconds at 95°C and 1 minute at 60°C for 40 
cycles.  Sybr green fluorescence is detected at the end of the 1-minute step.  Data analysis was 
performed using Sequence Detection System 1.9.1 for Macintosh using the ΔΔCt method.  Those 
genes with a fold regulation > 2 or < -2 fold with p < 0.05, (T-test) between control and test samples 
were considered significant.   
 
 
2.6 Proteomic Techniques 
2.6.1 Two Dimensional Gel Electrophoresis (2DE) 
 
Two-dimensional electrophoresis separates proteins by their isoelectric point (pI, the point at which 
the net charge on the protein is zero) and apparent molecular mass.  This gives a greater separation 
than that achieved in conventional SDS-PAGE where there is no charge-based separation.  The 
likelihood of the resulting spots containing multiple proteins co-migrating through the gel is reduced, 
enabling the quantitation of protein by scanning densitometry.  Analytical gels contained 100μg 
protein and were used were in quantitative gel analysis   Preparative gels contained 400μg protein and 
are used for mass spectrometry.   
 
2.6.1.1 Preparation of cell lysates 
 
SMC were grown in 50cm2 tissue culture dishes until almost confluent.  Cells were serum starved in 
DMEM containing 1% penicillin/streptomycin for 48 hours.  The medium was removed and cells were 
washed twice with 10mls PBS and once with 10ml 35mM sucrose.  Cells were scraped off the surface 
of the dish, in 1ml PBS per dish and transferred to 1.5ml Eppendorf tubes and centrifuged at 13.2k 
rpm for 1 minute to pellet cells.  The PBS was removed and the cells were lysed in urea lysis buffer 
containing protease inhibitor cocktail (Sigma) for 30 minutes on ice, with vortexing every 10 minutes.  
Cell debris was pelleted by centrifugation at 13.2k rpm, for 15minutes at 4°C and soluble lysates were 
removed and pooled together.  These were aliquotted into 100-200μl samples and frozen at -80°C until 
required. 
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2.6.1.2 Quantification of Protein  
 
The protein concentration of cell lysates from each sample was determined using the Bradford Assay.  
The Bradford assay is based on the reaction of proteins with the dye brilliant blue G.  Production of 
protein-dye complex causes a shift in the absorption maximum to 595nm.  This assay is compatible 
with low concentrations of reducing agents and detergents such as DTT and urea.  Bradford assays 
were carried out in a 96-well plate format as described on the manufacturer’s data sheet (Sigma).  A 
standard curve was set up using a serial dilution of BSA, with the highest standard being 2mg/ml BSA 
in lysis buffer containing protease inhibitor cocktail.  Standards were measured in duplicate and 
samples in triplicate.  5μl of sample/protein standard was added per well and 250μl of Bradford 
reagent was added.  The 96-well plate was incubated for 5-15 minutes at room temperature before 
being read on a plate reader at 620nm (Multiskan Ascent, Thermo Lab-systems).  
 
2.6.1.3 Iso-electric focusing 
 
Between 100μg and 400μg of protein, measured by Bradford assay, was diluted to a final volume of 
450μl with rehydration buffer (Urea, 9.5M, CHAPS, 0.5% (w/v), DTT, 0.2% (w/v), Pharmalyte 0.2% 
(w/v) and trace amounts of bromophenol blue) and used to rehydrate one 18cm IPG strip with a pH 
range of 4-7.  IPG strips were rehydrated with protein for 20-24 hours on an IPG strip holder (GE 
Healthcare) covered with PlusOne cover oil (GE Healthcare).  A pH range of 4-7 was used specifically 
as this range encompassed the majority of proteins and therefore provided a better separation 
compared to a pH 3-10 IPG strip of the same length.  IPG strips were focused using a MultiPhor™ II 
apparatus (GE Healthcare) at 0.05A/strip for 75kilo-volt hours (kVh).  The voltage was gradually 
increased over approximately 5 hours as shown in Table 2.5.  IPG strips were stored at -80°C until 
needed for the second dimension. 
 
2.6.1.4 Equilibration of IPG Strips 
 
Each IPG strip was incubated in 10ml SDS Equilibration buffer (Urea, 9.5M, SDS, 2% (w/v), Glycerol 
(33% v/v), Tris-HCl pH 8.8, 25mM, bromophenol blue, trace), containing 1,4-dithiothreitol (DTT) 
(1% w/v) for 15 minutes to ensure that all disulphide bonds and thiol groups were fully reduced.  The 
strips were then incubated in SDS equilibration buffer containing iodoacetamide (IAA) (4.8% w/v) to 
carboxyamidate the thiol groups, preventing reformation of disulfide bonds.  The strips were rinsed 
twice with MilliQ water (approx 10mls) before being loaded onto the gel.   
Chapter 2  Materials & Methods 
 
 
 
84
2.6.1.5 Polyacrylamide Gel Electrophoresis 
 
The second dimension was carried out by SDS-Polyacrylamide gel electrophoresis using precast large 
12.5% gels cast onto plastic (GE Healthcare).  After equilibration was complete, IPG strips were 
placed horizontally across the top of the SDS gel, ensuring that no air bubbles were between the gel 
and the IPG strip.  SeeBlue Prestained Markers (Invitrogen) were loaded at the acidic end of the IPG 
strip.  The IPG strip and markers were sealed into place with 1% agarose solution in 1 x SDS running 
buffer with trace amounts of bromophenol blue. 
The gels were run in a Dalt6 gel tank (GE Healthcare), using buffers purchased from GE Healthcare 
for use with pre-cast gels.  Electrophoresis buffers were maintained at a constant 10°C using a 
recirculating cooler (Fisher Scientific).  The gels were run initially at 2W per gel for 15minutes and 
then at 2.5W per gel for a further 30minutes.  Gels were then run at 30W per gel, or a total of 100W 
(maximum) until the bromophenol blue dye had run off the end of the gel. 
 
2.6.1.6 Silver staining 
 
Gels were stained using a modified ‘PlusOne’ silver staining protocol that is compatible with mass 
spectrometry(Yan, Wait et al. 2000) (Table 2.6).  The protocol was amended for use with plastic 
backed gels in which less surface area is exposed to the silver staining reagents.  I increased the 
incubation times for the sensitisation and silver nitrate steps to 1 hour each, to ensure good silver 
staining.  The gels were stored 4°C. 
 
2.6.2 Quantitative Gel Analysis using Progenesis Samespots 
 
Triplicate analytical 2D gels, each containing 100µg of protein, were run for each donor to average out 
gel-to-gel variation in order to obtain average spot volumes for statistical analyses.  2D Gels were 
scanned on a gel scanner (Image-scanner III, GE Healthcare) and images saved as 16-bit TIFF files.  
Images were analysed using Progenesis SameSpots software version 3.3 (Nonlinear Dynamics, 
Newcastle, UK) to identify proteins that were differentially expressed between plaque and medial 
SMC, or whose expression was altered during stimulation.   
 
The SameSpots programme aligns each spot on the gel image with the equivalent spot on all other 
gels.  This alignment is done at the pixel level so that each pixel in a spot matches the corresponding 
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pixel on all other gel images in the experiment.  It corrects for positional variations of the spots 
between gels and creates a spot outline that is identical across all gels.  Additional background 
subtraction and normalisation correct for measurement variation between gels.  After alignment, gel 
images are divided into groups i.e., plaque SMC, aortic SMC and the spots that have a statistically 
significant difference in volume are identified.   
 
2.6.3 Statistical Analysis 
 
All statistics were performed using the Progenesis Stats tool incorporated into the software.  
Parametric tests are used (T-test for 2 groups and One Way ANOVA for 3 or more groups) with 
p<0.05 as significant.  The log of the normalised value is used for the statistical tests, as recommended 
by Nonlinear Dynamics, as these values fit the Gaussian distribution.  For presentation purposes, 
graphs of the spot volumes were created using GraphPad Prism version 5.0 for Windows (GraphPad 
Software, San Diego California USA, www.graphpad.com).  The spot volumes can be exported into 
an Microsoft Excel spreadsheet and interrogated further.  The mean spot volumes for each donor were 
calculated from the normalised spot volumes of the three replicate gels.  Error bars represent standard 
error of the mean (SEM) of the average spot volume.  Statistics shown on the graph are those 
calculated by Progenesis Samespots.   
 
Spots that were statistically significant (p<0.05) and differed in expression by >1.2 fold were included 
in the analysisand accepted as a 'real' result.  Those spots which did not meet this criteria were 
manually excluded from the analysis.  Despite this criteria, there is still a 5% chance of false positives, 
i.e. where there is a statistical significance but there is no real difference, especially with a large 
number of spots being analysed.  Manual analysis of all the spots with p<0.05 helped to eliminate 
some of these spots.  In the Progenesis Stats tool, there is an adjusted p-value (q-value), which takes 
into account the false discovery rate (FDR).  For example, a q-value of 0.05 indicates that 5% of the 
significant tests will be a false positive.   
 
2.6.4 Mass Spectrometry 
2.6.4.1 In gel digestion 
 
Gel spots are excised from the gel using a scalpel.  Tryptic digest of the proteins is performed using an 
in-gel digestion method using a robotic digestion system (Progest, Genomic Solutions).  Briefly, gel 
pieces are destained using a solution of potassium ferricyanide (30mM) and  sodium thiosulfate 
Chapter 2  Materials & Methods 
 
 
 
86
(100mM) and then washed in  ammonium hydrogen carbonate buffer (100mM) and dehydrated in 
100% acetonitrile.  Amino acid side chains were reduced with DTT (10mM)and then free thiol groups 
were carbamidomethylated with  iodoacetamide (55mM)in ammonium hydrogencarbonate buffer.  Gel 
pieces were washed in ammonium hydrogen carbonate buffer and deehydrated again with acetonitrile.  
Gel pieces are re-swelled in digestion buffer containing 6.25µg/ml trypsin (Promega) in ammonium 
hydrogen carbonate (50mM).  Digest is carried out for 6 hours.  Peptides are recovered by extraction 
with ammonium hydrogen carbonate solution (25mM) and extracted in 5% formic acid and 
acetonitrile.  
 
2.6.4.2 Electrospray Mass Spectrometry 
 
Samples were analysed by liquid chromatography coupled to tandem electrospray mass spectrometry 
(LC-ESI-MS/MS).  Spectra were recorded using a Q-Tof spectrometer (Micromass, Manchester, UK) 
interfaced to a Micromass CapLC capillary chromatograph. Samples were dissolved in 0.1% formic 
acid and aliquots were injected onto a 300 μm x 5 mm Pepmap C18 column (LC Packings, 
Amsterdam, NL) and eluted with an acetonitrile/0.1% formic acid gradient. The capillary voltage was 
set to 3,500 V. A survey scan over the m/z range 400-1300 was used to identify protonated peptides 
with charge states of 2, 3 or 4, which were automatically selected for data-dependent MS/MS analysis, 
and fragmented by collision with argon. The resulting product ion spectra were transformed onto a 
singly charged m/z axis using a maximum entropy method (MaxEnt3, Waters) and proteins were 
identified by correlation of uninterpreted spectra to entries in SwissProt/TrEMBL, using ProteinLynx 
Global Server (Version 1.1, Waters).   
 
2.6.4.3 Protein Identification by database searching with Mascot Server 
 
Proteins were identified by matching tandem mass spectra to sequence entries in the NCBI database, 
using Mascot (www.matrixscience.com).  The search criteria were as follows: fixed modification of 
carbamidomethylation was allowed due to treatment of the cysteine groups with iodacetamide during 
in-gel digestion; one missed cleavage per peptide was allowed; a peptide tolerance of ±1.2Da and a 
peptide charge of 1+ were set; MS/MS tolerance was set to 0.6Da; error tolerant search was also 
enabled. 
 
The Mascot scoring algorithm assigns a statistical significance to each individual peptide or fragment 
ion match (Perkins, Pappin et al. 1999).  For each observed peptide, a score is given called the ions 
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score, which is a probability that the match is a random event.  The ion score is -10*log (P), where P is 
the probability that the observed match is a random event.  Individual ions scores above 56 indicate an 
identity or extensive homology (p<0.05).  A high score represents a low probability that the match is 
random.  Any matched proteins are represented in a histogram with a cumulative probability-based 
score.  Based upon this information, I assumed that identifications based on two independently 
matching non-identical peptides, with a combined ions score of over 100 were likely to be valid.  
Candidate matches that did not meet these criteria were accepted only after manual review of the 
spectra.  The identified protein is the protein first in the list generated by Mascot top protein, matched 
to Homo sapiens.  Protein matches using the identified peptide sequences were further confirmed 
using the Basic Local Alignment Search Tool (BLAST) search on the NCBI website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
 
2.7 General reagents 
2.7.1 Tissue Culture 
 
DMEM, RPMI, HBSS, sterile H2O and penicillin/streptomycin were purchased from PAA 
Laboratories Ltd (Yeovil, UK), SmGM2 medium (PromoCell GmBH, Heidelberg, Germany), red cell 
lysis buffer (Sigma-Aldrich, UK), 0.25% Trypsin-EDTA (Gibco, Invitrogen, Paisley, UK), human 
recombinant TNFα (R&D Systems, Abingdon, UK), cholesterol complexed with methy;-β-
cyclodextrin (Sigma). 
 
2.7.2 Immunostaining 
 
Normal goat serum, normal rabbit serum and secondary antibodies were purchased from Dako 
(Denmark). Paraformaldehyde, haematoxylin (VWR International Limited, Leicestershire, UK), 
Vector ABC (Vector, Peterborough, UK), Avidin/Biotin blocking kit (Vector), Cholesterol Methyl- β-
cyclodextrin (Sigma), Oil Red O (VWR), propidium iodide (Molecular probes, Invitrogen). 
 
2.7.3 Gene expression 
 
RNA extraction kit and QiaShredders (Qiagen Limited, Crawley, UK), TurboDNase (Ambion 
Incorporated, Austin, USA), primers (Eurofins MWG Operon, Germany), Taq polymerase and 
Chapter 2  Materials & Methods 
 
 
 
88
Platinum UDG Supermix (Invitrogen), MMLV (Promega), RT2 profiler array and First Strand cDNA 
kit (SA Biosciences, USA), Taqman probes (Applied Biosystems, Warrington, UK). 
 
2. 7.4 Two Dimensional Electrophoresis 
 
Dalt Precast gels, Dalt gel buffer kit, PlusOne cover oil, urea, sodium dodecyl sulphate (SDS), CHAPS 
& pharmalyte were all purchased from GE Healthcare (Amersham, UK), DTT, iodoacetamide and 
sodium acetate are from Sigma.  Silver nitrate (Fischer Scientific, Loughborough, UK), sodium 
bicarbonate, sodium thiosulphate, formaldehyde (38% w/v), acetic acid, methanol were all purchased 
from VWR.  
 
2.7.5 General Chemicals & Solutions 
 
10xPBS (VWR), Hydrogen Peroxide (Sigma), LPS-free gelatin (Sigma).  All other chemicals were 
from VWR. 
 
2.8 Recipes 
2.8.1 Buffers 
 
2.8.1.1 General Buffers 
 
10 x PBS (pH 7.4) 137 mM NaCl 
     2.7 mM KCl  
    4.3 mM Na2HPO4 
    1.47 mM KH2PO4 
 
 
10 x TBS   500 mM Tris.HCl pH 7.4   
    1500 mM NaCl 
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50 x TAE   242g Tris-base  
    57.1ml Glacial Acetic Acid   
    18.6 g EDTA  
 
MACS buffer   0.5% FCS, 2mM EDTA, 1 x PBS 
 
1 x RIPA buffer  50mM Tris-HCl  
    150mM NaCl  
    1mM EDTA  
    0.1% SDS    
    1mM sodium orthovanadate 
    1% NP-40  
    10mM sodium pyrophosphate 
     25mM beta-glycerophosphate 
 
RLT buffer   RLT buffer (Qiagen), 1µl beta mercaptoethanol per ml RLT buffer 
 
2.8.1.2 Electrophoresis buffers 
 
4 x Reducing Sample Buffer   250mM trisHCl, pH 6.8 
      40% glycerol 
      50mM DTT 
      0.8% SDS 
      0.05% (w/v) bromophenol blue 
 
4 x Non-reducing Sample Buffer  250mM trisHCl, pH 6.8 
      40% glycerol 
      0.8% SDS 
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      0.05% (w/v) bromophenol blue 
 
1x Tris-Acetate running buffer   50mM Tricine  
      50mM Tris base  
      0.1% SDS  
      pH 8.24 
 
1x MOPS running Buffer  (pH 7.7)  50mM MOPS  
      50mM Tris base 
      0.1% SDS  
      1mM EDTA 
    
2.8.1.3 Immunoblotting buffers  
 
Blocking solution    5% low fat milk powder in 1x PBS 
Wash buffer for immunoblotting  1x PBS, 0.01% Tween-20 
 
2.8.1.4 ELISA buffers  
 
ELISA wash buffer    1x PBS, 0.01% Tween-20 
ELISA Stop Acid    1M H2SO4 
 
2.8.2 Oil Red O 
 
Oil Red O solution    1% Oil red O in 100% isopropanol 
Dextrin solution    1% w/v dextrin 
Working solution    3:2 (Oil red O: Dextrin solution) 
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2.8.3 2DE Buffers 
 
Lysis Buffer     9.5M Urea 
      2% (w/v) CHAPS 
      1% (w/v) DTT  
      0.8% (v/v) Pharmalyte 3-10  
 
Rehydration Buffer      9.5M Urea 
      0.5% (w/v) CHAPS,  
      0.2% (w/v) DTT  
      0.2% (w/v) Pharmalyte  
      Bromophenol blue (trace) 
 
Equilibration Buffer      9.5M Urea 
      2% (w/v) SDS  
      33% v/v Glycerol  
      25mM Tris-HCl pH 8.8 
      Bromophenol blue (trace) 
 
Running buffers    Dalt gel buffer kit  (GEHealthcare, cat # 17-6002-50) 
 
2.8.4 Silver staining reagents 
 
Silver Staining     (per litre) 
Fix      100ml acetic acid 
      400ml methanol 
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Sensitise     5% sodium thiosulphate 
      68g sodium acetate 
300ml Methanol 
       
Silver Nitrate     2.5g silver nitrate 
 
Developer     25g Sodium carbonate 
      400μl Formaldehyde (added just before use) 
      
Stop solution     14.6g EDTA 
Chapter 2  Materials & Methods 
 
 
 
93
 
Antibody Species Clone Source Application Concentration/ Dilution 
Primary antibodies      
Alpha tubulin mouse DM1A Sigma WB 1:5000 
Phospho-p38 MAPK rabbit 3D7 Cell Signalling Technologies WB 1: 1000 
Phospho-p44/42 MAPK rabbit polyclonal Cell Signalling Technologies WB 1: 1000 
Phospho-JNK mouse G9 
98F2 
Cell Signalling Technologies WB 1: 1000 
IκBα rabbit sc847 Santa Cruz WB 1: 1000 
Phospho serine78 Hsp27 mouse JBW502 Millipore / Upstate WB 1:2000 
αSMA mouse 1A4 Dako IHC 
IF 
1:500 
1:1000 
SM-MHC mouse ID8 / 
SMMS1 
Chemicon IF  
WB, 
1:1000 
1:500 
SMemb / NM-MHC goat polyclonal Santa Cruz WB 1:500 
TNF receptor p55 mouse 16803 R&D Systems WB  1:500 
TNF receptor p75 mouse 22221 R&D Systems WB  
IHC 
1:500 
25µg/ml 
Annexin 1 rabbit polyclonal Invitrogen WB 
IHC 
1:500 
1:100 
Annexin 2 rabbit Polyclonal 
IgG 
Santa Cruz WB 
IHC 
1:500 
1:50 
Hsp60 mouse LK1 Abcam WB 
IHC 
1:500 
1:50 
CD68 Rat FA-11 AbD Serotec IHC  
Isotype control IgG2α mouse MADNP-2 AbD Serotec IHC 25µg/ml 
Secondary antibodies      
Swine anti-rabbit - HRP swine - Dako WB 1:2000 
Rabbit anti mouse - HRP rabbit - Dako WB 1:2000 
Rabbit anti-goat HRP rabbit - Dako WB 1:2000 
Goat anti-rabbit goat - Dako IHC 1:400 
ELISA antibodies      
Interleukin 6 - capture rat MQ2-
13A5 
BD Pharmingen E 1µg/ml 
Interleukin 6 - biotin rat MQ2-
39C3 
BD Pharmingen E 500ng/ml 
Interleukin 8- capture mouse G265-5 BD Pharmingen E 2µg/ml 
Interleukin 8 - biotin mouse G265-8 BD Pharmingen E 500ng/ml 
MCP-1- capture  mouse 23007 R&D Sytems E 2µg/ml 
MCP-1 biotin goat  R&D Sytems E 25ng/ml 
TNFα- capture mouse MAb1 BD Pharmingen E 4µg/ml 
TNFα biotin mouse MAb11 BD Pharmingen E 500ng/ml 
MMP-3 capture   Biosource E 3µg/ml 
MMP3- biotin   Biosource E 50ng/ml 
 
Table 2.1 Antibodies used in this study. WB: western blot, IHC: Immunohistochemistry, IF: 
immunofluorescence, E: ELISA, HRP; horse radish peroxidase, Ig: immunoglobulin, IL-6; interleukin 
6, IL-8; interleukin 8, MCP-1; monocyte chemoattractrant protein-1, MMP-3; matrix 
metlloproteinase-3, NM-MHC; non-muscle myosin heavy chain, TNFα; tumour necrosis factor alpha. 
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Table 2.2 Parameters for reverse transcription PCR.  An example of a PCR program used to 
amplify cDNA for GAPDH analysis.  The initial denaturation stage was held for 4 minutes at 95°C.  
The reaction then cycled through steps 2, 3 and 4, before returning to step 2 again.  This cycle was 
repeated 30 times to amplify the gene.  An extra polymerise step was added at the end of the reaction.   
 
 
 
 
 
 
 
 
 
 
 
Gene  Sequence 
αSMA 
 
Forward 
Reverse 
CTGTTCCAGCCATCCTTCAT 
CCGTGATCTCCTTCTGCATT 
SM-MHC 
 
Forward 
Reverse 
AGGAAATCTTGCTGCAGGTG 
TTGCTCTTGAGTGCGTTCAC 
SMemb / 
NM-MHC 
Forward 
Reverse 
CAGTTCCCGCTGGAGTTTAC 
TCGCACTGAGAAGAAGCTGA 
Calponin 
 
Forward 
Reverse 
GGAGCTGAGAGAGTGGATCG 
GTGCCAATTTTGGGTTGACT 
GAPDH 
 
Forward 
Reverse 
ATGAGGTCCACCACCCTGTT 
CATGGAGAAGGCTGGGGCTC 
Oligo d(T)  TTTTTTTTTTTTTTT 
 
 
Table 2.3 Primer sequences used in this study.  The sequences of the forward and reverse primers 
are provided for each gene investigated. αSMA: smooth muscle alph-actin, SM-MHC: smooth muscle 
myosin heavy chain, SMemb/NM-MHC; embryonic isoform of smooth muscle myosin heavy chain/ 
Non-muscle myosin heavy chain, GAPDH; Glyceraldehdye-3-Phosphate Dehydrogenase, Oligo d(T); 
an oligomer of 15 deoxythymidine resiudes (used for cDNA production). 
 
 
 
 
Step Process Temperature (°C) 
Time 
(minutes) 
1 Denature 95 4 
2 Denature 95 1 
3 Anneal 60 45s 
4 Polymerise 72 45s 
5 Polymerise 72 4 
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Gene Taqman Assay ID NCBI Reference sequence 
TNFR I Hs00533560_m1 NM_001065.2 
TNFRII Hs00153550_m1 NM_001066.2 
CCR1 Hs00174298_m1 NM_001295.2 
 
 
 
Table 2.3 Taqman PCR probes used in this study.  Sequences of Taqman primers are proprietary 
information.  The assay ID number for Applied Biosystems and the NCBI reference sequence is listed  
 
 
 
 
Table 2.4 List of Genes on the RT2 Profiler PCR array for Atherosclerosis.  Gene bank refers to 
the accession number on the NCBI website.  There are 84 atherosclerosis related genes, 5 
housekeeping genes (ACTB, B2M, HPRT1, RPL13A and GAPDH) and controls. 
 
Gene bank Symbol Description Gene Name 
NM_005502 ABCA1 ATP-binding cassette, sub-family A (ABC1), 
member 1 
ABC-1/ABC1 
NM_000789 ACE Angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
ACE1/CD143 
NM_001122 ADFP Adipose differentiation-related protein ADRP 
NM_000039 APOA1 Apolipoprotein A-I MGC117399 
NM_000384 APOB Apolipoprotein B (including Ag(x) antigen) FLDB 
NM_000041 APOE Apolipoprotein E AD2/LPG 
NM_004324 BAX BCL2-associated X protein Bax zeta 
NM_000633 BCL2 B-cell CLL/lymphoma 2 Bcl-2 
NM_004049 BCL2A1 BCL2-related protein A1 ACC-1/ACC-2 
NM_138578 BCL2L1 BCL2-like 1 BCL-XL/S 
NM_001196 BID BH3 interacting domain death agonist FP497 
NM_001165 BIRC3 Baculoviral IAP repeat-containing 3 AIP1/API2 
NM_002982 CCL2 Chemokine (C-C motif) ligand 2 GDCF-2/GDCF-2 HC11 
NM_002985 CCL5 Chemokine (C-C motif) ligand 5 D17S136E/RANTES 
NM_001295 CCR1 Chemokine (C-C motif) receptor 1 CD191/CKR-1 
NM_000648 CCR2 Chemokine (C-C motif) receptor 2 CC-CKR-2/CCR2A 
NM_000610 CD44 CD44 molecule (Indian blood group) CDW44/CSPG8 
NM_001795 CDH5 Cadherin 5, type 2, VE-cadherin (vascular 
epithelium) 
7B4/CD144 
NM_003879 CFLAR CASP8 and FADD-like apoptosis regulator CASH/CASP8AP1 
NM_000090 COL3A1 Collagen, type III, alpha 1 (Ehlers-Danlos 
syndrome type IV, autosomal dominant) 
EDS4A 
NM_000757 CSF1 Colony stimulating factor 1 (macrophage) MCSF 
NM_000758 CSF2 Colony stimulating factor 2 (granulocyte-
macrophage) 
GMCSF 
NM_001901 CTGF Connective tissue growth factor CCN2/HCS24 
NM_001964 EGR1 Early growth response 1 AT225/G0S30 
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NM_000501 ELN Elastin (supravalvular aortic stenosis, Williams-
Beuren syndrome) 
SVAS/WBS 
NM_000118 ENG Endoglin (Osler-Rendu-Weber syndrome 1) CD105/END 
NM_004102 FABP3 Fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor) 
FABP11/H-FABP 
NM_000043 FAS Fas (TNF receptor superfamily, member 6) ALPS1A/APO-1 
NM_000508 FGA Fibrinogen alpha chain Fib2 
NM_002006 FGF2 Fibroblast growth factor 2 (basic) BFGF/FGFB 
NM_002026 FN1 Fibronectin 1 CIG/DKFZp686F10164 
NM_001945 HBEGF Heparin-binding EGF-like growth factor DTR/DTS 
NM_000201 ICAM1 Intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor 
BB2/CD54 
NM_000874 IFNAR2 Interferon (alpha, beta and omega) receptor 2 IFN-R/IFN-alpha-REC 
NM_000619 IFNG Interferon, gamma IFG/IFI 
NM_000575 IL1A Interleukin 1, alpha IL-1A/IL1 
NM_000877 IL1R1 Interleukin 1 receptor, type I CD121A/D2S1473 
NM_004633 IL1R2 Interleukin 1 receptor, type II CD121b/IL1RB 
NM_000586 IL2 Interleukin 2 IL-2/TCGF 
NM_000588 IL3 Interleukin 3 (colony-stimulating factor, multiple) IL-3/MCGF 
NM_000589 IL4 Interleukin 4 BSF1/IL-4 
NM_000879 IL5 Interleukin 5 (colony-stimulating factor, 
eosinophil) 
EDF/IL-5 
NM_002203 ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 
BR/CD49B 
NM_002205 ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
CD49e/FNRA 
NM_000887 ITGAX Integrin, alpha X (complement component 3 
receptor 4 subunit) 
CD11C 
NM_000211 ITGB2 Integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 
CD18/LAD 
NM_002253 KDR Kinase insert domain receptor (a type III receptor 
tyrosine kinase) 
CD309/FLK1 
NM_016270 KLF2 Kruppel-like factor 2 (lung) LKLF 
NM_005559 LAMA1 Laminin, alpha 1 LAMA 
NM_000527 LDLR Low density lipoprotein receptor (familial 
hypercholesterolemia) 
FH/FHC 
NM_002309 LIF Leukemia inhibitory factor (cholinergic 
differentiation factor) 
CDF/D-FACTOR 
NM_005577 LPA Lipoprotein, Lp(a) AK38/APOA 
NM_000237 LPL Lipoprotein lipase HDLCQ11/LIPD 
NM_002421 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) CLG/CLGN 
NM_002422 MMP3 Matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
MMP-3/SL-1 
NM_002445 MSR1 Macrophage scavenger receptor 1 CD204/SCARA1 
NM_003998 NFKB1 Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 1 (p105) 
DKFZp686C01211/EBP-
1 
NM_000603 NOS3 Nitric oxide synthase 3 (endothelial cell) ECNOS/NOS III 
NM_000905 NPY Neuropeptide Y PYY4 
NM_005693 NR1H3 Nuclear receptor subfamily 1, group H, member 3 LXR-a/LXRA 
NM_002607 PDGFA Platelet-derived growth factor alpha polypeptide PDGF-A/PDGF1 
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NM_002608 PDGFB Platelet-derived growth factor beta polypeptide 
(simian sarcoma viral (v-sis) oncogene homolog) 
PDGF2/SIS 
NM_002609 PDGFRB Platelet-derived growth factor receptor, beta 
polypeptide 
CD140B/JTK12 
NM_005036 PPARA Peroxisome proliferative activated receptor, alpha NR1C1/PPAR 
NM_006238 PPARD Peroxisome proliferator-activated receptor delta FAAR/NR1C2 
NM_015869 PPARG Peroxisome proliferator-activated receptor gamma NR1C3/PPARG1 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and cyclooxygenase) 
COX1/COX3 
NM_002957 RXRA Retinoid X receptor, alpha NR2B1 
NM_000450 SELE Selectin E (endothelial adhesion molecule 1) CD62E/ELAM 
NM_000655 SELL Selectin L (lymphocyte adhesion molecule 1) CD62L/LAM-1 
NM_003006 SELPLG Selectin P ligand CD162/CLA 
NM_002575 SERPINB2 Serpin peptidase inhibitor, clade B (ovalbumin), 
member 2 
HsT1201/PAI 
NM_000602 SERPINE1 Serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
PAI/PAI-1 
NM_000454 SOD1 Superoxide dismutase 1, soluble (amyotrophic 
lateral sclerosis 1 (adult)) 
ALS/ALS1 
NM_000582 SPP1 Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1) 
BNSP/BSPI 
NM_000660 TGFB1 Transforming growth factor, beta 1 CED/DPD1 
NM_003238 TGFB2 Transforming growth factor, beta 2 TGF-beta2 
NM_003248 THBS4 Thrombospondin 4 TSP4 
NM_002160 TNC Tenascin C (hexabrachion) HXB/TN 
NM_000594 TNF Tumor necrosis factor (TNF superfamily, member 
2) 
DIF/TNF-alpha 
NM_006290 TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 A20/OTUD7C 
NM_001078 VCAM1 Vascular cell adhesion molecule 1 CD106/DKFZp779G2333 
NM_003376 VEGFA Vascular endothelial growth factor A VEGF/VEGF-A 
NM_000552 VWF Von Willebrand factor F8VWF/VWD 
NM_004048 B2M Beta-2-microglobulin B2M 
NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome) 
HGPRT/HPRT 
NM_012423 RPL13A Ribosomal protein L13a RPL13A 
NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase G3PD/GAPD 
NM_001101 ACTB Actin, beta PS1TP5BP1 
SA_00105 HGDC Human Genomic DNA Contamination HIGX1A 
SA_00104 RTC Reverse Transcription Control RTC 
SA_00104 RTC Reverse Transcription Control RTC 
SA_00104 RTC Reverse Transcription Control RTC 
SA_00103 PPC Positive PCR Control PPC 
SA_00103 PPC Positive PCR Control PPC 
SA_00103 PPC Positive PCR Control PPC 
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Time 
(minutes) 
Voltage 
(V) 
Current 
(Amps) 
40 100 0.138 
40 180 0.140 
30 300 0.150 
30 450 0.150 
30 700 0.118 
20 1000 0.060 
20 1500 0.041 
20 2000 0.037 
10 2500 0.034 
10 3000 0.045 
~20hrs 3500 0.051 
Total 75 kVh 
 
Table 2.5 Isoelectric focusing on MultiphorII system for 3 IPG strips.  This table gives an example 
of how the voltage was gradually increased during IEF to focus 3 IPG strips, to reach a maximum of 
3500V for a total of 75kVh.  The maximum current per IPG strip should not exceed 0.05Amps, 
therefore the maximum current shown here is 0.15 Amps (3 x 0.05A). 
 
 
Step Solution  Time (minutes) 
1 Fix 15 
2 Sensitisation 60 
3 Wash 5 
4 Wash 5 
5 Silver stain 60 
6 Wash 1 
7 Wash 1 
8 Wash 1 
9 Develop 10 (maximum) 
10 Stop 10 
11 Wash 5 
12 Wash 5 
13 Wash 5 
 
Table 2.6 Protocol for Silver-staining of 2D-gels.  Minor modifications were made to this protocol; 
fixation step was carried out overnight rather than for 15 minutes.  For pre-cast gels, sensitisation and 
incubation with Silver nitrate were increased to 1 hour to ensure good staining. Volumes of solutions 
were also increased for pre-cast gels, to 300-400ml per gel, to ensure adequate coverage of the gel.  
For all gels approximately 100ml of developer was added initially and discarded when the solution 
became cloudy.  Fresh developer was added so that gels were developed in clean solution.  Gels were 
developed for approximately 10minutes before the developing solution was discarded and the reaction 
stopped with EDTA.  (Taken from (Yan, Wait et al. 2000). 
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3. Introduction 
 
Mature SMC in physiological conditions exhibit low rates of proliferation, migration and cell death.  
During atherosclerosis, SMC acquire the ability to migrate, proliferate and produce extracellular 
matrix proteins.  The acquisition of these characteristics, which resembles their developmental 
phenotype more than that of a mature SMC, is known as phenotypic modulation (Chamley-Campbell, 
Campbell et al. 1979) (Owens 1995) and is a critical process in the progression of atherosclerosis.  The 
migration of SMC from the medial layer to the intima indicates progression from a “fatty streak” to a 
more developed lesion (Ross 1999).  The production of extracellular matrix proteins and formation of 
the fibrous cap mark the formation of an advanced lesion (Stary, Chandler et al. 1995).  Thus, SMC 
play an important role in atherosclerosis.  Accordingly, much research has been dedicated to study 
SMC and elucidate the mechanisms involved in their phenotypic modulation.   
 
SMC are traditionally characterised and identified by their expression of contractile proteins including 
smooth muscle α-actin (αSMA), smooth muscle myosin heavy chain (SM-MHC), calponin and 
SM22α.  Positive identification of αSMA alone is not sufficient for identification of SMC to the 
exclusion of other cell types, as discussed in section 1.2.1, so a panel of markers must be used.  Gary 
Owens described a continuum of SMC differentiation from embryonic to mature (Owens 1995) (see 
Chapter 1.2.1 and Figure 1.3).  However, this process appears to be reversed during atherosclerosis as 
the expression of these proteins decreases during atherosclerosis.  This confounds efforts to identify 
SMC from tissues containing different cell types.  SM-MHC is perhaps the only one of these proteins 
that may be specific to SMC (Owens 1995).  There are two smooth muscle cell specific isoforms of 
the myosin heavy chain; SM1 and SM2 but their expression changes during development (Aikawa, 
Sivam et al. 1993).  A third isoform of MHC normally only seen in embryonic SMC (SMemb), is up 
regulated in SMC from atherosclerotic lesions (Aikawa, Sivam et al. 1993) (Kuro-o, Nagai et al. 
1991). 
 
The process of phenotypic modulation is more than simply a passive loss of positive differentiation 
signals.  Rather, it is an actively controlled process, with external stimuli influencing the expression of 
SMC marker proteins.  For example, stimulation of rat aortic SMC in vitro with PDGF, leads to 
proliferation of SMC and also reduced expression of αSMA (Blank and Owens 1990).  In this study, 
proliferation was only observed in the first 36 hours, despite continuous stimulation with PDGF.  In 
contrast, αSMA expression was suppressed as long as PDGF was present, and subsequently αSMA 
was increased upon removal of PDGF.  The transcriptional control mechanisms that regulate 
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expression of these genes have now been elucidated.  For example, myocardin acts as a transcriptional 
co-activator with serum response factor (SRF) in the expression of several SMC genes including 
αSMA and SM-MHC (Yoshida, Sinha et al. 2003).  Conversely, the transcription factor Krüppel like 
factor-4 (KLF-4) inhibits the expression of these genes (Liu, Sinha et al. 2005).   
 
Alterations in contractile protein expression are accompanied by an increase in the size and number of 
organelles (Chamley-Campbell, Campbell et al. 1979).  Enlarged endoplasmic reticulum and golgi 
apparatus are required for the synthetic SMC to produce extra cellular matrix (ECM) proteins.  During 
development, SMC synthesise matrix proteins, which stabilise newly formed vessels.  Similarly, SMC 
in atherosclerotic lesions have increased synthetic ability compared to medial SMC, although the ECM 
proteins synthesised here are different from those found in the media (Raines 2000).  For instance, 
basement membrane proteins such as laminin are down regulated, while there is up regulation of 
collagen I, elastin and proteglycans such as perlecan and versican (Thyberg 1996; Hultgardh-Nilsson 
and Durbeej 2007).  Disruption of the contact between SMC and ECM via the inhibition of integrins 
has been shown to contribute to vascular remodelling by increasing proliferation (Welser, Lange et al. 
2007).  Alterations in matrix affect the phenotype of intimal SMC, allowing increased proliferation 
and migration.  The production of ECM and soluble mediators by SMC in turn further influences SMC 
phenotype.  Consequently, the phenotype of SMC would be constantly changing throughout lesion 
development.   
 
Heterogeneity in SMC shape has been observed and this has been correlated with rates of proliferation 
and migration in vitro.  For example, different SMC phenotypes in culture had previously been 
identified from the porcine coronary artery as rhomboid shape (R-SMC) or spindle shaped (S-SMC) 
(Hao, Ropraz et al. 2002).  R-shaped SMC were found in the neointima of arteries after injury, while 
S-shaped SMC were found in the media.  Proteomic analysis comparing these SMC identified a low 
molecular weight calcium binding protein, S100A4 as being differentially expressed between medial 
and intimal SMC.  This protein was increased in R-SMC, and correlated to increased rates of 
proliferation and migration compared to S-SMC.  Down regulation of S100A4 expression with siRNA 
led to decreased proliferation of R-SMC.  These findings were confirmed in human coronary arteries, 
where S100A4 was found to be markedly increased in SMC of atherosclerotic and restenotic lesions 
compared to the media (Brisset, Hao et al. 2007).   
 
The ability to distinguish intimal SMC from medial SMC and other cell types using specific markers 
holds great potential for therapeutic intervention.  However, despite what is known about SMC and the 
phenotypic modulation, this objective is yet to be achieved.  Proteomic and genomic technologies have 
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the potential to identify proteins or genes that play a role in pathogenesis of disease.  A number of 
studies have employed these techniques to investigate differences in SMC phenotype in the context of 
atherosclerosis and restenosis.   
 
In a study using representational difference analysis (a PCR based technique), eight genes were 
identified as being increased in plaque SMC compared to medial SMC (Zhang, Goddard et al. 2002).  
These genes included insulin-like growth factor 1 binding protein (IGFBP) 2, cartilage link protein, 
laminin β1 and smooth muscle γ-actin.  Although this confirmed an earlier observation from the same 
group, that production of IGFBP-2 by plaque SMC is increased (Patel, Zhang et al. 2001), novel genes 
that could provide further information of SMC phenotype were not encountered.  Validation of these 
findings was performed using northern blot analysis and in situ hybridisation but information of 
corresponding protein levels was not available.   
 
Microarray analysis of SMC from human internal mammary artery compared to those from human 
saphenous vein identified 2 differentially expressed genes involved in the coagulation cascade (Payeli, 
Latini et al. 2008).  These vessels are used as bypass grafts for patients with coronary artery disease.  
Expression of tissue factor was 3 times lower in internal mammary artery compared to saphenous vein, 
whereas tissue plasminogen activator was 9-fold higher in internal mammary artery.  Tissue factor is a 
key protein in the initiation of thrombus formation and it can also induce SMC migration (Payeli, 
Latini et al. 2008).  Conversely, tissue plasminogen activator is involved in fibrinolysis.  These 
findings were validated at the mRNA and protein levels, and also tissue factor activity assays were 
performed.  Internal mammary artery SMC exhibited decreased thrombotic activity and migration 
compared to saphenous vein SMC, supporting evidence that patients who receive saphenous vein 
bypass grafts experience increased thrombotic events and bypass graft disease compared to those who 
receive internal mammary artery grafts (Loop, Lytle et al. 1986).   
 
The proteome of SMC from human saphenous vein has been mapped using 2-dimensional 
electrophoresis (2DE) (McGregor, Kempster et al. 2001) and this was later used to identify proteins 
that were differentially expressed when saphenous vein were subjected to simulated arterial blood 
flow (mimicking that experienced by HSV in grafting) (McGregor, Kempster et al. 2004).  These 
SMC experienced changes in protein expression associated with cytoskeletal remodelling.  The actin 
binding proteins CapZ and gelsolin were increased in those cells exposed to simulated arterial blood 
flow.  The expression of the small chaperone heat shock protein (Hsp) 27 was also increased overall, 
although the phosphorylated forms of Hsp27 were reduced, suggesting Hsp27 phosphorylation is 
important in cytoskeleton organisation.  The proteome and the secretome of cultured SMC from 
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normal human IMA was also mapped using 2DE and 83 intracellular and 18 secreted proteins were 
identified, respectively, providing useful reference maps (Dupont, Corseaux et al. 2005).   
 
To the best of my knowledge, a direct comparison of the proteomes of human medial and 
atherosclerotic SMC has yet to be performed.  Therefore, the aim of my study was to use 2DE and 
tandem mass spectrometry to study differences between human atherosclerotic and medial non-
atherosclerotic SMC.  I created a proteome reference map of human SMC from atherosclerotic and 
medial SMC, identifying as many proteins as possible on the 2D gel.  Quantitative analysis of the 2D 
gel images revealed differences in protein expression and proteins were identified using the proteome 
map.  By directly comparing the proteome of these SMC, I identified differences in protein expression, 
which distinguish AthSMC from AoSMC and may be useful in determining mechanisms that 
contribute to pathogenesis of the atherosclerosis. 
 
3.1 Morphology of SMC cultures 
 
The cell types used in this study were examined daily for morphological criteria in culture.  Human 
carotid plaque-derived SMC (AthSMC) and commercial human aortic SMC (AoSMC) show similar 
morphology with spindle-like shape (Figure 3.1 A & B).  Porcine SMC appeared smaller than the 
human SMC.  Many cells displayed the spindle-like morphology but 'epithelioid' or 'rhomboid' cell 
shapes were also observed in the porcine SMC cultures (Figure 3.1C and black arrows) in accordance 
with previous literature. 
 
Figure 3.1 Morphology of primary SMC used in this study. A) Human carotid plaque-derived 
SMC, B) Human aortic SMC, C) Porcine SMC.  Human primary SMC are spindle shape in culture 
(white arrows).  Porcine SMC adopt spindle shape as well as epithelioid shape (black arrows).  Carotid 
plaque SMC have different spatial organisation in culture.  (Magnification x 40)   
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3.2 Expression of smooth muscle cell phenotypic markers  
 
3.2.1 Porcine SMC 
 
Porcine carotid SMC were initially used in this study to establish SMC characterisation protocols.  
SMC from normal porcine carotid arteries were chosen specifically for their anatomical relevance to 
the site of human disease.  Immunopositivity for αSMA and SM-MHC by immunofluorescence 
microscopy was observed in virtually all cells (Figure 3.2).  Staining with both αSMA and SM-MHC 
resulted in the characteristic striated pattern that results from the assembly of the actin filament 
bundles.  Similar results were seen at both early and late passages indicating that porcine SMC retain 
their differentiated phenotype in culture.  This is in agreement with previous reports describing the 
maintenance of the differentiated state of porcine SMC in culture (Christen, Bochaton-Piallat et al. 
1999).  
 
3.2.2 Human Aortic SMC 
 
Non-diseased human carotid SMC are difficult to obtain and are not commercially available.  
Commercially available human aortic SMC (AoSMC) derived from the media of healthy donors were 
assessed for their suitability as a comparison.  Immunofluoresence staining of AoSMC was positive 
for αSMA and SM-MHC (Figure 3.2).   
 
3.2.3 Human Atherosclerotic SMC 
 
SMC isolated from human carotid plaque (AthSMC) by enzymatic digestion were stained for αSMA 
and SM-MHC to confirm SMC identity.  Immunopositivity for αSMA was found at varying levels 
between donors.  The characteristic pattern of actin filaments was present in these cells.  Low levels of 
SM-MHC were detected.  Confirmation of SMC identity of these cells was performed by 
immunostaining.  The size of these cells and that they produce large amounts of extracellular matrix 
proteins makes them difficult to analyse by more quantitative methods such as fluoresence activated 
cell sorting (FACS).   
 
In order to eliminate the possibility of contamination with other cell types, cultures were assessed for 
presence of fibroblast markers.  Two different antibodies for fibroblasts were tested.  However, SMC 
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were also positive for these markers, in addition to αSMA and SM-MHC.  Similar staining was also 
seen in aortic SMC.  Human skin fibroblasts were used as a positive control and were positive for the 
fibroblast markers but not αSMA or SM-MHC.  Therefore, I concluded that the fibroblast markers 
were not specific and could not differentiate between SMC and fibroblasts.  Leukocyte markers were 
not assessed due to the fact that only adherent cells were present in these cultures.  Non-adherent 
leukocytes would have been washed away at early passages.  Endothelial cell markers were not 
assessed in this study as they should have been removed during the isolation process.  However, 
staining with CD31 and Von Willebrand Factor could have been performed to confirm this.   
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Figure 3.2.  Expression of contractile proteins in SMC using immunofluorescence.  Porcine, 
human aortic SMC and human atherosclerotic SMC were stained for contractile proteins smooth 
muscle α-actin and smooth muscle myosin heavy chain.  Expression of contractile proteins was 
assessed in human atherosclerotic SMC isolated from enzymatic digestion and explant methodologies.  
At passage 3, SMC were plated onto LabTech slides, fixed and permeabilised before incubation with 
primary antibodies to smooth muscle α-actin and smooth muscle heavy chain myosin.  Secondary 
antibody conjugated to Alexa-488 fluorochrome, bound to the primary antibody is shown in green and 
Propidium iodide (PI) is shown as red indicating the cell nucleus.  Cells were viewed with 
immunofluorescence microscope.  Magnification x400. 
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As SM-MHC was not easily detectable in human cells by immunofluoresence, I performed 
immunoblotting with the same SM-MHC antibody (Figure 3.3).  The antibody detects both smooth 
muscle cell specific myosin heavy chains SM1 and SM2, which migrate to 204 and 200kDa in gel 
electrophoresis, respectively.  Porcine SMC were used as a positive control as they express high levels 
of SM-MHC, as seen in the immunofluoresence staining (Figure 3.3B).  Two bands could be seen at 
approximately 210kDa, representing the two SM-MHC isoforms, SM1 and SM2 (Figure 3.3).  SM1 
expression was variable and detected in porcine SMC, but only occasionally in AoSMC and AthSMC.  
SM2 was detected in all samples, with variable levels of expression.  This is in line with reports by 
Aikawa, et al who found that SM2 expression was decreased in SMC of atherosclerotic arteries 
(Aikawa, Sivam et al. 1993).  However, I did not observe the same findings in SM1 expression.  This 
could be due to differences in detection methods used and the different arteries examined.  Aikawa et 
al used cDNA probes and immunohistochemistry on sections of human aorta and coronary arteries to 
detect expression, whereas I used immunoblotting on the lysates of cultured SMC from aorta and 
carotid arteries.  It is possible that SM-MHC isoform expression may also alter during cell culture.  
Nevertheless, from this result I conclude that I detect at least one isoform of SM-MHC, which is the 
only known protein expressed by SMC alone.   
 
Expression of myosin heavy chain isoform SMemb was detected with an antibody specific to the 
human SMemb (Figure 3.3).  SMemb was expressed in both AoSMC and AthSMC.  SMemb was 
initially considered a marker of neointimal SMC as it was expressed by neointimal SMC in rabbit 
coronary arteries but not in normal adult medial SMC (Kuro-o, Nagai et al. 1991).  However, 
expression of SMemb was also detected in adult SMC of normal human coronary arteries (Aikawa, 
Sivam et al. 1993).  My results show SMemb is also expressed in human aortic medial SMC and 
human carotid intimal SMC, further confirming the SMC origin of the cells in culture.   
 
Interestingly, the alpha-tubulin was negative for the porcine SMC, despite strong expression of SM-
MHC.  Alpha-tubulin is highly conserved between human and porcine (96% sequence similarity, 
according to a BLAST search) and so the antibody should work with both species.  Therefore it is 
possible that the negative alpha-tubulin staining in Figure 3.3 is due to a technical problem with the 
western blot process.  
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Figure 3.3 Expression of smooth muscle myosin heavy chain isoforms.  SMC lysates were 
analysed by western blotting for expression of smooth muscle myosin heavy chain isoforms.  Porcine 
SMC lysate was used as a positive control for SM-MHC.  Cell lysates were run on a 4-12% Bis-Tris 
minigel with 1 x MOPS running buffer.  Proteins were transferred to PVDF membrane and membrane 
was probed with SM-MHC antibodies in 5% milk.  
 
 
As an additional means of phenotyping, I also investigated the expression of αSMA, SM-MHC, 
SMemb and calponin at the mRNA level using PCR (Figure 3.4).  This method is only semi-
quantitative.  However, expression of αSMA was similar between the AoSMC and AthSMC, while 
expression of SM-MHC was generally higher in AoSMC.  SMemb expression was low and only 
detected in AoSMC.  The SMC markers could not be detected in a minority of AthSMC donors 
(Figure 3.4, lane 4).  This is maybe representative of differences in the extent of phenotypic 
modulation of SMC in different donors.   
 
Some correlations could be made between protein and mRNA levels.  In figures 3.3 and 3.4, the 
AoSMC represent the same donors.  Both of these donors have high levels of SM-MHC protein and 
mRNA.  They also both express SMemb at the protein and mRNA levels (although very faint).  For 
the AthSMC, only one of the donors was used for both immunoblotting and PCR.  AthSMC in lane 5 
in Figure 3.3 and lane 7 in Figure 3.4 represent the same donor.  Different AthSMC donors were used 
for these experiments due to most of the cells being used for the proteomic studies and only when 
there were sufficient cells, could they also be used for immunoblot and PCR analysis.  
 
In conclusion, all SMC used in this study expressed the cell type markers αSMA, SM-MHC, SMemb 
and calponin, at the protein and mRNA level.  In accordance with the literature, porcine SMC were the 
most differentiated and AthSMC were less differentiated.  
Chapter 3  SMC characterisation & Proteomic Analysis 
 
 
 
109
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 mRNA expression of smooth muscle cell markers.  The expression of the genes for the 
SMC markers αSMA, SM-SMHC, SMemb and H1-calponin were assessed in different donors by PCR.  
The housekeeping gene, GAPDH was used as a loading control.  Lane 1; negative control, no cDNA, 
Lanes 2 & 3; AoSMC donors, Lanes 4-7; AthSMC from different donors.  Arrows in the SMemb and 
Calponin images indicate the PCR product, which is the upper band.  Lower bands are primer 
dimmers, a by-product of the PCR process. 
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3.3 Isolation of SMC by explantation 
 
3.3.1 Porcine SMC 
 
Isolation of SMC from explants of arterial tissue was first described by Chamley-Campbell (Chamley-
Campbell, Campbell et al. 1979).  Isolation of cells using this method may select for those cells with a 
more migratory ability and more likely to respond to cytokine and growth factor stimulation involved 
in the atherogenic process (Li, Fan et al. 2001).  Therefore, I attempted this method of SMC isolation.  
I initially used porcine carotid arteries to establish the methodology, utilising explants with different 
shapes (‘ring’ and ‘square’ explants) as described in (Saward and Zahradka 1997).  Cells appeared to 
migrate from the tissue within a few days of culture (Figure 3.5 A&B) and SMC were clearly visible 
after 3 weeks (Figure 3.5 C&D).  The morphology of SMC obtained from explants was spindle 
shaped.  However, both spindle and rhomboid shaped SMC were obtained from enzymatically 
digested carotid artery (Figure 3.1C).  In contrast, Hao et al showed that isolation of SMC by 
explantation led to a culture of rhomboid shaped SMC whereas spindle shaped SMC were obtained 
with enzymatic digestion (Hao, Ropraz et al. 2002).  These differences in SMC morphology between 
my study and that by Hao et al maybe due to the isolation of cells from different arteries as they have 
been shown to have different developmental origins; carotid SMC are derived from the neural crest 
whereas coronary artery SMC are derived from the proepicardium (Majesky 2007).   
 
3.3.2 Human Atherosclerotic SMC 
 
As the isolation of what appeared to be a pure SMC population was successful from porcine SMC, I 
applied this technique to human carotid endarterectomy specimens.  Adherent cells were visible after 
just 3 days in culture on average (Figure 3.6 A).  Interestingly, this time period was variable with 
different plaque specimens, from 3 to 14 days.  I did not observe clear differences in the cell 
morphology between SMC that were enzymatically digested and those that were allowed to migrate 
from the tissue.  Expression of SMC markers in explants-derived SMC was slightly higher in explant-
derived SMC compared to SMC derived from enzymatic digestion of plaques (Figure 3.2).  However, 
again this was variable between donors. 
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Figure 3.5 Porcine SMC migrate from explants of carotid artery. Observation of tissue explants by 
light microscopy.  Ring explants (A) and square explants (B), after 2 days in culture.  Some cells can 
be seen to migrate from the tissue although the cell type cannot be confirmed at this time point.  Ring 
(C) and square (D) explants after 3 weeks in culture.  Cells appear to be SMC shape, similar to those 
obtained by enzymatic digestion of artery.  Magnification x100. 
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Figure 3.6.  Isolation of SMC from explants of human carotid endarterectomy specimens. 
Observation of tissue explants by light microscopy.  A & B) Smooth muscle like-cells can be seen 
migrating from the tissue at just 3 days in culture.  Dark areas in the field of vision are the edges of the 
explant, included to show that the cells originate from this tissue.  C) Day 12.  Many cells have 
migrated from the tissue look like smooth muscle cells.  The cells are orientated in the same direction 
suggesting movement of cells away from the explant.  Magnification x 100 
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3.3.3 Isolation of medial carotid SMC 
 
The ideal control to with which to compare the atherosclerotic SMC would be SMC from the same 
artery and the same patient.  Therefore, I attempted to isolate SMC from non-diseased tissue that could 
be identified macroscopically on the endarterectomy specimens.  These explants were cultured 
separately from the atherosclerotic tissue.  However, I was successful in obtaining medial SMC in 
only two out of ten attempts.  Medial SMC were slow to migrate from the tissue, taking 1 to 2 weeks 
to become visible, compared to just a few days with the plaque SMC (Figure 3.7).  Additionally, fewer 
cells were obtained from the tissue overall compared to the atherosclerotic SMC, limiting their use in 
experiments at the same passage.   
 
 
 
 
 
Figure 3.7 Isolation of SMC from medial explants of carotid plaque specimens.  Observation of 
tissue explants by light microscopy.    A&B) Explants from medial sections of carotid plaque 
specimens after approximately 1week (A) and 2 weeks (B) in cell culture.  No cells appear to have 
migrated from the tissue at 1 week.  At 2 weeks, there are spindle shaped SMC beginning to migrate 
from the tissue C) Explants from another donors at approximately 3 weeks in culture.  This was a 
successful attempt at isolating medial SMC.  At 21 days in culture many SMC had migrated from the 
tissue.  Explant methodology was not always successful in isolating SMC from medial carotid tissue.  
Magnification x100 
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3.3.4 Experimental set up for exploration of the proteome 
 
Based on the outcome of this SMC characterisation study, I decided not to use porcine SMC in further 
studies.  Due to their retention of a more terminally differentiated state over many passages in culture, 
I felt that they were very different from SMC in human atherosclerotic disease and were not an 
appropriate control.  The limited success in growing non-atherosclerotic medial SMC from carotid 
explants hampered their use, particularly for proteomic studies where large numbers of cells are 
needed.  Therefore, I decided that the most suitable SMC for controls were the commercially available 
AoSMC.  In addition, I decided to use SMC from enzymatically-digested plaques, rather than 
explants-derived SMC.  As the method of enzymatic digestion generally resulted in more SMC ex-
vivo, less population-doublings in culture would be necessary to reach the cell numbers necessary and 
the cells would be more likely to retain their specific AthSMC characteristics.  Furthermore, this 
method of isolation matched that used for the isolation of AoSMC.   
 
For analysis of the proteome of AthSMC, I used SMC from ten donors to create 2D gel images and 
compared them to the 2D gel images from six AoSMC donors.  The mean age of the patients was 65.3 
years and the mean age of aortic donors was 31.5 years (see Appendix 2 for donor information).   
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3.4 Mapping the Smooth Muscle Cell Proteome 
 
To assist in the identification of differentially expressed proteins, I first put together a protein map of 
reference (Figure 3.8).  Preparative 2D gels containing 400µg protein, from AoSMC and AthSMC cell 
lysates were created and spots excised for analysis by mass spectrometry.  Protein identifications are 
listed in Table 3.1 and Appendix 1.  A total of 84 spots were positively identified from 192 spots cut 
from the gel for anlaysis.  The proteins were classified according to their gene ontologies from the 
UniProt website (www.uniprot.org) (Figure 3.9).  Chaperones and cytoskeletal proteins were the most 
abundant proteins. 
 
 
 
Figure 3.8 Two-dimensional reference map of the proteins in expressed in human smooth muscle 
cells.  SMC were used at passage 3 after 48 hours of serum starvation.  400µg protein was separated 
on a pH4-7 IPG strip followed by 12% SDS PAGE.  Triplicate gels were created for each sample.  
Spot pattern was visualised with silver staining and spots were excised for analysis by mass 
spectrometry.  Identified proteins are numbered and listed in Table 3.1.  Only spots that were 
positively identified are numbered.  Protein identifications are listed in Table 3.1 and Appendix1. 
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Table 3.1 Protein Identifications of the human SMC proteome.  Proteins were identified from 2D 
gels using mass spectrometry.  Numbers correlate to the gel image in Figure 3.11.  Only spots that 
were positively identified are listed.  A full table of proteins with accession numbers and identified 
peptides is shown in Appendix 1. 
 
 
Spot Protein Identification Function 
1 Vimentin cytoskeletal 
2 Vimentin cytoskeletal 
3 Vimentin cytoskeletal 
4 Heat shock protein 60 chaperone 
5 Mitochndrial heat shock protein 60 chaperone 
6 Stress-70 protein, mitochondrial / GRP 75 chaperone 
7 HSPA9 / HSP70 chaperone 
8 T-complex protein 1 subunit epsilon chaperone 
9 Protein disulphide isomerase A3 protein isomerase 
10 Protein disulphide isomerase A3 protein isomerase 
11 Isoform 2 of Caldesmon cytoskeletal 
12 Isoform 2 of Caldesmon cytoskeletal 
13 ATP synthase subunit beta, mitochondrial ATP synthesis 
14 ATP synthase subunit beta ATP synthesis 
15 Heat shock cognate 71 kDa protein chaperone 
16 Protein disulfide-isomerase protein isomerase 
17 Protein disulfide-isomerase protein isomerase 
18 Actin, cytoplasmic 1 cytoskeletal 
19 Actin, cytoplasmic 1 cytoskeletal 
20 Actin, cytoplasmic 1 cytoskeletal 
21 Actin, cytoplasmic 1 cytoskeletal 
22 Actin, cytoplasmic 1 cytoskeletal 
23 Actin, alpha 2 smooth muscle cytoskeletal 
24 Pyruvate Kinase M1/M2 glycolytic enzyme 
25 Alpha-enolase glycolytic enzyme 
26 Protein disulfide-isomerase protein isomerase 
27 Glutathione S-transferase omega-1 glutathione transferase 
28 Glutathione S-transferase omega-1 glutathione transferase 
29 Cathespin B protease 
30 Cathepsin D  protease 
31 Protein disulphide isomerase A3 protein isomerase 
32 Tubulin beta-1 chain cytoskeletal 
33 F-actin-capping protein subunit alpha-1 cytoskeletal 
34 Prolyl 4-hydroxylase subunit alpha-1 oxidoreductase 
35 Prolyl 4-hydroxylase subunit alpha-1 oxidoreductase 
36 F-actin-capping protein subunit alpha-1 cytoskeletal 
37 Pyruvate Kinase M1/M2 glycolytic enzyme 
38 Pyruvate Kinase M1/M2 glycolytic enzyme 
Alpha-enolase/ glycolytic enzyme 39 
Elongation factor Tu, mitochondrial translation elongation factor 
40 Annexin A2 isoform 2 calcium binding protein 
41 78 kDa glucose-regulated protein chaperone 
42 Heat shock protein beta-1 chaperone 
43 Triosephosphate isomerase 
protein isomerase / glycolytic 
enzyme 
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44 Triosephosphate isomerase 
protein isomerase / glycolytic 
enzyme 
45 Endoplasmic reticulum protein ERp29 protein folding / chaperone 
46 Pyruvate Kinase M1/M2 glycolytic enzyme 
47 Peroxiredoxin 4 antioxidant 
48 Endoplasmic reticulum protein ERp29 protein folding / chaperone 
49 Heat shock protein beta-1 chaperone 
Prohibitin unknown 50 
Chloride intracellular channel 4 chloride channel 
51 Annexin A2 calcium binding protein 
52 Peroxiredoxin 4 antioxidant 
53 Ubiquitin carboxyl-terminal hydrolase isozyme L1 ubiquitin conjugation enzyme 
54 Annexin A1 calcium binding protein 
55 Annexin A1 calcium binding protein 
56 78 kDa glucose-regulated protein chaperone 
57 Cathepsin B protease 
58 Perilipin-3 (Cargo selection protein TIP47) transport 
59 Chaperonin containing T-complex protein 1 subunit theta chaperone 
60 Proteasome subunit beta type-6 proteosome protease 
61 
Procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(Proline 4-hydroxylase), beta polypeptide, isoform 
CRA_b 
protein isomerase 
62 ATP synthase subunit delta, mitochondrial ATP synthesis 
63 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
metabolic enzyme                  
(citric acid cycle) 
64 Peroxiredoxin-2 antioxidant 
65 Glutathione S-transferase P glutathione transferase 
66 Proteasome subunit beta type-4 Proteosome 
67 Superoxide Dismutase antioxidant 
68 Heat shock protein beta-6 chaperone 
69 Thioredoxin-dependent peroxide reductase, mitochondrial [Precursor] chaperone 
70 Parkinsons disease protein 7 chaperone 
71 Proteasome subunit beta type-3 proteosome protease 
72 Heterogeneous nuclear ribonucleoprotein H mRNA processing 
73 Protein disulfide-isomerase A6 protein isomerase 
74 Elongation factor 2 Transcripiton 
75 26S proteasome ATPase subunit 2 Proteosome 
76 Aldehyde dehydrogenase, mitochondrial oxidoreductase 
77 Cytochrome b-c1 complex subunit 1, mitochondrial electron transport chain 
78 Triosephopshate isomerase 1 isoform 1 isomerase / glycolytic enzyme 
79 Proteasome alpha 1 subunit isoform 2 proteosome protease 
80 N-acetyl-beta-glucosaminidase prepropolypeptidepeptide glycosidase 
81 N-acetyl-beta-glucosaminidase prepropolypeptidepeptide glycosidase 
Glutathione S transferase glutathione transferase 82 
Peroxiredoxin-2 antioxidant 
83 Vimentin cytoskeletal 
84 Galectin-1 galactose binding 
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Figure 3.9 Pie chart of the identified proteins on SMC proteome reference map.  The 84 
identified proteins were classified according to their gene ontology categories for biological processes 
in UniProt.  Chaperone and cytoskleletal proteins are the most abundant of the identified proteins. 
Graph produced with Microsoft Office Excel 2007. 
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3.5 Identification of differentially expressed proteins  
 
Digital images of analytical 2D gels were quantitatively analysed with Progenesis SameSpots.  From 
those spots identified as being significantly different between the two groups, 29 differences were 
confirmed (Figure 3.10).  Of these, 13 spots were identified: eight spots were decreased in AthSMC 
and five spots were decreased in AthSMC compared to AoSMC (Table 3.2).  The identifications of 
these proteins were obtained from Mascot and further confirmed with BLAST searches in NCBI or 
UniProt, using peptide sequences obtained from MS/MS spectra (see Appendix 1, Figures A1.1 to 
A.20).  
 
Figure 3.10 Protein spots identified to be significantly different between aortic and plaque SMC. 
SMC were used at passage 3.  Gel images from analytical 2D gels, of unstimulated AoSMC and 
AthSMC containing 100µg protein per gel, were compared using Progenesis Samespots software.  
Triplicate gels were run for each donor.  Spots that were identified to be statistically significantly 
different between groups are circled in red and are numbered (p<0.05, T-test).  A p value < 0.05 was 
considered statistically significant.  Numbers correspond to protein ID on the Proteome Map in Figure 
3.11 and Table 3.1. 
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Mean Spot volumes (106 pixels)  
Spot Protein Identification Function Aortic            
(± SEM) 
Plaque            
(± SEM) 
T-test      
(p value) 
13 ATP Synthase ATP Synthesis 11.15    (±0.34) 8.84   (±0.31) 0.0004 
19 Actin cytoskeleton 11.25   (±0.92) 9.11   (±0.59) 0.032 
20 Actin cytoskeleton 23.38   (±1.22) 18.56   (±1.11) 0.018 
21 Actin cytoskeleton 18.89   (±0.52) 15.95   (±0.92) 0.037 
23 Actin cytoskeleton 7.27   (±0.63) 5.26   (±0.54) 0.007 
37 Pyruvate kinase metabolic enzyme 4.87   (±1.32) 7.57   (±1.17) 0.046 
49 Heat shock protein-27 chaperone 8.75   (±0.75) 10.79   (±0.47) 0.024 
52 Peroxiredoxin 4 antioxidant 8.27   (±0.90) 11.04   (±0.61) 0.019 
57 Cathepsin B protease 11.28   (±0.96) 13.89   (±0.72) 0.047 
60 Proteasome subunit beta 6 protease 6.67   (±0.3) 5.27   (±0.31) 0.014 
64 Peroxiredoxin 2 antioxidant 19.70   (±1.07) 22.45   (±0.63) 0.027 
76 Aldehyde Dehydrogenase -2 antioxidant 2.55   (±0.22) 1.93   (±0.086) 0.011 
83 Vimentin cytoskeleton 10.59   (±1.3) 6.16  (±0.38) 0.0017 
 
 
Table 3.2 List of protein differentially expressed between unstimulated aortic and plaque SMC.  
Mean spot volumes of the identified proteins were used to calculate fold change in expression, using 
Progenesis Samespots software.  The overall mean spot volume for each group was calculated from 
the mean spot volumes from the triplicate gels per donor.  Error is shown as standard error of the mean 
(S.E.M.) of the average spot volume.  Fold change is relative to plaque SMC compared to aortic SMC.  
Statistics were performed in Progenesis Samespots, using a two-tailed T-test.  A p value < 0.05 was 
considered statistically significant. 
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 3.5.1 Cytoskeletal proteins 
 
The spot volumes of these identified proteins were plotted graphically to display the expression 
patterns amongst donors.  Four spots identified as cytoplasmic actin (ACT_B, beta-actin) were down 
regulated in AthSMC compared to AoSMC (Figure 3.11).  This is consistent with the down regulation 
of actin during phenotypic modulation of SMC reported by Chamley-Campbell et al (Chamley-
Campbell, Campbell et al. 1979) and the decrease in actin staining in Figure 3.2.  The actin spots are 
all at the same molecular weight but have small changes in their pIs, from 5.3 to 6.0.  This difference 
in pI would occur by post-translational modifications, such as acetylation.  According to the Uniprot 
database (www.uniprot.org), actin can be post-translationally modified by acetylation, methylation or 
phosphorylation.  The N-terminus of actin is highly charged (see Figure 3.12 for amino acid sequences 
of human alpha-actin and beta-actin, which contain three aspartate or three glutamate resiudes 
respectively).  Acetylation of these charged amino acids results in a change of the overall charge of the 
actin molecule therefore increasing the pI (Abe, Saeki et al. 2000).  Additionally, acetylation of ε-
amino groups of lysine residues in actin is also thought to strengthen its associations with myosin 
(Choudhary, Kumar et al. 2009).   
 
Actins make up a large amount of the total protein in SMC.  Several actin isoforms are present in SMC 
including beta-actin, gamma-actin and alpha-actin.  Smooth muscle alpha-actin (αSMA) is the most 
abundant actin isoform in SMC (Owens 1995), although during the phenotypic modulation of SMC 
beta-actin has been reported to be expressed in higher amounts (Etienne, Pares-Herbute et al. 1998).  
Interestingly, αSMA did not appear as the first match in the BLAST search using the peptides 
identified (Appendix 2, Figure A1.2).  I used the BLAST tool to align the protein sequences of beta-
action to αSMA (ACTA_HUMAN) to examine the homology of these two proteins.  There is 94% 
homology between cytoplasmic actin and αSMA.  Sequence alignment is shown in Figure 3.12.  Only 
one peptide was detected in the regions where the sequence differed between the two proteins (Figure 
3.12), although this peptide was identified in several of the actin spots.   Therefore, the actin in these 
spots could also be αSMA.  
 
Spot 83, identified as vimentin was reduced by 31% in AthSMC compared to AoSMC (Figure 3.11).  
Vimentin is an intermediate filament protein of the cytoskeleton.  The observed molecular weight/pI 
(50/4.5) corresponds closely to the predicted values (53/5.06).  Vimentin can be phosphorylated, 
which may account for the slightly more acidic pI observed.  Other vimentin spots were also 
identified, although their expression was unchanged between the two groups (see Table 3.1).  
Vimentin is expressed in several different cell types and so it is of little use as a marker of SMC 
lineage or differentiation state.  
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Figure 3.11 Plaque SMC have decreased cytoskeletal proteins.  Spot volumes of actin spots 19, 20, 
21 and 23 were identified to be significantly different between AoSMC and AthSMC.  Expression of a 
vimentin isoform was also significantly decreased.  Spot volumes are presented here graphically as the 
mean average of the spot volume ± SEM.  * p <0.05, **p<0.01, T-test.  Statistics were performed in 
Progenesis Samespots. 
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Figure 3.12 Alignment of cytoplasmic actin and smooth muscle amino acid sequences.  
Cytoplasmic actin (ACTB_HUMAN) and smooth muscle alpha-actin (ACTA_HUMAN) were aligned 
using the sequence alignment tool in Uniprot.  Boxes indicate actin peptides identified by ESI MS/MS.  
These peptides can be found in either cytoplasmic actin or smooth muscle alpha-actin. 
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3.5.2 Heat shock protein 27 
 
Spot 49 was identified as the small molecular chaperone heat shock protein 27 (Hsp27).  The spot 
volume was increased in AthSMC compared to AoSMC by approximately 23% (Figure 3.13). 
Interestingly, spot 42 was also identified as Hsp27, although the expression of this spot was 
unchanged between AoSMC and AthSMC.  The pI of spot 49 is approximately 5.8, which corresponds 
to the presence of one phosphate group (McGregor, Kempster et al. 2004).  Hsp27 can be 
phosphorylated at 3 different serine residues; ser-15, ser-78 and ser-82 and therefore potentially 
detected at 4 different pIs, which become more acidic with increasing number of phosphate groups.  
The phosphorylation state of Hsp27 is thought to be important in the proliferation of SMC (Trott, 
McManus et al. 2009).  Additionally, in a proteomic study of human saphenous vein SMC exposed to 
simulated arterial blood flow, a change in the phosphorylation state of Hsp27 was associated with 
cytoskeletal changes (McGregor, Kempster et al. 2004).  However, the peptides identified in this 
analysis did not contain these sites of phosphorylation (Appendix 2, Figure A1.14C) and so the 
phosphorylation state could not be confirmed.   
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Figure 3.13 Plaque SMC have increased expression of a phosphorylated form of Heat shock 
protein 27.  Two spots on the 2D gel were identified as Hsp27; 42 and 49.  The two spots had the 
same molecular weight but differed in their pI by approximately 0.5, which could corresponds to a 
phosphorylation of Hsp27 (A).  Only spot 49 was significantly different between AoSMc and AthSMC 
(B).  Spot volumes are presented here graphically as the mean average of the spot volume ± SEM.  * p 
<0.05, T-test.  Statistics were performed in Progenesis Samespots. 
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3.5.3 Antioxidant proteins 
 
Peroxiredoxin-4 (Prdx4) was also identified as two separate spots, 52 and 47.  Spot 52, was identified 
as being increased in AthSMC compared to AoSMC by 33% (Figure 3.14).  Peroxiredoxins are a 
family of intracellular antioxidant enzymes involved in reducing harmful peroxide species.  To reduce 
peroxides, a cysteine residue at the active site is oxidised.  Peroxidredoxins often appear as a doublet 
on 2D gels, with the more acidic spot representing an oxidised form of the enzyme (Wagner, Luche et 
al. 2002). In Jurkat cells, experimental induction of oxidative stress with hydrogen peroxide led to an 
increase in the more oxidised forms of peroxiredoxins 2 and 3, demonstrating that they are markers of 
exposure to oxidative stress (Rabilloud, Heller et al. 2002).  In a proteomic analysis of the aortas from 
apoE-/- mice, there were increased levels of the oxidised 1-Cys peroxiredoxin, compared to apoE+/+ 
mice (Mayr, Chung et al. 2005), suggesting that oxidative stress is increased in atherosclerosis.  It 
would be expected that with increased levels of oxidised Prdx4, there would be a corresponding 
decrease in the reduced form, as described for 1-cys peroxiredoxin.  However, there was no difference 
in the volume of spot 47 between the two groups, possibly due to an up regulation in Prdx4 
expression, to cope with the increased oxidative stress.  Interestingly, Prdx4 has been shown to 
mediate activity of NFκB signalling (Jin, Chae et al. 1997) (Kabe, Ando et al. 2005).  The NFκB 
signalling pathway can be activated by ROS such as H2O2, although this is thought to be cell specific 
effect.  Over expression of Prdx4 in Hela cells was shown to inhibit the activation of NFκB, via the 
inhibition of IκB phosphorylation although, the exact mechanism could not be elucidated (Jin, Chae et 
al. 1997).  As this regulation relies on the ability of Prdx4 to reduce H2O2, if Prdx4 is already oxidised, 
then its ability to regulate NFκB activation would be reduced.   
 
Another cytosolic peroxiredoxin, Prdx2 (spot 64) was also increased in AthSMC compared to AoSMC 
(Figure 3.14).  Prdx2 was only detected as one spot with an observed molecular weight/pI of 20/5.59, 
which is close to the predicted values (21.7/5.67).  Similarly to Prdx4, Prdx2 may play a role in 
regulating cell signalling pathways, as over expression of prdx2 in Hela cells was shown to prevent 
NFκB activation by hydrogen peroxide (H2O2) (Kang, Chae et al. 1998).  Additionally, Prdx2 has also 
been shown to regulate PDGF signalling (Choi, Lee et al. 2005).  PDGF is an important factor for the 
proliferation and migration of SMC.  Stimulation of Prdx2-deficient mouse embryonic fibroblasts 
(MEFs) with PDGF, led to an increase in H2O2 production and increased activation of the PDGF 
receptor, compared to wild type MEFs.  Additionally, the intima of carotid arteries of Prdx2-/- mice 
subjected to wire injury was significantly larger than those in wild type mice (Choi, Lee et al. 2005). 
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Figure 3.14 The oxidised form of Peroxiredoxin-4 is increased in plaque SMC.  Peroxiredoxin-4 
was identified as spots 52 and 47 (A).  The change in pI of approx 0.2 suggests that spot 52 is an 
oxidised form of peroxiredoxin-4, which was increased in AthSMC (B).  The reduced form, spot 47 
was not significantly different between AthSMC and AoSMC (C).  Peroxiredoxin-2 was also 
significantly increased in AthSMC (D).  Spot volumes are presented here graphically as the mean 
average of the spot volume ± SEM.  * p <0.05, T-test.  Statistics were performed in Progenesis 
Samespots. 
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3.5.4 Mitochondrial Proteins  
 
Spot 13 was identified as the mitochondrial protein ATP Synthase subunit beta and was decreased in 
AthSMC by 21% (Figure 3.15).  ATP Synthase is the last protein complex (complex V) in the electron 
transport chain and uses the proton gradient across the inner mitochondrial membrane to produce ATP 
from ADP.  The beta subunit is part of the F1 catalytic core of complex V.  A decrease in this protein 
may indicate a decrease in ATP production.  This is contrary to what is expected as AthSMC are 
considered active and synthetic cells, with increased migration and producing ECM – cellular 
processes that require energy.  Therefore the decrease in ATP Synthase subunit-β could indicate 
mitochondrial damage.   
 
Spot 76 was identified as aldehyde dehydrogenase 2 and was decreased in AthSMC by 24% (Figure 
3.15).  Aldehyde dehydrogenase 2 is an important mitochondrial enzyme, involved in the 
detoxification of reactive aldehydes such as the ethanol metabolite acetaldehyde, malondialdehyde and 
4-hydroxy-2-nonenal produced in lipid peroxidation.  These aldehydes can react with amino groups of 
proteins and damage proteins in the mitochondria such as those in the electron transport chain.  
Aldehyde dehydrogenase 2 is therefore important in preserving mitochondrial function.  The function 
of aldehyde dehydrogenase 2 has been well characterised in cardiac cells and is important for 
cardioprotection (Wenzel, Muller et al. 2008) (Budas, Disatnik et al. 2009) (Lagranha, Deschamps et 
al. 2010).  A recent study using a murine model of ischemia/reperfusion (I/R) injury showed that 
female hearts have less injury than male hearts (Lagranha, Deschamps et al. 2010).  Proteomic 
analysis revealed an increase in phosphorylated (activated) aldehyde dehydrogenase 2 in female hearts 
compared to male hearts and following ischaemia/ reperfusion cardiac myocytes from the female 
hearts had less ROS than those in males (Lagranha, Deschamps et al. 2010).  Furthermore, increased 
oxidative stress deactivates aldehyde dehydrogenase 2 (Wenzel, Hink et al. 2007).  Decrease in 
aldehyde dehydrogenase 2 levels has been shown to increase mitochondrial oxidative stress (Wenzel, 
Schuhmacher et al. 2008).  Hence, a decrease in aldehyde dehydrogenase 2 in AthSMC in my study 
suggests they are less protected from oxidative stress.   
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Figure 3.15 Mitochodnrial proteins are decreased in atherosclerotic SMC.  Spot 13 was identified 
as ATP Synthase subunit beta (A), spot 76 was identified as aldehyde dehydrogenase 2 (B).  
Expressions of both proteins were decreased in AthSMC compared to AoSMC.  Spot volumes are 
presented as the mean average of the spot volume ± SEM.  *p <0.05, ***p<0.001, T-test.  Statistics 
were performed in Progenesis Samespots.   
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3.5.5 Glucose metabolism 
 
Pyruvate kinase, identified from spot 37 was increased in AthSMC by 50% (Figure 3.16).  Pyruvate 
kinase is a glycolytic enzyme, which catalyses the removal of a phosphate group from phosphoenol 
pyruvate, producing pyruvate and a molecule of ATP.  This is the final step in glycolysis.  An 
increased in glycolysis would generate more ATP, which may be required if mitochondrial ATP 
production is decreased due to mitochondrial damage.  The observed molecular weight and pI (37 and 
6.0) of this spot do not match with the predicted values (57.8 and 5.95) suggesting that this is a 
fragment of the full-length protein.  Other spots were also identified as pyruvate kinase, although their 
expression did not significantly differ between the two groups (spots 24, 38, and 46, see Table 3.1).   
 
3.5.6 Lysosomal Proteins 
 
Cathepsin B (spot 57) was also increased in AthSMC by 23% compared to AoSMC (Figure 3.16).  Its 
observed molecular weight/pI (27/5.3) corresponds well with the predicted values for the processed 
cathepsin B (27.8/5.23).  Cathepsin B is a cysteine protease found in lysosomes and its activity is 
optimal at acidic pH.  It is synthesised as a pro-enzyme and an N-terminal pro-peptide must be 
proteolytically cleaved for the protein to become active.  Increased mRNA and protein levels of 
cathepsin B were detected in lesions of apoE-/- mice (Ma, Malbon et al. 2008).  It is primarily 
expressed by SMC and macrophages (Lutgens, Cleutjens et al. 2007).  Its role in atherosclerosis has 
not been determined, although other cathepsins, cathepsin K and -S have been associated with matrix 
degradation and remodelling (Sukhova, Shi et al. 1998). 
 
3.5.7 Proteasome 
 
Spot 60, identified as proteasome subunit beta 6 was decreased in AthSMC by 21% (Figure 3.16).  
Proteasomes are a site for intracellular protein degradation.  The proteasome beta subunits make up the 
catalytic core of the 20S and 26S proteasome.  The ubiquitin proteasome system is not only involved 
with the degradation of misfolded proteins, but it is also involved in the regulation of cellular 
processes such as the cell cycle, apoptosis and inflammation. The proteasome has been implicated in 
atherosclerosis progression (Herrmann, Lerman et al. 2010).  Proteasome inhibition has been 
demonstrated to affect SMC cytoskeleton organisation and possibly SMC proliferation (Thyberg and 
Blomgren 1999).  Low levels of proteasome inhibition may also induce expression of protective anti-
oxidant enzymes (Meiners, Ludwig et al. 2006).  High levels of proteasome inhibition may result in 
cell death through NFκB (which is an anti-apoptotic pathway) (Herrmann, Lerman et al. 2010) 
Chapter 3  SMC characterisation & Proteomic Analysis 
 
 
 
131
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Differential expression of Pyruvate Kinase, Cathepsin B and Proteasome subunit 
beta -6.  The expression of pyruvate kinase (A) and cathepsin B (B) were significantly increased in 
AthSMC compared to AoSMC where as proteasome subunit beta 6 (C) was significantly decreased in 
AthSMC compared to AoSMC.  Spot volumes are presented here graphically as the mean average of 
the spot volume ± SEM.  * p <0.05, T-test.  Statistics were performed in Progenesis Samespots. 
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3.7 Discussion 
 
SMC are one of the most abundant arterial cell types present in the lesion.  Therefore the changes that 
occur in SMC behaviour and function are important in the progression of atherosclerosis and vascular 
remodelling.  The phenotype of smooth muscle cells is dynamic, with the ability to respond to external 
cues in their environment (Owens 1995).  Compared to SMC in other species such as the pig (which 
are more terminally differentiated and continue to express SMC markers throughout culture for at least 
5 passages (Christen, Bochaton-Piallat et al. 1999)), SMC in humans are less terminally differentiated 
and have a greater phenotypic plasticity.  Christen showed that porcine SMC continue to express high 
levels SMC markers such as αSMA and SM-MHC for 5 passages, although other markers such as 
desmin and smoothelin did decrease with passage number (Christen, Bochaton-Piallat et al. 1999).  In 
contrast to porcine SMC, SMC proteins decrease in human SMC over culture (Chamley-Campbell, 
Campbell et al. 1979).  The plasticity of human SMC is considered a survival advantage to the 
organism, to allow repair of the vessel following vascular injury.  However, the ability of SMC to 
respond to environmental cues such as proinflammatory mediators and lipids predisposes them to the 
acquisition of characteristics that may contribute to the development of vascular disease.   
 
In this study, I isolated SMC from enzymatically digested carotid plaque tissue.  SMC identity was 
confirmed using a panel of established markers and multiple methodologies.  Across all primary cells 
studied, porcine SMC appeared to be the most differentiated and AthSMC were the least 
differentiated.  AoSMC had intermediate features of these cells.  Although these markers are useful in 
determining SMC identity and may indicate the differentiation state of SMC, they do not provide 
further information about SMC behaviour in atherosclerosis.  To address this, I used proteomic 
analysis to compare the intracellular proteome of AthSMC to that of medial AoSMC, to identify 
differences in protein expression that may explain the behaviour of SMC in human atherosclerotic 
plaques.  Using quantitative 2D gel analysis, I identified 29 spots that were statistically significantly 
different between AthSMC and AoSMC.  Thirteen were characterised by tandem MS, which resulted 
in the identification of ten individual proteins.  Four spots were cytoplasmic actin, all of which were 
decreased in AthSMC.  This is consistent with previous descriptions of phenotypically modulated 
SMC (Chamley-Campbell, Campbell et al. 1979) (Owens, Kumar et al. 2004).  There was also a 
decrease in the expression of a vimentin isoform, further indicating changes in the cytoskeletal 
organisation.  
 
I was able to detect a post-translationally modified form of form of Hsp27, which could be a mono-
phosphorylated form.  This small molecular chaperone has several functions in SMC; playing a role in 
actin polymerisation, apoptosis and cell migration (Salinthone, Tyagi et al. 2008).  Hsp27 has been 
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previously identified as being differentially expressed in at least two different proteomic studies of 
SMC (McGregor, Kempster et al. 2004) (De Souza, Wait et al. 2005) and also atherosclerotic vessels 
(Martin-Ventura, Duran et al. 2004).  Martin-Ventura, et al showed that Hsp27 in the conditioned 
medium of vessels was decreased in atherosclerotic vessels compared to healthy vessels (Martin-
Ventura, Duran et al. 2004).  De Souza et al conducted a proteomic study on right ventricular biopsies 
from patients who had received cardiac transplantation, comparing samples from those patients who 
had developed cardiac allograft vasculopathy (transplant associated atherosclerosis) and those who 
had not (De Souza, Wait et al. 2005).  Diphosphorylated Hsp27 was detected in the blood vessels of 
the biopsy specimens taken from patients that had not developed cardiac allograft vasculopathy, and it 
was absent in those patients who had.  This suggested that diphosphorylated Hsp27 was protective.  A 
further study by the same group showed that over expression of Hsp27 or a hyperphosphorylated 
Hsp27 inhibited SMC proliferation, whereas expression of a unphosphorylated Hsp27 increased 
proliferation (Trott, McManus et al. 2009), suggesting that vascular protection could be mediated by 
inhibition of SMC proliferation.  In my study, levels of unphosphorylated Hsp27 did not differ 
between AthSMC and AoSMC but mono-phosphorylated Hsp27 was increased in AthSMC.  In light 
of the studies by Trott et al and De Souza et al, my finding of mono-phosphorylated Hsp27 may be 
suggestive of a differential proliferative state between the two SMC.  Further studies are required to 
compare the effects on mono- versus diphosphorylation of Hsp27.  Alternatively, Hsp27 is also 
phosphorylated in the p38 MAPK pathway, which may be activated by proinflammatory stimuli 
(Alford, Glennie et al. 2007).  Therefore, this phosphorylation could also be representative of 
activation of the p38 MAPK in AthSMC.  Interestingly, I have observed constitutive low levels of p38 
MAPK and ERK activation in unstimulated AthSMC in immunoblotting (unpublished observations). 
 
The expression patterns of other proteins identified in this analysis are compatible with increased 
oxidative stress in AthSMC.  Oxidative stress occurs due to an imbalance between the production of 
reactive oxygen or nitrogen species and the cell’s ability to detoxify them and repair damage caused to 
proteins, lipids and DNA (Valko, Leibfritz et al. 2007).  The oxidised form of Prdx4 was increased in 
AthSMC but there was no difference in the reduced form, suggesting that its expression is up 
regulated.  This may be a mechanism to withstand increased oxidative stress.  My findings confirm the 
observation of increased expression of oxidised form of cys-1 peroxiredoxin in lesions of the apoE-/- 
mouse compared to wild type mice (Mayr, Chung et al. 2005).  Oxidised cys-1 Prdx was found in the 
aortas of mice just 10 weeks old, suggesting that oxidative stress is an early event in lesion formation.  
Additionally, in older apoE-/- mice of 12 months, the level of oxidation correlated with lesion size.   
 
A consequence of increased oxidative stress is the accumulation of ROS-damaged proteins that need 
to be degraded by the proteasome.  ROS itself can influence proteasome activity.  Oxidative stress 
induced by hydrogen peroxide was shown to inactivate the proteasome in epithelial cells (Zhang, Zhou 
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et al. 2008) and lipid peroxidation products such as 4-hydroxynonenal (4-HNE) also impairs 
proteasome activity (Okada, Wangpoengtrakul et al. 1999).  In keeping with this finding, I observed a 
decrease in the proteasome catalytic subunit beta 6 in AthSMC, compared to AoSMC.   
 
Despite their detrimental effects, at low levels ROS act as intracellular cellular second messengers by 
altering the oxidative state of signalling molecules such as protein tyrosine kinases, protein tyrosine 
phosphatases, MAP kinases and the transcription factor NFκB.  NFκB is important in the regulation of 
genes involved in the immune response and inflammation, proliferation and apoptosis.  It can be 
regulated by oxidative stress (Li and Karin 1999) (Kabe, Ando et al. 2005) (Janssen-Heininger, 
Poynter et al. 2000).  ROS can act at different points of the cell signalling pathways that activate 
NFκB (Figure 3.17).  For example, H2O2 has been shown to increase IKK activity in Hela cells 
(Kamata, Manabe et al. 2002), which would lead to increased phosphorylation of IκBα on serine 
residues and its subsequent ubiquitination and degradation, allowing translocation of NFκB to the 
nucleus (Karin and Lin 2002).  ROS can also activate MAP Kinase pathways, particularly JNK, which 
can also activate NFκB via the interaction of JNK with the c-Rel subunit of NFκB, which induces 
NFκB transactivation (Kabe, Ando et al. 2005).  
 
Prdx4 has been identified as a regulator of NFκB signalling due to its ability to scavenge ROS (Jin, 
Chae et al. 1997).  The oxidised form of Prdx4 was increased in AthSMC in my study, suggesting 
uncontrolled activation of NFκB by ROS.  Indeed, activated NFκB is present in atherosclerotic 
lesions, particularly in regions of SMC and macrophages (Brand, Page et al. 1996).  Increased 
oxidative stress and resulting dysregulation of proinflammatory signalling could play a role in this 
activation.  In keeping with this data, I have shown that stimulation of AthSMC with TNFα leads to 
increased expression of genes controlled by NFκB, compared to AoSMC (see chapter 5).   
 
Chronic ROS exposure can result in mitochondrial dysfunction.  Mitochondria are particularly 
susceptible to damage by ROS as it is estimated that 90% of the cellular ROS species are generated at 
the mitochondria (Balaban, Nemoto et al. 2005).  This mechanism could be linked to my observation 
of decreased ATP Synthase subunit-β expression in AthSMC.  As this subunit of ATP Synthase is part 
of the catalytic domain, its decrease in expression suggests that AthSMC may have experienced 
damage to the protein of the electron transport chain.  If this is so, then SMC must generate ATP via 
other pathways.  In accordance with this, increases in glycolytic enzymes such as alpha-enolase and 
triose phosphate isomerase were seen in a previous proteomic study of the aorta of apoE-/- mice (Mayr, 
Chung et al. 2005).  In my study, pyruvate kinase was also differentially expressed. 
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Figure 3.17 Redox activation of NFκB signalling in the cytoplasm. Stimulation of cells with TNF, 
IL1 or LPS can induce ROS production at the mitochondria or NADPH oxidase enzymes.  This can 
lead to increased activation of IKK, which phosphorylates IκBα and allows translocation of NFκB to 
the nucleus.  JNK MAP Kinase pathway is also activated by ROS, which activates NFκB.  Actions of 
peroxidredoxins regulate ROS induced activation by eliminating the reactive ROS species.  (Diagram 
modified from Kabe, et al, Redox Regulation of activation: Distinct redox regulation between the 
cytoplasm and nucleus. Antioxidants & Redox Signalling, 2005.) 
 
 
Aldehyde dehydrogenase 2 is a key protein in the protection of mitochondria from some of the ROS-
induced damage.  In particular, aldehyde dehydrogenase 2 is involved in the bio-activation of organic 
nitrates.  This is particularly important for the conversion of nitroglycerin to •NO.  This could also 
contribute to a decrease in NO availability and subsequent endothelial dysfunction.  Interestingly, •NO 
formation was reduced in ALDH2-/- mice, contributing to vascular dysfunction (Wenzel, Schuhmacher 
et al. 2008).  The hearts of aldehyde dehydrogenase 2-/- mice show increased oxidative stress, with 
increased mtDNA damage and protein nitration compared to wild type mice (Wenzel, Schuhmacher et 
al. 2008).  Additionally, aldehyde dehydrogenase 2 is deactivated by oxidative stress, which further 
exacerbates the oxidative burden (Wenzel, Muller et al. 2008).  The observed decrease in aldehyde 
dehydrogenase 2 in AthSMC suggests that these cells may lack protective mechanisms against 
reactive aldehydes, compared to AoSMC.  .   
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Despite the process of isolation and cell culture, AthSMC appear to have retained characteristics 
acquired in vivo.  AthSMC show evidence of phenotypic modulation, demonstrated by decreased 
contractile protein expression.  Collectively, the study of the proteome in AthSMC revealed that the 
main distinguishing features of AthSMC are signatures of exposure to chronic oxidative stress and 
mitochondrial damage.  Oxidative stress is a prominent feature of atherosclerosis for which many 
contributing factors exist, e.g. oxLDL, ageing and inflammation (Knight-Lozano, Young et al. 2002; 
Reeve, Stenson-Cox et al. 2007; Li and Fukagawa 2010).  Our results are in keeping with previous 
studies that have shown oxidation of peroxiredoxins (Mayr, Chung et al. 2005).  Finally, my study was 
also able to identify decreased expression of mitochondrial proteins, indicating potential mitochondrial 
damage as an additional feature of AthSMC.   
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4. Introduction 
 
Acute vascular events due to atherosclerosis, such as myocardial infarction and stroke are the leading 
causes of death worldwide (Murray and Lopez 1997).  Plaque rupture is followed by thrombosis 
and/or embolism and is considered the main event in the pathogenesis of acute complications of 
atherosclerosis.  There were 17.1 million deaths from CVD in 2004 (WHO factsheet 317), with 7.2 
million deaths due to coronary heart disease and 5.7 million due to stroke.  Stroke is the second most 
common cause of death worldwide (Lopez, Mathers et al. 2006) and a major cause of mortality in the 
UK, contributing to approximately 53,000 deaths per year in the UK (British Heart Foundation 
statistics for stroke 2009, www.heartstats.org).  In addition to this, there are an estimated 110, 000 
individuals per year in the general UK population who experience their first stroke.  Stroke can be 
debilitating, with the patients losing speech, sensory and motor functions.  The cost of stroke to the 
National Health Service is approximately £2.5 billion (www.heartstats.org), which reflects the long 
process of rehabilitation for these patients.  
 
Eighty per cent of all strokes are ischemic in origin and atherosclerosis affecting the internal carotid 
artery is implicated in approximately 50% of patients.  Acute neurological symptoms arise as a result 
of flow limitation from a critically stenotic lesion or rupture of the plaque complicated by thrombosis 
and/or embolisation of plaque debris distally.  The current consensus for the management of 
symptomatic carotid artery disease is surgical carotid endarterectomy.  However, percutaneous 
treatments have now been evaluated.  Approximately 75% of patients with carotid artery disease are 
asymptomatic.  There is recent evidence to show that carotid endarterectomy surgery may be 
beneficial for asymptomatic patients, with a reduced 5 year-risk of ischemic stroke   (Halliday, 
Mansfield et al. 2004).  Symptomatic patients were defined in this study as experiencing focal 
neurological symptoms pertaining to the contralateral carotid artery (stroke, transient ischaemic attack) 
or ipsilateral carotid artery (amaurosis fugax), within the last 6 months.  Symptomatic status was 
always confirmed by the neuro-vascular multi-disciplinary team at Charing Cross Hospital.  Patients 
were labelled asymptomatic in this study when a carotid stenosis requiring surgery was identified 
during ultrasound in the absence of diagnostic neurological symptoms.   
 
Plaque composition, rather than plaque volume determines the risk of plaque rupture (Falk 1992).  
Thin-capped fibroatheroma (TCFA) are ‘vulnerable’ plaques that are prone to rupture.  These plaques 
are characterised by a large lipid core covered by a thin fibrous cap, which has been infiltrated by 
large numbers of inflammatory cells.  Rupture of the fibrous cap exposes the prothrombotic core of the 
plaque to the arterial blood flow, resulting in thrombosis, which may occlude the artery.  Comparisons 
of symptomatic and asymptomatic plaques by histological analysis revealed that plaque rupture is 
more common in symptomatic patients (Carr, Farb et al. 1996) (Golledge, Greenhalgh et al. 2000) 
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(Yuan, Zhang et al. 2002).  Additionally, symptomatic carotid plaques are enriched in macrophages, T 
cells and foam cells (Carr, Farb et al. 1996) (Jander, Sitzer et al. 1998), indicating that inflammation 
may play a role in plaque destabilisation similar to coronary artery disease (van der Wal, Becker et al. 
1994).  SMC are important in the production and maintenance of the fibrous cap (Libby 1995).  
Assessment of advanced human aortic plaques showed that those plaques with higher lipid or necrotic 
core as well as macrophage content were associated with thrombosis and ulceration, whereas those 
with less lipid and increased numbers of SMC were more stable (Davies, Richardson et al. 1993).   
In the apoE-/- mouse model, induction of SMC apoptosis led to reduced collagen content in the fibrous 
cap, increased inflammation and necrotic core (Clarke, Figg et al. 2006).  Thus, SMC phenotype and 
function may influence plaque stability.  
 
SMC are unique in the sense that they exhibit a high degree of plasticity even during adult life and 
they can change their phenotype and function in response to environmental clues (Owens, Kumar et al. 
2004).  There is evidence that the microenvironment in unstable plaques may be different from the one 
in stable plaques, with pro-inflammatory mediators and cells being up regulated during phases of 
instability (Libby, Sukhova et al. 1995) affecting SMC phenotype and function.  On this basis I 
hypothesised that SMC from plaques that caused acute symptoms might express differences in their 
proteome compared to SMC isolated from clinically silent plaques.  In this chapter I compare the 
protein expression patterns of SMC from carotid endarterectomy specimens obtained from 
asymptomatic and symptomatic patients in attempt to identify differences in SMC proteome, which 
may influence plaque stability.  Furthermore, as asymptomatic plaques can progress to symptomatic 
(Halliday, Mansfield et al. 2004), this comparison could theoretically act as a ‘virtual timeline’ 
demonstrating how SMC proteome may change during switching from clinically silent to unstable 
plaques.  Such comparison has never been attempted before. 
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4.1 Quantitative analysis of protein expression in aortic SMC and 
plaque SMC derived from symptomatic and asymptomatic 
patients 
 
Grouping 2D gel images of plaque SMC, according to the symptomatic status of the patients from 
which they were derived, allowed further differences in protein expression to emerge than seen in 
Chapter 3.  Out of the 10 plaque donors analysed in the previous chapter, six were symptomatic and 
four were asymptomatic according to the clinical criteria detailed in the Methods (see Appendix 2 for 
donor details).  A 3-way analysis was performed comparing AoSMC with SMC from asymptomatic 
and symptomatic patients (aAthSMC and sAthSMC, respectively).  Fifty-three of the spots identified 
as being significantly different between the three groups, were confirmed by visual inspection (Figure 
4.1).  Of these, 28 were identified by mass spectrometry (Table 4.1).  Eleven of these were also found 
in the study described in chapter three, whereas seven were newly identified spots.  
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Figure 4.1 Protein spots identified to be significantly different between aortic SMC and SMC 
from symptomatic and asymptomatic patients.  Gel images of analytical 2D gels from unstimulated 
AoSMC, aAthSMC and sAthSMC were compared using Progenesis Samespots.  Spots identified to be 
significantly different between the 3 groups are circled in red and are numbered (p< 0.05, One Way 
ANOVA).  Aortic donors, n= 6, asymptomatic donors, n=4, symptomatic donors, n=6.  Numbers 
correspond to protein ID on the Proteome Map in Figure 3.11.   
 
 
 
Table 4.1 (see next page) Proteins exhibiting statistically significant differences in expression 
between aortic SMC and SMC from symptomatic and asymptomatic patients.  Mean spot 
volumes were used to calculate fold change in expression.  Fold change is relative to aortic SMC or 
symptomatic plaque SMC (± Standard error of the mean).  Statistical significance was calculated in 
Progenesis Samespots, using One Way ANOVA (p< 0.05) and the calculated p-value is shown. 
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Table 4.1 Proteins exhibiting statistically significant differences in expression between aortic SMC and SMC from symptomatic and asymptomatic 
patients. 
Mean Spot Volumes (106) 
Spot Protein ID 
Swiss Prot 
Accession 
Number Aortic (±SEM) 
Symptomatic 
(±SEM)  
Asymptomatic 
(±SEM) 
One way        
ANOVA (p) 
4 Heat shock protein- 60 P10809 9.50    (±0.62) 10.01    (±0.92) 6.97     (±0.59) 0.042 
13 ATP Synthase subunit beta P06576 11.15     (±0.34) 8.78    (±0.5) 8.94    (±0.35) 0.0003 
16 Protein Disulphide Isomerase P07237 6.55    (±0.43) 5.95    (±0.29) 5.16     (±0.29) 0.037 
19 Actin P60709 11.25    (±0.95) 8.40    (±0.86) 10.18     (±0.41) 0.022 
20 Actin P60709 23.38    (±1.12) 17.19    (±1.43) 20.62     (±1.32) 0.022 
21 Actin P60709 18.89    (±0.52) 14.75    (±1.09) 17.75     (±1.29) 0.025 
22 Actin P60709 15.32    (±1.41) 9.70     (±0.97) 14.67     (±1.43) 0.004 
23 Actin P62736 7.27    (±0.59) 4.63     (±0.22) 6.21     (±0.49) 0.00082 
27 Glutathione S transferase omega-1 P78417 4.05     (±0.49) 2.68     (±1.6) 4.08     (±0.83) 0.021 
33 F-actin capping subunit alpha 1 P52907 12.65    (±1.1) 9.08     (±0.58) 13.22    (±0.96) 0.0003 
35 Prolyl 4 hydroxylase subunit alpha P13674 8.04    (±0.91) 10.54    (±0.56) 8.64     (±0.66) 0.013 
36 F-actin capping subunit alpha 1 P52907 4.31    (±0.31) 4.02     (±0.27) 5.67    (±18) 0.006 
48 Erp29 P30040 6.01    (±0.3) 7.53     (±0.47) 5.77    (±0.73) 0.043 
49 Heat shock protein-27 P04792 8.75    (±0.75) 10.37    (±0.58) 11.42    (±0.78) 0.049 
51 Annexin II P07355 3.22     (±0.35) 2.72    (±0.19) 3.51    (±0.17) 0.007 
52 Peroxiredoxin 4 Q13162 8.27    (±0.90) 10.11    (±0.81) 12.42   (±0.87) 0.012 
55 Annexin I P04083 9.88    (±0.46) 8.92    (±0.72) 12.35    (±1.25) 0.024 
56 Grp78 P11021 18.57    (±1.72) 19.01    (±1.37) 23.47    (±1.18) 0.013 
57 Cathepsin B P07858 11.28    (±0.96) 12.91    (±0.71) 15.35    (±1.22) 0.033 
60 Proteasome subunit beta 6 P28072 6.67    (±0.32) 4.66    (±0.27) 6.19    (±0.23) 0.001 
64 Peroxiredoxin 2 P32119 19.70    (±1.07) 21.83    (±0.70) 23.38    (± 1.14) 0.038 
65 Glutathione S transferase Pi P09211 21.33    (±0.75) 20.07    (±0.93) 25.45    (±1.45) 0.026 
66 Proteasome subunit beta 4 P28070 3.95    (±0.35) 3.84    (±0.53) 6.20     (±0.48) 0.014 
69 Peroxiredoxin 3 P30048 11.01    (±1.45) 11.01    (±0.35) 12.76    (±0.48) 0.034 
71 Proteasome subunit beta 3 P49720 2.96    (±0.39) 2.38     (±0.32) 4.19    (±0.59) 0.002 
75 26S protease regulatory subunit alpha P35998 3.36    (±0.15) 2.44    (±0.18) 3.03    (±0.15) 0.007 
76 Aldehyde Dehydrogenase -2 P05091 2.55    (±0.22) 1.85    (±0.11) 2.05     (±0.11) 0.005 
82 Glutathione S transferase P09211 5.06    (±0.47) 5.53     (±0.48) 8.10    (±0.52) 0.002 
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Actin was significantly down regulated in aAthSMc and sAthSMC (Figure 4.2).  The actin spot 22, 
which did not appear in the previous analysis, also emerged as being differentially expressed.  The 
mean spot volumes for all these actin spots were lowest in the sAthSMC and highest in AoSMC, 
suggesting that SMC from these plaques have a greater degree of phenotypic modulation with 
reduction of contractile proteins.  The actin binding protein F-actin capping protein subunit-α, 
followed the same pattern of expression as actin. 
 
The expression of mitochondrial proteins ATP Synthase subunit beta and aldedhyde dehydrogenase 
2 was not significantly altered between aAthSMC and sAthSMC (Figure 4.3). The main difference 
in expression was limited to the comparison between AoSMC and AthSMC (see chapter 3, Figure 
3.15). Another class of proteins with differential expression was the peroxiredoxins.  Expression of 
the oxidised form of peroxiredoxin 4 appeared to be significantly different between the groups 
being increased by 23% in aAthSMC compared to sAthSMC (Figure 4.4A) and 50% increased in 
aAthSMC compared to AoSMC.  The expression of unmodified/reduced Prdx2 was only slightly 
increased in aAthSMC compared to sAthSMC (Table 4.1).  Mitochondrial peroxiredoxin 3, (Prdx3) 
was increased by 16% in aAthSMC compared to sAthSMC and AoSMC (Figure 4.4B). Prdx3 is a 
key antioxidant in the mitochondria.  Only one spot was detected at a molecular weight/pI of 
23/6.4, which is more basic than its predicted value of 21.4/5.77.  No other spot was detected as 
prdx3.  The trend in the expression patterns of the all peroxiredoxins identified here is that they’re 
increased in aAthSMC compared to sAthSMC and AoSMC.  The largest difference is in the 
expression of the oxidised form of prdx4.  The expression of these proteins may be increased in 
response to increased oxidative stress, as previously described in chapter 3.   
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Figure 4.2 Expression of actin and actin binding proteins is lowest in SMC derived from 
symptomatic patients.  Graphical representation of spot volumes for the different actin spots on 
teh2D gel.  Expression is lowest in sAthSMC and highest in AoSMC, in all cases.  Error bars 
represent ± SEM of the mean spot volume from all donors.  Statistics were calculated in Same 
Spots (p < 0.05, One Way ANOVA).  Post-test statistical analysis was performed in Prism using 
One Way ANOVA with Tukey Post test (*p<0.05, **p<0.01).  Aortic donors; n= 6, symptomatic 
donors; n=6, asymptomatic donors; n=4. 
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      A                 B 
Figure 4.3 Expression of mitochondrial proteins is not altered between symptomatic and 
asymptomatic.  Graphical representation of spot volumes for ATP Synthase subunit beta (A) and 
Aldehyde dehydrogenase 2 (B).  There is no difference in mean spot volume between sAthSMC 
and aAthSMC for either protein, although they are significantly less than AoSMC.  Error bars 
represent ± SEM of the mean spot volume from all donors.  Statistics were calculated in Same 
Spots (p < 0.05, One Way ANOVA).  Post-test statistical analysis was performed in Prism using 
One Way ANOVA with Tukey Post test (*p<0.05).  Aortic donors; n= 6, symptomatic donors; n=6, 
asymptomatic donors; n=4. 
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Figure 4.4 Changes in expression of Peroxiredoxins 3 and 4.  A) Graphical representation of 
spot volume of oxidised peroxiredoxin 4.  There is a 23% increase in the oxidised form of 
peroxiredoxin 4 between symptomatic and asymptomatic AthSMC, and a 50% increase in 
aAthSMc compared to AoSMC.  B) Graphical representation of spot volume of peroxiredoxin-3. 
There is a small increase of 16% in aAthSMC compared to AoSMC and sAthSMC.  C) Spectra of 
the peptide GTAVVNGEFK for spot 69 matches peroxiredoxin 3.  Error bars represent ± SEM of 
the mean spot volume from all donors.  Statistics were calculated in Same Spots (p < 0.05, One 
Way ANOVA). Post-test statistical analysis was performed in Prism using One Way ANOVA with 
Tukey Post test (*p<0.05).  Aortic donors; n= 6, symptomatic donors; n=6, asymptomatic donors; 
n=4. 
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Spot 4 was identified as Heat shock protein 60 (Hsp60), and was decreased in aAthSMC by 20% 
(Figure 4.5), compared to both AoSMC and sAthSMC.  The observed molecular weight/pI 
(60/5.25) agrees well with its predicted value (57.9/5.24).  An adjacent spot (spot 5) was also 
identified as Hsp60 with a pI of 5.4, although its expression was not significantly altered between 
the 3 groups, suggesting it may be a post-translationally modified form that is differentially 
expressed.  Hsp60 is a mitochondrial chaperone, which assists in protein transportation from the 
cytoplasm to the mitochondria.  Its expression can be induced in response to cellular stress.  Hsp60 
and Hsp70 have been detected in the lesions of apoE-/- mice and the expression was localised to 
several cell types including SMC (Kanwar, Kanwar et al. 2001).  In this study, Hsp60 and -70 were 
detected in the lesions of 8- and 20-week-old apoE-/- mice but appeared to be down regulated in 40-
week-old mice.  Hsp 60 and -70 expression was also not present in the control arteries of 
normocholesterolemic mice.  This is in contrast to my findings where I see a decrease in Hsp-60 in 
aAthSMC.  In humans, Hsp60 has been detected in endothelial cells, macrophages and SMC from 
atherosclerotic lesions but not in the corresponding cells from normal arteries (Kleindienst, Xu et 
al. 1993).  Interestingly, Hsp60 is a potential biomarker for atherosclerosis as its presence in the 
serum is associated with cardiovascular disease (Pockley, Wu et al. 2000).  It has also been 
associated with increased carotid artery stiffness (Ellins, Shamaei-Tousi et al. 2008).  
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Figure 4.5 Heat shock protein 60 expression is significantly decreased in asymptomatic.  A) 
Mass Spectrum of the peptide AAVEEGIVLGGGCALLR from spot 4, identified as Heat shock 
protein 60.  B) Graphical representation of spot volume of Hsp60.  Hsp60 was lowest in aAthSMC 
compared to AoSMC and sAthSMC.  There is a 30% decrease in expression in aAthSMC 
compared to sAthSMC. Spot volumes are presented as the mean average of the spot volume for 
each condition.  Error bars represent ± SEM of the mean spot volume from all donors.  Statistics 
were calculated in Same Spots (p < 0.05, One Way ANOVA).  Post-test statistical analysis was 
performed in Prism using One Way ANOVA with Tukey Post test (*p<0.05).  Aortic donors; n= 6, 
symptomatic donors; n=6, asymptomatic donors; n=4. 
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Spot 55, which was differentially expressed, was identified as Annexin I (also known as annexin 
A1 or lipocortin 1, Figure 4.6).  Expression of annexin I was 35% higher in aAthSMC compared to 
sAthSMC, and 23% higher compared to AoSMC.  The observed molecular weight/pI of (25/5.2) 
does not correspond to the predicted values (38.5/6.64), suggesting it is a fragment of the full-
length protein.  Spot 54 was also identified as annexin I, which had a similar molecular weight but 
a slightly different pI of 5.3.  However, there was no significant difference in the expression levels 
of spot 54 (Figure 4.6B).  The peptides identified are between residues 128 and 238 of the annexin 
protein.  The full-length protein was not identified on the 2D gels.  Annexin I belongs to the 
annexin family of proteins, which bind (“annex”) to phospholipid membranes in a calcium-
dependent manner; the full-length protein may therefore be membrane associated and so it might 
have escaped detection in this study which was limited to the soluble, cytosolic cell fraction.   
 
Annexin I was first identified as a glucocorticoid inducible protein that mediates some of the 
effects of glucocorticoid treatment. Annexin I inhibits the activation of phospholipase A2 (PLA2), 
the rate-limiting enzyme in the synthesis of eicosanoids - inflammatory mediators derived from 
arachidonic acid that includes prostaglandins, prostacyclins and leukotrienes (Parente and Solito 
2004).  A lower expression of annexin I in sAthSMC suggest that there is increased production of 
eicosanoids, contributing to the inflammatory environment of the plaque.  Thus, annexin I may be 
an important modulator of the inflammatory response in SMC and may contribute to the stability of 
atherosclerotic plaques.   
 
Interestingly, annexin I-/- mice have exacerbated inflammation and are not sensitive to 
glucocorticoid treatment (Hannon, Croxtall et al. 2003).  LPS-induced endotoxic shock led to 
prolonged expression of TNF, IL-1 and IL-6 in annexin 1-/- mice, compared to the wild type 
(Damazo, Yona et al. 2005).  Furthermore, antigen-induced arthritis in annexin I-/- mice resulted in 
exacerbated arthritis with increased expression of IL-1β, TNFα, IL-6 and MIF mRNA (Yang, 
Morand et al. 2004).  It can be released by cells and prevent transendothelial migration of 
polymorphonuclear leukocytes (Perretti, Croxtall et al. 1996).  Studies using acetylated peptides of 
annexin I have shown that its anti-inflammatory activity is conferred by the first 26 N-terminal 
residues (Ac2-26) (Perretti, Ahluwalia et al. 1993) (Cirino, Cicala et al. 1993).  In a study of 
experimentally induced murine arthritis, disease was inhibited by intra-articular dexamethasone 
injection, in an annexin 1 dependent manner.  Injection of the acetylated annexin I peptide 
derivative Ac2-26 also significantly inhibited arthritis (Yang, Leech et al. 1997).   
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Another member of the annexin family, annexin II (also known as calpactin 1), was identified in 
spot 51 and was differentially expressed (Figure 4.7).  Annexin II was almost 30% higher in 
aAthSMC compared to sAthSMC.  Spot 51 has a molecular weight/pI of 35/5, which differs from 
the predicted value of 38.4/7.56.  Another spot was also identified as annexin II, in spot 40 (see 
reference map in Figure 3.11 and Appendix 1) with a similar molecular weight but with a pI of 6.5, 
which is also lower than the predicted pI value.  Therefore, these spots may be post-translationally 
modified forms of annexin-II.  Phosphorylation of annexin II has been reported, suggesting a 
possible post-translation modification.  Annexin II is phosphorylated on activation of the PDGF 
and insulin receptors (Brambilla, Zippel et al. 1991), which may affect its function.  Annexin II is 
thought to associate with phospholipids in membrane rafts and mediates interactions between 
cytoskeleton and the cytosolic side of plasma membranes, acting as a scaffold protein and 
participating in the assembly of F-actin (Rescher and Gerke 2004).  However, no phosphorylated 
peptides were detected in the mass spectrometry.   
  
Cell surface annexin II has been shown to act as a receptor for tissue plasminogen activator (tPa) 
and plasminogen and therefore has a role in fibrinolysis (Hajjar, Jacovina et al. 1994).  In the 
fibrinolysis cascade, tPa cleaves plasminogen to produce plasmin, which then cleaves fibrin.  
Annexin II knockout mice have decreased plasmin, reduced ability to clear injury-induced 
thrombus by, and accumulation of fibrin in microvessels (Ling, Jacovina et al. 2004).  Although 
fibrinolysis occurs on the endothelium, annexin II is also expressed by SMC.  Histological analysis 
of atherosclerotic abdominal aortic aneurysm showed annexin II was present in the fibrous cap and 
increased in the shoulder region (Hayashi, Morishita et al. 2008).   
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Figure 4.6 Annexin I is increased in asymptomatic.  A) The peptide GLGTDEDTLIEILASR for 
spot 55 matches the protein Annexin 1, B) Graphical representation of Annexin I spot volume.  
There is a 35% increase in Annexin I in aAthSMC compared to sAthSMC.  Error bars represent ± 
SEM of the mean spot volume from all donors.  Statistics were calculated in Same Spots (p < 0.05, 
One Way ANOVA).  Post-test statistical analysis was performed in Prism using One Way ANOVA 
with Tukey Post test (*p<0.05).  Aortic donors; n= 6, symptomatic donors; n=6, asymptomatic 
donors; n=4.  C) Amino acid sequence of annexin I shows peptides identified from spot 55 (red).   
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Figure 4.7 Annexin II is increased in asymptomatic.  A) The peptide GVDEVTIVNILTNR for 
spot 51 matches Annexin II, B) Graphical representation of Annexin II spot volume.  There is a 
29% increase in Annexin II in aAthSMC compared to sAthSMC.  Error bars represent ± SEM of 
the mean spot volume from all donors.  Statistics were calculated in Same Spots (p < 0.05, One 
Way ANOVA).  Post-test statistical analysis was performed in Prism using One Way ANOVA 
with Tukey Post test (*p<0.05).  Aortic donors; n= 6, symptomatic donors; n=6, asymptomatic 
donors; n=4.  C) Spot 40 was also identified as Annexin II, although its expression was unchanged.  
The change in pI of approximately 0.6 could represent a post-translational modification such as 
phosphorylation.  
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4.2 Validation of the Proteomic findings 
 
Amongst the proteins identified as differentially expressed between sAthSMC and aAthSMC, I 
decided to further investigate the expression of Hsp60, annexin I and annexin II as they were the 
protein with the largest differences and the most novel hits in the context of atherosclerosis.  
 
 
4.2.1 Validation of Heat shock proteins  
 
Expression of Hsp60 was validated by immunoblotting.  SMC lysates from three different donors 
for each group were assessed for Hsp60 expression.  Immunoblotting did not support the changes 
observed by 2D (Figure 4.8). Other spots on the 2D gel were also identified as Hsp60, although 
they were not identified as being differentially expressed.  This may have masked the differences 
seen in this particular spot.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 immunoblotting of Hsp60 expression.  Hsp60 expression does not appear to be 
different between SMC groups.  SMC lysates were separated by 1-dimensional electrophoresis 
using 4-12% mini-gel and proteins were transferred to PVDF membrane and immunoblotted for 
Hsp-60 using a monoclonal antibody to total Hsp-60.  Alpha-tubulin was used as a loading control.   
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4.2.2 Validation of Annexin I and Annexin II  
 
I went on to validate the annexins identified because of their potential relevance to inflammation 
and thrombosis.  Immunoblotting for annexin I and annexin II revealed the presence of two bands, 
an upper band at approximately 39kDa and a lower band at approximately 36kDa (Figure 4.9).  
Both annexin I and II have molecular weights of 36kDa, so the upper band of approximately 39kDa 
could be indicative of a modification, such as phosphorylation and the unphosphorylated protein is 
the lower band.  Covalent modification can influence electrophoretic mobility due to a 
conformational change in the protein (rather than due to a change in molecular mass, which is too 
small to be visible on a small 1-dimension gel).  Of note, both annexin I and annexin II were 
identified on the 2D gels in two spots (annexin I was identified in spot 54 and 55, annexin II was 
identified as spot 40 and 51, see Table 3.1 and Appendix 1) suggesting that fragments or post-
translational modifications of these proteins are present.  Annexin I and II can be phosphorylated 
by activation of PDGF or EGF receptors (Brambilla, Zippel et al. 1991) (Karasik, Pepinsky et al. 
1988) suggesting phosphorylation is the post translational modification causing the shift in pI 
observed on the 2D gels.  SMC in this experiment were subjected to 48 hours of serum starvation 
before cell lysis, with a change of medium at 24 hours to wash away serum components, which 
include growth factors such as PDGF.  However, as PDGF is produced by SMC themselves (Libby, 
Warner et al. 1988), this could lead to continued phosphorylation in an autocrine manner.  
Nonetheless, the immunoblotting results show that the total amount of annexin I was increased in 
SMC from asymptomatic plaques, in agreement with the proteomic analysis.  Immunoblotting 
showed that annexin II was not increased in asymptomatic patients compared to symptomatic 
patients.   
 
Densitometry was used to quantify the immunoblots (Figure 4.9B). Density was measured in pixel 
number.  Annexin I was significantly increased in SMC from asymptomatic plaques (p= 0.012).  
Annexin II was not increased in the asymptomatic group and expression was similar in all three 
groups.  More donors need to be examined to by immunoblot to further validate these results.   
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Figure 4.9 Immunoblotting of Annexin expression. A) SMC lysates were separated by 1-
dimensional electrophoresis using 4-12% mini-gel and proteins were transferred to PVDF 
membrane and immunoblotted for annexin 1 and 2.  As the annexins have a similar molecular 
weight, identical PVDF membranes were immunoblotted with antibodies for annexin I or annexin 
II.  Expression of alpha-tubulin was found to be even across all lanes. One representative gel is 
shown here out of 2 different experiments. B) Densitometry of immunoblots for annexin I and II.  
The number of pixels for each lane in the annexin I and annex II blots were normalised against that 
for the alpha-tubulin loading conrol.  Annexin I is significantly increased in SMC from 
asymptomatic plaques compared to AoSMC or SMC from symptomatic plaques (* p<0.05, One 
Way ANOVA).  Annexin II expression was not different between the groups.   
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4.3 Discussion 
 
The occurrence of vascular events due to plaque rupture is highly dependent on plaque biology (Falk 
1992).  Carotid artery plaque rupture and/or embolism are the most common causes of ischemic stroke 
(Carr, Farb et al. 1996).  As SMC synthesise extra-cellular matrix proteins that provide the tensile 
strength for the fibrous cap (Libby 1995), lack of matrix protein synthesis due to SMC senescence 
(Matthews, Gorenne et al. 2006) , apoptosis (Bennett, Evan et al. 1995) (Clarke, Figg et al. 2006) or 
exposure to IFNγ (Amento, Ehsani et al. 1991; Hansson and Holm 1991) can lead to plaque 
vulnerability.  MMPs synthesised by macrophages and neutrophils subsequently degrade extra-cellular 
matrix (Galis, Sukhova et al. 1994) (Galis, Sukhova et al. 1995).  Conversely, anti-inflammatory 
PDGF and TGFβ stimulate collagen synthesis promoting a thick fibrous cap (Amento, Ehsani et al. 
1991).   
 
 
The integrity of the fibrous cap is crucial to the stability of the plaque (Libby 1995).  It is all that 
stands between the arterial blood flow and the thrombogenic lipid core.  The vulnerable ‘thin capped 
fibrous atheroma’ (TCFA) has a fibrous cap of less than 65µm, fewer SMC, less ECM and it covers a 
larger necrotic core (Virmani, Kolodgie et al. 2000) (Burke, Farb et al. 1997).  Importantly, plaques 
with increased inflammation are more likely to rupture (van der Wal, Becker et al. 1994; Golledge, 
Greenhalgh et al. 2000).   
 
I was able to discover differences in protein expression between aAthSMC and sAthSMC indicating 
how SMC may change in response to environmental clues and in turn influence plaque biology.  Study 
of the proteome revealed that the unstable plaque microenvironment leads to reduction of expression 
of contractile fibres, a sign of phenotypic modulation, more so than within a stable plaque.  In Chapter 
3, I observed that AthSMC had overall reduced expression actin compared to AoSMC.  However, the 
loss of actin was indeed more pronounced in sAthSMC compared to both aAthSMC and AoSMC. This 
is in keeping with the concept of a continuum of differentiation and plasticity that is typical of human 
SMC (Owens 1995).  The expression of the oxidised form of peroxiredoxin 4 was notably higher in 
aAthSMC compared to sAthSMC.  Peroxiredoxin 3 expression was also higher in aAthSMC compared 
to sAthSMC.  This may indicate that by increasing peroxiredoxin expression, SMC from stable 
plaques are more able to cope with the increased oxidative stress.   
 
Other proteins differentially expressed in chapter 3 between AthSMC and AoSMC, i.e. the 
mitochondrial proteins aldehyde dehydrogenase 2 and ATP Synthase subunit beta, were not different 
when the symptomatic status of the donor was taken into account.  In the previous chapter I 
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hypothesised that the decrease in the expression of these mitochondrial proteins seen in AthSMC was 
due to mitochondrial damage.  My observations suggest that mitochondrial damage may not be linked 
to plaque instability but is a general feature of atherosclerosis.   
 
Annexin I was increased in aAthSMC compared to sAthSMC and AoSMC.  Annexin I exerts its anti-
inflammatory effects on cytosolic PLA2.  PLA2 will cleave arachidonic acid preferentially from the 
sn2 position of a glycerophospolipid such as those in the plasma membrane (Leslie 1997).  
Arachidonic acid is a substrate for the production of eicosanoids; lipid inflammatory mediators 
including prostaglandins, prostacyclins and leukotrienes (Figure 4.11).  Cytosolic PLA2 is activated by 
increased intracellular Ca2+ levels and phosphorylation by MAPK.  PLA2 is an important mediator in 
the regulation of arachidonic acid levels, making its inhibition an interesting therapeutic target.  Its 
expression can be induced by proinflammatory stimuli such as TNFα, IL-1 and IFNγ (Clark, 
Schievella et al. 1995). Reactive oxygen species such as hydrogen peroxide has also been shown to 
activate PLA2 via PKC and MAPK, thus linking its expression to oxidative stress (Rao, Runge et al. 
1995). Eicosanoids play a role in acute inflammation and mediate central roles in modulating 
inflammatory processes such as platelet activation, vasoconstriction and leukocyte-endothelial cell 
interactions and SMC migration (Dogne, Hanson et al. 2005) (Pratico 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.  Production of eicosanoids from arachidonic acid.  Arachidonic acid is cleaved from 
phospholipids in the plasma membrane by cPLA2.  Arachidonic acid is further modified by the actions 
of cyclooxygenase 2 (COX-2) and lipoxygenase to produce prostaglandins, prostacyclins, 
thromboxanes and leukotrienes.  Annexin I inhibits the action of cPLA2 resulting in decreased 
arachidonic acid liberation.  Anti-inflammatory actions of annexin I may also extend to the inhibition 
of COX-2. 
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The anti-inflammatory effects of annexin I extend further than the inhibition of PLA2.  Annexin I can 
modulate the behaviour of macrophages, neutrophils and T-lymphocytes by inhibiting migration, 
adhesion and proliferation, and inducing apoptosis (reviewed in (Kamal, Flower et al. 2005) and 
(Perretti and D'Acquisto 2009)).  It is also thought to stimulate release of IL-10 and inhibit iNOS 
synthesis at the mRNA level (Ferlazzo, D'Agostino et al. 2003) and inhibit the binding activity of 
NFκB to DNA (Zhang, Huang et al. 2010).  Therefore annexin I could be an important regulator of 
proinflammatory gene expression.  To date, there are no reports of a double knockout, ApoE-/- 
Annexin I-/- mice that would investigate the effects of annexin I in atherosclerosis, even though the 
annexin I-/- mice created by Hannon  et al is on the atherosclerosis-susceptible C57BL/6 strain 
(Hannon, Croxtall et al. 2003). 
 
Interestingly, extracellular lipoprotein-associated PLA2 (Lp-PLA2) has been identified as a risk factor 
for atherosclerosis and is associated with CVD (Garza, Montori et al. 2007).  Lp-PLA2 is secreted by 
macrophages, T-cells and mast cells, and associates with LDL in plasma where it can cleave oxidised 
phospholipids generating soluble proinflammatory mediators such as lysophosphatidylcholine, which 
promote plaque development (Wilensky and Macphee 2009).  Lp-PLA2 is now being targeted 
therapeutically with the development of darapladib by GlaxoSmithKline plc, now in phase III clinical 
trials (the Stabilisation of atherosclerotic plaque by initiation of Darapladib therapy, 
www.stabilitytrial.com).  Thus, targeting the actions of phospholipase enzymes and production of 
lipid-derived proinflammatory mediators, either intracellularly or extracellularly, can be beneficial in 
preventing cardiovascular events.   
 
There is little information of the role of annexin I in SMC, as attention has focused mainly on the 
inflammatory cells rather than the resident cells of the vasculature.  However, in my study its 
expression pattern in SMC indicates that it is related to plaque events and contributes to the regulation 
of inflammation.  My data suggests that aAthSMC have an increased ability to modulate inflammation 
in the plaque which contributes to plaque instability (van der Wal, Becker et al. 1994; Carr, Farb et al. 
1996) and that annexin I may be involved in protection from the development of a high risk plaque.  
The observation of higher levels in aAthSMC compared to AoSMC can indicate site-specific 
expression or it can indicate that the up regulation of annexin I is associated with development of the 
disease. The failure of such up regulation might be associated with plaque instability. 
 
Thrombosis associated with plaque rupture is a major cause of plaque instability (Spagnoli, Mauriello 
et al. 2004). Annexin II, acting as a co-receptor for tPa and plasminogen, facilitates fibrinolysis 
(Figure 4.11), which in turn may help prevent thrombus formation.  Annexin II expression was 
significantly lower in SMC from symptomatic plaques.  The annexin II deficient mouse rendered 
hyperhomocysteinemic by dietary means, has impaired fibrinolysis, perivascular fibrin persistence, 
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and attenuated angiogenesis (Loscalzo 2009).  As SMC can express pro-thrombotic tissue factor 
(Payeli, Latini et al. 2008) there may be a delicate balance of pro-thrombotic and anti-thrombotic 
actions, which may be disrupted in sAthSMC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Annexin II facilitates fibrinolysis.  Annexin II expressed at the cell surface binds tissue 
plasminogen activator (tPA) and plasminogen, facilitating the conversion of plasminogen to plasmin.  
Plasmin degrades fibrin, the fibrous protein that is the main constituent of blood clots.   
 
In conclusion, my study has identified differences in the expression of annexins between SMC from 
stable and unstable plaques.  Besides the anti-inflammatory actions of PPARα, (Staels, Koenig et al. 
1998), there are few reports of any anti-inflammatory and anti-thrombotic mediators being expressed 
by SMC.  Accordingly, this study reveals novel protective pathways in SMC that contribute to plaque 
stability.  Firstly, SMC from stable plaques have increased expression of the anti-inflammatory 
annexin I protein compared to SMC extracted from unstable plaques.  Increased inflammation leads to 
plaque rupture and thrombosis (Libby 2002).  Without such protective mechanism, SMC may 
succumb to the action of pro-inflammatory cytokines and eicosanoids resulting in decreased matrix 
protein synthesis or apoptosis.  Additionally, SMC from unstable plaques have decreased annexin II 
further increasing the likelihood of thrombosis.  My observations overall indicate that SMC, besides 
being involved in matrix synthesis, may additionally contribute to plaque stability through the 
expression of anti-inflammatory and anti-thrombotic mediators.  Such endogenous protective 
mechanisms could be exploited therapeutically in the future (Perretti and Dalli 2009).  
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5. Introduction 
 
Tumour necrosis factor alpha (TNFα) is a potent proinflammatory cytokine with diverse effects 
including leukocyte activation, induction of apoptosis or proliferation, and stimulation of production 
of adhesion molecules, MMPs (Galis, Muszynski et al. 1994) and leads the cascade of 
proinflammatory cytokines (Barath, Fishbein et al. 1990; Rayment, Moss et al. 1996) (Feldmann 
2009).     
 
TNFα belongs to a family with approximately twenty different members including TNFβ 
(lymphotoxin-α), lymphotoxin-β, CD40L and FasL (MacEwan 2002).  TNFα exists in two active 
forms; a 26kDa membrane bound form (mTNF), and a 17kDa soluble cytokine, produced by cleavage 
of mTNF.  The diverse effects of TNF signalling are mediated by two distinct receptors which are 
expressed on most cell types: TNFRI (also known as p55, p60 or CD120a) and TNFRII (also known 
as p75, p80 or CD120b).  There is only 28% sequence similarity between TNFRI and TNFRII, mostly 
confined to the extra-cellular domains.  The intracellular domains are largely unrelated and their 
signalling leads to two distinct pathways (Figure 5.1).  There is no catalytic activity in the cytoplasmic 
domains and signalling is mediated via the binding of adaptor molecules including TNF Receptor 
associated death domain (TRADD) and TNF Receptor Associated Factors (TRAFs).  Receptor p55 
contains a death domain motif, allowing it to bind to adaptors that also contain death domains, such as 
TRADD.  This can lead to pro-apoptotic signalling pathways (reviewed in (MacEwan 2002)).  
TRADD can also bind TRAFs, which interact with NFκB-inducing kinase (NIK) and MAP kinase 
kinases - leading ultimately to activation of NFκB and the MAP kinase pathways.  Receptor p75 does 
not contain a death domain and so cannot bind TRADD; however it can associate with TRAF-2 
thereby inducing the NFκB and MAP kinase pathways.  Therefore, signalling via p55 can lead to pro- 
and anti-apoptotic effects, whereas signalling via p75 is thought to be only anti-apoptotic (Figure 5.1). 
 
The importance of TNFα in the progression of atherosclerosis has been demonstrated in mouse 
models of atherosclerosis.  In the apoE-/- mouse, disruption of the TNFα gene has been shown to 
reduce lesion size.  In mice on a high fat diet, the plaque area in apoE-/- TNF-/- mice was 50% smaller 
than in apoE-/- mice (Branen, Hovgaard et al. 2004).  Branen, et al. showed that transplantation of bone 
marrow from apoE-/- TNF-/- into apoE-/- mice resulted in an 83% reduction in lesion size after 25 weeks.  
In the same study, treatment of apoE-/- mice with the TNF blocker recombinant soluble p55 also led to 
a reduction in lesion size indicating that TNFα plays an important role in atherosclerosis.  Similarly, 
Ohta, et al. showed a slightly smaller decrease in lesion size in apoE-/- TNF-/- mice on a normal chow 
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diet (Ohta, Wada et al. 2005).  In this model, expression levels of adhesion molecules ICAM-1 and 
VCAM-1, and the chemokine MCP-1 (CCL-2) were also significantly decreased, along with reduced 
scavenger receptor expression and uptake of oxLDL in double knockout mice.  The results of this 
study indicate that TNFα is involved in multiple actions on different cell types in the lesion such as 
adhesion molecule expression and foam cell formation. 
 
 
 
 
 
Figure 5.1 TNF Receptor signaling.  The two TNF receptors have difference in their cytoplasmic 
domains, which lead to different signalling pathways.  They can both activate MAP Kinase and NFκB 
signalling through interaction with the adaptor molecule TRAF.  Signalling via TNFRI (p55) can also 
initiate apoptosis, but TNFRII (p75) signalling cannot do this.  
Chapter 5  Effect of TNF on SMC 
 
163 
 
Intimal SMC from human plaques express TNFα, whereas medial SMC do not, as shown by in situ 
hybridisation and immunohistochemistry (Barath, Fishbein et al. 1990).  In a rabbit model of arterial 
injury, TNFα protein expression was induced in medial SMC within 2 days after arterial injury, but 
not in uninjured aorta (Tanaka, Sukhova et al. 1996).  TNFα production also co-localised with areas of 
SMC proliferation, suggesting that it has an autocrine effect on SMC.  Tanaka, et al. suggested that 
TNFα production was an early marker of SMC activation in arterial injury models.  Its production by 
intimal SMC from human atherosclerotic plaques suggests they are in a similar activated state.   
 
TNFα can also induce dose dependent SMC migration, via activation of MAPK signalling pathway 
(Goetze, Xi et al. 1999).  In rat aortic SMC, blocking antibodies to the TNF receptors demonstrated 
that signalling via receptor p55 was responsible for the observed migration.  In SMC from human 
saphenous vein, TNFα stimulation also induced migration by reducing the levels of actin fibres, which 
allows cytoskeletal reorganisation and is required for the early events of cell movement/ migration 
(Jovinge, Hultgardh-Nilsson et al. 1997).  In a model of intimal hyperplasia, TNFα-/- mice that 
underwent carotid ligation had 14-fold less intimal hyperplasia than wild type mice, suggesting a role 
for TNFα in SMC proliferation and migration into the intima (Rectenwald, Moldawer et al. 2000).  In 
the same study a less marked reduction was seen in IL-1-/- mice with 7-fold less intimal hyperplasia 
compared to wild type mice.  Cultured rat neointimal SMC exposed to TNFα showed increased levels 
of apoptosis compared to medial SMC (Niemann-Jonsson, Ares et al. 2001).   
 
SMC populations are known to be heterogeneous in cell shape (Hao, Gabbiani et al. 2003). Different 
shaped SMC may exhibit different characteristics in terms of growth rates and response to cytokines 
(Li, Fan et al. 2001), including TNFα.  'Epithelioid' SMC isolated from human thoracic aorta had a 
population doubling time of 39 hours, in comparison to spindle shaped SMC which had a population 
doubling time of 65 hours (Li, Fan et al. 2001).  Additionally, the epithelioid SMC had an increased 
response to growth factors such as PDGF, without any detectable differences in expression of SMC 
marker proteins αSMA, SM-MHC or calponin.  In studies cloning SMC from human saphenous vein, 
proliferation was induced by TNFα in spindle shaped SMC, whilst apoptosis was induced in 
epithelioid shaped SMC (Wang, Rao et al. 2005).   
 
Landry, et al showed that the transcription factor NFκB was activated in SMC after arterial injury in 
rats (Landry, Couper et al. 1997).  Neointimal rat SMCs displayed enhanced NFkB activation even 
when expanded in vitro.  They also expressed increased expression levels of P-selectin and 
chemokines and were shown to induce a 2.5-fold higher arrest of monocytes and "memory" T 
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lymphocytes than medial SMCs (Zeiffer, Schober et al. 2004).  In accordance with these data, 
previous observations in our laboratory showed that AthSMC display an enhanced production of 
NFkB dependent genes such as IL-6 and IL-8 after TNFα and IL-1 stimulation compared to AoSMC 
(Figure 5.2). I hypothesised that this heightened response of AthSMC to inflammatory stimuli could 
be a feature of intimal SMC and is associated with specific proteome changes.  In chapter 3, I 
demonstrated that there are several differences in the proteome between AoSMC and AthSMC under 
unstimulated conditions.  Further differences may emerge when these cells are subject to stimulation.  
In this chapter I characterised the response of AthSMC and AoSMC to TNFα by investigating gene 
expression patterns induced by TNFα, chemokine production and expression of TNF receptors.  I also 
compared the proteome of unstimulated and TNF-stimulated AthSMC and AoSMC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Cytokine production in atherosclerotic and non-atherosclerotic SMC.  IL-6 and IL-8 
production in SMC, with or without TNFα stimulation.  Plaque SMC produce statistically more IL-6 
and IL-8 compared to control SMC, when stimulated with TNF for 24 hours.  Data presented as mean 
± SEM, n = 10.  *** p< 0.001 (T-test) Experiments performed by Tina Navin.   
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5.1 Gene Expression patterns of TNF-stimulated SMC 
 
To investigate the effect of TNFα on SMC gene expression, I used a Q-PCR array that contained 
primer sequences for 84 atherosclerosis-related genes (see Table 2.1 for list of genes).  In this 
experiment, I was able to use plaque and non-atherosclerotic medial SMC derived from the same 
carotid endarterectomy specimen.  Thus, differences in gene expression cannot be attributed to genetic 
differences that would otherwise arise with comaprison of SMC from different patients.  Out of 84 
genes on the array, 17 were up regulated in response to TNF in AthSMC and 15 of these were also up 
regulated in medial SMC.  Interestingly, 5 genes were selectively up regulated in AthSMC and were 
not up regulated at all in AoSMC (Table 5.1, Figure 5.3).  Many of these genes pertained to the 
recruitment of inflammatory cells within the lesions, or to the differentiation of myeloid cells within 
the lesions or were related to apoptosis. 
 
Consistently, these genes were up regulated more in AthSMC compared to AoSMC.  For instance, E-
selectin was up regulated 1107-fold in plaque SMC but only 232-fold in medial SMC.  Similarly, 
VCAM-1 was up regulated 667-fold in AthSMC and 285-fold in medial SMC.  In contrast, the 
adhesion molecule ICAM-1 displayed little difference between AthSMC and medial SMC (20-fold 
and 18-fold for plaque and medial SMC respectively). The chemokine CCL5 (also known as 
Regulated upon Activation, Normal T cell Expressed and Secreted, RANTES) was induced more 
strongly in AthSMC compared to medial SMC (108-fold and 12-fold respectively).  CCL2 (MCP-1) 
expression was similar in AthSMC and medial SMC.  TNFα induced expression of the TNF gene, 
thereby up regulating itself in medial SMC and in AthSMC (257-fold and 172-fold respectively).  This 
is in contrast to the findings by Barath et al who found that only intimal SMC expressed TNF but 
medial SMC did not (Barath, Fishbein et al. 1990).  Differences between my result and those of Barath 
could be due to the different techniques used.  Barath et al used in situ hybridisation, which detects 
mRNA sequences in preserved tissue.  However, this technique may not be as quantitative as Q-PCR.  
Further studies are needed to clarify this discrepancy.   Colony stimulating factor-2 (CSF-2, also 
known as GM-CSF) was significantly up regulated in AthSMC by 30-fold but was it not statistically 
significant in medial SMC (Figure 5.2), whereas CSF-1 (M-CSF) was significantly up regulated in 
similar amounts in medial and AthSMC (5.2-fold and 5.5-fold respectively, Table 5.1). IL1α was also 
selectively up regulated in AthSMC but not medial SMC.   
 
Apoptotic genes were also induced by TNFα.  The anti-apoptotic gene, BIRC3 was strongly up 
regulated in AthSMC compared to medial SMC (194-fold and 59-fold, respectively), whereas BCL-2 
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was only significantly up regulated in AthSMC.  The pro-apoptotic gene, BID was only up regulated 
in TNFα stimulated AthSMC. Additionally, Lipoprotein a (Lp (a)) is an LDL-like particle to which 
apoB100 is bound to apoA and its levels in the plasma have been associated with increased risk for 
CHD (Tziomalos, Athyros et al. 2009).  It was up regulated by 8.2-fold selectively in AthSMC but not 
in AoSMC.  
 
Twelve genes were significantly down regulated in TNF-stimulated medial SMC, but there were no 
genes that were down regulated in AthSMC (Table 5.1).  Some of these genes were of particular 
interest as they play a role in lipid metabolism, which can be modulated by TNFα.  The receptor for 
low-density lipoprotein (LDLR) was decreased 2.3-fold and the ligand-activated transcription factors 
peroxisome proliferative activated receptor α (PPARα) and retinoic X receptor α (RXRα) were both 
decreased by 2.2 -fold.  LDLR mediates the internalisation of cholesterol rich LDL.  Mutations in this 
receptor cause hypercholesterolemia (Goldstein and Brown 2009).  However, another gene on the 
PCR array involved in cholesterol efflux, ABCA1 was not affected by TNFα stimulation.  PPARα and 
RXRα form heterodimers and are involved in regulating genes for lipid metabolism.  PPARα also 
plays a role in modulating inflammation (Chinetti, Fruchart et al. 2000) and deficiency of PPARα in 
mice leads to a prolonged inflammatory response when challenged with proinflammatory stimuli 
(Devchand, Keller et al. 1996).  In aortic SMC, PPARα ligands were shown to inhibit IL-1 induced 
IL-6 production and COX-2 expression through inhibition of NFκB signalling (Staels, Koenig et al. 
1998).  TNFα activates NFκB; therefore TNFα and PPARα could be antagonists of each other, with 
TNFα inhibiting PPARα expression (Beier, Volkl et al. 1997).  This could potentially be explained by 
the fact that as AthSMC have previously been exposed to TNFα in vivo for prolonged periods, they 
may already have decreased PPARα expression so further stimulation with TNFα in vitro had no 
effect.  However, I did not find a significant change in expression of PPARα between unstimulated 
medial and AthSMC to support this concept, so further investigation is required to probe this 
interesting concept.   
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Table 5.1 Atherosclerotic genes induced by TNFα in medial and plaque SMC. Quantitative PCR 
(Q-PCR) analysis of 84 atherosclerosis related genes was performed using Atherosclerosis RT2 
Profiler PCR Arrays (SA Bioscience) as per the manufacturer’s protocol.  cDNA was obtained from 
unstimulated plaque and medial SMC (from the same donor) or stimulated for 5 hours with 10ng/ml 
TNFα.  RT2 Profiler PCR arrays were run on ABI 7900HT machine and analysis was performed with 
Sequence Detection System 1.9.1 for Mac, using the ΔΔCt method.  Duplicate arrays were run per 
condition for unstimulated and TNF-stimulated plaque and medial SMC.  Those genes with a fold 
regulation > 2 or < -2 and p < 0.05, T-test between unstimulated and TNF-stimulated SMC were 
considered significant and are shown here.  Missing values represent values that were not significantly 
changed or < 2 fold. Plaque SMC n=1, Carotid Medial SMC, n=1. 
Medial SMC       
Unstimulated / TNF 
Plaque SMC          
Unstimulated / TNF 
Gene Gene Name 
T-test     
p value 
Fold 
regulation 
T-test     
p value 
Fold 
regulation 
ADFP Adipose differentiation-related protein 0.0459 -2.33 - - 
BCL2 B-cell CLL/lymphoma 2 - - 0.0461 2.11 
BCL2A1 BCL2-related protein A1 0.0179 5.83 0.0150 3.31 
BID BH3 interacting domain death agonist - - 0.0371 2.02 
BIRC3 Baculoviral IAP repeat-containing 3 0.0029 59.82 0.0007 194.35 
CCL2 Chemokine (C-C motif) ligand 2 0.0246 4.62 0.0022 5.32 
CCL5 Chemokine (C-C motif) ligand 5 0.0079 12.10 0.0027 108.20 
CSF1 Colony stimulating factor 1 (macrophage) 0.0068 5.21 0.0057 5.55 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) - - 0.0127 30.22 
CTGF Connective tissue growth factor 0.0064 -2.94 - - 
EGR1 Early growth response 1 0.0023 -3.18 - - 
ICAM1 Intercellular adhesion molecule 1  0.0027 18.09 0.0002 20.22 
IFNAR2 Interferon (alpha, beta and omega) receptor 2 0.0163 2.83 0.0060 3.17 
IL1A Interleukin 1, alpha - - 0.0432 3.39 
KDR Kinase insert domain receptor  0.0039 -2.30 - - 
LDLR Low density lipoprotein receptor  0.0008 -2.31 - - 
LIF Leukemia inhibitory factor 0.0281 2.18 0.0066 9.17 
LPA Lipoprotein, Lp(a) - - 0.0203 8.21 
PPARA Peroxisome proliferative activated receptor, alpha 0.0017 -2.22 - - 
RXRA Retinoid X receptor, alpha 0.0454 -2.24 - - 
SELE E -Selectin  0.0050 232.73 0.0029 1107.05 
SELPLG Selectin P ligand 0.0391 -3.04 - - 
SPP1 Secreted phosphoprotein 1 (osteopontin) 0.0129 -2.10 - - 
THBS4 Thrombospondin 4 0.0219 -3.29 - - 
TNF Tumor necrosis factor  0.0006 257.33 0.0012 172.15 
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 0.0003 10.95 0.0034 27.52 
VCAM1 Vascular cell adhesion molecule 1 0.0004 285.53 0.0035 667.44 
VEGFA Vascular endothelial growth factor A 0.0556 -2.03 - - 
VWF Von Willebrand factor 0.3364 -2.05 - - 
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Figure 5.3 Atherosclerosis related genes induced by TNFα in medial and plaque SMC.  
Expression of those genes with the highest up regulation is shown.  Atherosclerosis-related genes were 
assessed using quantitative PCR gene arrays, using cDNA from SMC stimulated with 10ng/ml. TNFα 
for 5 hours.  Duplicate PCR arrays were used per sample to produce replicate ct values for the same 
gene.  Analysis was performed using the ΔΔCt method.  Those genes with a statistical significant up 
regulation > 2 fold are displayed here (p < 0.05).  Abbreviations:  BIRC3: Baculoviral IAP repeat-
containing 3, CCL5: Chemokine (C-C motif) ligand 5, CSF2: Colony stimulating factor 2, SELE: E-
Selectin, TNF: Tumour necrosis factor, VCAM1: Vascular cell adhesion molecule-1.  Plaque SMC 
n=1, Carotid Medial SMC, n=1 
 
 
Chapter 5  Effect of TNF on SMC 
 
169 
 
5.2 TNFα induces chemokine production in SMC  
 
To further characterise the effect of TNFα on SMC, I investigated whether SMC produced soluble 
mediators other than IL-6 and IL-8 upon TNFα stimulation.  I used a Luminex platform, which allows 
the simultaneous detection and quantitation of several analytes in the same sample.  I assayed for the 
presence of 16 cytokines and chemokines: Fractalkine, GM-CSF, IFNα2, IFNγ, IL-1α, IL-1β, IL-2, IL-
4, IL-10, IL-12 p40, IP-10, MCP-1, RANTES, sCD40L, TNFα and VEGF.  Only 4 out of these 
analytes were detected in the supernatants of SMC that had been stimulated with TNF (Figure 5.4); 
MCP-1, RANTES, Fractalkine and IP-10 (interferon-γ inducible protein, CXCL10) in stimulated 
SMC.  TNF-stimulated AthSMC expressed higher levels of RANTES and IP-10 than AoSMC.  
Production of Fractalkine and MCP-1 in TNF-stimulated AoSMC was similar to that of TNF-
stimulated AthSMC.  These data are in keeping with the PCR array.  LPS can induce the production of 
these chemokines so it was important to ensure LPS contamination was not responsible for the 
observed results.  A sample of medium from these experiments was tested for LPS by Limulus assay, 
and the result was below the detection limit. 
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Figure 5.4 TNFα induces chemokine production in SMC.  Cell culture supernatants from AoSMC 
and AthSMC stimulated with or without TNFα for 24 hours were assayed by Luminex.  Fractalkine, 
RANTES, MCP-1, IP-1 were detectable at various levels in AoSMC and AthSMC.  Error bars 
represent ± SD from duplicate measurements of each sample.  White bars; AoSMC, Black bars, 
AthSMC. 
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5.3 TNF Receptor Expression in SMC 
 
My observation that plaque SMC have an increased response to TNFα led me to hypothesise that there 
might be a difference in the expression of the TNF receptors, between AthSMC and AoSMC.  
Therefore, I investigated the protein expression of the two TNF receptors p55 and p75 in AthSMC and 
AoSMC.   
 
5.3.1 Protein levels of TNF Receptors 
 
I assessed the protein levels of the TNF receptors in AthSMC and AoSMC using immunoblotting.  
Levels of p55 were low in all SMC samples with no difference between AoSMC and AthSMC (Figure 
5.5).  Interestingly, AthSMC expressed higher amounts of p75 than AoSMC, although with some 
degree of variation between donors.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Protein levels of the TNF Receptors in unstimulated SMC.  SMC lysates for 2 AoSMC 
donors and 3 plaque donors were western blotted for p55 and p75.  Low levels of p55 were detected in 
all samples. There was no difference in p55 between plaque and AoSMC. AthSMC appeared to 
express higher amounts of p75 than AoSMC, although the levels varied between plaques.  Alpha-
tubulin was used as a loading control.  
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I also investigated the effect of TNF stimulation on the expression of the TNF Receptors.  The levels 
of p55 were low and no increase was observed in TNF-stimulated SMC (Figure 5.6).  However, there 
was a large increase in the amount of p75 protein in SMC stimulated with TNFα (Figure 5.6).  This 
effect was seen in both AoSMC and AthSMC.  This observation is in accordance with previous studies 
(Vandenabeele, Declercq et al. 1995) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 TNF receptor p75, but not p55 increases with TNFα stimulation.  SMC whole cell 
lysates from cells stimulated with or without TNFα for 24 hours were western blotted for the TNF-
receptors.  TNFα stimulation caused an increase in p75 expression in AoSMC and AthSMC.  Levels 
of p55 expression did not change with TNFα stimulation. Alpha-tubulin was used as a loading control.   
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5.3.3 TNRII expression in the plaque 
 
As p75 was more highly expressed in AthSMC, I looked at its expression in human plaque tissue using 
immunohistochemistryon frozen sections of carotid endarterectomy specimens.  There was positive 
staining for p75 in the intima of the plaque (Figure 5.7) , which corresponded to areas of αSMA as 
well as CD68 staining suggesting its localisation to SMC and macrophages.  On the outer edges of the 
plaque, which contain medial sections, there was very little positive staining for p75.  This area stained 
positively for αSMA and so is probably a section of the medial layer of the artery.  This suggests that 
plaque SMC express higher levels of p75 than medial SMC, confirming the results seen in the 
immunoblotting (Figure 5.7).  
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Figure 5.7 Immunohistochemistry of TNFRII in human carotid artery plaque tissue.  Sequential sections of frozen carotid endarterectomy specimens 
were stained for TNFRII, αSMA and CD68, using the Avidin-Biotin complex method.  Sections were counter stained with hematoxylin to visualise the 
nucleus.  The TNFRII staining localised to areas of intimal SMC (large arrow heads), but not present in medial SMC (small arrow heads).  TNFRII was also 
localised to areas of CD68 staining indicating macrophage expression (long arrows).  Original magnification: x 10.  Representative images are shown for 3 
plaques. 
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5.3.4 Is Soluble TNFRII is shed by SMC? 
 
Soluble cytokine receptors act as natural inhibitors of cytokines.  They sequester extracellular 
cytokines and therefore regulate their physiological effects in immune and inflammatory responses.  
Additionally, shedding of the cell surface receptor decreases the levels of intact and active receptors 
on the cell, reducing the effectiveness of the cytokine.  Soluble TNF receptors are up regulated at 
sites of chronic inflammation, such as the arthritic joint (Cope, Aderka et al. 1992) and both 
receptors have been shown to correlate with rheumatoid factor, disease activity score (DAS28) and 
erythrocyte sedimentation rate (ESR) (Valle, Ledezma-Lozano et al. 2009).  They have also been 
detected in patients with coronary artery disease. In patients with peripheral vascular disease and 
ischemic heart disease, sTNFRII was increased compared to control subjects, whereas p55 levels 
were unchanged (Blann and McCollum 1998).  The biological anti-TNF agent Etancercept is a 
fusion protein containing a dimeric soluble p75 receptor and works by sequestering circulating 
TNFα. 
 
As p75 was strongly up regulated in response to TNFα, I went on to investigate whether it was also 
released by SMC.  I assessed the concentrations of soluble p75 in the supernatants collected from 
unstimulated and TNF-stimulated AoSMC and AthSMC by ELISA.  For comparison, I analysed the 
supernatants collected from plaque cell cultures, 24 hours after enzymatic digestion.  Soluble p75 
was not detected in the supernatants from SMC cultures but it was present in some of the 
supernatants of whole plaques (Figure 5.8).  Supernatants from a total of 20 plaques were analysed, 
but soluble p75 was only detected in four (20%).  Therefore, any soluble p75 contributing to the 
measurable amounts in the serum of patients probably does not originate from plaque SMC, but 
rather from other cell types such as macrophages and T-lymphocytes.  
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Figure 5.8 Soluble TNFRII is present in atheroma supernatants but it is not shed by SMC.  
Supernatants from AthSMC and AoSMC cell culture stimulated ± TNF (10ng/ml) for 24 hours were 
analysed for sTNFRII by quantikine ELISA.  Atheroma supernatants (Plaque1, 2, etc) were also 
analysed for sTNFRII.  sTNFRII was not detectable in SMC supernatants but it was detected in 4 out 
of 20 atheroma supernatants.  Error bars represent ±SD of duplicate measurements.  N.D.: not 
detectable. 
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5.4 Proteomic analysis of TNF-stimulated SMC 
 
In addition to the response of SMC to TNF stimulation, I investigated the effects of TNF on the SMC 
proteome.  Previous studies show that TNF induces SMC migration and proliferation (Jovinge, 
Hultgardh-Nilsson et al. 1997; Goetze, Xi et al. 1999), which are characteristics of phenotypically 
modulated SMC.  Therefore, TNF could contribute to the changes in protein expression that were 
characterised in chapter 3.   
 
Cell lysates of unstimulated and TNF-stimulated AthSMC and AoSMC were separated on analytical 
2-dimensional gels as described in Chapter 2.  In this study, seven AthSMC and three AoSMC 
donors were used (See Appendix 2 for donor information).  I compared the proteome of unstimulated 
AoSMC, unstimulated AthSMC, TNF-stimulated AoSMC and TNF-stimulated AthSMC.  Twenty 
one spots were identified as having a statistically significant difference in expression (Figure 5.9) of 
which twelve were identified by mass spectrometry (Table 5.2).  In the TNF-stimulated SMC there 
were ten proteins with decreased expression compared to unstimulated SMC.   
 
The effect of TNF stimulation on the proteome shed light on the mechanisms of the changes of the 
proteome in AthSMC that were identified in Chapter 3.  The proteins differentially expressed after 
TNF stimulation could be classified according to ontology as pertaining to cytoplasmic proteins, 
antioxidants, proteases and ATP synthesis.  There was a trend towards more profound changes being 
induced by TNF in AthSMC.  However, the differences between the 2 cell types were less dramatic 
than the ones identified from the gene expression studies in Figure 5.3.  This could be due to the 
different techniques utilised. 
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Figure 5.9 Differentially expressed proteins in TNF stimulated SMC.  Aortic (n=3) and plaque 
SMC (n=7) were stimulated with and without 10ng/ml TNFα for 24 hours.  Cells were lysed and 
100µg of protein was used to create analytical 2D gels.  Three replicate gels were created for each 
condition from each donor.   2D-gel images were analysed by Progenesis Samespots version 3.3.  
Twenty-one spots were identified to have a statistically significant difference between unstimulated 
and TNF-stimulated (p < 0.05, One Way ANOVA), which are circled in red.  Twelve out of the 
twenty-one proteins were identified by mass spectrometry and are numbered.  The number 
corresponds to the spot number on proteome map in chapter 3 and the table of identifications in 
Table 5.2. 
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Table 5.2 Identification of proteins that change with TNF stimulation.  Spot number corresponds to the image in Figure 5. 9 and the SMC reference map 
in chapter 3.  Mean spot volumes represent the average number of pixels (106) from the mean spot volume from each donor, under each condition (± 
Standard Error of the Mean). The fold changes of TNF-stimulated/unstimulated plaque and TNF-stimulated aortic/unstimulated aortic SMC are shown.  
Statistics were performed in Progenesis Samespots v 3.3 using the log of the mean spot volumes using One-Way ANOVA (p<0.05).   
 
Mean Spot Volumes (106 Pixels, ±SEM) 
Spot Protein Identification Aortic 
Unstimulated   Aortic TNF 
Plaque 
Unstimulated Plaque TNF 
p- value (One 
Way ANOVA) 
13 ATP Synthase subunit beta 11.15 (±0.4) 10.76 (±0.83)  9.47 (±0.33) 8.26 (±0.39) 0.00001 
18 Actin 18.68 (±0.16) 16.51 (±1.09) 16.74 (±1.37) 13.80 (±1.3) 0.003 
19 Actin 11.88 (±0.68) 10.02  (±0.29) 9.84  (±0.58) 8.79  (±0.63) 0.001 
20 Actin 22.62  (±0.66) 21.99  (±1.21) 18.54  (±0.93) 19.58  (±0.69) 0.002 
22 Actin 17.86  (±1.23) 15.17  (±0.66) 14.38  (±0.84) 11.44  (±0.53) 0.002 
27 Glutathione S Transferase Omega 1 4.83  (±0.68) 2.82  (±0.32) 3.66  (±0.47)  2.73  (±0.14) 0.00008 
33 F-actin capping subunit alpha 1 15.22  (±0.55) 11.97  (±0.31) 12.05  (±1.01) 10.36  (±0.83) 0.0005 
57 Cathepsin B 12.28  (±0.17) 12.72  (±0.27) 14.78  (±1.12) 11.72  (±1.03) 0.28 
65 Glutathione S Transferase Pi 22.20  (±0.15) 26.72  (±0.7) 22.10  (±1.28) 22.93  (±1.33) 0.043 
76 Aldehyde Dehydrogenase 2.89 (±0.43) 2.03 (±0.08) 1.97 (±0.13) 1.49 (±0.16) 0.00006 
79 Proteasome alpha 1 sunbunit isoform 2 4.61  (±0.32) 5.87 ( (±0.16) 3.73  (±0.11) 5.58  (±0.47) 0.012 
81 Beta-Hexosaminidase subunit beta 3.62  (±0.41) 2.99  (±0.42) 2.11  (±0.33) 1.62  (±0.19) 0.00006 
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5.4.1 Cytoskeletal proteins 
 
Four spots identified as cytoplasmic actin-1 were altered with TNF stimulation in both AthSMC and 
AoSMC (spot 18, 19, 20 and 22, Figure 5.10).  Actin presents itself as a trail of consecutive spots, all 
with the same molecular mass of approximately 40 kDa, with a range of pIs from 5.2 to 6.0.  These 
different spots represent different post-translational modifications of actin that alters the pI as 
previously discussed in chapter 3 (section 3.5).  The trend in the expression of all actin spots was that 
it was more highly expressed in AoSMC compared to AthSMC, as seen previously in chapter 3.  
Additionally, actin expression was decreased in TNF-stimulated SMC compared to unstimulated 
SMC.  This occurred in both AthSMC and AoSMC, indicating that TNFα has a similar effect in both 
cell types (Figure 5.10).   
 
The actin binding protein, F-actin capping protein subunit alpha-1 (also known as CapZα1) was also 
decreased by TNFα stimulation (Table 5.2).  CapZα1 was expressed at lower levels in plaque SMC 
compared to AoSMC.  There were significant decreases in TNF-stimulated AoSMC and AthSMC 
compared to the unstimulated cells.  CapZα1 forms a heterodimer with the CapZβ subunit and binds 
to the barbed end of actin filaments modulating actin filament growth.  Its decrease in TNF-stimulated 
SMC correlates with the decrease in actin expression. 
 
The overall decrease of the actin and actin binding protein levels in AthSMC compared to AoSMC is 
indicative of the less contractile SMC.  TNFα contributes to this effect by decreasing actin levels and 
associated proteins.  This effect is linked to SMC migration (Goetze, Xi et al. 1999) (Jovinge, 
Hultgardh-Nilsson et al. 1997) and proliferation (Rectenwald, Moldawer et al. 2000; Wang, Rao et al. 
2005), both of which involves changes in the cytoskeleton to allow movement and reorganisation of 
cellular components.  
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Figure 5.10 Actin cytoskeleton is altered by TNFα stimulation.  Expression of cytoskeletal actin is 
decreased in AthSMC compared to AoSMC or decreased in TNF-stimulated SMC compared to 
unstimulated.  Statistics were calculated in Same Spots (p < 0.05, One Way ANOVA).  Post-test 
statistical analysis was performed in Prism using One Way ANOVA with Tukey Post test (*p<0.05, 
**p<0.01).  AoSMC, n=3, AthSMC, n=7 
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5.4.2 Mitochondrial Proteins 
 
The mitochondrial proteins, ATP Synthase subunit-beta and aldehyde dehydrogenase-2, were 
decreased with TNFα stimulation in AthSMC (Figure 5.11).  Spot 13, identified as ATP Synthase 
subunit-beta was decreased in TNF-stimulated AthSMC compared to unstimulated (13%), but not in 
TNF-stimulated AoSMC.  Spot 76, identified as aldehyde dehydrogenase 2 was also decreased in 
TNF-stimulated AoSMC and in TNF-stimulated AthSMC compared to the unstimulated by 30%, and 
by 25% respectively.  Both proteins were identified in Chapter 3 as being significantly reduced in 
AthSMC compared to AoSMC (Figure 3.28) and such differences were confirmed in this analysis.  
TNF stimulation causes a further decrease in expression of these proteins indicating that exposure to 
TNF in vivo could be a contributing factor to the reduction of ATP Synthase subunit-beta and 
aldehyde dehydrogenase 2 seen in AthSMC. Indeed, exposure to TNFα is able to induce in AoSMC 
levels of aldehyde dehydrogenase 2 comparable to the ones of unstimulated AthSMC. 
 
 
 
 
 
 
Figure 5.11 TNFα stimulation affects the levels of mitochondrial proteins.  Mitochondrial proteins 
ATP Synthase beta and aldehyde dehydrogenase 2, and glutathione S transferase omega 1 are 
decreased in AthSMC compared to AoSMC, with a further decrease with TNF stimulation.  Spot 
volumes are presented here graphically as the mean average of the spot volume ± SEM.  Statistics 
were calculated in Same Spots (p < 0.05, One Way ANOVA).  Post-test statistical analysis was 
performed in Prism using One Way ANOVA with Tukey Post test (*p<0.05, **p<0.01).  AoSMC, 
n=3, AthSMC, n=7 
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5.4.3 Antioxidant proteins 
 
I detected changes in the levels of glutathione S-transferase omega-1 (GSTO1) and glutathione S-
transferase pi-(GSTP1) with TNF stimulation (Figure 5.12, Table 5.2).  GSTs are a super family of 
enzymes, which act as a cellular defence against toxic and carcinogenic molecules and their actions 
protect cells from free radicals and reactive oxygen species (Hayes and Pulford 1995; Hayes and 
Strange 1995).  The two GSTs identified in this study belong to different classes of GSTs and are only 
distantly related at the genetic level, with no shared sequence similarity (Board, Coggan et al. 2000). 
There were significant decreases in GSTO1 in both TNF-stimulated AoSMC (42%) and AthSMC 
(25%) compared to the unstimulated SMC (Figure 5.12).  GSTO1 was also decreased in unstimulated 
AthSMC compared to AoSMC.  Spot 27, identified as GSTO1 has an experimental molecular mass of 
approximately 33kDa and a pI of 5.0.  The predicted values are 27kDa and pI 6.24.  On the SMC 
reference map (see chapter 3, Figure 3.11, Table 3.1) another spot (spot 28) was also identified as 
GSTO1 although its expression was not changed significantly with TNF stimulation.  Spot 28 has a 
similar molecular mass and a pI of approximately 5.2.  The presence of two different spots both 
identified as GSTO1, suggests that both may be post-translationally modified forms of GSTO1.  
According to the Uniprot database, GSTO1 can be acetylated on multiple lysine residues, which may 
cause the shift in pI.   
 
Spot 65 identified as GSTP1 was instead increased by TNF stimulation (Figure 5.12).  In TNF-
stimulated AoSMC, GSTP1 was increased by 20% but expression was not changed in AthSMC (Table 
5.2). This spot identified as GSTP1 has a molecular weight of 23kDa and pI of 5.8, similar to its 
predicted value.  Therefore it would appear that the increase seen in TNF-stimulated AoSMC is due to 
an increase in absolute protein levels rather than in post-translationally modified forms as detected for 
GSTO1.  Interestingly GSTP1 expression has been associated with plaque stability as its expression 
was decreased in unstable plaques compared to stable plaques from carotid arteries (Lepedda, Cigliano 
et al. 2009).  I did not detect any significant difference in expression of GSTP1 between unstimulated 
AoSMC and AthSMC.  Further studies are needed to clarify these discrepancies and to explore the 
relationship between TNF, GSTP1 and plaque destabilisation. 
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Figure 5.12 Differential expression of two Glutathione S Transferases with TNF stimulation.  
Glutathione S Transferase Omega is decreased in TNF stimulated AoSMC and AthSMC compared to 
unstimulated comparators.  Spot volumes are presented here graphically as the mean average of the 
spot volume ± SEM.  Statistics were calculated in Same Spots (p < 0.05, One Way ANOVA).  Post-
test statistical analysis was performed in Prism using One Way ANOVA with Tukey Post test 
(*p<0.05).  AoSMC, n=3, AthSMC, n=7 
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5.4.4 Proteasomal subunits 
 
There was a significant increase spot 79, identified as proteasome subunit α1, in both TNF-stimulated 
AoSMC and AthSMC (Figure 5.13).  Its expression was similar in unstimulated AoSMC and 
AthSMC.  Proteasome subunit α1 is part of the 20S core of the 26S proteasome complex.  The core of 
the proteasome is made up of 28 subunits arranged in four stacked ring-like structures.  The rings at 
either end are formed by seven alpha subunits and the central rings are formed by beta subunits.  
Cytosolic proteins are targeted for protein degradation by the ubiquitin-proteasome pathway and this 
pathway is important for protein degradation and protein ‘quality control’ in all eukaryotic cells.  
However, studies blocking the ubiquitin- proteasome system have shown protection from oxidative 
stress (Meiners, Ludwig et al. 2006; Dreger, Westphal et al. 2010). The increase in proteasome subunit 
α1 in TNF stimulated SMC might indicate further mechanism to fend off oxidative stress within the 
atherosclerotic plaque. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 TNF alters the expression of Proteasomal subunit alpha 1. Proteasome subunit alpha-1 
is increased with TNF stimulation in AoSMC and AthSMC.  Spot volumes are presented here 
graphically as the mean average of the spot volume ± SEM.  Statistics were calculated in Same Spots 
(p < 0.05, One Way ANOVA).  Post-test statistical analysis was performed in Prism using One Way 
ANOVA with Tukey Post test (**p<0.01).  AoSMC, n=3, AthSMC, n=7 
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5.4.4 Lysosomal Proteins 
 
Lysosomal protease Cathespin B was decreased in TNF-stimulated AthSMC compared to 
unstimulated AthSMC (Figure 5.14).  It was increased in unstimulated AthSMC compared to AoSMC 
as shown in Chapter 3 (Figure 3.28, Table 3.2).  Interestingly, cathepsin B expression was not changed 
in TNF-stimulated AoSMC.  This spot has a molecular weight of approximately 25kDa and a pI of 
5.3, similar to the predicted values of cathepsin B.   
 
Beta-hexosaminidase is another lysosomal enzyme that degrades GM2 gangliosides.   It was decreased 
in TNF-stimulated AthSMC (Figure 5.14).  There was also a decrease in TNF-stimulated AoSMC but 
this was not significant.  The observed molecular weight/pI was 34/5.6) does not agree with the 
predicted values (49.9/5.9), suggesting that it could be a fragment of the full length protein.  Defects in 
the gene for this protein results in Sandhoff disease, a lysosomal storage disorder that results 
neurological conditions.  There are no reports of this protein in atherosclerosis. 
 
 
 
Figure 5.14.  Lysosomal protein expression is decreased in TNF-stimulated SMC.  Cathepsin B 
expression is decreased in AthSMC with TNF-stimulation, but there is no effect on AoSMC.  Beta-
hexosaminidase expression is decreased in AthSMC compared to AoSMC and decreased in TNF-
stimulated SMC compared to unstimulated SMC.  Spot volumes are presented here graphically as the 
mean average of the spot volume ± SEM.  Statistics were calculated in Same Spots (p < 0.05, One 
Way ANOVA).  Post-test statistical analysis was performed in Prism using One Way ANOVA with 
Tukey Post test (*p<0.05, **p<0.01, p< 0.001).  AoSMC, n=3, AthSMC, n=7 
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5.5 Discussion 
 
In chapters 3 and 4, I identified distinguishing protein signatures of SMC in atherosclerosis. In this 
chapter and the following chapter I set out to investigate the molecular mechanisms contributing to the 
changes in SMC.  Inflammation and hypercholesterolemia are strong factors to which SMC are 
exposed to in the microenvironment of an atherosclerotic plaque.  To this aim, I set out to characterise 
the effect of the exposure to such factors on the proteome and cellular responses of SMC.  In this 
chapter I investigated the effects of the proinflammatory cytokine TNFα on SMC, while in the next 
chapter I focused on the effect of cholesterol.   
 
Previous work in our laboratory suggested that AthSMC respond more to proinflammatory stimuli 
compared to non-atherosclerotic SMC, with increased production of molecules such as IL-6 and IL-8. 
This “proinflammatory phenotype” could be part of the phenotypic modulation that SMC undergo 
during atherosclerosis.  Hence, I investigated the effects of TNFα on gene expression using a qPCR 
gene array. I demonstrated that AthSMC have a greater up regulation of selected genes in response to 
TNF stimulation including adhesion molecules (E-selectin, VCAM-1), chemokines (CCL5/RANTES), 
the myeloid cell differentiation factor GM-CSF, and anti-apoptosis genes BIRC3, Bcl-2, and BID.  
 
In order to validate the findings of the PCR array, we performed a Luminex panel for cytokines and 
chemokines on TNF-stimulated AoSMC and AthSMC.  Out of 16 analytes, only MCP-1, RANTES, 
Fractalkine and IP-10 were detectable at low levels from unstimulated SMC and were increased upon 
TNF-stimulation.  Interestingly, while the two cell types did not differ in terms of the levels of TNF-
induced CCL2/MCP-1 and Fractalkine, AthSMC released a higher amount of CCL5/RANTES and IP-
10.  Such differences were in accordance with the gene expression data that identified no differences 
in MCP-1 expression but higher expression of RANTES in AthSMC after stimulation with TNF.  
Regrettably the PCR array panel used did not contain primers for IP-10 and fractalkine.  
 
Importantly, the chemokines detected in the Luminex panel are amongst the most relevant in 
atherosclerosis.  MCP-1 is chemoattractant for monocytes, while Fractalkine is chemoattractant 
monocytes and T-cells (Braunersreuther, Mach et al. 2007).  IP-10 is an IFNγ inducible gene that 
specifically recruits the proatherogenic lymphocyte subset Th1 within the human atherosclerotic 
plaque (Mach, Sauty et al. 1999).  Expression of different chemokines results in the recruitment of 
different monocyte subsets during disease development (Weber, Zernecke et al. 2008).  Monocytes 
expressing CD14hiCD16-, also express the chemokine receptors CCR2 and CXCR2, which bind MCP-
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1 and IL-8 respectively.  Alternately, monocytes which are CD14lowCD16+, expresses the receptor 
CX3CR1, which is the receptor for fractalkine, but do not express CCR2.  Interestingly, Cheng et al 
showed that the plaques that develop in areas of low shear stress are larger and more vulnerable.  They 
were also characterised by a specific chemokine profile, with increased levels of IP-10, fractalkine and 
GRO α/KC compared to lesions that formed at regions of oscillatory shear stress (Cheng, Tempel et 
al. 2007).  MCP-1 and IP-10 were expressed at both sites of lesion formation, suggesting they are 
involved in early events.  However, fractalkine was specifically up regulated at later time points, 
indicating a role in later stages of disease.  Additionally, fractalkine inhibition led to an increase in 
thickness of the fibrous cap re-iterating its role in later stages of atherosclerosis and also plaque 
vulnerability.  In my study, stimulation of both AthSMC and AoSMC with TNF resulted in up 
regulation of IP-10, MCP-1, RANTES and fractalkine, indicating SMC are involved in recruiting 
monocytes at early and later stages of atherosclerosis.  Importantly, as the AthSMC in my study are 
derived from advanced plaques, expression of fractalkine may contribute to increased plaque 
vulnerability.   
 
SMC can also express chemokine receptors themselves indicating that chemokines are involved in 
SMC responses in atherosclerosis and arterial injury (Weber, Zernecke et al. 2008).  SMC from 
atherosclerotic lesions have been shown to express functional chemokine receptors CCR1, CCR2 
(Hayes, Jordan et al. 1998), CCR5 (Schecter, Calderon et al. 2000) and CXCR3 (Lucas, Bursill et al. 
2003) suggesting that SMC respond to chemokines.  In keeping with these observations, we were also 
able to show that CCR-1 expression is increased in AthSMC compared to AoSMC (Chapter 6, Figure 
6.13) confirming once again that the in vivo phenotype may be at least partially preserved in ex vivo 
conditions and validating our approaches. MCP-1 has been shown to have a proliferative effect on 
SMC (Schecter, Berman et al. 2003) and in a rat  model of arterial injury, antibodies against MCP-1 
led to attenuated intimal hyperplasia (Furukawa, Matsumori et al. 1999).  IP-10 was also shown to 
induce proliferation and migration of cultured rat SMC (Wang, Yue et al. 1996).  Chemokine 
expression by SMC from advanced plaques could play a role in plaque destabilisation and thrombotic 
activities.  MCP-1 can induce tissue factor expression on SMC (Schecter, Berman et al. 2003) where 
as other chemokines can activate platelets and induce MMP production (Aukrust, Halvorsen et al. 
2008).  In unstable plaques, which characteristically have higher levels of inflammation and a thin 
fibrous cap, localised chemokine production by SMC could contribute to plaque destabilisation and 
thrombotic events. AthSMC in my study produced large amounts of chemokines with TNFα 
stimulation, which could contribute to continued recruitment of immune cells at later stages of 
atherosclerosis.  Unfortunately due to the low sample numbers, no comparison of SMC and the 
difference in their response to TNF could be made according to the symptomatic status of the patient 
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from which they were derived.  The use of SMC from more patients may allow any differences to 
become evident.   
 
Overall my data so far have highlighted an enhanced responsiveness to TNF in AthSMC. This 
‘priming’ for TNF activation and expression of NFκB-dependent genes is consistent with previous 
reports of up regulation of NFkB responses in intimal SMC.  SMC in atherosclerotic plaques exhibit 
NFκB activation (Brand, Page et al. 1996).  Similarly, in rat arterial injury models SMC exhibit low 
levels of constitutively active NFκB and reduced levels of inhibitory proteins IκBα and IκBβ and that 
this is accompanied by production of chemokines and adhesion molecules and increased monocyte 
recruitment (Landry, Couper et al. 1997) (Zeiffer, Schober et al. 2004).  However, similar evidence 
has been lacking in humans.  
 
Several factors can induce NFκB activation.  ROS are well-characterised inducers of NFκB activation 
(Janssen-Heininger, Poynter et al. 2000) (Schreck, Rieber et al. 1991).  In turn, chronic blockade of 
NFκB activity in a rat model of spontaneous hypertension led to decreased ROS formation and 
mitochondrial damage (Elks, Mariappan et al. 2009).  Therefore a vicious cycle is established as 
NFκB leads to production of inflammatory mediators including TNF and IL-1, which act further to 
activate NFκB.  My findings in chapter 3 that highlight an increased oxidative stress, vouch for a 
contribution of ROS in potentiating TNF-dependent responses in atherosclerosis. 
 
Additionally, I was able to reveal a further molecular mechanism for such priming by studying the 
levels of TNF receptors.  I demonstrated a selective increase of TNFRII (p75) expression in AthSMC 
compared to AoSMC in unstimulated conditions AthSMC.  Such levels were further up regulated by 
exposure to TNF, indicating that in SMC – as published for other cell types – TNF contributes in 
amplifying its own biological effect increasing p75 expression at the site of inflammation. 
Immunohistochemistry of human atherosclerotic plaque sections revealed that p75 co-localised with 
SMC in the intimal regions, but there was little or no p75 in the medial region.  As p75 was up 
regulated by TNF stimulation in AthSMC in vitro, the proinflammatory environment of the plaque 
could be the cause of the increased p75 expression seen in AthSMC in vivo.  However, there was little 
expression in the medial SMC in the histology, suggesting that medial SMC are not exposed to TNFα 
to the same extent.  Thus, increased expression of TNF receptor p75 may be a feature of AthSMC.  
SMC are exposed to proinflammatory stimuli over long periods of time as the plaque develops, this 
would result in an up regulation of p75, resulting in an increased sensitivity to TNFα and establishing 
a vicious cycle.  Unpublished observations from our laboratory also show that IL-1 receptor is also up 
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regulated in AthSMC compared to AoSMC (data not shown), indicating that the signalling of other 
cytokines and receptors might be altered in AthSMC.   
 
A number of in vivo studies have been performed to elucidate the roles of the TNF receptors in 
atherosclerosis.  The original report of p55 deletion in a model of cholate diet induced atherosclerosis 
in Bl6 mice showed an increase in the lesion development (Schreyer, Peschon et al. 1996).  However, 
in LDLR-/- mice lacking p55 only in bone marrow derived cells, lesions were 22% smaller than the 
LDLR-/- p55+/+ mice and contained smaller foam cells and fewer macrophages, suggesting a role of 
macrophage p55 expression in atherosclerotic lesions (Xanthoulea, Gijbels et al. 2008).  In advanced 
lesions of apoE-/- p55-/- mice, there was no difference in the plaque composition or stability of 
advanced lesions in the innominate (bracheocephalic) artery, compared with apoE-/- p55+/+ mice 
(Blessing, Bea et al. 2004).  Additionally, in apoE-/- mice that received arterial grafts from p55-/- mice, 
lesions were 50% smaller lesions than those mice receiving wild type grafts (Zhang, Peppel et al. 
2007). 
 
Also, p75 contributes to the development of atherosclerosis as lesions in apoE-/- p75-/- mice were 43% 
smaller than in apoE-/- p75+/+ mice (Chandrasekharan, Mavrakis et al. 2007).  Receptor p75 was also 
shown to be required expression of the adhesion molecules VCAM-1, ICAM-1 and E-selectin 
(Chandrasekharan, Siemionow et al. 2007).  In addition to this, leukocyte adhesion to the endothelium, 
rolling and transmigration was also reduced in p75-/- mice due to the impaired adhesion molecule 
expression by endothelial cells.   
 
The role of two receptors appears to diverge when the effect of the genetic deletion is tested in the 
context of intimal hyperplasia.  TNFα-/- mice have 7-fold less intimal hyperplasia after carotid wire 
injury (Zimmerman, Selzman et al. 2002).  The same authors later showed that p55-/- mice but not in 
p75-/- mice were protected from carotid arterial injury, indicating that TNF has a role in the 
establishment of intimal hyperplasia predominantly through the p55 (Zimmerman, Reznikov et al. 
2003).  In this study, the reduction of neointimal area in p55-/- mice was correlated with reduced NFκB 
mRNA and protein levels, indicating that signalling through p55 induces NFκB (Zimmerman, 
Reznikov et al. 2003).  
 
The effect of TNF stimulation on SMC has been extensively investigated in several targeted responses 
including proliferation, migration and inflammation.  However, the study of a SMC proteome upon 
TNF stimulation has never been performed before.  Hence I set out to investigate the changes in the 
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proteome upon SMC stimulation.  Investigation into the effects of TNFα on the SMC proteome 
revealed statistically significant changes in the volumes of several 2D gel features.  Interestingly, TNF 
stimulation was able to recapitulate some of the findings relative to the AthSMC proteome discussed 
in chapter 3, most notably the decrease in expression of actin and associated proteins and 
mitochondrial proteins. 
 
My finding of a decrease in actin and the associated protein CapZα1 after TNF stimulation suggests 
that TNF may have a role in the loss of contractile phenotype in SMC.  This provides a link between 
the phenotypic modulation of SMC and the proinflammatory environment of the plaque.  Previous 
studies have shown that TNF can lead to re-organisation of the cytoskeleton resulting in migration of 
SMC (Jovinge, Hultgardh-Nilsson et al. 1997) (Goetze, Xi et al. 1999). 
 
The loss of CapZα1 was also reported in a proteomic study of human saphenous vein SMC exposed to 
simulated arterial flow (McGregor, Kempster et al. 2004).  McGregor et al showed that the actin 
binding protein CapZα2 was decreased 3-fold after 90 minutes of exposure to arterial flow, suggesting 
it is important in actin re-modelling. Our data show that this change is potentially induced also by 
TNF. 
 
In chapter 3, I identified a loss of mitochondrial proteins ATPase subunit β and aldehyde 
dehydrogenase 2 as a feature of AthSMC.  In the current chapter, I described that TNF stimulation is 
able to reproduce such finding ex vivo even in control AoSMC.  As discussed previously in chapter 3, 
their decrease in expression suggests that these cells have undergone mitochondrial damage due to 
ROS.  TNF can induce ROS production at the mitochondria (Corda, Laplace et al. 2001) although 
specific studies in SMC are not present in the literature, making this a novel finding.  Interestingly, 
intra-peritoneal injection of TNF into rats has been shown to induce mitochondrial oxidative stress in 
the heart by altering the activity of membrane transition pores (Mariappan, Soorappan et al. 2007).  
More interestingly, in the rats who received TNF there was increased superoxide production in the 
mitochondria of the left ventricle and decreased enzyme activity of complex I in the electron transport 
chain (Mariappan, Elks et al. 2009).  Expression levels of the subunits that comprise complex I were 
decreased and there was also significantly decreased ATP levels in TNF treated rats demonstrating 
that TNF induced mitochondrial damage affects ATP production.  These effects were inhibited and 
returned to levels observed in the controls rats by using scavenger molecules that reduce superoxide 
(Mariappan, Elks et al. 2009).  Therefore, the decrease in mitochondrial protein expression that I 
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observed is most likely to be mediated by increased ROS production by TNF signalling, linking TNF 
exposure and increased mitochondrial damage. 
However, it should be noted that the only protein with an increased expression in TNF-stimulated 
SMC, was proteaseome subunit alpha-1, a member of the proteasome complex.  The increase in 
subunits of the proteasome complex suggests an increase in protein degradation.  TNF-induced protein 
degradation has been observed in cancers and other inflammatory diseases (Li and Reid 2000).  In 
models of cachexia associated with cancers, increased ubiquitin-proteasme activity was associated 
with a increased weightloss (Khal, Wyke et al. 2005).  Therefore, TNF could be responsible for the 
decreases seen in protein expression in this study.   
 
In conclusion, I demonstrated in this chapter that SMC derived from human established atherosclerotic 
lesions are primed to TNF responses via the enhanced expression of the TNFRII probably induced by 
TNF itself in a vicious cycle.  This enhanced response of atherosclerotic SMC might contribute to 
enhanced recruitment of mononuclear cells within the atherosclerotic lesions and to other cellular 
responses, including apoptosis and production of growth factors.  Finally, I showed here that TNF is 
able to reproduce in vitro some of the changes in the proteome of SMC present in AthSMC even in 
control AoSMC.  These features include loss of actin and associated contractile proteins and 
mitochondrial proteins.  These findings identify TNF as a strong modulator of SMC phenotype and 
function of SMC within the human atherosclerotic plaque. 
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6. Introduction 
 
Accumulation of cholesterol, other lipid and lipoproteins in the artery wall is a fundamental feature of 
atherosclerosis.  Its presence in the artery wall is an initiating step of atherosclerosis (Watson, 
Leitinger et al. 1997) (Ross 1999) (Furnkranz, Schober et al. 2005).  Cells in the vascular wall 
accumulate lipid as cytoplasmic droplets of triglyceride or cholesterol esters.  Cells that accumulate 
large amounts of lipid are known as foam cells.  Classically, it is macrophages that become foam cells 
but some foam cells are also of SMC origin (Faggiotto, Ross et al. 1984) (Glukhova, Ornatsky et al. 
1987). 
 
Accumulation of cholesterol by cells results in its incorporation into the plasma membrane or 
endoplasmic reticulum (ER) membrane where it can disrupt membrane fluidity and homeostasis.  The 
enzyme acyl-CoA:cholesterol acyl transferase (ACAT) converts free cholesterol into neutral 
cholesterol esters (CE), which are stored in cytoplasmic vesicles thereby preventing this disruption.  
Macrophages are particularly sensitive to ACAT inhibition (Warner, Stoudt et al. 1995) and 
accumulation of free cholesterol results in cytotoxicity and cell death (Tabas 1997).  Cell death leads 
to enlargement of the necrotic core, which is a feature of vulnerable plaques.  In contrast, SMC have 
higher resistance to ACAT inhibition and do not experience cytotoxicity or cell death with 
accumulation of free cholesterol (Rong, Kusunoki et al. 2005). Thus, SMC could also contribute to 
foam cell formation, which could be beneficial in later stages of atherosclerosis when macrophage 
foam cells have died. 
 
Different subpopulations of SMC may preferentially accumulate lipid (Argmann, Sawyez et al. 2004).  
Using cloned SMC from human internal thoracic artery (Li, Fan et al. 2001), Argmann observed that 
spindle-shaped SMC accumulated more cholesterol esters than smaller epithelioid-shape SMC when 
incubated with VLDL, suggesting that SMC-derived foam cells in atherosclerotic lesions are derived 
from a particular SMC sub-set. There is evidence to suggest that lipid present in the intima may 
contribute to the phenotypic modulation of SMC.  Interestingly, oxidised phospholipids (oxPLs) 
generated from the oxidation of LDL have been shown to decrease the expression contractile proteins 
in SMC, indicating a phenotypic modulation.  For instance, 1-palmitoyl-2-arachidonyl-sn-glycero-3-
phosphocholine (PAPC) and 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC) 
were shown to reduce the mRNA levels of αSMA and SM-MHC in rat aortic SMC (Pidkovka, 
Cherepanova et al. 2007) (Cherepanova, Pidkovka et al. 2009).  This effect was mediated by activation 
of the translational repressor Krüppel-like transcription factor (KLF)-4 and suppression of the co-
activator myocardin, which act at the promoters of these genes.  Similar results were seen in mouse 
aortic SMC where cholesterol loading with a soluble form of cholesterol led to a decrease in αSMA, 
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SM-MHC, h1-calponin and α-tropomyosin (Rong, Shapiro et al. 2003).  The macrophage marker and 
scavenger receptor CD68, Mac-2 and the cholesterol efflux molecule ABCA1 were also increased 
indicating the acquisition of a macrophage-like state by AthSMC.   
 
Moreover, exposure to lipoproteins also affects deposition and assembly of extracellular matrix 
components. Human SMC incubated with native LDL and VLDL had defective assembly of collagen 
type I and fibronectin, which are matrix proteins produced by medial SMC (Frontini, O'Neil et al. 
2009).  This was mediated by inactivation of the Src signalling pathway, which reduced tensin and 
FAK phosphorylation and abnormal integrin clustering. Rat aortic SMC stimulated with oxPLs had 
increased production of collagen type VIII and versican (Cherepanova, Pidkovka et al. 2009).  
Production of collagen type VIII was required for SMC migration, suggesting that production of 
particular matrix proteins by SMC may allow their migration into the intima. 
 
Accumulation of cholesterol in the endoplasmic reticulum (ER) membrane can induce ER stress.  The 
cholesterol content in the ER membrane is generally low so cholesterol enrichment of the membrane 
results in the loss of membrane fluidity and affects the function of ER membrane proteins (Tabas 
1997).  Free cholesterol accumulation in peritoneal macrophages in vitro has been shown to induce ER 
stress and activate the unfolded protein response (UPR) (Feng, Yao et al. 2003).  Similarly, Li et al 
showed that free cholesterol accumulation in macrophages induced expression of TNF and IL-6 
mRNA and protein, which was mediated by cholesterol-induced activation of the NFκB and MAPK 
pathways (Li, Schwabe et al. 2005).  Interestingly, the incubation of human atherosclerotic SMC with 
soluble cholesterol led to a large increase in the ‘alarmin’ protein high mobility group box-1 
(HMGB1), although activation of UPR was not investigated (Porto, Palumbo et al. 2006).  
 
As the intimal accumulation of cholesterol is an initiating step of atherosclerosis and is likely to 
precede phenotypic modulation of SMC, I hypothesised that cholesterol could be responsible for 
induction of a proinflammatory phenotype, as seen in carotid plaque SMC in previous chapters of this 
thesis.  Cholesterol is present in the intima throughout all stages of plaque development and could act 
as a constant stimulus to SMC. 
 
During early stages of SMC cell culture obtained by enzymatic digestion of carotid plaques and before 
SMC isolation, I often observed SMC loaded with lipid droplets, indicating the presence of SMC foam 
cells in carotid plaques (Figure 6.1 A).  To quantify the cholesterol present in the carotid plaques from 
which the SMC were derived, I measured the levels of free cholesterol and total cholesterol (free 
cholesterol plus cholesterol esters) in the supernatants collected from the enzymatically digested 
plaques, 24 hours after digestion.  Total cholesterol content between plaques varied from 2 to 6μg/ml 
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(0.53- 1.58mM/L) (Figure 6.1).  Free cholesterol made up approximately half of the total cholesterol 
measured (Figure 6.1 B).  Free cholesterol is therefore present on the plaque millieu and is available to 
cells.   
 
In this chapter, I investigated the effects of cholesterol on SMC using the model of cholesterol loading 
reported by Rong, et al and Porto et al (Rong, Shapiro et al. 2003; Rong, Kusunoki et al. 2005)  
(Porto, Palumbo et al. 2006) and its ability to induce a proinflammatory phenotype in AoSMC.  This 
model, with cholesterol complexed with methyl-β-cyclodextrin (chol:MβCD), allows the effect of free 
cholesterol to be investigated, independently of the effects of lipoproteins and their modifications.  As 
cholesterol is a large hydrophobic molecule, its delivery to cells in aqueous culture medium is 
difficult.  Methyl-β-cyclodextrins are cyclic oligosaccharides with a hydrophilic external face and a 
hydrophobic internal cavity, which can encapsulate molecules such as cholesterol which are very 
hydrophobic (Christian, Haynes et al. 1997).  Such molecules have been used to enrich cellular 
cholesterol content, which can be esterified to cholesterol ester by ACAT.  I used commercially 
available cholesterol complexed with methyl-β-cyclodextrin as a source of free cholesterol.  In this 
model, cholesterol is delivered directly to the plasma membrane (Christian, Haynes et al. 1997).  I 
refer to cholesterol in complex with Methyl-β-cyclodextrins as ‘soluble cholesterol’. 
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Figure 6.1 SMC foam cells and free cholesterol are present in carotid atherosclerotic plaques.  
A) A representative picture of lipid laden SMC from carotid plaque (passage 1).  SMC containing lipid 
droplets were visible in cell cultures from enzymatically digested plaques (black arrows).  
Magnification x100.  B) Supernatants of three enzymatically digested carotid plaques were assayed for 
free cholesterol and total cholesterol (free cholesterol + cholesterol esters).  Plaque supernatants varied 
in their cholesterol content.  Free cholesterol makes up approximately half of total cholesterol content.  
Error bars represent ± standard deviation of triplicate values.  Cholesterol quantitation performed by 
Amanda Cross 
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6.1 Cholesterol loading of human aortic SMC 
 
To investigate whether the SMC in this system could take up cholesterol, I incubated cells with 
soluble cholesterol.  Lipid accumulation was visualised by Oil Red O staining (Figure 6.2).  
Intracellular lipid droplets could be seen in those cells incubated with soluble cholesterol.  In the 
absence of soluble cholesterol, AoSMC showed no sign of Oil Red O positive lipid droplets (Figure 
6.2A).  The uptake of cholesterol appeared to be dose-dependent.  AoSMC incubated with 100μg/ml 
of soluble cholesterol showed more lipid droplets per cell than those cells incubated with 10μg/ml 
soluble cholesterol (Figure 6.2 B-D).  Additionally, the total number of cells containing lipid droplets 
increases with higher cholesterol concentrations.   
 
 
 
Figure 6.2 Human aortic SMC take up free cholesterol.  Human aortic SMC were plated on lab-tek 
slides and left to adhere for 24 hours.  SMC were serum starved for 24 hours before incubation with a 
range of cholesterol concentrations (0-100μg/ml) in serum-free DMEM for up to 72hours.  Serum 
starvation was necessary so that any change in SMC could be attributed to the soluble cholesterol, 
rather than other stimuli present in serum.  Cells were fixed and stained with Oil Red O to visualise 
neutral lipid droplets and counterstained with haematoxylin to visualise the nuclei.  A) No cholesterol, 
B) 10µg/ml cholesterol, C) 50µg/ml cholesterol, D) 100μg/ml cholesterol.  Representative pictures 
from 1 out of 3 experiments.  Magnification: x20. 
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6.2 Cholesterol loading of plaque SMC 
 
I investigated whether uptake of soluble cholesterol was similar in AthSMC (Figure 6.3).  
Interestingly, some AthSMC stained positive with Oil Red O for lipid droplets even prior to 
cholesterol loading (Figure 6.3 A), suggesting that these SMC had previously been exposed to 
cholesterol in vivo.  This observation is in line with my observations in early cell culutre (Figure 6.1) 
and the findings of Porto et al, who showed that SMC cultured from atheroslcerotic plaque already 
contained lipid droplets before exposure to soluble cholesterol (Porto, Palumbo et al. 2006).  I 
observed differences in the cholesterol uptake between SMC derived from different plaques.  For 
example, the total number of cells that stained positive for neutral lipid varied between AthSMC from 
different donors, as well as the number of droplets per cell (intensity of staining) (Figure 6.3).  
Cholesterol uptake by AthSMC as indicated by Oil Red O, did not increase significantly as compared 
to baseline staining, and it was more variable.   
 
When plated on lab-tek slides, I observed that AthSMC often died within the first 24 - 48 hours after 
cholesterol loading.  Visual observations with light microscopy suggested that AthSMC were 
undergoing apoptosis, as seen by changes in cell morphology and cell membrane (see Figure 6.3 C-D).  
This was in contrast to AoSMC, where extermely low levels of cell death was seen and the cells 
retained their spindle shape morphology.  As AthSMC have already been exposed to lipid in vivo, 
further cholesterol loading could be cytotoxic despite reports by Rong et al that claim SMC are 
resistance to the cytotoxic effects of cholesterol accumulation experienced by macrophages (Rong, 
Kusunoki et al. 2005).  I therefore investigated the effect of cholesterol loading on the  cell viability 
using a cell viability assay (MTS assay) (Figure 6.4).  In this test, the quantity of the formazan product 
produced, as measured by the absorbance at 450nm, is directly proportional to the number of viable 
cells.  No statistical difference in the cell viability was observed with cholesterol or TNFα stimulation 
at 24 hours compared to unstimulated cells in either the aortic or plaque SMC (Figure 6.4 A &B).  
However, there was a general trend of decreasing cell viability from 24 hours to 72 hours in all 
conditions, which is probably due to prolonged serum starvation (Figure 6.4C).  As cholesterol loading 
of AthSMC was variable in, I decided to use AoSMC for further cholesterol loading experiments.   
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Figure 6.3 Plaque SMC show evidence of previous exposure to a hyperlipidemic environment. 
Plaque SMC were incubated with cholesterol in serum free DMEM for 72hours.  After  72 hours cells 
were fixed and stained with Oil Red and counterstained with haematoxylin. Cholesterol droplets could 
be seen in some plaque SMC which were not stimulated with exogenous soluble cholesterol, 
suggesting previous exposure to cholesterol.  A) No cholesterol, B) 10µg/ml cholesterol, C) 50µg/ml 
cholesterol, D) 100ug/ml cholesterol. Representative pictures from 1 out of 3 experiments.  
Magnification: x20. 
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Figure 6.4 Effect on Cholesterol loading or TNFα stimulation on SMC viability.  Cholesterol 
loading for 24 hours does not affect cell viability.  A) AoSMC and B) AthSMC were plated in 6 wells 
of a 96 well plate, per condition, at a density of 5x103 cells per well.  Cells were serum starved for 
24hours and then incubated with 50µg/ml cholesterol, 10ng/ml TNF or both for a further 24 hours.  
MTS solution was added after 24 hours and left for 1-4 hours before measuring the absorbance at 
450nm. No significant difference was found between the conditions. C) MTS assay of AoSMC 
stimulated with cholesterol or TNFα for 24, 48 and 72 hours.  There is a statistically significant 
decrease in cell viability at 72 hours but this not due to stimulation with cholesterol or TNFα (*** p < 
0.0001, Two Way ANOVA with Tukey post test).  A representative experiment is shown out of a total 
of 3.  Data are shown as ± standard deviation of 6 measurements.   
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6.3 Cholesterol loading of SMC induces cytokine production 
 
Accumulation of free cholesterol in macrophages was shown to induce production of TNF and IL-6 
(Li, Schwabe et al. 2005).  Similarly, cholesterol loading of atherosclerotic SMC led to production of 
HMGB1(Porto, Palumbo et al. 2006).  Therefore, I investigated whether cholesterol loading induced 
cytokine production in AoSMC.  Incubation of AoSMC with different concentrations of soluble 
cholesterol showed an increase in IL-6 production (Figure 6.5).  Interestingly, at concentrations above 
50μg/ml, no further increase in IL-6 production was observed.  This may be due to decreased cell 
viability at higher concentrations.  Cell apopotsis was seen in the plaque SMC incubated with high 
concentrations of cholesterol (Figure 6.3)  As IL-6 production peaked at 50μg/ml, this was the 
concentration of soluble cholesterol used in further cholesterol loading experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Cholesterol induces IL-6 production in aortic SMC.  AoSMC were serum starved for 24 
hours before stimulation with 10, 20 50, 100 and 200μg/ml cholesterol for 24hours.  After 24 hours, 
supernatants were removed and assayed for IL-6 by ELISA.  A representative experiment is shown out 
of a total of 3.  Error bars represent ± standard deviation.  (p < 0.05, One way ANOVA with Tukey 
post test)  
 
This significant increase in IL-6 production in cholesterol-loaded SMC led me to investigate 
production of other cytokines and chemokines.  I analysed production of IL-6, IL-8, TNFα and MCP-
1 in AoSMC and AthSMC (Figure 6.6).  IL-6 production was reproducibily higher in cholesterol 
loaded AoSMC and AthSMC compared to unstimulated cells.  There was no difference in IL-6 
production between AoSMC and AthSMC.  IL-8 production was also significantly higher in 
cholesterol stimulated AoSMC and AthSMC.  TNF was not induced by cholesterol loading.  MCP-1 
could not be detected from either cell type using the ELISA kit.
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Figure 6.6 Cholesterol loading of SMC induces IL-6 and IL-8 production but not TNFα or 
MCP-1.  AoSMC and AthSMC were incubated with or without 50µg/ml soluble cholesterol, for 
24hours.  Supernatants were removed and assayed for IL-6, IL-8, TNF and MCP-1 by ELISA.  IL-6 
and IL-8 production was significantly increased in cholesterol stimulated SMC compared to 
unstimulated cells.  There was no difference in TNF production in cholesterol loaded and unstimulated 
cells.  MCP-1 was not detected. *p <0.05, ***p< 0.001, Two-tailed T-test.  Error bars are shown as ± 
standard error of the mean.  Aortic SMC: n=3, plaque SMC: n=3 
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As MMPs can also be produced by SMC and are important for SMC migration and proliferation 
(Newby 2006), I investigated whether cholesterol loading could also induce MMP production (Figure 
6.7).  In the media, SMC constitutively produce MMP-2 (Newby 2006), which can be up regulated by 
injury or mechanical stretch where as MMP-1, -3 and - 9 can be induced by proinflammatory 
cytokines such as IL-1α and TNFα (Galis, Muszynski et al. 1994).  However, cholesterol did not 
induce expression of MMP-1, MMP-2 or MMP-3 from AoSMC or AthSMC (Figure 6.7).  MMP-9 
could not be detected at all.   
 
Despite the production of IL-6 and IL-8 by cholesterol loaded SMC, production of other 
proinflammatory mediators did not appear to be increased with cholesterol loading.  This interesting 
difference led me to compare the response of SMC to soluble cholesterol, with that of the potent 
proinflammatory cytokine TNFα.  I used IL-6 to measure the response of the cells to the stimuli.  TNF 
stimulation of AoSMC led to the production of IL-6 which was approximately double that induced by 
soluble cholesterol alone (Figure 6.8).  Furthermore, combined stimulation of AoSMC with soluble 
cholesterol and TNFα, led to an apparent synergistic effect with greater amounts of IL-6 produced 
than with either TNFα or cholesterol.  The amount produced here was approximately 9 times that of 
cholesterol stimulation and 4 times that of TNFα stimulation.   
 
In summary, AoSMC and AthSMC respond to cholesterol loading by production of proinflamamtory 
mediators IL-6 and IL-8.  Furthermore, combined cholesterol loading and TNF stimulation had an 
additive effect on inducing cytokine production.   
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Figure 6.7 MMP production in SMC stimulated with cholesterol and TNFα. Aortic and plaque 
SMC were incubated with 50µg/ml cholesterol or TNFα for 24hours in serum free DMEM.  
Supernatants were removed and assayed for MMP-1, -2, 3 and -9 by Luminex.  Error bars represent 
standard error of the mean (SEM).  Statistical analysis was performed in Prism using two tailed T-test, 
where p< 0.05 was considered significant.  N.D. = not detected,  n= 3 aortic, 3 plaque. 
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Figure 6.8 Combined cholesterol loading and TNF stimulation results in increased IL-6 
production compared to cholesterol or TNFα alone.  AoSMC at passage 4 were incubated with 
either 50µg/ml cholesterol, 10ng/ml TNFα or both for 24hours.  After 24 hours, supernatants were 
removed and assayed for IL-6 by ELISA.  Statistical significant increases in IL-6 were seen with 
individual cholesterol and TNFα stimulation compared to unstimulated cells (* p < 0.05 and *** p < 
0.001 respectively).  Combined stimulation with cholesterol and TNFα led to a synergistic production 
of IL-6 that was significantly greater than unstimulated cells, and cholesterol or TNFα stimulation 
alone (*** p < 0.001).  One way ANOVA with Tukey post test, error bars represent ±SD.  Results are 
representative of 3 experiments. 
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6.4 Signalling pathways induced by Cholesterol loading 
 
Previous studies of cholesterol loading in macrophages have shown that it leads to activation of 
MAPK and NFκB signalling pathways (Li, Schwabe et al. 2005).  These pathways were activated 
within 3 hours of stimulation with acLDL and led to an increase in IL-6 and TNFα mRNA and protein 
levels.  Therefore, I investigated what signalling pathways were being activated in SMC by cholesterol 
loading.  Immunoblotting for phosphorylated MAP kinases showed that soluble cholesterol had not 
activated these signalling pathways (Figure 6.9) whereas TNFα stimulation activated p38 and p44/42 
just 15 minutes after stimulation.  Furthermore, phosphorylation of p38 by TNF was still detectable at 
30minute and p44/42 phosphorylation was detectable up to 1 hour after stimulation.  NFκB activation 
was indirectly detected by the degradation of IκBα, which allows translocation of NFκB into the 
nucleus (Figure 6.9).  TNFα stimulation showed degradation of IκBα at 15 and 30 minutes.  
Activation of NFκB, p38 and p44/42 by TNFα but not by cholesterol suggested two different 
mechanisms by which IL-6 and other cytokines were being produced. 
 
Li, et al demonstrated that cholesterol induced activation of these pathways in macrophages was 
sustained for 16 hours (Li, Schwabe et al. 2005).  I therefore looked at similar time points.  As IL-6 
and IL-8 were detected at 24 hours, it was likely that any signalling pathways would be activated in 
this time frame.  SMC were stimulated with cholesterol and TNFα for 2, 4, 6, 8, 12 and 16 hours, 
using the 15-minute time point as a positive control to ensure TNFα activation of p38 and p44/42 
(Figure 6.10).  With TNFα stimulation, degradation of IκBα and phosphorylation of p38 and p44/42 
were seen at 15 minutes, as before.  However, no further phosphorylation could be detected at later 
time points with TNFα stimulation.  No phosphorylation of p38 or p44/42 or IκB degradation was 
seen at any of the time points, with cholesterol stimulation.  From this I concluded that cholesterol was 
not activating any of the MAP kinase pathways or NFκB, suggesting an alternative mechanism to 
cytokine production compared to TNF.  Additionally, activation of NFκB by acetylated LDL by Li 
could be due to TLR stimulation by the LDL proteins rather than by the cholesterol component 
(Stewart, Stuart et al.). 
 
It is worth noting that in despite of a lengthy period of serum starvation of 24 hours prior to 
stimulation, there is still a constant activation of p44/42 in the absence of stimuli (Figure 6.9).  This 
activation is further increased with TNFα stimulation as seen in Figure 6.9 and 6.10.  There may also 
be some constant p38 activation, albeit at very low levels.  This constitutive activation could account 
for the baseline levels of IL-6 and IL-8 production seen in unstimulated SMC (Figure 6.6). 
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Figure 6.9 Immunoblotting of signalling pathways upon cholesterol loading and TNFα 
stimulation.   Cells were stimulated with free cholesterol or TNFα for 15minutes, 30minutes, 1 hour 
or 2 hours before lysing in RIPA buffer.  Samples were run on a 4-12% Bis-Tris mini gel (Invitrogen) 
and proteins transferred to a PVDF membrane.  The membrane was probed for phospho-JNK, 
phospho-p38, phospho-ERK and IκBα.  Alpha-tubulin was used as a loading control.  TNFα was able 
to induce phosphorylation of p38 MAPK and p44/42, and degradation of IκBα within 15 minutes of 
stimulation.  This effect was also seen at 30 minutes and 1 hour.  Phospho-JNK was not detectable.  
Cholesterol did not induce any of these MAP Kinase signalling pathways within this time point. 
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Figure 6.10 Immunoblotting of signalling pathways upon cholesterol loading and TNFα 
stimulation over 16 hours.   Cells were stimulated with free cholesterol or TNFα for 15-minutes, 2, 4, 
6, 8, 12 and 16 hours before lysing in RIPA buffer.  Samples were run on a 4-12% Bis-Tris mini gel 
(Invitrogen) and proteins transferred to a PVDF membrane.  The membrane was probed for phospho-
JNK, phospho-38, phospho-p44/42 and IκBα. Alpha-tubulin was used as a loading control.  TNFα 
was able to induce phosphorylation of p38 MAPK and p44/42, and degradation of IκBα within 15 
minutes of stimulation.  Phospho-JNK was not detectable.  Cholesterol did not induce any of these 
MAP Kinase signalling pathways within this time point 
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6.5 Cholesterol trafficking to the Endoplasmic Reticulum 
 
The absence of MAPK or NFκB activation led me to pursue alternative signalling pathways.  The 
study by Li et al demonstrated that the cholesterol-induced cytokine production could be inhibited by 
an inhibitor of vesicle transport to the ER; 3β-(2-Diethylaminoethoxy)-Androstenone.HCl (U18666A), 
which also suggested that cytokine production was a result of ER stress and activation of the UPR (Li, 
Schwabe et al. 2005).  Soluble free cholesterol is thought to be taken up by cells via its incorporation 
into the plasma membrane and it can be transported to the ER via vesicles as part of the vesicle 
membrane.  Inhibition of this vesicle transport would therefore inhibit the delivery of cholesterol to the 
ER.   
 
To investigate whether soluble cholesterol was inducing the UPR in my SMC, I used the inhibitor 
U18668A at the same concentration as Li et al (70nM).  Inhibition of endocytic transport to the ER 
with U18666A would inhibit cholesterol transport to the ER, preventing activation of the UPR and 
potentially reduce cytokine production (Kellner-Weibel, Geng et al. 1999) (Li, Schwabe et al. 2005). 
 
AoSMC were incubated with soluble cholesterol or TNFα as before, but in the presence or absence of 
the inhibitor U18666A (Figure 6.11).  In the absence of the inhibitor, IL-6 production was induced by 
cholesterol and even more so by TNFα, similarly to that reported previously in Figure 6.8.  In the 
presence of U18666A, the amount of IL-6 produced during cholesterol stimulation was significantly 
reduced (Figure 6.11).  In contrast, there was no significant difference in IL-6 production with TNF 
stimulation, in the presence or absence of the inhibitor.  Furthermore, where there was an increase in 
IL-6 production with combined stimulation by cholesterol and TNF, the presence of inhibitor reduced 
IL-6 levels back to those levels seen with TNF stimulation alone (p < 0.05, Figure 6.11).   
 
Unstimulated SMC in the presence of the inhibitor had increased IL-6 production compared to those 
cells in the absence of inhibitor.  This may be due to an unforeseen stress induced by the inhibitor 
leading to an increase in IL-6 production.  Interestingly, the amount of IL-6 produced by cholesterol 
loaded cells in the presence of the inhibitor was reduced to an amount similar ot the unstimulated cells.   
 
I concluded that cholesterol taken up by SMC was being trafficked to the ER, which resulted in ER 
stress and subsequent production of IL-6 and IL-8.  This is a different mechanism of cytokine 
production to that induced by TNF stimulation.  Accumulation of cholesterol by SMC in vivo could 
therefore result in chronic ER stress and low level cytokine production.   
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Figure 6.11 Cholesterol-induced IL-6 production is inhibited by U18666A.   SMC were incubated 
with either soluble cholesterol or TNF, or both for 24 hours, in the absence or presence of 70nM 
U18666A.  The amount of IL-6 produced by SMC stimulated with both TNF and cholesterol was 
reduced to that produced with TNF stimulation alone with U18666A.  Error bars represent ± standard 
deviation, (*p< 0.05, ** p < 0.005, Two-tailed T-test) results.  Results are representative of 3 
individual experiments. 
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6.6 Gene expression studies of cholesterol-loaded SMC 
 
I investigated whether cholesterol loading of AoSMC modified expression of atherosclerosis related 
genes using PCR arrays (see chapter 2, Table 2.4 for list of genes and details).  AoSMC were 
stimulated for 5 hours with cholesterol (50μg/ml), TNFα (10ng/ml) or with a combination of both.  
Those genes that showed a statistically significant up or down regulation of at least 2-fold and p < 
0.05, T-test are shown in Table 6.1 and Figure 6.12.  Cholesterol loading induced a different pattern of 
gene expression in SMC to that seen with TNFα stimulation (Figure 6.12).  Only eleven out of 84 
genes on the atherosclerosis array were statistically significantly up or down regulated with cholesterol 
loading, whereas 27 genes were with TNFα stimulation.   
 
 
Cholesterol / 
Unstimulated 
TNFα 
/Unstimulated  
Cholesterol &TNFα 
/ Unstimulated 
Gene Gene Name 
T-Test    
p value 
Fold  
Regulation 
T-Test    
p value 
Fold  
Regulation 
T-Test     
p value 
Fold  
Regulation 
BCL2A1 BCL2-related protein A1 - - 0.0000 10.94 0.0001 14.98 
BID BH3 interacting domain death agonist - - 0.0142 3.30 0.0042 3.23 
BIRC3 Baculoviral IAP repeat-containing 3 - - 0.0008 46.75 0.0016 62.03 
CCL2 Chemokine (C-C motif) ligand 2 - - 0.0004 13.33 0.0003 14.37 
CCL5 Chemokine (C-C motif) ligand 5 - - 0.0131 375.33 0.0124 386.68 
CCR1 Chemokine (C-C motif) receptor 1 0.0064 358.79 - - - - 
CSF1 Colony stimulating factor 1 (macrophage) 0.0173 -5.67 0.0194 4.01 0.0145 3.72 
CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 0.0166 -3.14 0.0026 52.42 0.0006 90.51 
CTGF Connective tissue growth factor - - 0.0218 -4.53 0.0018 -4.48 
EGR1 Early growth response 1 - - 0.0388 -6.60 0.0007 -4.52 
HBEGF Heparin-binding EGF-like growth factor - - 0.0447 2.30 0.0217 3.15 
ICAM1 Intercellular adhesion molecule 1 - - 0.0016 17.11 0.0010 18.06 
IFNAR2 Interferon (alpha, beta and omega) receptor 2 - - 0.0066 6.64 0.0008 7.26 
IL1A Interleukin 1, alpha - - 0.0414 3.60 0.0110 6.96 
ITGA5 Integrin, alpha 5 0.0025 -2.68 - - - - 
ITGAX Integrin, alpha X 0.0110 -6.33 0.0303 -4.85 0.0013 -8.54 
KLF2 Kruppel-like factor 2  - - 0.0252 -2.64 0.0410 -2.37 
LDLR Low density lipoprotein receptor 0.0440 -3.22 - - - - 
LIF Leukemia inhibitory factor - - 0.0255 13.66 0.0076 17.33 
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MMP1 Matrix metallopeptidase 1 (interstitial collagenase) - - 0.0159 3.19 0.0070 3.48 
NOS3 Nitric oxide synthase 3 - - 0.0099 2.01   
PDGFB Platelet-derived growth factor beta - - 0.0048 71.85 0.0081 104.33 
PPARD Peroxisome proliferator-activated receptor delta 0.0148 -49.97 - - - - 
PTGS1 Prostaglandin-endoperoxide synthase 1 0.0457 -2.17 - - - - 
RXRA Retinoid X receptor, alpha 0.0184 -15.06 0.0342 -2.22 - - 
SELE Selectin E 0.0444 16.02 0.0033 1288.97 0.0033 1663.49 
SELL Selectin L 0.0288 -14.55 - - - - 
SELPLG Selectin P ligand - - 0.0089 -2.64 - - 
SERPIN
B2 Serpin peptidase inhibitor 2 - - 0.0126 4.57 0.0003 4.96 
SERPIN
E1 Serpin peptidase inhibitor 1 - - 0.0203 3.40 0.0359 2.85 
TNF Tumour necrosis factor - - 0.0001 576.83 0.0000 891.44 
TNFAIP
3 
Tumour necrosis factor, alpha-
induced protein 3 - - 0.0010 24.54 0.0000 27.67 
VCAM1 Vascular cell adhesion molecule 1 - - 0.0002 431.14 0.0001 556.41 
 
 
Table 6.1 Atherosclerosis-related genes induced by cholesterol loading of aortic SMC.  PCR 
arrays containing atherosclerosis-related genes were performed using cDNA from AoSMC stimulated 
for 5 hours with cholesterol, TNFα or a combination of both.  PCR arrays were run on ABI 7900HT 
machine and analysis was performed with Sequence Detection System 1.9.1 for Mac, using the ΔΔCt 
method.  Duplicate arrays were run per condition for unstimulated, cholesterol-stimulated and TNF-
stimulated AoSMC.  Those genes with a fold regulation > 2 or < -2 and p < 0.05, T-test between 
unstimulated and TNF-stimulated SMC were considered significant and are shown here.  Missing 
values represent values that were not significantly changed or < 2 fold. 
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Figure 6.12 Cholesterol induces few atherosclerosis-associated genes in comparison to TNFα.  
Atherosclerosis gene arrays were performed using cDNA from SMC stimulated with 50μg/ml 
cholesterol, 10ng/ml TNFα or a combination of both.  Only those genes with a statistically significant 
difference between stimulated and unstimulated SMC are shown (p<0.05).  A) Genes affected by 
cholesterol stimulation, B) The genes induced by TNFα stimulation, C) Genes induced by combined 
cholesterol and TNFα stimulation.  Abbreviations: BCL2A1: B-cell CLL/lymphoma 2 related protein 
A1, BIRC3: Baculoviral IAP repeat-containing 3, CCR1: Chemokine (C-C motif) receptor 1, CCL2: 
Chemokine (C-C motif) ligand 2, CCL5: Chemokine (C-C motif) ligand 5, CSF1: Colony stimulating 
factor 1 (macrophage), CSF2: Colony stimulating factor 2 (granulocyte-macrophage), ICAM1: 
Intercellular adhesion molecule 1, ITGA5: Integrin α5, ITGAX: Integrin αX, LDLR: Low density 
lipoprotein receptor, LIF: Leukaemia inhibitory factor, PDGFB: Platelet-derived growth factor 
receptor, beta, PPARD: Peroxisome proliferator-activated receptor delta, PTGS1: Prostaglandin-
endoperoxide synthase 1, RXRA: Retinoid X receptor α, SELE: Selectin E, SELL: Selectin L, TNF: 
Tumour necrosis factor, TNFAIP3: Tumour necrosis factor, alpha-induced protein 3, VCAM: 
Vascular cell adhesion molecule-1. 
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6.6.1 Effect on lipid metabolism genes 
 
In the cholesterol-stimulated cells, genes with differential expression were involved in cell adhesion, 
cell recruitment and lipid metabolism (Figure 6.12A).  Of note, the LDL receptor was down regulated 
by 3-fold in soluble cholesterol stimulated cells, in keeping with previous studies showing suppression 
of LDLR gene transcription via inhibition of the transcription factor SREBP (Brown and Goldstein 
1986).  The genes for the nuclear receptors retinoid-X-receptor alpha (RXRA) and peroxisome 
proliferator-activated receptor delta (PPARD) were also down regulated as were integrin alpha-5 
(ITGA5) and integrin alpha-X (ITGAX).  Integrins are important for the formation of focal adhesions. 
In support of our observations, Frontini, et al, reported disorder of integrins-α5 in human aortic SMC 
loaded with LDL and VLDL, accompanied by defective assembly of collagen fibrils (Frontini, O'Neil 
et al. 2009). 
 
The pattern of gene expression induced by TNFα has been discussed in chapter 5 and similar results 
were obtained in this experiment (Figure 6.12B).  Combined stimulation of SMC with cholesterol and 
TNFα resulted in a further up regulation of some genes regulated by TNFα alone.  For example, E-
selectin, which was up regulated by 1288-fold by TNFα, was up regulated by 1663-fold with the 
combined stimulation.  Similarly, TNF, VCAM1, CCL5 and to a lesser extent, PDGF also showed the 
same enhanced expression.  These results are in keeping with the effect on IL-6 production with 
combined stimulation.  Therefore, although the effect seen by cholesterol loading is quite small in 
comparison to TNFα, in combination, these two stimuli exert an additive proinflammatory effect. 
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6.6.2 CCR1 expression by AthSMC  
 
Besides enhancing the effect of TNF, soluble cholesterol appeared to increase the expression of the 
chemokine receptor CCR1.  This effect was limited to cholesterol loading but not present with TNF 
stimulation.  I investigated the expression of CCR1 by validating the increase with quantitative RT-
PCR.  Unfortunately, the results of the gene array were not replicated.  Firstly, CCR1 expression was 
hard to detect in AoSMC and CCR1 was up regulated by only 1.7-fold in cholesterol-stimulated SMC.  
This result was only achieved once, despite replicate PCR being performed.  For comparison, I also 
looked at CCR1 expression in AthSMC.  I observed that AthSMC have increased CCR1 expression 
compared to AoSMC, although there is variation between donors.  
 
 
 
Figure 6.13 CCR1 gene expression levels in aortic and plaque SMC.  Taqman PCR was performed 
on cDNA from AoSMC stimulated with 50μg/ml cholesterol or 10ng/ml TNFα for 5 hours.  A) CCR1 
expression in AoSMC stimulated with cholesterol or TNFα.  B) CCR1 expression in unstimulated 
AoSMC and AthSMC.   
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6.7 Proteomic analysis of cholesterol-Loaded SMC  
 
To investigate the changes in the SMC proteome that occurred with cholesterol loading, 2D gels were 
created from AoSMC stimulated with or without cholesterol for 24 hours.  Gel images were analysed 
with Progenesis Samespots, as before.  There were eleven spots, which had statistically different spot 
volumes between groups (Figure 6.14).  From the SMC reference map in chapter 3, six of these 
proteins were identified.  
 
 
Figure 6.14 Effect of cholesterol loading on the SMC proteome.  AoSMC were serum starved for 
24 hours before being stimulated with or without 50μg/ml cholesterol for a further 24 hours.  Cells 
were lysed and 100µg of protein was used to create analytical 2D gels.  Three replicate gels were 
created for each condition from each donor.  2D-gel images were analysed by Progenesis Samespots 
version 3.3 to identify spots that changed under experimental conditions.  Eleven spots were identified 
to have a statistically significant difference between unstimulated and TNF-stimulated (p < 0.05, T-
test), which are circled in red.  Six out of the eleven proteins were identified.  Spot number 
corresponds to spot number on SMC proteome map in chapter 3 and appendix 1. 
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Table 6.2. Identification of proteins that change during cholesterol loading.  Spot number 
corresponds to the image in Figure 6.14 and the SMC reference map in chapter 3.  Mean spot volumes 
represent the average number of pixels (106) from the triplicate gels for each condition (± Standard 
Deviation).  The fold changes of cholesterol/unstimulated AoSMC are shown.  Statistics were 
performed in Progenesis Samespots v 3.3 using the log of the mean spot volumes using T-test (p 
<0.05).   
 
 
These six proteins identified as having a statistical difference between unstimulated SMC and 
cholesterol loaded SMC have a range of functions: glycolytic enzymes, chaperone, lysosomal protease 
and redox regulation.  Four out of the six proteins were decreased in the cholesterol loaded AoSMC 
compared to unstimulated AoSMC (Table 6.2 and Figure 6.15). 
 
Interestingly, the two glycolytic enzymes pyruvate kinase and triose phosphate isomerase have 
contrasting expression patterns.  Pyruvate kinase is increased in cholesterol-loaded AoSMC by 1.5 
fold compared to unstimulated AoSMC, where as triose phosphate isomerase is decreased by 1.4 fold 
(Figure 6.15).  However, spot 46, which was identified as pyruvate kinase, does not correspond to the 
theoretical molecular weight or pI of the full-length pyruvate kinase protein (observed molecular 
weight/pI: 27/6.2 versus theoretical molecular weight/pI: 57.8/7.95).  Spot 37 was also identified as 
pyruvate kinase and was differentially expressed between AoSMC and AthSMC in chapter 3.  The 
location of triose phosphate isomerase, as spot 78 on the proteome map is near to that of its theoretical 
molecular weight and pI (observed molecular weight/pI: 27/6.5 versus theoretical molecular weight/pI: 
22.5/6.5).  .   
 
The other protein with increased expression in expression in cholesterol-loaded SMC is T-complex 
protein 1 subunit theta (TCP1-theta). There is an increase of approximately 1.2 fold in cholesterol-
loaded AoSMC compared to unstimulated AoSMC.  This is a cytosolic chaperonin involved in folding 
Average Mean Volume  (106 pixels) 
Spot Protein Identification Unstimulated 
(± SD) 
Cholesterol    
(± SD) 
p value    
(T- test) 
29 Cathespin B 22.80  (±1.07) 18.04 (±0.56) 0.002 
78 Triose phosphate isomerase 1 3.75  (±0.68) 2.172 (±0.36) 0.019 
46 Pyruvate Kinase M1/M2 2.14 (±0.33) 3.13 (±0341) 0.033 
59 T-complex protein 1 subunit alpha 4.485 (±0.93) 5.31 (±0.52) 0.031 
72 Heterogeneous nuclear ribonucleoprotein H 13.36 (±2.02) 9.27 (±0.98) 0.026 
69 Peroxiredoxin 3 13.41 (±1.1) 10.37 (±0.61) 0.013 
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of actin and tubulin proteins and is a subunit of a larger complex of chaperones called the chaperone 
containing TCP-1 complex (CCT) (Kubota, Hynes et al. 1995).  Its increased expression in 
cholesterol-loaded cells suggests that due to the accumulation of lipid droplets in the cytosol, there 
may be some re-organisation of the cytoskeleton.   
 
The lysosomal protease cathepsin B is decreased by 1.26 fold in cholesterol-loaded AoSMC compared 
to unstimulated AoSMC.  The location of this protein on the 2D gel almost corresponds to the 
theoretical molecular weight and pI (36.8/5.8 versus observed 36/5.4).  Interestingly, cathepsin B was 
also decreased in TNF-stimulated SMC in chapter 5 (Figure 5.13). 
 
Heterogeneous nuclear ribonucleoprotein (hnRNP H) is also decreased in cholesterol loaded AoSMC 
compared to unstimulated AoSMC by 1.4-fold.  The theoretical molecular weight and pI do not match 
the observed (49/5.89 versus 20/6.8 respectively).  Therefore this could be a fragment of hnRNP H.  
This protein is involved with RNA splicing in the nucleus before the translation of mRNA in the 
cytoplasm.   
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Figure 6.15 Cholesterol loading of Aortic SMC induces changes in protein expression.  Graphical 
representation of the expression of those proteins identified to have a statistical significant difference 
in expression between unstimulated and cholesterol stimulated AoSMC.  Spot volumes are presented 
as the mean average of the spot volume ± SEM.  Statistics were performed in Progenesis Samespots v 
3.3 using the log of the mean spot volumes using T-test (*p <0.05, **p< 0.005). 
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6.8 Discussion 
 
The aim of the work described in this chapter was to investigate whether cholesterol induced a 
proinflammatory phenotype in SMC and changes in SMC proteome.  Accumulation of lipid in the 
neointima is an initiating step of atherosclerosis.  Macrophages, recruited to the intima by chemotactic 
responses to modified-LDL take up lipid via scavenger receptors.  SMC may also express scavenger 
receptors, such as CD68 (Porto, Palumbo et al. 2006) and take up lipid, acquiring a foam cell like 
appearance.  The presence of lipid in the intima at such an early stage of atherosclerosis, implicates 
itself as a potential inducer of the phenotypic modulation of SMC.  Indeed, oxidised phospholipids 
have been shown to decrease expression of SMC markers in rat aortic SMC (Pidkovka, Cherepanova 
et al. 2007) (Cherepanova, Pidkovka et al. 2009).  However, incubation of human aortic SMC with 
native LDL and VLDL showed no change in the SMC markers but defective assembly of collagen 
fibrils occurred (Frontini, O'Neil et al. 2009).   
 
I decided to investigate the effects of cholesterol using a commercially available form of soluble 
cholesterol, which was easy to deliver to cells and it would not introduce new proteins into the system.  
This was used in the studies by Porto et al (Porto, Palumbo et al. 2006) and Rong, et al (Rong, Shapiro 
et al. 2003).  Cholesterol, in complex with methyl-β-cyclodextrin has been shown to be efficient at 
delivering cholesterol to the plasma membrane (Rong, Kusunoki et al. 2005) and allows the effect of 
cholesterol to be investigated independently, in a protein free environment and free from the effects of 
lipoproteins and their modifications, which may have additional effects on SMC phenotype (Pidkovka, 
Cherepanova et al. 2007) (Cherepanova, Pidkovka et al. 2009).   
 
Incubation of AoSMC with soluble cholesterol showed accumulation of neutral cholesterol esters as 
shown by Oil Red O staining, similar to that observed in other studies (Rong, Kusunoki et al. 2005) 
(Porto, Palumbo et al. 2006).  Lipid droplets appeared to be located in the cytoplasm and in the peri-
nuclear area.  Interestingly, I observed that not every SMC in culture acquired lipid droplets.  This 
may be explained by previous findings of Argmann, et al who showed that only select populations of 
SMC take up lipid (Argmann, Sawyez et al. 2004). Another interesting observation that I made was 
that some AthSMC stained positive for Oil Red O even prior to the exposure to exogenous soluble 
cholesterol.  This confirms my other observations of lipid-laden SMC during cell culture.  AthSMC 
did not appear to take up exogenous cholesterol as well as AoSMC.  Nor did increasing cholesterol 
concentrations lead to an increase in the number of lipid droplets in AthSMC, as occurred in AoSMC.  
This could potentially be explained by the fact that cholesterol has been shown to allosterically 
regulate the enzyme acyl-CoA:cholesterol acyl transferase (ACAT) at high concentrations (Chang, 
Lee et al. 1998).  AthSMC that have already been exposed to cholesterol in vivo during plaque 
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development could have a decrease in ACAT activity, thereby limiting the number of cholesterol 
esters visible with Oil Red O staining.  As a result, I mainly used AoSMC in subsequent experiments 
with soluble cholesterol, using AthSMC where possible for comparison.   
 
In other studies, cholesterol loading of cells has been shown to induce production of proinflammatory 
mediators such as IL-6 and TNF in macrophages (Li, Schwabe et al. 2005) and HMGB1 in SMC 
(Porto, Palumbo et al. 2006).  I set out to investigate whether the proinflammatory behaviour of 
AthSMC described in chapter 5 was due to exposure to cholesterol.  I was able to show IL-6 and IL-8 
production by AoSMC after stimulation with soluble cholesterol.  Other cytokines and chemokines 
that were induced by TNF were not up regulated by cholesterol.  Finally, cholesterol had an additive 
effect when cells were stimulated with TNF. 
 
This finding was corroborated by the results of the gene expression study with PCR arrays. The 
pattern of gene expression in the PCR arrays was suggestive of a different response to soluble 
cholesterol compared to TNF.  Whereas TNFα stimulation resulted in the up regulation of genes 
involved with inflammation, adhesion molecules and apoptosis, stimulation with soluble cholesterol 
mainly resulted in the down regulation of genes involved with lipid metabolism such as LDLR, 
PPARδ and RXRα.  Only two genes on the array were up regulated by cholesterol: E-selectin and 
CCR1.  The up regulation of CCR1 in cholesterol stimulated AoSMC was surprising as I could not 
find any other reports of cholesterol inducing the expression of chemokine receptors.  CCR1 was not 
up regulated by TNFα stimulation or with the combined stimulation.  Conversely, the expression of 
two chemokines on the PCR array, CCL2 (MCP-1) and CCL5 (RANTES) were up regulated by TNFα 
but not cholesterol.  E-selectin was further up regulated in AoSMC stimulated with both soluble 
cholesterol and TNFα, suggesting an additive effect as seen with IL-6 production.  However, further 
validation of CCR1 up regulation in cholesterol-stimulated SMC using quantitative RT-PCR did not 
confirm this result.  The use of other PCR arrays with a different panel of genes, i.e. oxidative stress, 
UPR, etc, may provide further information on the effects of cholesterol on SMC.   
 
As TNF activates signalling pathways such as MAP kinases and NFκB, I investigated whether these 
were also activated with cholesterol loading.  Activation of these pathways by external stimuli such as 
cytokines can be detected within minutes and I detected phosphorylation of p38 and p44/42 MAP 
kinases within 15 minutes of TNFα stimulation.  Degradation of IκBα was also detected at 15 minutes 
with TNFα.  However, these pathways were not activated by stimulation with soluble cholesterol and 
were not detected despite a prolonged time course.  In contrast, the study by Li et al showed that 
cholesterol accumulation in macrophages resulted in activation of NFκB, p38, JNK and p44/42 within 
3 hours of stimulation and was sustained up to 16 hours (Li, Schwabe et al. 2005).  The disparities 
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between my study and that by Li, et al is probably due to the differences in models of cholesterol 
accumulation.  Li, et al used acetylated LDL, which is taken up by scavenger receptors on the cell 
surface (Li, Schwabe et al. 2005).  This is a receptor-mediated process and so delivery of cholesterol 
into the cell should be rapid.  In my study, the cholesterol used is soluble and not attached to protein.  
It is delivered to the cell via the plasma membrane rather than via receptor mediated processes 
(Christian, Haynes et al. 1997).   
 
Li et al showed that activation of the UPR was responsible for the induction of signalling cascades and 
cytokine production induced by cholesterol.  This involves trafficking of cholesterol to the ER, via 
lysosomes, where the increased cholesterol concentration n the membrane acts as an endogenous 
signal to activate UPR signalling pathways.  I used the same inhibitor of cholesterol trafficking to 
investigate whether IL-6 production in my cells was a result of ER stress due to increased cholesterol.  
At nanomolar concentrations, U18666A interferes with cholesterol trafficking to the ER (Feng, Yao et 
al. 2003).  Stimulation of AoSMC with cholesterol plus U18666A resulted in decreased in IL-6 
production, compared to cholesterol stimulation alone.  The inhibitor had no effect on TNF-induced 
IL-6 production, but U18666A reduced the synergistic effect of combined cholesterol and TNF 
stimulation to the IL-6 levels seen by TNFα alone.  Therefore I concluded that soluble cholesterol is 
transported to the ER, which leads to ER stress and that this induces cytokine production.   
 
Proteomic analysis of AoSMC stimulated with cholesterol for 24 hours, showed only few changes in 
protein expression.  Out of the eleven protein spots, I identified six using the SMC reference map in 
chapter 3 (Figure 3.8).  These proteins had a diverse range of functions including glucose metabolism, 
chaperones, RNA splicing and antioxidants.  As only one AoSMC donor was used in this experiment 
and so few proteins were identified, it is hard to conclude the effect of cholesterol loading on SMC.  
Interestingly, I did not observe changes in actin levels between unstimulated AoSMC and cholesterol-
stimulated AoSMC.  This is in contrast to the previous chapter, where TNF stimulation led to 
decreased expression of actin and actin binding proteins.  Similarly, Pidkova et al also reported 
suppression of αSMA and SM-MHC by oxidised phospholipids (Pidkovka, Cherepanova et al. 2007).  
From this, I can conclude that cholesterol alone does not induce per se change in SMC contractile 
proteins.   
 
The expression of some proteins can be linked to ER stress and the UPR.  Chaperonin T-complex 
protein 1 theta was increased in cholesterol loaded SMC.  T-complex protein 1-theta is a subunit of a 
larger chaperonin complex that is highly conserved throughout eukaryotes.  It is involved in the 
folding and re-folding of cytosolic proteins such as actin and tubulin.  Its increase in expression in this 
study suggests that protein folding may have increased within the cytoplasm as a response to alleviate 
Chapter 6  Effect of cholesterol on SMC 
 
224 
 
the ER of unfolded proteins (Ron and Walter 2007).  Additionally, the expression of Heterogeneous 
nucleoriboprotein H, a nuclear protein involved with RNA splicing of pre-mRNA, which was reduced 
in cholesterol loaded AoSMC, suggests that synthesis of new proteins has decreased in attempt to 
resume ER homeostasis.  The analysis of the SMC proteome after a longer exposure to cholesterol and 
the use of more donors may provide a ‘protein signature’ of cholesterol loading that may resemble the 
AthSMC proteome, as seen in chapter 3.  Further proteomic investigation into the effect of cholesterol 
loading may show evidence of ER stress.   
 
In summary, accumulation of cholesterol in SMC does not result in a ‘classical’ proinflammatory 
response per se.  Rather, it induces ER stress and activation of UPR signalling pathways that result in 
a mild proinflammatory-like response with cytokine production, which is further enhanced when SMC 
encounter other proinflammatory mediators such as TNFα.  Proteomic data supports the evidence for 
ER stress with increased chaperone expression and decreased RNA processing proteins.  
Consequently, ER stress is a feature of atherosclerotic SMC, and contributes to the phenotypic 
modulation of SMC as atherosclerosis progresses.  Long term adaption to chronic ER stress to avoid 
induction of apoptotic pathways may drive further change in SMC behaviour.   
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7. Discussion 
 
In the past thirty years of atherosclerosis research, the role of smooth muscle cells has commanded 
much attention from researchers.  Most of this focus has been directed toward proliferation and 
migration of SMC and more recently, phenotypic modulation.  We now have a fundamental 
understanding of SMC biology and the role of SMC in atherosclerosis.  Despite extremely low rates of 
SMC proliferation in established human disease in vivo (Gordon, Reidy et al. 1990), the “response to 
injury” model by Russell Ross illustrates the contribution of SMC to the atherosclerotic lesion. In this 
model SMC migrate from the media into the intima upon injury to the arterial wall (Ross and Glomset 
1973).  The early work of Benditt and Benditt proposed that intimal SMC arose from monoclonal 
proliferation from a single cell (Benditt and Benditt 1973).  This concept has now evolved with the 
identification of different subpopulations of SMC within the artery wall, which have different 
proliferative and migratory capabilities (Hao, Gabbiani et al. 2003).  Intimal SMC may also be derived 
from progenitor cells of adventitial or haemopoietic origin (Li, Chen et al. 2000; Sata, Saiura et al. 
2002; Caplice, Bunch et al. 2003). 
 
Succinctly, the role of the SMC in atherosclerosis is –after migrating to the intima - to produce the 
fibrous extracellular proteins that form a considerable part of atherosclerotic plaque (Kragel, Reddy et 
al. 1990) and provide the tensile strength of the fibrous cap, encasing the lipidic and necrotic core, 
thereby deserving the definition of “guardians of the plaque” (Libby 1995).  To fulfil this role, SMC 
undergo a “phenotypic modulation”, a phrase originally coined by Julie Chamley-Campbell just over 
thirty years ago (Chamley-Campbell, Campbell et al. 1979) describing the morphological changes of 
SMC from contractile to a synthetic state.  The term “phenotypic modulation” is now used more 
broadly to describe changes observed in behaviour of SMC in vascular diseases (Owens, Kumar et al. 
2004). In advanced atherosclerosis SMC also undergo lipid accumulation (Argmann, Sawyez et al. 
2004; Porto, Palumbo et al. 2006). 
 
The aim of my thesis was to take a proteomic approach in studying the precise changes taking place in 
SMC in human atherosclerotic disease.  Few proteomic studies have been directed at the human 
atherosclerotic SMC, with other models, such as the apoE-/- mice and porcine SMC proving more 
amenable (Mayr, Chung et al. 2005; Brisset, Hao et al. 2007).  Additionally, other studies have looked 
at whole tissues with mixed cell populations (Duran, Martin-Ventura et al. 2007), (Martin-Ventura, 
Duran et al. 2004; Park, Park et al. 2006).  Therefore the work presented here is a novel study aimed at 
SMC and enabled by an available source of human carotid atherosclerotic tissue.  
 
Chapter 7  Final Discussion 
 
227 
 
I hypothesised that the phenotypic modulation of SMC in atherosclerosis was a programming that 
could be maintained in ex vivo culture.  Accordingly, differences in intracellular protein expression 
would be apparent in atherosclerotic SMC when compared to non-atherosclerotic medial SMC.  
Identification of a ‘protein signature’ in atherosclerotic SMC could shed light on disease-specific 
changes in SMC at late and clinically relevant stages of the disease.  In addition, I could investigate 
the effects of specific proatherogenic stimuli, in attempt to reproduce this atherosclerotic protein 
signature in vitro.   
 
 
7.1 The Proteomic signature of human atheroma-derived SMC is 
the exhaustion of antioxidant mechanisms and mitochondrial 
damage 
 
I used human atherosclerotic SMC (AthSMC) derived from ten different patients undergoing carotid 
endarterectomy surgery.  As medial SMC could not be reliably cultured from endarterectomy 
specimens the most suitable control SMC were commercially available aortic medial SMC (AoSMC).  
Six different AoSMC donors were used.  I used 2-dimensional gel electrophoresis as my proteomic 
tool of choice, as it allowed visualisation of the SMC proteome and comparison of protein expression 
and post-translational modifications across several different donors.  To visualise the proteins, I chose 
silver staining due to its sensitivity and ability to detect proteins in the nanogram range and its 
compatibility with mass spectrometry (Chevallet, Luche et al. 2006). Quantitative gel image analysis 
(Samespots) was used to identify differences between SMC derived from diseased and control tissue.  
 
The concept of phenotypic modulation was confirmed in the 2D gel analysis with the decrease in actin 
in AthSMC compared to AoSMC, supporting my hypothesis that the cells maintain their phenotype in 
vitro and that this could be observed in the protein pattern on the 2D gels.  An advantage of 2-
dimensional electrophoresis is the ability to detect post-translational modifications as they induce 
changes in the isoelectric point of the protein.  They cannot be detected by other methods unless a 
detailed search of the mass spectra is performed.  This enabled detection of oxidised form of 
peroxiredoxin-4, which was increased in AthSMC compared to AoSMC, confirming previous findings 
by Mayr et al of increased 1 Cys-peroxiredoxin oxidation in the aortas of apoE-/- mice (Mayr, Chung 
et al. 2005).  An oxidised state of peroxiredoxins may imply the exhaustion of endogenous scavengers 
of reactive oxidative species and it may result in uncontrolled oxidative damage to intracellular 
components.  In addition I was able to identify a decrease in expression of proteins resident in the 
mitochondria, indicative of mitochondrial damage: Aldehyde dehydrogenase 2 and ATP Synthase 
subunit beta.  Damage of mitochondrial DNA is known to be induced by exposure to reactive oxygen 
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species and is a feature of atherosclerosis (Ballinger, Patterson et al. 2000).  However, my data suggest 
that in advanced human disease the mitochondrial damage is more extensive and it involves not only 
proteins encoded by mitochondrial DNA, but also proteins that are synthesised in the nuclear genome.  
These findings may hint at more extensive mitochondrial damage induced by a lifetime of exposure to 
oxidative stress.  Such damage appears to be extensive and irreversible as it is retained by AthSMC 
during cell culture, suggesting it is a permanent change that is not rectified by removing the cells from 
the atherogenic environment.   
 
In attempt to dissect the mechanisms that might lead to such atherosclerotic SMC protein signature, I 
studied the effects of well-characterised proatherogenic stimuli such as exposure to cholesterol (Rong, 
Shapiro et al. 2003) and the proinflammatory cytokine TNF (Feldmann 2009).  Proteomic analyses of 
TNF-stimulated SMC revealed that TNF decreases actin expression, aldehyde dehydrogenase 2 and 
ATP Synthase subunit beta expression.  TNF had similar effects on protein expression in both AoSMC 
and AthSMC.  The expression level of proteins in AoSMC stimulated with TNF was often similar to 
that of unstimulated AthSMC, suggesting that similar stimulation of AthSMC occurs in vivo.  Hence, 
TNF stimulation was able to reproduce at least some of the changes in the proteome seen in AthSMC.  
In support of my observations, TNF has been shown to decrease actin in SMC (Jovinge, Hultgardh-
Nilsson et al. 1997) and induce mitochondrial damage in other cell types (Kim, Xu et al. 2010) 
(Mariappan, Soorappan et al. 2007) (Mariappan, Elks et al. 2009).   
 
The effect of exposure to cholesterol was strikingly different from the changes after TNF exposure and 
pointed towards signs of induction of the unfolded protein response.  Intracellular free cholesterol 
accumulates in the ER membrane where it induces ER stress (Tabas 1997). The unfolded protein 
response is activated by ER stress and is an adaptive mechanism to cope with reduced ER function, 
while restoring ER homeostasis (Ron and Walter 2007) (Rutkowski and Kaufman 2007).  One of the 
early consequences to increased ER stress is the cessation of protein synthesis, except for those 
proteins which may assist in the folding of other proteins, such as chaperones (Rutkowski and 
Kaufman 2007).  Protein folding in the cytoplasm may be up regulated to relieve the ER of this 
function, which is otherwise a primary role for the ER (Ron and Walter 2007).  I found up regulation 
of a cytosolic chaperone Chaperonin T-complex protein 1 theta, which is suggestive of increased 
protein folding in the cytoplasm after exposure to cholesterol.  In support of this I found a decrease in 
expression of the nuclear protein Heterogeneous nucleoriboprotein H, involved with RNA splicing of 
pre-mRNA, suggests that synthesis of new pre-mRNA as well as synthesis of new proteins has 
decreased in attempt to resume ER homeostasis. Free cholesterol in macrophages is known to induce 
cytokine production, potentially due to ER stress (Li, Schwabe et al. 2005) (Feng, Yao et al. 2003) 
(Tabas 2004).  I replicated this evidence in SMC by observing up regulation of IL-6 and IL-8 when 
SMC were incubated with free cholesterol.  I found that this up regulation was due in part to 
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cholesterol being trafficked to the ER where it increased ER stress, probably as a result of increased 
cholesterol accumulation in the ER membrane (Tabas 1997).  These findings complement the evidence 
of the proteomic analysis and collectively suggest induction of ER stress and the unfolded protein 
response in cholesterol-exposed SMC. 
 
 
7.2 The expression of annexins distinguish SMC derived from 
stable and unstable plaques 
 
The novelty of this study was the identification of differences in the SMC proteome between patients 
with carotid disease of different symptomatic status.  Plaque composition rather than plaque volume is 
related to the risk of plaque rupture (Falk 1992) and SMC apoptosis and reduction of matrix synthesis 
has been strongly implicated in plaque rupture (Clarke, Figg et al. 2006).  Other aspects of SMC 
function may also have a role in these events.  I set out to discover them by studying the differences 
between the proteome of SMC derived from stable and unstable plaques.  In this analysis differences 
in actin levels were apparent between SMC derived from symptomatic patients and asymptomatic 
patients; with ‘symptomatic SMC’ expressing lower levels.  This suggested that these SMC were even 
more ‘phenotypically modulated’ and so further differences in protein expression were eagerly 
anticipated.  
 
To the best of my knowledge, I was able to identify for the first time that annexin I was significantly 
increased in SMC from asymptomatic patients.  This cytoplasmic protein is an endogenous inhibitor to 
the enzyme phospholipase A2 (PLA2) (Perretti and D'Acquisto 2009), which is the key enzyme 
involved in the generation of prostaglandins, prostacyclins and leukotrienes (Damazo, Yona et al. 
2005; Perretti and D'Acquisto 2009).  SMC have been shown to express leukotriene receptor BLT1 
and stimulation with leukotriene B4 leads to proliferation and migration via NFκB activation (Back, 
Bu et al. 2005).  Annexin I also exerts more general anti-inflammatory role on innate immunity and 
small molecular mimics are under investigation (Perretti and Dalli 2009).  The increased expression of 
annexin I in asymptomatic SMC indicates that an enhanced ability of SMC to mitigate a pro-
inflammatory environment is crucial for the maintenance of an asymptomatic plaque.  Contrasting 
lower levels of annexin I in SMC from symptomatic patients suggests these cells may herald a more 
proinflammatory state.   
 
Intriguingly, the expression of annexin I was higher in asymptomatic carotid SMC than control Aortic 
SMC, suggesting that its expression is increased during development of disease. However, the 
expression levels of annexin I in the non-atherosclerotic carotid media are unknown and could be 
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different from that in AoSMC.  Glucocorticoids are the main established inducers of annexin I (Lim 
and Pervaiz 2007) although the mechanisms leading to its up regulation in physiology and disease are 
still ill-defined (Perretti and D'Acquisto 2009).  Annexin I is usually up regulated during 
differentiation and may play a role in migration of cells (Bizzarro, Fontanella et al. ; de Graauw, van 
Miltenburg et al.).  Alternatively, it can be induced by cellular stressors such as oxidative stress (Rhee, 
Kim et al. 2000).  Further investigation would be needed to explore the significance of this novel 
finding in a larger patient population as the role of annexin has not been yet studied in the context of 
plaque instability.   
 
The need for modulating inflammation in the context of atherosclerosis is all the more essential in 
light of my observation that SMCs from the human atherosclerotic plaque are primed for TNFα 
stimulation leading to gene expression compatible with NFκB activation (Figure 5.3).  There is 
historical and recent evidence in the literature demonstrating that SMC can participate in inflammatory 
and immune processes; such as the expression of MHC class II (Hansson, Jonasson et al. 1986) 
(Stemme, Fager et al. 1990) cytokine and chemokine expression (Moyer, Sajuthi et al. 1991) (Barath, 
Fishbein et al. 1990) (Raines and Ferri 2005) (Zeiffer, Schober et al. 2004).  Several explanations 
could be put forward for this finding.  Firstly, ROS can activate signalling through NFκB (Kabe, Ando 
et al. 2005).  Indeed the proteomic analysis revealed protein modification indicative of exposure to 
severe oxidative stress in these cells (Figure 3.24).  NFκB activity has been shown to be increased in 
aged cells (Helenius, Hanninen et al. 1996), which is partly due to increased oxidative stress (Li and 
Fukagawa 2010).  Therefore, this increased responsiveness to TNF can be partly explained by the 
increased oxidative stress experienced by atherosclerotic SMC.  An additional explanation for the 
‘TNF-priming’ of AthSMC is my finding that AthSMC express higher levels of TNFRII than control 
SMC.  This was confirmed with immunohistochemistry analysis which showed that TNFRII was 
expressed by SMC in the plaque but not by SMC in the media.  In accordance with previous studies 
the expression of TNFRII was brought about by exposure with TNF itself, indicating that the increase 
of TNFRII in intimal SMC could be a sign of previous exposure to TNF.  
 
 
7.3 Study Limitations 
 
As previously mentioned in chapter 1, SMC from different vascular beds have different embryonic 
origins (Majesky 2007) and therefore may respond differently to stimuli.  According to Majesky, SMC 
from the carotid artery are derived from the neural crest whereas aortic artery SMC can be derived 
from the mesoderm (abdominal aorta) or somites (descending thoracic aorta) depending on the region 
of aorta.  Therefore, there maybe some inherent differences already present between the carotid and 
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aortic SMC used in this study and so the differences that I have discovered may be in part due to the 
difference in developmental origins of these cells.  In chapter 3, I determined that the aortic SMC were 
the best available non-atherosclerotic SMC for this study.  However, there was no information 
provided from the supplier as to the region of the aorta from which these cells are derived.  To my 
knowledge the comparison of the proteome of healthy SMC from different arteries has not been 
performed to address this, nor has the comparison of AthSMC from different arteries.  These would be 
interesting questions to investigate, to assess the variation in the SMC proteome at site-specific 
locations.   
 
Similarly, there may be differences within the AthSMC population as plaque composition is not 
uniform; proximal or upstream regions are thought to be exposed to increased shear stress and contain 
higher numbers of macrophages with increased MMP activity, and fewer SMC, whereas the 
downstream regions contain more SMC and there is higher levels of matrix synthesis (Dirksen, van 
der Wal et al. 1998) (Slager, Wentzel et al. 2005).  In my study, any differences in the SMC from 
different regions of the carotid plaque would have been masked as the SMC from the whole plaque 
was isolated in one culture.  To address this question, the plaque could be divided into ‘upstream’ and 
‘downstream’ fragments before SMC isolation.    
 
There choice of proteomic tools used also limit the questions that you can answer.  Due to my 
decisions to examine the intracellular proteome and to use a narrow pH gradient, I analysed only a 
fraction of the whole SMC proteome.  The majority of proteins identified were cytoskeletal proteins 
and chaperones (see Figure 3.9).  The use of a wider pH gradient such as 3-10, would have increased 
the number of potential proteins to identify as well as representing a wider range of biological 
functions including more metabolic enzymes, antioxidants, mitochondrial proteins and proteasome 
subunits.     
 
In the 2D gel analysis, I was surprised to see that the maximum relative fold increase or decrease in 
expression of the proteins identified in this analysis was ‘only’ 1.3 or 1.4 fold.  In other proteomic 
analyses, the fold increases in expression levels of some proteins have been measured as 3-fold 
(McGregor, Kempster et al. 2004) or have even reached up to 15-fold (Mayr, Chung et al. 2005).  I 
postulated several reasons for this difference.  Firstly, there are some disadvantages to the silver 
staining technique.  The main ones being that it has only a 10-fold linear dynamic range and the 
reaction is stopped at an arbitrary and subjective time point (determined by the person who is staining) 
to avoid over development (Patton 2002).  Therefore if the silver staining process is not stopped at the 
right time, the differences in the spot intensity are not linear.  This can result in variation in the gel-to-
gel reproducibility.  Despite attempts to standardize the silver staining, there would always be a certain 
level of some human error in this technique.  The silver nitrate also binds to areas of the gel that do not 
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contain protein, so background staining can also interfere with the measurement of spot intensity.  
Progenesis Samespots software does take into account the background and substracts this from the 
spot volume, producing a normalised spot volume.   
 
I chose silver staining due to its sensitivity and ability to detect proteins in the nanogram range and its 
compatibility with mass spectrometry (Chevallet, Luche et al. 2006).  However, there are now more 
sensitive stains available with equal or better sensitivity (i.e. SYPRO-Red), which are more suited for 
quantitative analysis and compatible MS.  However, the use of DIGE or other fluorescent stains, as 
mentioned in section 1.3, may not be suitable for use on these gel as the gels in this thesis were plastic-
backed, which have their own autofluorescence.  
 
Other possible improvements to this study involve alterations to experimental procedures, including a 
longer stimulation with TNF and cholesterol.  In vivo, SMC are exposed to such atherogenic factors 
over a lifetime, but I only stimulated with TNF and cholesterol for 24 hours.  This was aimed at 
keeping this the same as the other experiments performed with these stimuli.  However, with hindsight 
I would have stimulated the SMC with TNF for at least 48 hours.  A timecourse experiment to analyse 
the proteomic changes due to stimulation with TNF or soluble free cholesterol would also have been 
interesting as more changes would have emerged.   
 
 
7.4 Future Studies 
As with all investigations using human tissue specimens, the more samples analysed, the better the 
study.  It would be interesting to increase the number of donors used in this study, particularly for the 
analysis of SMC from symptomatic and asymptomatic patients.  To further the study in this thesis, 
validation of the differentially expressed proteins is required.  Firstly, it would be interesting to show 
that the plaque SMC do indeed have increased oxidative stress and mitochondrial damage, as I 
inferred from the proteomic data.  Investigation of the other peroxiredoxins and other anti-oxidant 
enzymes such as thioredoxins could determine this.  Additionally, to address the mitochondrial 
damage, I would compare the expression levels of other proteins in the electron transport chain as well 
as the extent of mitochondrial DNA damage in AoSMC and AthSMC.   
 
Expression of annexin I and annexin II in plaque SMC must be further investigated by 
immunohistochemistry and gene expression analysis.  It may also be possible to investigate the 
potential anti-inflammatory effects of the annexin I fragment Ac2-26 on SMC (Perretti, Ahluwalia et 
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al. 1993).  The differential expression of annexin I could also be a feature of the whole plaque in 
general and not just limited to SMC.   
 
 
7.5 Concluding comments 
 
In comparing the proteome of the human atherosclerotic SMC to that of the non-atherosclerotic SMC, 
I have uncovered a characteristic protein signature demonstrating that the life of an intimal SMC in the 
lesion is very stressful.  Atherosclerotic SMC have increased oxidative stress, ER stress and 
mitochondrial damage.  These stressors have been characterised in atherosclerotic lesions and as well 
as macrophages but there is little in the literature about these effects in SMC.  Therefore, these 
findings are novel.  The culmination of these stressors results in an SMC population with an increased 
sensitivity to inflammatory stimuli.  As a result they express adhesion molecules, chemokines and 
cytokines, which amplify the local inflammatory response.  In addition, the ability of cells to resolve 
inflammation is an important feature, the lack of which may exacerbate the proinflammatory state and 
endanger plaque stability.  
 
In conclusion, the results of my study point towards a proinflammatory state of SMC in 
atherosclerosis, the extreme of which may have adverse consequences in terms of plaque stability.  
This paradigm shift argues that it is not necessarily the number of SMC in the plaque, but rather the 
proinflammatory state and anti-inflammatory capacity of the SMC, which determines the fate of the 
plaque.  
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Proteins from the reference map in Figure 3.8 were identified by Tandem Mass Spectrometry 
 
Spot  Protein Identification Swiss Prot Entry Name 
Swiss 
Prot 
Accession 
Number 
Predicted    
M wt / pI 
Observed   
M wt / pI Peptide Sequences 
Mascot 
Score 
% 
cover 
1 Vimentin VIME_HUMAN P08670 53.5/5.06 65/4.7 R.EYQDLLNVK.M 35 23 
          R.QVDQLTNDKAR.V 60   
          L.LAELEQLKGQGK.S 82   
          R.KVESLQEEIAFLK.K 111   
          R.ISLPLPNFSSLNLR.E 79   
          R.ETNLDSLPLVDTHSK.R 59   
          R.DGQVINETSQHHDDLE.- 40   
          RLLQDSVDFSLASAINTEFK.N 122   
2 Vimentin VIME_HUMAN P08670 53.5/5.06 70/4.9 R.ISLPLPNFSSLNLR.E 172 3 
3 Vimentin VIME_HUMAN P08670 53.5/5.06 80/5.2 R.SLYASSPGGVYATR.S 60 9 
          R.ISLPLPNFSSLNLR.E 161   
          R.DGQVINETSQHHDDLE.- 23   
4 Mitochndrial Heat shock protein 60 CH60_HUMAN P10809 57.9/5.24 60/5.25 R.VTDALNATR.A 34 5 
          R.AAVEEGIVLGGGCALLR.C 50   
5 Mitochndrial heat shock protein 60 CH60_HUMAN P10809 57.9/5.24 60/5.4 R.VTDALNATR.A 36 11 
         K.GANPVEIRR.G 33   
         K.VGGTSDVEVNEK.K 67   
         R.GVMLAVDAVIAELKK.Q + Oxidation (M) 41   
          K.ISSIQSIVPALEIANAHR.K 46   
6 
Stress-70 protein, mitochondrial / 
GRP 75 GRP75_HUMAN P38646 68.8/5.44 70/5.5 R.QAASSLQQASLK.L 79 8 
         K.DAGQISGLNVLR.V 48   
         K.VQQTVQDLFGR.A 38   
          K.SQVFSTAADGQTQVEIK.V 104   
7 HSPA9 / HSP70 Q8N1C8_HUMAN Q8N1C8 73.8/6.04 73/5.7 R.QAASSLQQASLK.L 59 9 
         K.DAGQISGLNVLR.V 59   
         K.VQQTVQDLFGR.A 43   
         R.TTPSVVAFTADGER.L 50   
          K.LLGQFTLIGIPPAPR.G 26   
8 T-complex protein 1 subunit epsilon TCPE_HUMAN P48643 59.3/5.45 65/5.7 R.IADGYEQAAR.I 41 6 
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         R.SLHDALCVIR.N 19   
          K.DVDFELIKVEGK.V 52   
9 Protein disulphide isomerase A3 PDIA3_HUMAN P30101 54.3/5.61 60/5.8 R.LAPEYEAAATR.L 22 15 
         K.IFRDGEEAGAYDGPR.T 27   
         R.FLQDYFDGNLKR.Y 40   
         K.LSKDPNIVIAK.M 61   
         R.GFPTIYFSPANK.K 36   
          .EATNPPVIQEEKPK.K 41   
10 Protein disulphide isomerase A3 PDIA3_HUMAN P30101 54.3/5.61 60/6.0 R.LAPEYEAAATR.L 70 20 
         K.LSKDPNIVIAK.M 47   
         R.DGEEAGAYDGPR.T 36   
         R.FLQDYFDGNLKR.Y 43   
         R.EATNPPVIQEEKPK.K 36   
         R.KTFSHELSDFGLESTAGEIPVVAIR.T 58   
          .SDVLELTDDNFESR.V 54   
11 Isoform 2 of Caldesmon CALD1_HUMAN Q05682-2 65.7/6.37 80/6.4 K.GNVFSSPTAAGTPNK.E 30 12 
          K.QQEAALELEELKK.K 57   
          R.RGETESEEFEKLK.Q 27   
          R.IAYQRNDDDEEEAAR.E 29   
          K.IDSRLEQYTSAIEGTK.S 33   
          K.SAKPTKPAASDLPVPAEGVR.N 8   
          K.GNVFSSPTAAGTPNKETAGLK.V 4   
12 Isoform 2 of Caldesmon CALD1_HUMAN Q05682-2 65.7/6.37 80/6.5 K.RLQEALER.Q 20 5 
         K.GNVFSSPTAAGTPNK.E 14   
         K.TTTTNTQVEGDDEAAFLER.L 77   
13 ATPB_HUMAN P06576 51.7/5.0 55/5.1 LVLEVAQHLGESTVR   10 
  
ATP synthase subunit beta, 
mitochondrial        TIAMDGTEGLV     
          IMNVIGEPIDER     
          AIAELGIYPAVDPLDSTSR     
14 ATP synthase subunit beta ATPB_HUMAN P06576 51.7/5.0 50/5.1 R.FTQAGSEVSALLGR.I 91 10 
          K.VLDSGAPIKIPVGPETLGR.I 43   
          R.AIAELGIYPAVDPLDSTSR.I 34   
15 Heat shock cognate 71 kDa protein HSP7C_HUMAN P11142 70.7/5.37 40/4.9 K.VCNPIITK.L 31 3 
          R.ARFEELNADLFR.G 32   
16 Protein disulfide-isomerase PDIA1_HUMAN P07237 55.2/5.69 45/5.2 K.THILLFLPK.S 25 8 
          K.VDATEESDLAQQYGVR.G 85   
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          K.HNQLPLVIEFTEQTAPK.I 15   
17 Protein disulfide-isomerase PDIA1_HUMAN P07237 55.2/5.69 45/5.25 R.ILEFFGLK.K 46 3 
            R.LITLEEEMTK.Y + Oxidation (M) 11   
18 Actin, cytoplasmic 1 ACTB_HUMAN P60709 41.6/5.29 45/5.3 K.AGFAGDDAPR.A 49 3 
19 Actin, cytoplasmic 1 ACTB_HUMAN P60709 41.6/5.29 45/5.35 R.GYSFTTTAER.E 38 3 
20 Actin, cytoplasmic 1 ACTB_HUMAN P60709 41.6/5.29 45/5.4 R.AVFPSIVGR.A 20 8 
          K.AGFAGDDAPR.A 45   
          R.GYSTFTTTAER.E 32   
21 Actin, cytoplasmic 1 ACTB_HUMAN P60709 41.6/5.29 45/5.45 K.AGFAGDDAPR.A 43 12 
          R.GYSTFTTTAER.E 64   
          K.DSYVGDEAQS.K 51   
          K.QEYDESGPSIVHR.K 89   
22 Actin, cytoplasmic 1 ACTB_HUMAN P60709 41.6/5.29 45/5.5 K.AGFAGDDAPR.A 43 5 
          R.GYSTFTTTAER.E 63   
23 Actin, alpha 2 smooth muscle ACTA_HUMAN P62736 41.7/5.24 45/6.0 K.SYELPDGQVITIGNER.F 16 4 
24 Pyruvate Kinase M1/M2 KPYM_HUMAN P14618 57.8/7.95 48/6.2 K.GVNLPGAAVDLPAVSEK.D 61 18 
          R.LDIDSPPITAR.N 48   
          K.ITLDNAYMEK.K + Ooxidation (M) 26   
          R.NTGIICTIGPASR.S 41   
          K.IYVDDGLISLQVK.Q 68   
          K.GADFLVTEVENGGSLGSK.K 42   
          
K.FGVEQDVDMVFASFIR.K + Oxidation 
(M) 81   
25 Alpha-enolase ENOA_HUMAN P06733 47/6.99 48/6.6 R.YISPDQLADLYK.S 33 7 
          K.FTASAGIQVVGDDLTVTNPK.R 27   
26 Protein disulfide-isomerase PDIA1_HUMAN P07237 55.3/4.69 40/5.25 R.ILEFFGLK.K 30 6 
          K.THILLFLPK.S 38   
          K.VDATEESDLAQQYGVR.G 102   
27 Glutathione S-transferase omega-1 GSTO1_HUMAN P78417 27.6/6.24 36/5.0 R.HEVININLK.N 46 10 
          K.GSAPPGPVPEGSIR.V 40   
28 Glutathione S-transferase omega-1 GSTO1_HUMAN P78417 27.6/6.24 36/5.2 K.VPSLVGSFIRS.S 28 10 
          K.GSAPPGPVPEGSIR.V 53   
29 Cathespin B CATB_HUMAN P07858 27.7/5.23 38/5.4 K.LPASFDAR.E 34 10 
          K.ICEPGYSPTYK.Q 28   
          K.ICEPGYSPTYKQDK.H 28   
30 Cathepsin D  CATD_HUMAN P07339 37.8/5.60 36/5.45 R.VGFAEAAR.L 40 5 
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          K.FDGILGMAYPR.I + Oxidation (M) 16   
31 Protein disulphide isomerase A3 PDIA3_HUMAN P30101 54.3/5.61 35/5.45 R.LAPEYEAAATR.L 46 10 
          R.DGEEAGAYDGPR.T 43   
          K.DLLIAYYDVDYEK.N 34   
          K.IFRDGEEAGAYDGPR.T 23   
32 Tubulin beta-1 chain TBB1_HUMAN Q9H4B7 50.3/5.05 38/5.6 R.FPGQLNADLR.K 58 12 
          K.LAVNMVPFPR.L 39   
          R.ALTVPELTQQVFDAK.N 70   
          R.EIVHIQAGQCGNQIGAK.F 26   
33 
F-actin-capping protein subunit 
alpha-1 CAZA1_HUMAN P52907 32.8/ 5.45 38/5.7 K.EASDPQPEEADGGLK.S 50 10 
            K.FTITPPTAQVVGVLK.I 33   
34 Prolyl 4-hydroxylase subunit alpha-1 P4HA1_HUMAN P13674 59.1/5.70 40/5.8 K.SFLTAEDCFELGK.V 56 6 
          R.QYFPNDEDQVGAAK.A 58   
          R.LQDTYNLDTDTISK.G 33   
35 Prolyl 4-hydroxylase subunit alpha-1 P4HA1_HUMAN P13674 59.1/5.70 37/5.8 R.QYFPNDEDQVGAAK.A 58 5 
          R.LQDTYNLDTDTISK.G 33   
36 
F-actin-capping protein subunit 
alpha-1 CAZA1_HUMAN P52907 32.8/ 5.45 38/5.89 R.TSVETALR.A 30 23 
          R.LLLNNDNLLR.E 61   
          M.ADLEEQLSDEEKVR.I 121   
          K.DIQDSLTVSNEVQTAK.E 93   
          K.IQVHYYEDGNVQLVSHK.D 56   
37 Pyruvate Kinase M1/M2 KPYM_HUMAN P14618 57.8/7.95 37/6.0 R.LDIDSPPITAR.N 27 10 
          R.NTGIICTIGPASR.S 54   
          K.IYVDDGLISLQVK.E 89   
          K.FGVEQDVDMVFASFIR.K + oxidation (M) 60   
38 Pyruvate Kinase M1/M2 KPYM_HUMAN P14618 57.8/7.95 38/6.2 R.NTGIICTIGPASR.S 50 8 
          K.IYVDDGLISLQVK.Q 52   
          R.TATESFADPILYRPVAVALDTK.G 14   
39 Alpha-enolase/ ENOA_HUMAN P06733 47/6.99 38/6.4 R.EGLEIK.N 61 1 
                
   Elongation factor Tu, mitochondrial EFTU_HUMAN P49411 45/6.31   R.GTVVTGTLER.G 31 28 
          R.AEAGDNLGALVR.G 53   
          R.DLEKPFLLPVEAVYSVPGR.G 22   
40 Annexin A2 isoform 2 ANXA2_HUMAN P07355 38.4/7.56 36/6.5 R.DLYDAGVKR.K 26 27 
          K.TPAQYDASELK.A 63   
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          R.TNQELQEINR.V 52   
          K.GVDEVTIVNILTNR.S 70   
          K.SALSGHLETVILGLLK.T 56   
          K.GLGTDEDSLIEIICSR.T 70   
          K.TDLEKDIISDTSGDFRK.L 96   
41 78 kDa glucose-regulated protein GRP78_HUMAN P11021 70.4/5.01 34/6.6 R.VEIIANDQGNR.I 64 6 
          R.TWNDPSVQQDIK.F 44   
          K.NQLTSNPENTVFDAK.R 66   
42 Heat shock protein beta-1 HSPB1_HUMAN P04792 22.8/5.98 29/6.3 R.LFDQAFGLPR.L 53 27 
          Q.LGGPEAAKSDETAAK.- 98   
          R.AQLGGPEAAKSDETAAK.- 45   
          K.LATQSNEITIPVTFESR.A 67   
43 Triosephosphate isomerase TPIS_HUMAN P60174 26.5/6.51 29/6.5 K.IAVAAQNCYK.V   14 
            K.SNVSDAVAQSTR.I     
            K.TATPQAQEVHEK.L     
44 Triosephosphate isomerase TPIS_HUMAN P60174 26.5/6.51 30/6.8 K.FFVGGNWK.M 15 24 
          K.SNVSDAVAQSTR.I 68   
          R.IIYGGSVTGATCK.E 76   
          K.QSLGELIGTLNAAK.V 73   
          R.HVFGESDELIGQK.V 57   
          K.VVLAYEPVWAIGTGK.T 52   
45 
Endoplasmic reticulum protein 
ERp29 ERP29_HUMAN P30040 25.8/6.08 27/6.5 K.SLNILTAFQK.K 45 14 
          K.GALPLDTVTFYK.V 60   
          R.DGDFENPVPYTGAVK.V 60   
46 Pyruvate Kinase M1/M2 KPYM_HUMAN P14618 57.8/7.95 29/6.3 R.NTGIICTIGPASR.S   6 
          K.GVNLPGAAVDLPAVSEK.D 60   
47 Peroxiredoxin 4 PRDX4_HUMAN Q13162 26.6/5.54 28/5.9 R.LVQAFQYTDK.H 43 13 
          R.QITLNDLPVGR.S 15   
          K.DYGVYLEDSGHTLR.G 46   
48 
Endoplasmic reticulum protein 
ERp29 ERP29_HUMAN P30040 25.8/6.08 27/6.1 K.FDTQYPYGEK.Q 36 18 
          K.ESYPVFYLFR.D 22   
          K.GALPLDTVTFYK.V 80   
          R.DGDFENPVPYTGAVK.V 55   
49 Heat shock protein beta-1 HSPB1_HUMAN P04792 22.8/5.98 30/5.8 R.VSLDVNHFAPDELTVK.T  40 29 
          K.LATQSNEITIPVTFESR.A  77   
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          R.LFDQAFGLPR.L  53   
          R.AQLGGPEAAKSDETAAK  35   
50 Prohibitin Q6PUJ7_HUMAN Q6PUJ7 29.8/5.57 34/5.7 R.FDAGELITQR.E 31 11 
          K.AAELIANSLATAGDGLIERR.K 133   
                
  Chloride intracellular channel 4 CLIC4_HUMAN Q9Y696 28.6/5.45   K.GVVFSVTTVDLK.R 54 16 
          K.NSRPEANEALER.G 24   
          K.AGSDGESIGNCPFSQR.L 118   
51 Annexin A2 ANXA2_HUMAN P07355 38.4/7.56 35/5.9 M.STVHEILCK.L 65 15 
          K.TPAQYDASELK.A 42   
          K.GVDEVTIVNILTNR.S 26   
          K.GLGTDEDSLIEIICSR.T 19   
52 Peroxiredoxin 4 PRDX4_HUMAN Q13162 26.6/5.54 28/5.7 R. LVQAFQTDK.H 21 23 
          R.QITLNDLPVGR.S 47   
          R.TREEECHFYAGGQVYPGEASR.V 14   
          R.QGGLGPIRIPLLSDLTHQISK.D 120   
53 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 UCHL1_HUMAN P09936 24.8/5.33 27/5.4 K.QTIGNSCGTIGLIHAVANNQDK.L   19 
          K.LGFEDGSVLK.Q     
          R.EFTEREQGEVR.F     
54 Annexin A1 ANXA1_HUMAN P04083 38.5 / 6.64 24/5.3 K.DITSDTSGDFR.N 22 23 
          K.GVDEATIIDILTK.R 41   
           K.GLGTDEDTLIEILASR.T 104   
          K.AAYLQETGKPLDETLKK.A 27   
          K.GGPGSAVSPYPTFNPSSDVAALHK.A 41   
55 Annexin A1 ANXA1_HUMAN P04083 38.5 / 6.64 24 / 5.2 K.GLGTDEDTLIEILASR.T 123 9 
          K.GTDVNVFNTILTTR.S 16   
56 78 kDa glucose-regulated protein GRP78_HUMAN P11021 70.5/5.01 29/5.10 R.VEIIANDQGNR.I 64 6 
          R.ITPSYVAFTPEGER.L  37   
          R.IINEPTAAAIAYGLDKR.E 70   
57 Cathepsin B CATB_HUMAN P07858 27.8/5.23 27/5.3 R.GQDHCGIESEVVAGIPR.T 30 10 
          K.NGPVEGAFSVYSDFLLYK.S 98   
58 
 Perilipin-3 (Cargo selection protein 
TIP47) PLIN3_HUMAN O60664 47/5.3 34/4.9 R.TLTAAAVSGAQPILSK.L  92 11 
          R.LGQMVLSGVDTVLGK.S + Oxidation (M)  96   
          R.GLDKLEENLPILQQPTEK.V  33   
59 Chaperonin containing T-complex TCPQ_HUMAN P50990 59.4/4.92 25/4.8 R.LVPGGGATEIELAK.Q 65 5 
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protein 1 subunit theta 
          K.LATNAAVTVLR.V 31   
60 Proteasome subunit beta type-6 PSB6_HUMAN P28072 21.9/4.91 22/4.9 R.TTTGSYIANR.V  41 8 
            R.QVLLGDQIPK.F 51   
61 Procollagen-proline, 2-oxoglutarate 4-dioxygenase  B3KTQ9_HUMAN B3KTQ9 21.2/4.47 22/4.4 K.NFEDVAFDEK.K 18 11 
  
(Proline 4-hydroxylase), beta 
polypeptide, isoform CRA_b        K.NFEDVAFDEKK.N 37   
          R.TVIDYNGER.T 35   
62 
 ATP synthase subunit delta, 
mitochondrial ATPD_HUMAN P30049 17/4.53 22./4.5 R.IEANEALVK.A 47 17 
          K.AQAELVGTADEATR.A 54   
          K.AQAELVGTADEATRAEIQIR.I 40   
63 ODO2_HUMAN P36957 15.3/7.5 22./5.2 K.ASAFALQEQPVVNAVIDDTTK.E 49 9 
         R.GLVVPVIR.N 28   
  
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase 
complex, mitochondrial        R.NVEAMNFADIER.T 61   
64 Peroxiredoxin-2 PRDX2_HUMAN P32119 21.7/5.67 20/5.9 K.ATAVVDGAFK.E 62 27 
          K.ATAVVDGAFKEVK.L 27   
          K.LGCEVLGVSVDSQFTHLAWINTPR.K 24   
          K.EGGLGPLNIPLLADVTR.R 24   
65 Glutathione S-transferase P GSTP1_HUMAN P09211 23.5/5.43 23/5.9 M.PPYTVVYFPVR.G 31 18 
          K.ASCLYGQLPK.F  40   
          K.FQDGDLTLYQSNTILR.H 39   
66  Proteasome subunit beta type-4 PSB4_HUMAN P28070 24.3/5.47 23/5.9 R.AIHSWLTR.A 32 7 
          K.QPVLSQTEAR.D 44   
67 Superoxide Dismutase SODC_HUMAN P00441 15.8/5.7 20/6.05 K.AVCVLKGDGPVQGIINFEQK.E 43 45 
          K.GDGPVQGIINFEQK.E  68   
          R.HVGDLGNVTADK.D 76   
          
R.HVGDLGNVTADKDGVADVSIEDSVISLS
GDHCIIGR.T 105   
          K.DGVADVSIEDSVISLSGDHCIIGR.T 88   
68 Heat shock protein beta-6 HSPB6_HUMAN O14558 17.1/5.95 20/6.4 R.ASAPLPGLSAPGR.L 49 14 
          K.HFSPEEIAVK.V 27   
69 
Thioredoxin-dependent peroxide 
reductase, mitochondrial  PRDX3_HUMAN P30048 21.4/5.77 23/6.4 K.GTAVVNGEFK.D 45 22 
  [Precursor] (Peroxiredoxin 3)        K.HLSVNDLPVGR.S 51   
          R.GLFIIDPNGVIK.H 29   
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          R.DYGVLLEGSGLALR.G 71   
          R.GLFIIDPNGVIKHLSVNDLPVGR.S 87   
70 Parkinsons disease protein 7 PARK7_HUMAN Q99497 19.8/6.33 22/6.5 K.VTVAGLAGK.D 33 30 
          R.DVVICPDASLEDAK.K 15   
          K.VTVAGLAGKDPVQCSR.D 55   
          R.DVVICPDASLEDAKK.E 31   
          R.GPGTSFEFALAIVEALNGK.E 117   
71 Proteasome subunit beta type-3 PSB3_HUMAN P49720 22.8/6.13 24/6.5 R.FGPYYTEPVIAGLDPK.T 54 17 
          R.LYIGLAGLATDVQTVAQR.L 106   
72 
Heterogeneous nuclear 
ribonucleoprotein H HNRH1_HUMAN P31943 49.1/5.81 24/6.9 R.GLPWSCSADEVQR.F 18   
          K.HTGPNSPDTANDGFVR.L 58   
73  Protein disulfide-isomerase A6 PDIA6_HUMAN Q15084 46.1/4.95 36 /6.4 K.LAAVDATVNQVLASR.Y 87   
74 Elongation factor 2 EF2_HUMAN P13639 95.2 / 6.52 45/6.55 K.SDPVVSYR.E 12 4 
          R.ETVSEESNVLCLSK.S 63   
          R.GLKEGIPALDNFLDKL 33   
75 26S proteasome ATPase subunit 2 PRS7_HUMAN P35998 48.5/5.72 53/6.1 R.ALDEGDIALLK.T 35 9 
          K.ACLIFFDEIDAIGGAR.F 55   
          R.FDDGAGGDNEVQR.T 61   
76 
 Aldehyde dehydrogenase, 
mitochondrial ALDH2_HUMAN P05091 54.4/5.69 54/6.2 K.LLCGGGIAADR.G 35 8 
          R.ANNSTYGLAAAVFTK.D 61   
          K.VAEQTPLTALYVANLIK.E 55   
77 
Cytochrome b-c1 complex subunit 1, 
mitochondrial QCR1_HUMAN P31930 49.1/ 5.43 49/5.8 R.LCTSATESEVAR.G 11 10 
          K.NNGAGYFLEHLAFK.G 58   
            K.AVELLGDIVQNCSLEDSQIEKER.D 64   
78 
Triosephopshate isomerase 1 isoform 
1 TPIS_HUMAN P60174 26.5/6.51 30/6.5 K.SNVSDAVAQSTR.I 23 11 
          K.VVLAYEPVWAIGTGK.T 34   
79 Proteasome alpha 1 subunit isoform 2 PSA1_HUMAN P25786 29.5./6.15 34/6.6 R.LVSLIGSK.T 39 13 
          R.ETLPAEQDLTTK.N 15   
          R.NQYDNDVTVWSPQGR.I 57   
80 HEXB_HUMAN P07686 49.9/5.90 34/5.4 K.VLDIIATINK.G 42 13 
  
N-acetyl-beta-glucosaminidase 
prepropolypeptidepeptide 
          K.KLESFYIQK.V 64   
            K.DSAYPEELSR.V 15   
            K.VEPLDFGGTQK.Q 13   
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            K.LAPGTIVEVWK.D 59   
            K.EISEVFPDQFIHLGGDEVEFK.C 22   
81 
N-acetyl-beta-glucosaminidase 
prepropolypeptidepeptide HEXB_HUMAN 49.9/5.90 49.9/5.90 34/5.6 K.VLDIIATINK.G 54 8 
          K.KLESFYIQK.V 31   
          K.VEPLDFGGTQK.Q 10   
          K.GSIVWQEVFDDK.A 25   
82 Glutathione S transferase GSTP1_HUMAN P09211 23.2/5.4 19/5.8  K.FQDGDLTLYQSNTILR.H 91 17 
           K.ALPGQLKPFETLLSQNQGGK.T  36   
                 
  Peroxiredoxin-2 PRDX2_HUMAN P32119 21.7/5.67 19/5.8 R.KEGGLGPLNIPLLADVTR.R 41 15 
          R.QITVNDLPVGR.S 48   
83 Vimentin VIME_HUMAN P08670 53/5.06 50/ 4.5 R.ISLPLPNFSSLNLR.E 43 11 
          R.KVESLQEEIAFLKK.L 45   
          R.QVQSLTCEVDALKGTNESLER.Q 66   
84 Galectin-1 LEG1_HUMAN P09382 14.5/5.4 14/5.1 R.FNAHGDANTIVCNSK.D 27 11 
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26/10/09  Digest Louise 2D gel  spot #H5
14November09Q_29   MaxEnt 3  20 [Ev-97895,It20,En1] (-1.000,2,Cmp); Combine 20 (20:25) 2: TOF MSMS 995.03ES+ 
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Figure A1.1 Identification of spot 13 as ATP Synthase.  The spot was excised from a preparative 
2D gel of AoSMC or AthSMC and digested with trypsin as described in materials and methods.  A) 
The spectrum shows mass-to-charge (m/z) ratio plotted against relative abundance. The B-ions are 
shown in blue and the y-ions shown in red.  B) Search of the NCBI non-redundant database using 
BLAST of the peptide AIAELGIYPAVDPLDSTSR.  The top 10 matches are shown, with the 
identification of the human protein below.  The E-value is a measure of the likelihood that the amino 
acid sequence matches the protein sequence in the database by chance.  A 100% match of the peptide 
entered and human protein sequence is shown. C) Amino acid residues shown in red represent all the 
peptides identified by ES MS/MS for this protein.   
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28/10/09  Digest Louise 2D gel  #2H4
21January10Q_27   MaxEnt 3  21 [Ev-271903,It20,En1] (-1.000,3,Cmp); Combine 21 (21:26) 2: TOF MSMS 506.93ES+ 
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Figure A1.2 Identification of spot 20 as Actin.  The spot was excised from a preparative 2D gel of 
AoSMC or AthSMC and digested with trypsin as described in materials and methods.  A) The 
spectrum shows mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown 
in blue and the y-ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of 
the peptide QEYDESGPSIVHR.  The top 10 matches are shown, with the identification of the human 
protein below.  The E-value is a measure of the likelihood that the amino acid sequence matches the 
protein sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown. C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
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26/10/09  Digest Louise 2D gel  spot #F9
14November09Q_09   MaxEnt 3  23 [Ev-200813,It20,En1] (-1.000,2,Cmp); Combine 23 (22:27) 2: TOF MSMS 680.33ES+ 
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Figure A1.3 Identification of spot 37 as Pyruvate Kinase.  The spot was excised from a 2D gel of 
AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum shows 
mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-
ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
NTGIICTIPASR.  The top 10 matches are shown, with the identification of the human protein below.  
The E-value is a measure of the likelihood that the amino acid sequence matches the protein sequence 
in the database by chance.  A 100% match of the peptide entered and human protein sequence is 
shown.   C) Amino acid residues shown in red represent all the peptides identified by ES MS/MS for 
this protein. 
MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMI
KSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTA
EVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVT
EVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGE
KGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVI
CATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIY
HLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTR
NPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSG
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26/10/09  Digest Louise 2D gel  spot #D4
11November09Q_40   MaxEnt 3  8 [Ev-79691,It20,En1] (-1.000,2,Cmp); Combine 8 (8:13) 3: TOF MSMS 954.00ES+ 
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Figure A1.4 Identification of spot 49 as Hsp27.  The spot was excised from a 2D gel of AoSMC and 
digested with trypsin as described in materials and methods.  A) The spectrum shows mass-to-charge 
(m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-ions shown in 
red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
LATQSNEITIPVTFESR.  The top 10 matches are shown, with the identification of the human protein 
below. The E-value is a measure of the likelihood that the amino acid sequence matches the protein 
sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.  C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPL
PPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDG
VVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLAT
QSNEITIPVTFESRAQLGGPEAAKSDETA 
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26/10/09  Digest Louise 2D gel  spot #D5
11November09Q_41   MaxEnt 3  19 [Ev-175171,It20,En1] (-1.000,2,Cmp); Combine 19 (15:21) 2: TOF MSMS 613.36ES+ 
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Figure A1.5 Identification of spot 52 as Peroxiredoxin 4.  The spot was excised from a 2D gel of 
AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum shows 
mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-
ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
QITLNDLPVGR.  The top 10 matches are shown, with the identification of the human protein below.  
The E-value is a measure of the likelihood that the amino acid sequence matches the protein sequence 
in the database by chance.  A 100% match of the peptide entered and human protein sequence is 
shown.  C) Amino acid residues shown in red represent all the peptides identified by ES MS/MS for 
this protein. 
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26/10/09  Digest Louise 2D gel  spot #E2
11November09Q_50   MaxEnt 3  15 [Ev-25990,It20,En1] (-1.000,3,Cmp); Combine 15 (15:20) 2: TOF MSMS 608.93ES+ 
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Figure A1.6 Identification of spot 57 as Cathepsin B.  The spot was excised from a 2D gel of 
AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum shows 
mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-
ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
GQDHCGIESEVVAGIPR.  The top 10 matches are shown, with the identification of the human 
protein below.  The E-value is a measure of the likelihood that the amino acid sequence matches the 
protein sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.  C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
MWQLWASLCCLLVLANARSRPSFHPLSDELVNYVNKRNTTWQAGHNFYNVDMSYLKRLCG 
TFLGGPKPPQRVMFTEDLKLPASFDAREQWPQCPTIKEIRDQGSCGSCWAFGAVEAISDR 
ICIHTNAHVSVEVSAEDLLTCCGSMCGDGCNGGYPAEAWNFWTRKGLVSGGLYESHVGCR 
PYSIPPCEHHVNGSRPPCTGEGDTPKCSKICEPGYSPTYKQDKHYGYNSYSVSNSEKDIM 
AEIYKNGPVEGAFSVYSDFLLYKSGVYQHVTGEMMGGHAIRILGWGVENGTPYWLVANSW 
NTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI 
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26/10/09  Digest Louise 2D gel  spot #B1
11November09Q_13   MaxEnt 3  1 [Ev112114,It20,En1] (-1.000,2,Cmp); Combine 1 (1:7) 2: TOF MSMS 542.30ES+ 
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Figure A1.7 Identification of spot 60 as Proteasome subunit beta 6.  The spot was excised from a 
2D gel of AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum 
shows mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue 
and the y-ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the 
peptide TTTGSYIANRV.  The top 10 matches are shown, with the identification of the human protein 
below.  The E-value is a measure of the likelihood that the amino acid sequence matches the protein 
sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.  C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
 
MAATLLAARGAGPAPAWGPEAFTPDWESREVSTGTTIMAVQFDGGVVLGADSRTTTGSYI 
ANRVTDKLTPIHDRIFCCRSGSAADTQAVADAVTYQLGFHSIELNEPPLVHTAASLFKEM 
CYRYREDLMAGIIIAGWDPQEGGQVYSVPMGGMMVRQSFAIGGSGSSYIYGYVDATYREG 
MTKEECLQFTANALALAMERDGSSGGVIRLAAIAESGVERQVLLGDQIPKFAVATLPPA 
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26/10/09  Digest Louise 2D gel  spot #A10
11November09Q_10   MaxEnt 3  3 [Ev-46905,It20,En1] (-1.000,2,Cmp); Combine 3 (1:7) 2: TOF MSMS 489.81ES+ 
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Figure A1.8 Identification of spot 64 as Peroxiredoxin 2.  The spot was excised from a 2D gel of 
AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum shows 
mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-
ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
ATAVVDGAFKE.  The top 10 matches are shown, with the identification of the human protein 
below.  The E-value is a measure of the likelihood that the amino acid sequence matches the protein 
sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.   C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
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26/10/09  Digest Louise 2D gel  spot #G7
14November09Q_19   MaxEnt 3  21 [Ev-69884,It20,En1] (-1.000,2,Cmp); Combine 21 (21:26) 2: TOF MSMS 764.39ES+ 
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Figure A1.9 Identification of spot 76 as Aldehyde Dehydrogenase 2.  The spot was excised from a 
2D gel of AoSMC and digested with trypsin as described in materials and methods.  A) The spectrum 
shows mass-to-charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue 
and the y-ions shown in red.  B) Search of the NCBI non-redundant database using BLAST of the 
peptide ANNSTYGLAAAVFTK.  The top 10 matches are shown, with the identification of the human 
protein below.  The E-value is a measure of the likelihood that the amino acid sequence matches the 
protein sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.  C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
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26/10/09  Digest Louise 2D gel  spot #H6
14November09Q_30   MaxEnt 3  14 [Ev-132505,It20,En1] (-1.000,2,Cmp); Combine 14 (13:18) 3: TOF MSMS 785.90ES+ 
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Figure A1.10 Identification of spot 83 as Vimentin.  The spot was excised from a 2D gel of AoSMC 
and digested with trypsin as described in materials and methods.  A) The spectrum shows mass-to-
charge (m/z) ratio plotted against relative abundance.  The B-ions are shown in blue and the y-ions 
shown in red.  B) Search of the NCBI non-redundant database using BLAST of the peptide 
ISLPLPNFSSLNLR.  The top 10 matches are shown, with the identification of the human protein 
below.  The E-value is a measure of the likelihood that the amino acid sequence matches the protein 
sequence in the database by chance.  A 100% match of the peptide entered and human protein 
sequence is shown.  C) Amino acid residues shown in red represent all the peptides identified by ES 
MS/MS for this protein. 
Sequences producing significant alignments:   Score  E-Value 
      (bits)  
 
SP:VIME_RAT P31000 Vimentin OS=Rattus norvegicus GN=Vim PE=1 SV=2   47  3e-04 
SP:VIME_PIG P02543 Vimentin (Fragments) OS=Sus scrofa GN=VIM PE=... 47  3e-04 
SP:VIME_PANTR Q5R1W8 Vimentin OS=Pan troglodytes GN=VIM PE=2 SV=4   47  3e-04 
SP:VIME_MESAU P02544 Vimentin OS=Mesocricetus auratus GN=VIM PE=... 47  3e-04 
SP:VIME_MACFA Q4R4X4 Vimentin OS=Macaca fascicularis GN=VIM PE=2... 47  3e-04 
SP:VIME_HUMAN P08670 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4   47  3e-04 
SP:VIME_CRIGR P48670 Vimentin (Fragment) OS=Cricetulus griseus G... 47  3e-04 
SP:VIME_CERAE P84198 Vimentin OS=Cercopithecus aethiops GN=VIM P... 47  3e-04 
SP:VIME_BOVIN P48616 Vimentin OS=Bos taurus GN=VIM PE=1 SV=3   47  3e-04 
TR:Q3HWE5_PIG Q3HWE5 Vimentin (Fragment) OS=Sus scrofa domestica... 47  3e-04  
 
>SP:VIME_HUMAN P08670 Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 
Length = 466 
 
Score = 46.9 bits (103), Expect = 3e-04 
Identities = 14/14 (100%), Positives = 14/14 (100%)
MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGV 
YATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDK 
VRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAE 
DIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEE 
EIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSE 
AANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQD 
TIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSS 
LNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE  
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A2.1 Patient characteristics 
 
A summary of the patient characteristics whose plaques were used in this study are given below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics of patient Number (n=10) 
Symptomatic  6 
Asymptomatic 4 
Gender: Male 4 
             Female 6 
Mean age 65.3 (53-77) 
Smoker 5 
Hypertension 5 
Type 2 Diabetes Mellitus 3 
Statins  9 
Appendix 2   
 
276 
 
A2.2 Donor information for carotid and aortic SMC used in the 
proteomic analyses  
 
Age, gender and symptomatic status of the patient are given below.  Age is given in years.  For 
atherosclerotic SMC, symptomatic status is given. Symptomatic Status: 0: asymptomatic. 1: 
symptomatic.  Gender: M: male, F: female.  Details of aortic SMC donors were provided by Promocell 
when cells were purchased.  For the analysis of unstimulated SMC, 10 plaque and 6 aortic SMC 
donors were used.  For the TNF-stimulation, 7 plaques and 3 aortic SMC donors were used.  For 
cholesterols stimulation, 1 aortic SMC donor was used.   
 
Plaque SMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Donor Symptomatic status Age Gender 
Baseline 
analysis 
TNF 
stimulation 
1 1 76 F √   
2 1 49 M √  √ 
3 1 65 M √  √ 
4 1 71 F √  √ 
5 0 65 M √  √ 
6 1 77 F √   
7 0 71 F √   
8 0 59 M √   
9 1 67 F √   
10 0 68 F √   
11 0 71 F  √ 
12 0 59 M  √ 
13 1 67 F  √ 
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Aortic SMC 
 
Donor Age Gender Baseline analysis 
TNF 
stimulation 
Cholesterol 
stimulation 
1 22 F √   
2 22 F √    
3 46 M √    
4 41 M √  √   
5 41 M √  √   
6 17 F √  √  √ 
 
 
 
 
 
 
 
